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Resumo 
A levedura Saccharomyces cerevisiae, tal como todos os microrganismos, é 
usualmente considerada como um organismo unicelular. Contudo, os microrganismos 
formam mais frequentemente comunidades multicelulares macroscópicas que 
apresentam diferenciação celular, e são coordenadas por um complexo sistema de 
comunicação, e suportadas por uma matriz extracelular (MEC). A presença deste tipo de 
suporte das comunidades multicelulares de S. cerevisiae foi descrita no início deste 
século. Apesar disso, a informação relacionada com a sua composição e organização 
tridimensional é escassa. Assim, o principal objetivo deste trabalho foi realizar a 
primeira abordagem sistemática aos principais componentes da MEC de levedura. Para 
o efeito, foram desenvolvidas metodologias para (1) obter de forma reprodutível uma 
considerável e homogénea biomassa de leveduras produtora de MEC, e (2) extrair e 
fracionar a MEC produzida de forma a obter frações analiticamente puras de proteínas e 
polissacáridos, compatíveis com a aplicação de metodologias analíticas de alto-débito 
como o GC-MS e o DIGE.  
A análise detalhada da fração proteica permitiu a identificação de mais de 600 
proteínas. A maioria destas tem função e localização intracelulares, e é aqui identificada 
extracelularmente pela primeira vez, o que pode indicar um moonlighting 
surpreendentemente elevado. A presença de todas as enzimas associadas à glicólise e à 
fermentação, assim como ao ciclo do glioxilato, levanta suspeitas sobre a possibilidade 
de haver metabolismo extracelular. Além disso, um grande número de proteínas 
associadas à síntese, remodelação e degradação de outras proteínas foi identificado, 
incluindo elementos da família HSP70 e várias proteases. De realçar a presença das 
exopeptidases Lap4, Dug1 e Ecm14, e das metaloproteinases Prd1, Ape2 e Zps1, que 
partilham um domínio funcional zincin com as metaloproteinases da MEC de Eucariotas 
superiores. A presença adicional de proteínas intervenientes em várias vias de 
sinalização, como as Bmh1 e Bmh2, e da homing endonuclease Vde, que partilha o 
domínio Hedgehog/inteína com os morfogenos de Eucariotas superiores, sugere que a 
MEC de levedura poderá, tal como nesses organismos, mediar sinalização intercelular. 
 As análises cromatográfica e eletroforética da fração glicosídica revelaram 
claramente a presença de dois polissacáridos. A análise por espectrometria de massa 
identificou glucose, manose e galactose na composição destes polissacáridos. Foram 
ainda observados indícios da presença de ácido urónico. A indução de metacromasia 
sugeriu que os polissacáridos detetados apresentam substituição química. A 
 x 
possibilidade desta corresponder a sulfatação foi testada através de um teste de atividade 
anticoagulante. Das diversas amostras de MEC de diferentes estirpes de levedura 
usadas, o duplo mutante gup1Δgup2Δ apresentou, ao contrário da estirpe Wt, razoável 
atividade anticoagulante indicadora da presença de grupos sulfato.  
Os efeitos da deleção do gene GUP1 na composição da MEC de levedura 
proporcionaram uma perspectiva mais detalhada da composição molecular e 
mecanismos a ela associados. Observaram-se alterações nas frações protéica e 
glicosídica. A deleção resultou na ausência de várias proteínas, associadas 
principalmente com o metabolismo de fontes de carbono, defesa e resgate da célula, 
bem como síntese, modificação e degradação de proteínas, e organização celular. 
Adicionalmente, a deleção deste gene também teve um grande impacto na composição 
glicosídica da matriz, levando ao desaparecimento do polissacárido de maior peso 
molecular detetado na estirpe Wt. Globalmente, os efeitos da deleção do GUP1 na MEC 
mostram que a estrutura desta é muito dinâmica e que se encontra sob controlo apertado 
das células que compõem o agregado multicelular.  
As funções sugeridas para as proteínas ortólogas das Gup1 e Gup2 de levedura, 
respetivamente Hhatl e Hhat, nas vias de sinalização de Eucariotas superiores esteve na 
origem da construção de uma bateria de estirpes de levedura recombinantes 
transformadas com os ortólogos da via Hedgehog de ratinho, mosca e homem, para 
futura avaliação. Da mesma forma, foram clonados em S. cerevisiae os recetores de 
mamífero para o ácido hialurónico (AH), CD44 e HMMR. Estes transformantes foram 
submetidos ao crescimento na presença de AH de diferentes tamanhos moleculares. As 
estirpes exprimindo ambos os recetores foram igualmente sensíveis à presença de AH 
de elevado peso molecular, mas foram diferentemente sensíveis à presença de AH de 
tamanho molecular intermédio. As células expressando o recetor CD44 mostraram-se, 
tal como em Eucariotas superiores, sensíveis à presença de AH 50 kDa, apresentando 
uma forte redução da taxa específica de crescimento. Isto indica a expressão funcional 
dos recetores de AH em levedura e a provável conservação da maquinaria celular de 
resposta a este componente da MEC dos Eucariotas superiores.  
Este trabalho é o primeiro a apresentar um estudo detalhado sobre as frações 
protéica e glicosídica secretadas para a matriz extracelular de S. cerevisiae durante o seu 
crescimento em comunidades multicelulares, oferecendo a primeira abordagem 
proteómica e glicómica da sua composição e organização. Globalmente, este trabalho 
permite prever que a MEC de levedura exerça funções equivalentes às conhecidas da 
MEC de Eucariotas superiores. 
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Abstract  
The yeast Saccharomyces cerevisiae, as all microbes, is generally regarded as a 
unicellular organism. However, microorganisms live more frequently in macroscopic 
multicellular aggregates, presenting cellular differentiation, coordinated by complex 
communication, and supported by an extracellular matrix (ECM). The presence of this 
type of structure supporting multicellular life-style of S. cerevisiae was first described 
early this century. However, the information available on the yeast ECM components 
and three-dimensional spatial organization is scarce. Hence, this work aimed to provide 
a first methodical insight into the molecular composition of the yeast ECM major 
components. A methodology was developed capable of reproducibly obtaining ECM-
producing homogenous yeast mats, and extracting and fractionating the yeast ECM into 
analytical-grade fractions. This was developed in order to be fully compatible with the 
application of high-throughput analytical techniques, like GC-MS and DIGE.  
The in-depth analysis of the proteins in the yeast ECM identified more than 600 
proteins, most of which being ascribed to intracellular functions and localization, and 
therefore found extracellularly for the first time. This might indicate unexpectedly 
extensive moonlighting. The entire sets of enzymes from glycolysis and fermentation, as 
well as gluconeogenesis through glyoxylate cycle were highly represented, raising 
considerable reason for doubt as whether extracellular metabolism might exist. 
Moreover, a large number of proteins associated with protein fate and remodelling were 
found. These included several proteins from the HSP70 family, and proteases, 
importantly, the exopeptidases Lap4, Dug1 and Ecm14, and the metalloproteinases 
Prd1, Ape2 and Zps1, sharing a functional zincin domain with higher Eukaryotes ECM 
metalloproteinases. The further presence of the broad signalling cross-talkers Bmh1 and 
Bmh2, as well as the homing endonuclease Vde that shares a Hedgehog/intein domain 
with the Hh morphogens from higher Eukaryotes, suggest that analogously to the tissues 
in these organisms, yeast ECM is mediating signalling events. 
The chromatographic and electrophoretic analysis of the sugar fraction revealed 
the clear presence of two distinct polysaccharides. Mass spectrometry identified 
glucose, mannose and galactose in their composition. Evidence was also obtained of the 
presence of uronic acids. Both polysaccharides showed chemical substitution, as 
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indicated by metachromasia, and the existence of sulphate groups was assessed through 
an anticoagulant activity test. From several ECM samples from different yeasts strains 
surveyed, the double mutant gup1Δgup2Δ displayed a relatively high anticoagulant 
activity, which was not observed in Wt, likely related to the presence of sulphate 
groups.  
The effects of the deletion of GUP1 gene in the composition of yeast ECM were 
also assessed, providing a more in-depth perspective of the ECM components and 
molecular mechanisms associated. Alterations in both protein and sugar fractions were 
observed. The deletion of GUP1 led to the absence of several ECM proteins, mainly 
associated with the carbon metabolism, cell rescue and defence, protein fate and cellular 
organization. Additionally, the disruption of this gene impacted in the composition of 
the ECM sugar fraction, through the disappearance of the higher molecular weight 
polysaccharide that had been detected in the Wt sample. The effects of GUP1 deletion 
on the ECM show that its structure is very dynamic, and that it is under the tight control 
of the cells composing the aggregate.  
S. cerevisiae Gup1 and Gup2 orthologues have suggested regulatory roles in the 
Hedgehog signalling pathway from higher Eukaryotes, in which organisms these 
proteins are known as Hhatl and Hhat, respectively. This led to the engineering the 
yeast mutants defective on either or both GUP1 and GUP2 by expressing these genes 
orthologues from fly, human and mouse, yielding a collection of transformants for 
future assessment. Similarly, the mammalian receptors of hyaluronic acid (HA), CD44 
and HMMR, were cloned into the yeast S. cerevisiae. The engineered strains were 
subjected to growth in the presence of different molecular sizes of HA, and were 
identically and differentially sensitive to, respectively, high and intermediate molecular 
weight HA. The strain expressing CD44 presented a high growth sensitivity to the 
presence of 50 kDa HA as in high Eukaryotes. The HA receptors are therefore 
functional in the yeast cell, and the cellular machinery to respond to HA stimuli appears 
to be fairly conserved.  
The present work is the first to present a comprehensive detailed study on the 
protein and polysaccharide fractions secreted during growth in S. cerevisiae 
multicellular aggregates. Overall, this work gives a first insight of the multicellular 
communities of S. cerevisiae proteomics and glycomics, ascertaining yeast ECM with 
putative roles derived from its components that resemble ECM from higher Eukaryotes. 
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“In life, love and business, we need to do three things: 
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Life in community 
Communication is probably one of the most fundamental processes of any living 
organism. From the complex behaviours of higher eukaryotes populations to the 
response of a single cell microorganism to an extracellular stimulus, almost everything 
is about understanding what is around and how to behave towards that. How this 
information exchange is performed and processed greatly influences the organism 
survival. 
Regarding the several factors influencing the signalling process, namely the signal 
nature and target, one of the most important factors is the medium through which the 
communication is performed, the environment surrounding the cell. However, almost 
every cell has its own particular environment, with wide variations in osmolarity, pH, 
oxygen as well as nutrients. Therefore, several strategies have been adopted by the cells 
to cope with these changes, from spore formation to increase the genetic pool of the 
population and survive extreme conditions in the yeast Saccharomyces cerevisiae [1] to 
social cooperation to form a multicellular structure in response to starvation in the 
amoeba Dictyostelium discoideum [2]. In multicellular organisms tissues [3], as well as 
in microbial biofilms [4], extracellular environment actually consists in an extracellular 
matrix (ECM) in which the cells are imbedded, that provides support and connects the 
cells. This scaffolding structure, besides storing water and offering physical protection, 
promotes cell communication, provides substrates to cell migration and can act as 
signals source, either by releasing stored molecules or by interacting with cells and 
generating new signals [5, 6]. Present across all levels of multicellular organization 
complexity, ECM has been receiving increasing attention.  
Mammalian ECM – The space-filler that stole the spotlight 
Mammals are amongst the most complex life-forms on Earth. Yet, their survival as 
organisms keeps closely linked to the needs of individual cells, regardless of their 
localization/specialization in tissues, organs and systems. In order to meet those needs, 
cells have to be fed nutrients and oxygen and get rid of wastes. This operates through a 
tight regulated process across the whole organism. The coordination of the resulting 
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homeostasis ultimately relies in the communication of stimuli between distant cells. A 
good example is the production of insulin in the pancreas, which stimulates the liver and 
muscle cells to take up the glucose in the blood, which otherwise becomes toxic [7]. 
Besides this long distance talk, the local communication between neighbouring cells is 
no less vital. In fact, the coordinated response to a remote stimulus is dependent of an 
efficient synchronization of the target cells, through signals exchanged between nearby 
cells. In this regard, the ECM is an especially important mediator, as it can block, delay 
or promote the signal [3]. 
Chemically, the ECM is mainly composed of water, proteins and polysaccharides, 
produced by the resident cells of a particular tissue and further modified by cells as 
needed to respond to particular stimuli. As such, its composition is actually very 
dynamic and tissue-specific [8], at the same time being modulated by and modulating 
almost all cell processes, through integration of mechanical stimulus and activation of 
specific receptors, as well as the regulation of growth factors storage and presentation 
[5, 6]. Thus, any major response or cell rearrangement depends on an efficient 
communication between these two partners, as the matrix can modulate the 
communication between cells and the cells can alter and reorganize the matrix. The 
ECM main players of this biochemical and biomechanical dialogue are always the 
same: the fibrous proteins, as collagens or fibronectin [5, 9], and the branched 
proteoglycans, as perlecan [10]. Interactions between the different ECM building blocks 
form a three-dimensional structure that provides support and shape to tissues and 
organs, and substrate to cell migration [11, 12]. Actually, there are two major types of 
structurally different mammalian ECM: the interstitial stroma, a fibrous and porous 
matrix supporting the cells through thread-like fibrils, and the basement membrane, a 
sheet-like structure supporting epithelia that divides tissue compartments. The 
misregulation of the cell-cell and cell-matrix interactions have a major impact in the 
organism survival, with a wide range of pathologies described [12-16]. 
The Collagen family 
Collagens are the main family of fibrous proteins in vertebrates, being the main 
components of constitutive tissue and amounting to 30% of whole-body protein [8]. The 
28 collagenous proteins described so far, numbered in Roman numerals (I-XXVIII) [17], 
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are trimeric molecules organized in a right-handed triple helix (Fig. 1) [18]. Such 
quaternary structure is formed by either identical (homotrimer) or two/three different 
monomers (heterotrimer) twisted around the same central axis (Table 1). Each collagen 
monomer, named α-chain, is composed of collagenous domains (Col domains) and 
flanking non collagenous regions (NC domains). Col domains consist of repeating 
tripeptide that naturally self-organizes in a left-handed helix due to the high content in 
glycine and proline [19, 20]. The most common motifs in Col domains are Glycine-
Proline-X and Glycine-X-Hydroxyproline, where X can be any amino acid except 
glycine, proline or hydroxyproline. The presence of glycine every three residues, with 
its small side chain –H, allows a tightly packed triple helix. The presence of proline 
stabilizes the collagen at higher temperatures, coupled with the hydrogen bridges 
between chains and strong electrostatic interactions [19]. The NC domains are capable of 
interfering with several cellular processes, as angiogenesis [21] and tumour growth [22], 
and interacting with other ECM molecules, such as fibronectin and a laminin 5/6 
complex [23]. 
The fibril forming collagens are the types I, II, III, V, XI, XXIV and XXVII, and 
usually present a helical domain with a perfect Gly-X-Y repetition over 1,000 amino 
acids long, the major helix. These collagens usually present one small triple helical 
domain in the amino end, the minor helix. These molecules undergo processing, once 
the major helix is formed, and associate and align in a quarter stagger alignment 
forming banded fibrils (Fig. 1). Such process is aided and regulated by other fibrillar 
collagens, type V and XI nucleate fibrils of Col I and II regulating fibril diameter [17, 18, 
20]. Collagens XXIV and XXVII are rather unique members of the fibrillar collagens 
sub-family, presenting interruptions in their major helix [17]. The exact number of 
interruptions is not unanimously accepted, with some controversy regarding the 
presence of a small helix [24-26]. These molecules have been discovery recently [25, 26], 
but present structural resemblances to invertebrates’ collagens, implying a probable 
ancient origin [24, 27]. However, not all collagen molecules form fibrils. Actually, most 
collagenous proteins feature several interruptions in the helical domain and are unable 
to form a fibril, being subdivided in several subgroups according to their nature and 
structural function [17, 18].  
The Fibril Associated Collagens with Interrupted Triple helices, FACITs, are the 
larger group of non-fibrillar collagens, particularly abundant in the basement membrane. 
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Comprising types IX, XII, XIV, XVI, XIX, XX, XXI and XXII, the FACITs are 
able to cross-link the surface of fibrillar collagens, producing distinct fibril surface 
properties and contributing to the biomechanical diversity of banded fibrils [29]. These 
collagens present several triple helical domains linked by short NC domains, as well as 
a large amino end domain featuring a thrombospondin sub domain [29, 30]. But their 
most distinctive features are the two G-X-Y imperfections in the Col2 domain and the 
two highly conserved cysteine residues separated by four amino acids in the NC1-Col1 
domain boundary. Some of these molecules are able to interact with other matrix 
components, e.g., ColXII can covalently bound glycosaminoglycans and form 
proteoglycans. 
 
 
Figure 1. Overview of the steps involved in the production of collagen fibrils. Procollagen α-chains are synthesized 
in the ER, where a large number of post-translational modifications occur (not depicted). These monomers fold to 
form a rod-like triple-helical domain through interactions between the C-propeptides, usually presenting major and 
minor helices. After the full formation of the major helix, the procollagen undergoes the removal of the N- and C-
propeptides, accomplished in the Golgi. The collagens are then able to interact and form ultrastructures, namely 
fibrils. Adapted from [28] 
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Non-fibrillar collagens are able to form several ultrastructures depending on the 
tissue properties, namely networks, beaded filaments and anchoring fibrils [31], the 
distinction between these structural groups is rather difficult as some collagens can 
assume more than one tri-dimensional ultrastructure, e.g., collagen VI [18].  
Network forming collagens, particularly type IV, are especially abundant in the 
basement membranes. This particular ECM type occurs in several body locations, with 
significant differences in the biomechanical properties of the tissues, contributing to the 
diversity of network-like structures. [31]. These collagens, IV, VIII and X, usually 
present an N-terminal 7S domain, responsible for inter-collagen interactions, a Col 
domain featuring around 20 interruptions and a C-terminal NC domain. These collagens 
network are formed by the combination of 4 molecules 7S domains into an antiparallel 
tetramer. The NC domains of each collagen molecule interact with the NC domain of 
other tetramer molecules to form a dimer [17, 31]. These inter-collagen interactions form 
a bi-dimensional grid-like structure. These collagen monomers can interact in different 
manners, yielding different supramolecular assemblies, namely hexagonal networks 
[31]. 
The single member of the anchoring fibril forming group, collagen VII, is 
responsible for connecting epidermis and dermis, tethering the basement membrane to 
the dermis [32]. This large collagen presents two NC domains flanking a large Col 
domain, at the N- and C-terminal ends, which assemble into anchoring fibrils. These 
fibrils, structurally different from the banded fibrils, are formed by antiparallel dimers 
connected by overlapping C- terminal ends. Several dimers assemble into a non-
staggered fibril through lateral association, after proteolytic processing of the NC2 
domain [17, 18]. These collagen ultrastructures are stabilized by transglutaminase cross-
links. Collagen VII usually forms homotrimers, and present a very low affinity for other 
molecular collagens; nonetheless, the anchoring role results from tight interactions with 
dermal fibrils, showing that some interactions are only possible in the supramolecular 
level [20, 31]. 
Types VI, XXVI and XXVIII homotrimers assemble into beaded filaments, a 
thread-like ultrastructure [20, 31]. These proteins present a relatively short triple helical 
domain, featuring two interruptions, flanked by two globular domains [33]. These 
globular domains are especially important in the lateral association that leads to 
tetramerization, which for collagen VI occurs still inside the cell [34]. Two monomers 
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dimerize through the central overlapping of the C- terminal globular with the helical 
domain. This staggered dimer is stabilized by the formation of a supercoil between the 
helical domains of the monomers, reinforced by disulphide bonds near the ends of the 
overlapped region [35]. The dimmers associate into tetramers through lateral association, 
which in turn can form end-to-end linear aggregates, beaded filaments, or networks, 
hexagonal lattices. Such collagens, especially type VI, interact with a wide range of 
ECM molecules, including other collagens, non-collagenous proteins and 
glycosaminoglycans [31], which greatly influence the formation of these supramolecular 
structures, e.g., the hexagonal lattice is favoured by the presence of byglycan. These 
interactions are particularly important for the formation of different architectures in 
adjacent regions or tissues [31], allowing a tight control on different mechanisms and 
functions occurring in such close locations. 
While most collagens are secreted, a particular group consists of membrane 
spanning proteins [17]. Collagens XIII, XVII, XXIII, and XXV all form homotrimers, 
with a single hydrophobic transmembrane domain and a cytoplasmic N- terminal end 
domain [17, 31]. The extracellular C- terminus domain contains several COL domains 
with NC interruptions, increasing flexibility. The extracellular helical domain assembly 
is performed from N- to C- terminus, unlike the fibrillar collagens [31]. This ectodomain 
is involved in the epithelial cells anchoring to the basement membrane, extending from 
the cell to bind laminin [17], complementing the anchor-forming type VII action, that 
also interacts with laminin to anchor the dermis. All these type II transmembrane 
proteins are subject of proteolytic shedding between the membrane and the first COL 
domain, originating soluble forms [36]. 
Table 1. The Collagen family. Genes, trimers composition and associated pathologies. 
Type of 
Collagen 
Genes Molecular Structure Diseases and Disorders 
I COL1A1, COL1A2 α1(I)2α2(I) 
α1(I)3 
Osteogenesis imperfecta; Ehlers – 
Danlos syndrome; Infantile cortical 
hyperostosis [37-40]. 
II COL2A1 a α1(II)3 Spondyloepiphyseal dysplasia; 
Spondyloepimetaphyseal dysplasia; 
Stickler syndrome [40-42]. 
III COL3A1 α1(III)3 Ehlers–Danlos syndrome; 
Dupuytren’s contracture [37, 38, 43]. 
IV COL4A1, COL4A2, 
COL4A3, COL4A4, 
COL4A5, COL4A6 
α1(IV)2α2(IV) 
α3(IV)α4(IV)α5(IV) 
α5(IV)2α6(IV) 
Alport syndrome; Goodpasture's 
syndrome [44, 45]. 
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V COL5A1, COL5A2, 
COL5A3 a 
α1(V)2α2(V) 
α1(V)3 
α1(V)α2(V)α3(V) 
Ehlers–Danlos syndrome (Classical) 
[46]. 
VI COL6A1, COL6A2, 
COL6A3, COL6A5 a*  
α1(VI)α2(VI)α3(VI) 
α1(VI)α2(VI)α4(VI) 
α1(VI)α2(VI)α5(VI) 
α1(VI)α2(VI)α6(VI) 
Ulrich myopathy; Bethlem myopathy; 
Atopic dermatitis [47, 48]. 
VII COL7A1 a α1(VII)3 Epidermolysis bullosa dystrophica [49, 50]. 
VIII COL8A1, COL8A2 α1(VIII)2 α2(VIII) 
α1(VIII)3 
α2(VIII)3 
Corneal endothelial dystrophies [51]. 
IX COL9A1, COL9A2, 
COL9A3 a 
α1(IX)α2(IX)α3(IX) Multiple epiphyseal dysplasia; 
Autosomal recessive Stickler 
syndrome [40, 52]. 
X COL10A1 α1(X)3 Schmid metaphyseal dysplasia [53, 54] 
XI COL11A1, COL11A2 a 
COL2A1 b 
α1(XI) α2(XI) α3(XI) Collagenopathy, types II and XI; 
Stickler syndrome [52, 55, 56]. 
XII COL12A1 a α1(XII)3  
XIII COL13A1 a α1(XIII)3  
XIV COL14A1 a α1(XIV)3  
XV COL15A1 α1(XV)3  
XVI COL16A1 α1(XVI)3  
XVII COL17A1 α1(XVII)3 Junctional epidermolysis bullosa [57]. 
XVIII COL18A1 a α1(XVIII)3 Knobloch syndrome [58, 59]. 
XIX COL19A1 α1(XIX)3  
XX COL20A1 α1(XX)3  
XXI COL21A1 α1(XXI)3  
XXII COL22A1 α1(XXII)3  
XXIII COL23A1 α1(XXIII)3  
XXIV COL24A1 α1(XXIV)3  
XXV COL25A1 a α1(XXV)3  
XXVI EMID2 α1(XXVI)3  
XXVII COL27A1 α1(XXVII)3  
XXVIII COL28A1 α1(XXVIII)3  
XXIX  COL29A1 (COL6A5)  *  
a. Several gene products by alternative splicing. 
b. COL2IA1 product is known as α3(XI) when assemble in a type XI collagen heterotrimer. 
 *       Collagen XXIX was described by [60] and later proved to be Collagen VI α-chain 5 by [61]. 
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Multiplexin collagens, including type XV and XVIII, are basement membrane 
molecules that undergo proteolytic cleavage to yield antiangiogenic endostatins. As full-
length molecules, these collagens present a central COL domain flanked by NC 
domains, at both N- and C- terminus [62]. These collagens present high homology 
between their COL and NC domains; however, present different tissues distribution, 
type XV is mainly expressed in the heart and skeletal muscle, whereas type XVIII is the 
main multiplexin in the smooth muscle [17]. The carboxyl terminal domain can be 
cleaved to generate endostatin and restin, which present distinct antiangiogenic 
properties [63]. Furthermore, both collagens XV and XVIII molecules are proteoglycan 
core proteins with an attached chondroitin sulphate and heparan sulphate 
glycosaminoglycan, respectively [64, 65]. The structural role of these multiplexins, as 
well as the diverse functions of the soluble shed forms help these collagenous proteins 
to regulate a wide range of cell-cell and cell-matrix processes [31]. 
In all, collagens play important roles in the ECM structural and signalling 
functions. Accordingly, a high number of syndromes result from mutations in these 
molecules (Table 1). 
Non-Collagenous proteins 
Much of the ECM regulatory functions are accomplished by non-collagenous 
glycoproteins [8]. Most of them present several functional domains, which allows a tight 
interaction with specific receptors and other ECM molecules, this way mediating 
important cell-cell and cell-matrix communication [66-68]. These domains are frequently 
coded by a single exonic unit, allowing a genomic shuffle throughout evolution [69]. 
Multidomain glycoproteins, like laminins, thrombospondins, fibronectin, tenascins, 
elastins or fibrilins (Fig. 2, Fig. 3 and Fig. 4), regulate cell adhesion, structural elements 
rearrangement. They also intervene in cell-matrix adhesion or cytoskeleton mechanical 
coupling [8, 9, 70]. These proteins are frequently subject of alternative splicing, which 
increases the number of forms [69], e.g., the fibronectin gene originates around 20 
different proteins through alternative splicing (Fig. 2) [71]. Such diversity allows the 
cells to exert complex fine-tuning of the ECM processes in a tissue specific manner.  
Fibronectins (FNs) are dimeric glycoproteins composed by highly similar 250 kDa 
monomers [72]. These monomers are composed of three repeating domains, functionally 
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and structurally different: type I (FN-I) is a 40 amino acids domain repeated 12 times; 
type II (FN-II) presents two repeats of 60 amino acids long chain; and type III (FN-III) 
are 90 amino acids long sequences that, due to alternative splicing, may be present 15-
17 times (Fig. 2 A). All domains present two antiparallel β-strands. However, types I 
and II are stabilized by intra-chain disulphide bonds, while FN-III forms a flexible 
seven stranded barrel that undergoes conformational changes [71]. A single gene, FN1, 
encodes for all the described FN proteins [73], these proteins result from the alternative 
splicing of the single pre-mRNA [71, 73]. In humans, 20 different FN forms arise from 
three major splicing sites in the FN transcript: two extra type III domains between FN-
III 7 and 8, domain EIII-B, and between FN-III 11 and 12, domain EIII-A; and a 
variable domain between FN-III 14 and 15, V domain (Fig. 2 A) [69, 74]. These extra 
type III domains, EIII-A and EIII-B, may be both included or just one in the FN 
sequence, as in cellular FNs, or both absent, as occurs in the plasma FN [72]. This 
happens because each extra domain is coded by a single exonic unit that may be 
included or skipped during alternative splicing. However, the V domain is coded by a 
large exon that undergoes subdivision, yielding several different size domains [9]. The 
 
Figure 2. Domain architecture for Fibronectin (A), and Laminin (B). These proteins present several domains, 
typically encoded by different exonic units that are subject to alternative splicing and generate different protein 
forms (as the EIII-A, EIII-B and V domains indicated for fibronectin). Extra-large linker indicated by arrow head. 
Adapted from [69]and [75]. 
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different FN monomers, resulting from the alternative splicing of these three regions, 
present differences regarding solubility and cell adhesive or ligand binding ability. 
Monomers assemble into antiparallel dimers through the interaction formation of 
disulphide bonds between two cysteine residues, present near the C- terminal end of 
each chain [74]. The disulphide isomerase activity described for the last FN-I modules 
mays facilitate this reaction [76]. The covalently linked FN dimer is secreted as a soluble 
and compact protein [72, 74]. Such compact configuration depends on intramolecular 
ionic interactions between FN-III domains 2-3 and FN-III 12-14 [77], and prevents FN 
fibril formation in solution [78]. The fibrillogenesis occurs after FN interaction with 
integrin cell surface receptors, αβ heterodimers with two transmembrane domains [79, 
80]. Several integrins interact with FN and aid the cell adhesion process, but only 
integrin α5β1 is able recruit and bind soluble FN [81]. The FN binding to α5β1 activates 
the receptor intracellular domain, which interacts with the actin cytoskeleton and 
promotes receptor clustering. The receptor-dimer clusters promote FN-FN interactions, 
and the initially compact dimers undergo a conformational extension [82]. The FN-I 1-5 
modules are especially important to inter-chain interactions [78]. After dimer extension, 
these five modules recognize and bind several regions within FN. Fibrillogenesis 
depends on the interaction between these amino end domain, FN-I 1-5, and the first two 
FN-III. These two FN-III modules are connected by an extra-large linker that allows 
conformational changes within the FN molecule and regulates FN interactions (Fig. 2 
A, arrow head) [72]. FN fibrils can further associate and form thicker bundles, 
stabilizing the ECM [9]. Besides FN-FN binding regions, FN presents motifs that 
interact with several other ECM molecules, namely heparin and fibrin [71]. FN different 
domains allow simultaneous binding to cell receptors and ECM constituents, integrating 
cell-matrix communication. The three dimensional organization of the multiple domains 
and their flanking residues contribute to regulate this information exchange [9]. 
Laminins are main constituents of the basal lamina, one of the stratified layers 
composing the basement membrane, promoting cell differentiation and regulating cell 
migration and adhesion [83]. These glycoproteins are composed of three structurally 
and functionally distinct polypeptide chains, referred as α-, β- and a γ-, which assemble 
into a parallel coiled-coil trimeric structure [75, 83, 84]. Similarly to most ECM proteins, 
laminin monomers are composed by tandem repeats of several functional domains (Fig. 
2 B) [84]. The interaction of the different variants of each subunit, five α-, three β- and 
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three γ-, produces the great biological diversity of laminins [85, 86]. The laminin family 
presents a characteristic domain architecture: a large amino end globular domain (L-N), 
several EGF-like domains interspersed by globular domains (L-IV), an α -helical coiled-
coil domain, the family defining domain, and a large carboxyl end globular L-G domain 
(Fig. 2 B) [75, 84]. Each monomer subtype presents small differences regarding this 
typical architecture: α- chains present 2 globular L-IV domains, some truncated forms 
lack L-IV domains, and exhibit five subdivisions of the L-G domain (Fig. 2 B); β-chains 
present small interruptions in the coiled-coil domain, termed β-knob, and lack L-G 
domain. Subunit β3 misses L-IV domain, while β1 and β2 present a different globular 
domain (L-F); and γ-chains present a singular L-IV domain and do not possess the 
carboxyl end L-G domains, while subunit γ2 also lacks N- terminus L-N globular 
domain [75, 87]. The C- terminus L-G domain, present in α-chains, is extremely 
important in interactions with cell receptors. It presents two functionally different 
subdivisions (L-G 1-3 and L-G 4-5) that can assume different configurations and 
interact with several ECM molecules. Intracellularly, the trimer assembly initiates with 
the β- and γ-chains coiled-coil domains interaction and dimerization. A particular γ-
chain C- terminus 10 amino acids motif is critical for this step. This dimer intermediate 
is retained in the cytoplasm until α-chain recruitment and binding, after which it 
undergoes secretion [75, 86]. Secreted laminins may go through modifications, namely 
proteolytic cleavage and glycosylation, which modulate signals and change interaction 
with cell receptors. The L-G 4-5 domain cleavage, by the action of proteases, can 
modulate the signal from promoting cell migration to supporting cell adhesion [88, 89]. 
The secreted and processed laminins can form different supramolecular structures, like 
fibrils and meshes. The kind of laminin structure depends on a biophysical and 
biochemical dialogue between cells and ECM. Non-migrating keratinocytes assemble 
rosette-like structures, while migrating keratinocytes form laminin trails that guide and 
promote cell movement [90]. In turn, fibrillar laminin integrates the cell cytoskeleton 
with the ECM structure and help transmit biomechanical signals that regulate tissue 
properties [91]. Laminin ultrastructure assembly occurs when its L-G domains interacts 
with cell receptors and receptor-like molecules, namely integrins and dystroglycan. The 
cell-bound heterotrimers start interacting with each other, through small arms L-N 
domains, and reorganize to form a three dimensional network [92], which promotes 
tissues structural coordination. Laminin supramolecular assemblies can present a single 
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laminin type, or several laminin family members. Temperature and Ca2+ greatly 
influence these assemblies by promoting conformational changes in the L-N domains 
[86], therefore, environmental changes cause cellular responses that implicate in the 
ECM structure and composition.  
Tenascins are a small family of ECM glycoproteins, comprising four members, 
which present adhesion-modulating properties [70, 93]. Tenascin shares some structural 
similarities with FN, i.e., several tandem repeats of FN-III modules (Fig. 3 A) that 
interact frequently. However, tenascin and FN present antagonizing functions, 
influencing each other actions [94]. These molecules mediate the cell-matrix interactions 
and promote cell motility, influencing cell proliferation and differentiation and some 
types of programmed cell death, namely anoikis [94], which is also a cell motility-
related process. Present mostly in the central nervous system, these proteins exhibit 
several functional domains organized in a conserved manner: three to four small amino 
end α-helical repeats (TA), extremely important to oligomerization, several EGF-like 
repeats followed by FN-III modules, and a carboxyl end fibrinogen-like globular 
domain (FBG) (Fig. 3 A). These monomeric chains can assemble into trimers, which 
can further associate into a hexabrachion ultrastructure, whereas some splice variants 
form dimers [70, 93]. The formation of this hexameric structure depends on two steps: 
firstly, three monomers associate through the TA helical repeats and form a short triple 
stranded coiled coil, the trimer is stabilized by intrachain disulphide bonds formed 
between cysteine residues; secondly, two different trimers TA domains interact and 
associate homophilically [70]. The resulting hexamer presents six arms with a terminal 
globular domain (FBG) originating from a central core; the proximal portions of the 
arms, composed EGF-like repeats, are thin and rigid, whereas the distal portions, 
composed of FN-III modules, are thick and flexible. These molecules, present 
exclusively in vertebrates, are able to interact with several cell surface proteins, 
integrins and cell adhesion molecules, as well as with ECM molecules, aggrecan, 
versican or neuron. Tenascins are also able to modulate the action of several serine 
proteases and matrix metalloproteinases, leading to ECM reorganization [70]. Such 
interactions occur mainly through FN-III and FBG domains; nevertheless, EGF-like 
domains were shown to act as low affinity ligands for EGF receptors [93]. As such, 
tenascins are capable of complex interactions with both the cells and other molecules, 
regulating focal adhesion kinase- and Rho-mediated signalling pathways [95], and 
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influencing morphogenetic pathways [96]. Given the broad field of action of these 
proteins, namely promoting cell migration, the deregulation of the associated 
metabolism and functions relates with several pathologies, namely cancer and Ehlers–
Danlos syndrome [97, 98]. 
Thrombospondin family comprises multidomain calcium-binding glycoproteins 
[99], interacting with a wide range of cell surface components, ECM molecules or 
growth factors, and modulating cell-cell and cell-matrix communications. These ECM 
proteins present several tissue specific functions, from wound healing and angiogenesis 
to inflammatory response [100]. Thrombospondin family members are divided in two 
subgroups, according to their domain architecture and oligomerization [101]. All 
thrombospondins present a highly conserved domain organization in the carboxyl 
portion of each polypeptide [100], comprising three EGF-like domains followed by 
several calcium binding thrombospondin type III domains (TSP-3), and a C- terminal 
end globular domain (TSP-C; Fig. 3 B). However, the N-terminal portion of these 
molecules presents several differences. The subgroup A members present an N-terminal 
globular domain (TSP-N), important for oligomerization, a von Willebrand factor 
module, also present in some collagens, and three thrombospondin type I repeats (TSP-
1). The subgroup B presents a distinct amino end domain and an extra EGF-like repeat, 
lacking both the von Willebrand and TSP-1 domains [102-105]. The differences in the 
amino end domains influence these molecules oligomerization. The subgroup A 
monomers TSP-N interact and assemble into a triple left handed coiled-coil, whereas 
subgroup B TSP-N domains form a pentamer [99, 101]. Both structures present high 
flexibility, which changes according to the amount of calcium ions bound to TSP-3. 
After assembly, these molecules undergo secretion and are either incorporated in the 
matrix or suffer proteolytic cleavage to yield anti-inflammatory and antiangiogenic 
fragments [106]. ECM-integrated thrombospondin may interact with integrins to 
modulate cell attachment and migration, or with some growth factors, TGF-β interacts 
specifically with subgroup A thrombospondin TSP-1 domains [107, 108]. The 
thrombospondin role in angiogenesis and cell migration is of special importance in 
pathological conditions as cancer or vascular diseases, reason why it has been 
considered as a potential therapeutic target [109]. 
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Fibrillin family comprises large and highly homologous secreted glycoproteins that 
are unusually rich in cysteine (12-13%) [110, 111]. These glycoproteins are secreted as a 
large 350 kDa proprotein. Convertases from the Furin family cleave the small N- 
terminal peptide (14-48 amino acids) and the larger C- terminal sequence (120-140 
amino acids). The small size of the amino end peptide hinders its study, and almost all 
information available on the profibrillin processing is about the carboxyl end domain 
excision [112, 113]. These domains present several conserved Cys residues that may help 
stabilize the profibrillin structure in the first stages after secretion [114]. Currently, there 
are three known fibrillin isoforms, fibrillin -1, -2 and -3 [115-117]. Similarly to other 
ECM proteins, these isoforms present several functional domains organized in a highly 
conserved fashion, ≈100% homology [110]. Fibrillins present a large number of EGF-
like functional domains (Fig. 4 A), most of which (42-43) contain specific amino acid 
residues that mediate calcium binding (cb-EGF) [118-120]. The amino acid motif 
responsible for calcium binding is conserved, but the affinity changes significantly 
between individual domains [121, 122]. Calcium plays a vital function in the structural 
stabilization of fibrillin [119, 123, 124], as well as in the protection of proteolytic 
degradation [125]; or the regulation of interactions with ligands [126-128]. The EGF-like 
 
 
Figure 3. Domain architecture for Tenascin (A), and Thrombospondin (B). These glycoproteins present tandem 
repeats of several functional domains that allow interactions with other ECM molecules, e.g., von Willebrand factor 
(vWF) interacts with several growth factors and influences cell response to several stimuli. Adapted from [69]. 
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domains present six conserved Cys residues that form intradomain disulphide bonds, 
stabilizing the structure. Such three-dimensional organization, helped by interdomain 
interactions and short linker sequences, leads to a rod-like structure formed by tandem 
repeats of calcium loaded EGF domains [110].  
The fibrillin protein presents other domains interspersing the EGF-like domain 
repetitions, namely the TGF-β-binding protein-like domains (TB) (Fig. 4 A), which 
interact with growth factors, mainly TGF-β and BMP [129]. The TB domains present 
four disulphide bonds between conserved Cys residues. Some EGF-like domains 
present some homology to TB domains, especially in the amino half of the protein, and 
are sometimes named hybrid domains [130, 131]. The hybrid domains are particularly 
important to the establishment of intermolecular connections. These domains present 
nine Cys residues, and the ninth residue is free and solvent accessible, enabling the 
formation of higher-order assemblies [132].  
The main distinguishing characteristic among the different isoforms is a domain 
which structure is unknown, the Proline Rich Region (PRR) (Fig. 4 A). These domains 
present low homology between the different isoforms; the fibrillin -1 isoform is 
especially enriched in Pro residues, whereas the fibrillin -2 protein present a Gly rich 
domain, and the fibrillin -3 PRR’s domain is enriched in both Pro and Gly residues 
[110]. Other structural differences include the number and position of the integrin 
binding site motif Arg-Gly-Asp, the predicted tyrosine sulphation sites and the 
predicted N- and O-glycosylation sites. Early metabolic labelling experiments dismissed 
the presence of sulphation [133], whereas the role of glycosylation remains unknown. 
The interaction of fibrillin with several integrins, namely αvβ3, α5β1 and αvβ6, through 
the Arg-Gly-Asp was reported [134-137].  
Despite many efforts and a wide range of techniques used, the molecular 
organization of individual fibrillin monomers in microfibrils is not completely resolved. 
Hence, most of the information available is focused in the multicomponent microfibrils, 
whose main constituent is fibrillin. The assembly of fibrillin in such structures may 
depend on self-interactions. Fibrillin self assembles into multimers in solution, forming 
heterodimers between fibrillin -1 and -2 [138], and truncated forms lacking either the N- 
or C- terminal halves show high affinity for each other [139]. Interactions of fibrillin 
with other ECM components, namely fibronectin and heparan sulphate proteoglycans 
(HSPG), also influences the assembly of microfibrils. Perlecan, an HSPG, interacts with 
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fibrillin through several identified heparan sulphate binding sites and promotes 
microfibril formation [142], whereas free heparan sulphate or heparin compete for the 
binding sites and strongly inhibits the microfibril formation [127, 143, 144]. The assembly 
of a fibronectin network is crucial for the deposition of microfibrils.  
Interactions between fibronectin, integrins and fibrillin regulate the microfibril 
assembly into bundles [145, 146]. The three-dimensional structure of mature microfibrils 
is maintained by a high degree of cross-linking. Disulphide bonds between Cys resides, 
and ε (γ-glutamyl)-lysine cross-links catalysed by transglutaminases, are the main 
intermolecular cross-links [147, 148]. Fibrillins present 361 different Cys residues, and 
the ones responsible for the intermolecular disulphide bonds are still unknown, although 
the ninth residue from the hybrid domains is a likely candidate. The disulphide bonds 
are formed after a few hours of secretion and help the stabilization of the molecule in 
the early phases [110]. The ε (γ-glutamyl)-lysine cross-links are formed in later stages of 
the maturation process in an irreversible way [148, 149], and as much as 15% of all lysine 
residues may be cross-linked [148].  
Fibrillin interacts directly with the ECM proteoglycan perlecan, allowing the 
tethering of microfibrils to the basement membrane components, and acting as stress-
bearing entities to ensure tissue integrity [142]. Some evidence shows that the basement 
membrane may provide nucleation sites for microfibrils formation [150]. In tissues, 
microfibrils present a uniform appearance, forming thread-like structures of 10-12 nm 
 
Figure 4. Domain architecture for fibrillin (A) and elastin (B). These proteins present several domains, which allow 
the interaction between microfibrils and elastin monomers to form elastic fibres. Adapted from [140] and [141]. 
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of diameter organized in bundles. However, the microfibrils extracted from tissues 
present a different structural organization, displaying a beads-on-a-string ultrastructure 
on rotary shadowing electron microscopy [151-153]. The experimental procedures may 
remove or lead to the partial loss of protein components of the microfibrils from the 
interbead regions [154]. Nevertheless, this beads-on-a-string structure displays 
remarkable elastic properties; it can be stretched up to 100 nm in a reversible manner, 
and only higher periodicities lead to permanent deformation [155-157]. 
Microfibrils are ubiquitously distributed in the ECM of most tissues and contribute 
to their physical properties. Microfibrils are particularly important in the connective 
tissue present in several types of fibrous tissue, underlying differences regarding density 
and cellularity. It can also be found in more specialized and recognizable variants of 
connective tissue, like bone, tendons, cartilage and adipose tissue [158]. In blood vessels, 
lungs and skin, microfibrils act as scaffolds for the deposition of elastin in early stages 
of elastic fibres formation, and decorating the surface of mature fibres [159]. As 
mentioned above, microfibrils are able to interact with several ECM proteins, regulating 
elastic fibre synthesis and cross-linking formation [160, 161]. These supramolecular 
aggregates are also present in tissues lacking elastin [162]. In kidneys or the ciliary 
zonules of eyes, microfibrils assemble into bundles and provide tensile strength and 
shear stress resistance to tissues [111]. The vital role of fibrillin in the cardiovascular, 
skeletal and ocular systems is intimately connected with the severity of the syndromes 
arising from mutations on this ECM protein. The most common fibrillin-associated 
pathology is the connective tissue disorder known as the Marfan syndrome. It 
corresponds to several symptoms, including mitral valve disease, progressive dilatation 
of the aortic root, dolichostenomelia, arachnodactyly, scoliosis and ectopia lentis. More 
than 1.000 distinct mutations were identified in the FBN1 gene, coding for fibrillin-1 
[163]. The Marfan syndrome may derive from insufficient expression of the protein or its 
exaggerated degradation, or from the incorporation of mutated or truncated forms of the 
protein in the microfibrils compromising its function [110].  
Elastin is synthesized almost exclusively during specific developmental stages – 
from mid-gestation to postnatal [164-166]. In aorta, elastin expression decreases when 
blood pressure stabilizes after birth, and almost no synthesis of elastin is found in adult 
tissue [167-169].  
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The hydrophobicity and insolubility of elastin is a major obstacle to its structural 
characterization. Most of the available information derives from the soluble tropoelastin 
monomers, elastin proteins before the extensive cross-linking. Tropoelastin is trypsin-
sensitive, allowing the study of the structural organization of the molecules. The tryptic 
digestion of this monomer revealed the presence of two main classes of peptides 
composing the protein: (1) small peptides rich in alanine, deriving from the regions 
protected by cross-links in elastin; and (2) large peptides rich in hydrophobic amino 
acids, responsible from the biologically relevant elastic properties [170-173]. 
Accordingly, the later analysis of the tropoelastin cDNA showed that this protein 
presents alternating hydrophobic and lysine-rich domains [174-176]. The lysine rich 
domains are important for the cross-linking of tropoelastin, and proper functioning of 
the elastic fibres. The secretion and deposition of elastin in the ECM and formation of 
highly cross-linked multimeric proteins is not fully understood. The synthesis of 
tropoelastin happens in membrane-bound polysomes, and the protein is transported 
along the Golgi apparatus to the secretory vesicles [177, 178]. The tropoelastin secretion 
occurs through a distinct mechanism from other ECM proteins. The protein reaches the 
extracellular space through an acidic endosomes in the presence of a 67 kDa chaperone 
[179-181]. Once in the extracellular space, tropoelastin forms small aggregates on the cell 
surface, initiating cross-linking [182-184]. This reaction is mediated by the enzyme 
protein lysine-6-oxidase, which oxidizes selective lysine residues in peptide linkage to 
α-aminoadipic δ-semialdehyde, also known as allysine [185].  
Two main cross-links can be found in elastin: (1) the condensation of an allysine 
residue with and lysine residue, dehydrolysinonorleucine, or (2) the condensation of two 
allysine residues, allysine aldol [186-188]. These two cross-links can further condense 
with each other to form more complex cross-links, desmosine or isodesmosine [189]. 
There is also evidence that desmosine/isodesmosine cross-links can be oxidized by 
reactive oxygen species resulting in dihydrooxopyridine forms [190]. The interaction 
with other ECM molecules, namely proteoglycans, facilitates the self-association of 
tropoelastin monomers [191]. Interactions with proteoglycans mediate the releasing of 
the chaperone protein and initiation of cross-linking [181, 192].  
Elastin is a protein with high longevity, and resistant to several proteases, but not to 
elastases. These proteases are responsible for the turnover of elastin, targeting amino 
acids with small hydrophobic chains [193]. Elastases are produced by pro-inflammatory 
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cells, but some bacteria can produce some potent elastases that mediate the infectious 
process [194, 195]. The degradation of elastin releases peptides capable of signalling to 
several cell types [196-199]. From these peptides, the most active biologically, Val-Gly-
Val-Ala-Pro-Gly, regulates several pathways and processes, namely protein kinase C 
[200] and Ras-independent ERK1/2 pathways [201], as well as the G-protein associated 
opening of l-type calcium channels [202]. Abnormal elastin degradation can trigger 
responses and lead to pathologies. However, the major pathologies are related to elastin 
loss-of-function mutations, either leading to proteins that lack the capacity to assemble 
into fibres [203-205], or severely mutated proteins that are marked for degradation by 
regulatory mechanisms of the cells [206]. The Supravalvular Aortic Stenosis, the major 
elastin-related pathology, is autosomal dominant disease, and mutations leading to this 
condition include small deletions, removing multiple exons from the elastin gene, and 
nonsense or frameshift mutations [185]. 
Matrix Metalloproteinases (MMPs) 
ECM dynamic environment results from the constant remodelling of its 
components, with a tightly regulated synthesis and degradation. While synthesis is 
under the responsibility of cells, like fibroblast, the degradation is performed by matrix 
metalloproteinases (MMPs) [207]. These tissue specific metallopeptidases, also known 
as matrixins, are capable of degrading virtually all ECM components, influencing tissue 
structure, growth factor release and cell migration [208]. Under normal conditions, 
MMPs present very low activity, being activated by the presence of cytokines, growth 
factors or hormones. MMPs untimely activation is associated with several pathological 
conditions [209], which is in accordance with these extracellular multidomain enzymes 
being primarily translated into inactive pre-proenzymes (Fig. 5).  
These proteins typically present a signal peptide directing towards secretion, a 80 
amino acids long propeptide, followed by a catalytic domain with Zn2+ affinity 
connected to a hemopexin-like domain through a linker, or hinge domain (Fig. 5 A). 
These proteins undergo ER-Golgi secretion, during which the signal peptide is excised, 
and are released in an inactive proenzyme state, proMMP. The propeptide presents a 
“cysteine switch” motif that binds to the Zn-binding domain and keeps the MMP 
inactive [208, 210]. The proMMPs activation is a tightly regulated step-wise process. The 
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propeptide presents a proteinase susceptible “bait sequence” that can be excised by 
several proteinases, both endogenous and exogenous. The initial propeptide degradation 
allows its complete removal by self-catalysis or by the action of other active MMP, and 
inherent enzyme activation, [210]. 
 
 
 
 
MMPs present structural diversity depending on their substrate. MMP-7 and -26, 
also known as matrilysins, do not present the linker and the hemopexin-like domain and 
are unable to degrade interstitial collagen (Fig. 5 B) [212]. Gelatinases, MMP-2 and -9, 
present three fibronectin type II domains within the catalytic domain (Fig. 5 C). These 
domains allow the cleavage of type IV collagen, elastin, and gelatins [210]. The 
Figure 5. Matrix metalloproteinases (MMPs) structural organization. MMPs are present in the ECM either as 
secreted forms (A-D) or membrane tethered forms (E-F). Adapted from [211]. 
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hemopexin-like domain is vital for the triple helical collagen unfolding. Collagenases 
mutated in this domain are able to degrade non-collagenous proteins but are unable to 
unfold and degrade collagen [213]. Some matrixins present a furin-recognition domain 
within the propeptide (Fig. 5 D), which allows the intracellular activation of the MMP 
by furin proconvertase, and subsequent secretion in an active form [118]. Some 
stromelysins, namely MMP-11, present the furin recognition site, are active both 
intracellularly and extracellularly. Membrane-tethered MMPs, both membrane spanning 
proteins (Fig. 5 E) and GPI anchored (Fig. 5 F), also present furin recognition site and 
are inserted in the cell surface in an active form. They present collagenolytic activity 
and are responsible for the processing of several proMMPs [210]. Given the MMPs 
profound impact in tissue organization, cell motility and overall ECM metabolism, cells 
present several mechanisms to regulate these proteinases activity, from timely 
regulation of cellular location to endogenous inhibitors, and ultimately proteolysis [210]. 
Endogenous inhibitors, like α-macroglobulin and tissue inhibitors of MMPs 
(TIMPs), allow a higher control and are the main regulatory system of MMP activity. α-
macroglobulin is a high molecular weight tetramer. It inhibits most proteinases by 
entrapping the enzyme inside its four subunits and directing the complex for receptor-
mediated endocytosis [210]. TIMPs are small proteins, 180-190 amino acids long, 
presenting a wedge-like structure divided in two subdomains, an amino- end domain 
and a carboxyl end domain. The N- terminal end domain slots into the MMPs active site 
and chelate the ionic zinc. TIMPs are able to inhibit MMPs to different extents. For 
example, TIMP-1 is a poor inhibitor of membrane tethered MMPs [207, 210]. As for 
other ECM proteins, engineered forms of MMPs inhibitors were generated to serve as 
pharmacological treatments for numerous diseases [209, 214]. Ultimately tissues 
homeostasis depends on MMPs and MMPs inhibitors constant interplay.  
Proteoglycans and Glycosaminoglycans  
Proteoglycans (PGs) and glycosaminoglycans (GAGs) are another important group 
of functional molecules of the mammalian ECM vital for structural and signalling 
purposes. PGs are composed of a core protein, substituted with one or more covalently 
attached GAGs. GAGs/mucopolysaccharides are long linear heteropolysaccharides 
composed of a hexosamine (glucosamine or galactosamine, frequently N-substituted) 
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and a hexuronic acid (glucuronic acid or iduronic acid), attached to the protein core 
through a conserved oligosaccharide [215]. The newly synthesized GAG chains may 
undergo several modifications: O-sulphation of hydroxyl groups, deacetylation and 
subsequent N- sulphation, and epimerization of glucuronic acid to iduronic acid. These 
linear mucopolysaccharides contribute the most for the PGs high size and weight, and 
as such its properties tend to dominate the chemical properties of the PGs [10]. 
Hyaluronan 
Hyaluronan is in several ways exceptional in regard to the other GAGs. It is the 
only non-sulphated GAG, composed by a repetition of a dimer of glucuronic acid 
(GlcA) and N-acetyl-glucosamine (GlcNAc) (Table 2). HA is not attached to a peptide, 
although it interacts with several proteins presenting HA binding motifs, namely the PG 
hyalectans (Fig. 6) and the membrane receptors hyaladherins.  
HA is synthesized in the plasma membrane, by opposition to the Golgi apparatus as 
happens with the remaining glycosaminoglycans [216]. The enzymes responsible for its 
synthesis, Hyaluronan synthases (HAS), are capable of establish both β-1,3 and β-1,4 
linkages, and simultaneously export the newly synthesized HA chain to the extracellular 
space, through a pore constituted by the enzyme itself. Again in opposition to the other 
GAGs, the increase in size of the HA chain is obtained by addition of new residues to 
the reducing end of the chain [217]. There are several HAS with different properties and 
expression patterns, in particular their specificity as to the different size of the 
synthesized products [216, 218-220]. The HA turnover and production of HA fragments 
biologically relevant is the role of a different set of enzymes, the hyaluronidase (HYAL) 
family [219]. It is the concerted action of these different HAS and HYAL enzymes that 
maintain the amount and size of HA within physiological boundaries for ECM 
structural and functional homeostasis, i.e., in the correct size to fulfil scaffolding or 
signalling tasks. The maintenance of HA homeostasis can occur through three different 
pathways: 
(1) local cellular turnover - the specific HA membrane receptors being the main 
responsible molecules for the binding of HA that precedes internalization and 
degradation; 
(2) tissue level turnover - where HA is drained into the vascular and lymphatic 
systems and guided to liver and kidneys for degradation; 
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(3) free radicals-dependent turnover - under oxidative conditions the scission of HA 
can be promoted by divalent cations [219, 221].  
Alterations in this tightly regulated equilibrium between synthesis and degradation 
can lead to developmental defects or tumourigenesis [221-223]. HA is required for proper 
craniofacial development, as deregulation of its biosynthetic process leads to severe 
defects during Xenopus laevis embryogenesis [224]. On the other hand, increased HA 
overproduction promotes cell invasion and metastasis formation [225]. Besides its role in 
the disease progression, HA also presents several biomedical applications given its 
biophysical and biochemical properties, particularly in joint injury recovery [226], tissue 
engineering [223] or cartilage regeneration [227]. Additionally, it has been recognizably 
important in skin regeneration after burning or other serious injuries, as well as anti-
ageing treatment, facial aesthetics, and other cosmetic applications. This non sulphated 
GAG is a vital ECM molecule, interacting with several cell surface receptors as well as 
other ECM molecules and regulating several cellular processes [219].  
Sulphated Glycosaminoglycans  
Chondroitin Sulphate (CS) is a sulphated GAG composed of GlcA and N- Acetyl-
Galactosamine (GalNAc; Table 2). This GAG is found connected to a protein core 
through a conserved oligosaccharide linker – Xyl-Gal-Gal-GlcA [228] forming a CS-PG. 
Firstly, a xylopyranoside is added to a serine residue in the core protein, through the 
action of a xylosyl transferase in the Endoplasmic Reticulum (ER) [229]. Secondly, two 
galactose residues are sequentially added to the nascent chain [228]. Such process occurs 
in the early Golgi, and it is the result of the action of two different galactosyl 
transferases, Gal I and Gal II transferases [230]. Finally, the addition of GlcA occurs in 
the late Golgi by the action of GlcA I transferase [231]. When this process is completed, 
the CS chain grows by the alternate addition of GalNAc and GlcA. However, in 
opposition to HA synthesis, where a single enzyme performs all steps, the CS chain 
elongation requires the coordination of several enzymes that cooperate to catalyse each 
step [228, 232]. These newly formed chains can present several modifications; 
phosphorylation of the xylose residue in the linker oligosaccharide and sulphation of the 
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GalNAc and GlcA residues are the most commons [232]. CS frequently presents 4- and 
/or 6-O-sulphation of the GalNAc, and 2- or more rarely 3-O-sulphation of the GlcA 
[228]. Sulphation introduces another level of complexity to the CS-PGs molecules. 
Fibroblast growth factors bind to highly sulphated CS, while proteins like netrin and 
semaphorins interact with CS in a sulphation pattern dependent manner [234]. Such 
selective binding process allows the control of several molecules availability, regulating 
several cellular processes. CS-PGs regulate processes so diverse as skeletal 
morphogenesis and cartilage organization or cell differentiation and motility [235].  
The most common CS-PGs are members of the hyalectan subfamily, comprising 
aggrecan, neurocan, brevican and versican. These CS-PGs present HA binding motifs 
 
Table 2.  Chemical composition of the glycosaminoglycans. Adapted from [233]. 
  
Hyaluronan Chondroitin Sulphate 
  
  
  
Heparan Sulphate Dermatan Sulphate 
  
  
 
Keratan Sulphate  
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and are involved in brain development and regulate tissue growth and plasticity [236, 
237]. Brevican is associated with the myelination process [238], and it regulates the nodal 
matrix assembly [239]. Alteration of CS-PGs synthesis/degradation is associated with 
the disease process in cancer, with increased cell motility, angiogenesis and metastasis, 
and atherosclerosis, favouring lipoprotein oxidation and accumulation [240].  
Dermatan sulphate (DS) is the main GAG in the skin and results from the 
epimerization of some GlcA residues in CS to Iduronic acid (IdoA; Table 2). Similarly 
to CS, DS is found connected to a protein core through a conserved oligosaccharide 
linker – Xyl-Gal-Gal-GlcA [228], forming DS-PG. Besides the IdoA epimerization, DS 
is also modified by 4- and/or 6-O-sulphation of the GalNAc, and 2-O-sulphation of 
IdoA [241]. These alterations, through a complex enzymatic system, result in three 
distinct hexuronic forms, and four possible hexosamine residues present in the chain, 
increasing the amount of information present within the sugar moiety. Such complexity 
is associated with the role of DS in the anti-coagulation process, as well as cell 
proliferation and migration, infection and wound repair [242]. DS is capable of forming 
a stable complex between serine protease inhibitor Heparin Cofactor II (HCII) and 
thrombin. Thrombin is a procoagulant protease that starts the blood-clotting cascade. 
The DS-mediated interaction of this protease with HCII inhibits this process [243]. DS 
also inhibits the clotting process by enhancing the activity of an endogenous inhibitor, 
the Activated Protein C (APC). APC interacts with different GAGs, but DS has the 
most potent effect on its activity [241]. Some studies describe a potent antithrombotic 
effect of DS [244-246], significantly higher than heparin. The correspondent exact 
mechanism still remains unknown [242].  
DS-PGs are particularly expressed in skin, cardiovascular system and central 
nervous system [241, 242]. In skin, the normal tensile strength is regulated by the 
interaction between collagen fibrils and tenascin-X. This interaction is mediated by the 
DS-PG decorin. Decorin core protein binds to fibrillar collagen and tenascin-X binds to 
the sugar moiety. The disruption of this interaction results in increased skin fragility 
[247, 248]. Decorin role in atherosclerosis plaque formation was also described [249]. This 
proteoglycan interacts with low-density lipoproteins and helps its docking process to 
collagen. DS-PGs are also involved in arterial mechanical strain and inflammation-
mediated angiogenesis [241]. In the central nervous system of patients with several 
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diseases, the levels of CS/DS-PGs are elevated, e.g., in Alzheimer these PGs localize to 
the lesions [250, 251], being powerful enhancers of amyloid fibrillogenesis [252]. 
Heparan sulphate (HS) is the main GAG of the cellular surface, substituted in 
transmembrane and GPI anchored PGs, and heparin (highly sulphated HS) is the main 
GAG present in intracellular storage granules [253]. This sulphated GAG is constituted 
by a repeating disaccharide subunit comprising a Glucosamine residue and a GlcA/ 
IdoA residue, where some GlcA residues are epimerized during chain elongation to 
IdoA (Table 2). However, the glucosamine residue presents more possible chemical 
substitutions than other GAGs groups. It can be N- acetylated, N- sulphated or 
unmodified. These disaccharide units present variable O- sulphation. The glucosamine 
presents 3- and/or 6-O sulphation, whereas the IdoA residues may present 2-O-
sulphation [254]. Similarly to CS and DS, the HS chain elongation occurs after the 
assembly of a Xyl-Gal-Gal-GlcA oligosaccharide linker. Firstly, a GlcNAc is 
transferred by the action of the EXTL glycosyl transferase family [255]. The three 
known isoforms are able to attach the first residue to the non-reducing end of the chain, 
but EXTL3 is the main isoform in vivo [256]. The chain elongation happens by the 
alternate addition of GlcA and GlcNAc residues, by the action of the HS polymerases 
Ext1 and Ext2 [254]. During chain polymerization several alterations occur. The N- 
deacetylation/ N-sulphation reaction appears to be the first, generating several N- 
Acetylated portions and N- Sulphated portions [257]. The epimerization of the C5 
hydroxyl group of some GlcA residues, and 2-O sulphation of most of the resulting 
IdoA residues also appear to occur in an early step of the chain elongation, through a 
coordinated interaction of the responsible enzymes [258]. The 3- and 6-O sulphation of 
the glucosamine occurs after these initial steps. However, evidence suggest that 
sulphation of the growing HS chain stimulates the elongation process and results in 
increased chain length [259].  
HS is present in the surface of every mammalian cell. It forms a polysaccharide 
coating that mediates many of the cell interactions with other cells, as well as with 
growth factors, chemokines, morphogens and enzymes. The dynamic modification of 
this envelope allows the cell to change its sensibility to some signals and modulate its 
responses. HS and heparin regulatory role is especially important in cellular processes, 
like membrane trafficking and signalling, or whole-organism processes, like 
embryogenesis, as well as in pathophysiological conditions, metastasis and angiogenesis 
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[253]. In fact, evidence shows that HS can behave as pro or anti-tumorigenic based 
solely in its presence as a membrane tethered PG or a free soluble GAG chain in the 
ECM [260]. Heparin presents high anti-inflammatory and antimetastatic activities [246, 
261]. However, the main utilization of this GAG is as anticoagulant and antithrombotic, 
being commonly used to treat thromboembolic disorders [253]. This highly sulphated 
GAG interacts and mediates the inhibition of thrombin by the HCII [241] and the cell 
surface P-selectin recognition by platelets during metastasis formation [262]. Besides, 
HS also interacts with several ECM proteins through conserved sugar motifs, namely 
TGF-β or FGF family [263-265], promoting and mediating several protein-protein 
interactions, e.g. between the FGF 2 and its receptor [266]. HS-PGs also influence the 
Wnt morphogenic pathway and have a role in the embryo patterning [267], since 
deregulations of these PGs sulphation patterns are associated with developmental 
defects [268] and tumourigenesis [269]. 
Finally, keratan sulphate (KS) is a very unusual GAG since it does not present the 
uronic acid subunit, therefore consisting of a poly-N-acetyllactosamine, a linear chain of 
GlcNAc repetitions (Table 2). It is synthesized by the alternate and sequential steps of 
galactosylation and N-acetyl–glucosamylation, and followed by an extensive sulphation 
[270]. KS presents a wide array of chain sizes and sulphation pattern, leading to a great 
variability of the global charges of KS substituted molecules. It is attached to the core 
protein through several oligosaccharides, distinct from CS, DS and HS linker [271, 272]. 
KS is the main GAG in the cornea, where it regulates the collagen matrix assembly 
and the cornea water content, but it is also present in the brain and cartilage. The KS 
location is closely related with its organization, especially with its oligosaccharide 
linker structure [273]. KSI, the main glycoform in the cornea, is N- attached to an Asn 
residue in the core protein through a complex branched linker; the KSI chain elongates 
from the C6 branch of a mannose residue, whereas the C3 branch is capped with a 
lactosamine disaccharide and a syalic acid. This GAG presents two non-sulphated 
disaccharides in the reducing end, followed by 10-12 disaccharide units sulphated in the 
GlcNAc residue. Its non-reducing end consists of a domain of variable length (8-34 
residues) composed of disulphated disaccharides. Nonetheless, the structure of this KS 
subtype and its modifications may be more tissue dependent than type specific. KSI 
from different origins, namely cartilage, can present elongation of the mannose C3 
chain, fucosylation of some residues, as well as different sulphation pattern [274]. 
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Another KS subtype, KSII, is attached to the core protein through a linker very similar 
to the mucin core-2, a GalNAc residue O-kinked to a Ser/Thr residue [275]. This KS 
subtype also presents a branched structure; the C3 of the GlcNAc is attached to a Gal 
residue and capped with a syalic acid, while the C6 elongates with sulphated 
lactosamine units. Typically, KSII is composed by 5-11 highly sulphated disaccharides; 
it consists almost entirely of disulphated subunits and some interspersed monosulphated 
disaccharides [276]. The KSII chain is terminated by a neuraminic acid residue, after a 
terminal GlcNAc; several of GlcNAc residues are fucosylated. KSII is found substituted 
only in aggrecan core proteins; this core protein present amino acid motifs in its 
sequence that correlates with KS substitution [277].  KS subtype III, KSIII, is present 
mostly in the brain, where proteins are frequently substituted with O- linked short 
lactosamines; KSII chain are attached to Ser residues through a O- linked mannose 
linker, and are considered an extended and sulphated versions of such glycoforms. 
Some points of evidence show a possible role of KS-PGs in Alzheimer’s disease [278, 
279], arthritis [280] and ocular defects [281]. 
Proteoglycans  
GAGs are highly functional molecules, and tend to dominate the biochemical 
properties of glycoconjugates. Nevertheless, the protein core of each GAG will 
determine its distribution, function and molecular interactions, as well as performing 
regulatory functions PGs can be substituted by a single GAG, as decorin [282], or by 
several units of different GAGs , as versican and aggrecan [283, 284]. A few of these 
GAGs are excreted to the extracellular space, as the small leucine-rich PGs (SLRPs) or 
the large molecular weight aggrecan (Fig. 6). Some are membrane tethered, through a 
GPI anchor, like the heparan sulphate PG glypican, or by a membrane spanning protein 
core, as syndecan [10, 285]. The molecular diversity arising from the different 
combinations of PGs protein cores with one or more types of GAGs leads to a wide 
variety of biological roles. 
a) Intracellular PGs 
Serglycin, named after the serine-glycine rich motif along its sequence, is an 
intracellular PG stored in secretory granules, stored in secretory granules (Fig. 6) [286, 
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287]. This intracellular PG is mostly frequent in hematopoietic cells, mast cells and T 
lymphocytes [288], but can also be found in endothelial or smooth muscle cells. 
 
 
 
Figure 6. Proteoglycans families and their associated locations. All mammalian cells produce proteoglycans, 
which are then secreted, inserted into the membrane or stored in secretory granules. The two major families of the 
surface-associated proteoglycans are syndecans, transmembrane heparan sulphate PGs, and glypicans, GPI-
anchored PGs. Serglycin is an intracellular PG, substituted with heparin chains, found in secretory granules of 
mast and endothelial cells. The secreted extracellular PGs include the hyalectans – aggrecan, versican, neurocan 
and brevican – which present hyaluronan binding domains, the SLRPs – decorin, biglycan and lumican – which 
interact with several ECM proteins, namely collagen, and basement membrane PGs, agrin and collagen XVIII and 
perlecan. Adapted from [289]. 
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Serglycin was initially labelled as a macromolecular form of heparin [290], and later 
described as a protease resistant core protein for CS and heparin substituted intracellular 
PGs [291]. All serglycin family members present a highly conserved amino end 
sequence and a characteristic long extension of Ser-Gly repeats [286]. These Ser residues 
act as GAGs substitution sites and their close location originates a densely substituted 
PG, the presence of a tightly packed sugar coat is involved in the protease resistance 
[291].  
Serglycin PGs present a wide variety of GAGs substitution and sulphation degree; 
mast cells present serglycin substituted with highly sulphated heparin, whereas 
circulating cells, like T lymphocytes, present less sulphated GAGs [287]. This 
intracellular PG is very important for granulopoiesis, the formation of intracellular 
secretory granules [286]. These granules are important for the storage of preformed 
molecules, such as histamine, serotonin and several proteases, enabling the quick 
release of immune active molecules in response to certain stimuli, namely 
inflammation. The high anionic charge of this heparin substituted PG seems vital for the 
formation and organization of these granules; the storage of several molecules is 
dependent of interactions with the GAG chains [287]. The activation of serglycin storing 
cells, namely mast cells, leads to the secretion of this PG and its associated molecules. 
Several molecules remain associated with serglycin GAG chains after secretion; this 
provides protection from proteolytic cleavage or enables selective substrate 
presentation. Alterations on serglycin synthesis or sulphation result in alterations of 
secretory granules morphology, changes in the typical electron dense regions and 
metachromatic properties [288, 292], affecting the storage of several molecules [293]. 
Accordingly, the lack of N-deacetylase/ N-sulphotransferase, the enzyme 
responsible for IdoA 2-N-sulphation, leads a phenotype similar to serglycin deficiency 
[294]. Animals lacking serglycin synthesis present several immune defects, whereas 
several myeloma cell lines present increased serglycin expression. Myeloma derived 
serglycin seems to interfere in bone mineralization, with frequent reports of myeloma 
associated osteoporosis. Altered expression of this PG is also associated with 
nasopharyngeal carcinoma, associated with poor prognosis, or acute myeloid leukaemia. 
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b) Membrane tethered PGs 
Membrane tethered PGs comprise single spanning transmembrane syndecans and 
GPI-anchored glypicans (Fig. 6). These PGs interact with several cytokines, 
chemokines, growth factors and morphogens, through HS and CS chains, and act as 
reservoirs of such molecules [295]. The selective degradation of these chains allows the 
formation of morphogens functional gradients, with a significant role in embryogenesis 
and morphogenesis [296, 297]. Syndecan and glypican cooperate with several cell surface 
receptors, namely integrins, acting as co-receptors and modulating several cell-cell and 
cell-matrix interactions [298]. These PGs play an important role in the internalization of 
several bound ligands, relevant for lipoprotein metabolism in liver [299]. While these 
PGs share some functional roles, mostly due to similar HS substitution, they present 
inherent structural and functional differences. 
Syndecans are type I transmembrane core proteins that present HS or CS 
substitutions (Fig. 6). This PG family is composed of four members, syndecans 1-4, that 
share a conserved structure. These PGs present a short cytoplasmic tail, followed by a 
single spanning transmembrane domain, and an extracellular domain, ectodomain, 
presenting three to five GAG attachment sites [300]. The cytoplasmic tail presents two 
conserved regions (C1 and C2) interrupted by a variable region (V). The region C1, 
immediately after the membrane, is highly conserved in the four members of this 
family[301]; it is vital for dimerization of syndecans [120] and interactions with several 
proteins, namely ezrin and Src kinase [302, 303]. The other conserved region, C2, 
comprises the distal portion of the cytoplasmic tail; it presents two conserved tyrosine 
residues and a post synaptic density-95/ disc large protein / zonula occludens-1 (PDZ)-
binding site at the carboxyl end. Such PDZ-binding site is extremely important for 
interactions with several proteins presenting PDZ domains, as syntenin, synectin, 
synbindin and calcium/ calmodulin dependent serine protein kinase (CASK/LIN-2) [304-
307]. The variable region is highly heterogeneous. Syndecan-4, the best studied case, 
presents a phosphatidylinositol-4,5-biphosphate (PIP2) binding site involved in 
dimerization and syndecan recycling [308]. The transmembrane domain is composed of 
a single transmembrane span with a SDS resistant motif, GXXXG. This motif is highly 
conserved and enhances the dimerization of syndecans [309]. The ectodomain presents a 
small motif responsible, contiguous the membrane surface, for enhancing self-
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association and interaction with several proteins, promoting protein kinase C activation 
[310, 311].  
Syndecans interact with a wide range of functional molecules, growth factors and 
morphogens, regulating and modulating several vital processes, namely wound healing, 
inflammation, angiogenesis or neural patterning [312]. Most of the functions associated 
with syndecan are performed by its CS or HS chains. However, the ectodomain is 
capable of interactions with several ECM molecules, as well as with cell surface 
receptors [313, 314]. MMPs promote the proteolytic release of some of the membrane 
bound syndecan [315], reducing transmembrane signal transduction [316]. Ectodomains 
proteolytic shedding produces soluble molecules that compete with bound syndecan for 
the same ligands [317]. Shed syndecan is present in high amounts in fluids surrounding 
lesions, regulating inflammation during wound healing [318]. Syndecans modulate 
chemokine gradients an regulate leukocyte recruitment during inflammatory response 
[319]. In colitis animal model, animals deficient for syndecan-1 show prolonged and 
excessive leukocyte recruitment [320]. These PGs modulate the action of several growth 
factors, as well as morphogens, and disruptions of such processes are associated with 
tumour progression. Syndecan expression is altered in prostate [321], breast [322] or 
colon [323] cancer. Low syndecan-1 expression is associated with worst prognosis in 
lung [324] and colorectal cancer [325], while myeloma presents high amounts of these 
proteins [326, 327]. Being important cell surface components, syndecans are also target 
by virus, bacteria and parasites during infection [319].  
Glypicans are HS-PGs tethered to the outer membrane leaflet through a GPI anchor 
(Fig. 6) [328]. Glypican proteins are encoded by 6 known genes in humans and several 
homologues across metazoa. Glypican proteins usually present 555-580 amino acids 
and are divided in two subgroups, due to sequence similarities: glypicans -1, -2, -4 and -
6 compose subgroup I; whereas glypicans -3 and -5 belong to subgroup II. These PGs 
present 14 conserved cysteine residues that stabilize the chain through disulphide bonds 
[329]. However, there is no crystallographic data available and the three-dimensional 
structure is unknown [328]. Glypicans present a cysteine rich domain (CRD), which 
presents a weak homology to the cysteine-rich domain of Frizzled proteins [330]. This 
domain is frequently subject of proteolytic cleavage by a furin-like convertase, by 
which way a core protein may be produced, composed of two subunits bound together 
by disulphide bonds [331]. Glypicans are HS substituted near the membrane, maybe 
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mediating interactions with other cell surface molecules. These GPI anchored proteins 
are distributed by the lipid ordered domains, lipid rafts, across the membrane, but, 
unlike other GPI proteins, a significant amount of glypican can be found outside rafts, 
which may be due to GAG chains interactions [332]. The GPI anchor may be cleaved by 
the action of a lipase [333], producing soluble forms that regulate the formation of 
several signalling molecules gradients. 
Glypicans interact with several growth factors, namely Fibroblast Growth Factor 
and Bone Morphogenetic Proteins (BMPs), but are particularly important in the 
regulation of Wnt and Hedgehog (Hh) morphogenic pathways [296, 334]. The shedded 
forms of glypican are vital for Wnt and Hh transport and gradient formation, promoting 
or inhibiting these signalling pathways. Glypican promotes Wnt signalling, by 
stabilizing the interaction between Wnt and its receptor Frizzled [334, 335], but it inhibits 
Hh signalling by competing with Patched, the Hh receptor, for Hh binding [296]. Given 
its important role in several signalling pathways, it is not surprising the role of altered 
expression of glypicans in pathophysiological processes [336-339]. Glypicans seem 
involved in prion protein conversion in lipid rafts, with evidence of interactions of 
prions with Glypican GAG chains [338, 340]. Mutations in Glypican -3 and -4 are 
associated with a overgrowth syndrome, Simpson-Golabi-Behme [336], which includes 
both prenatal and postnatal overgrowth due to increased cell proliferation and alteration 
in apoptosis, a process regulated by these glypican PGs [337, 341]. Similarly, the 
increased cell proliferation and apoptosis repression in the absence of glypican has been 
described in several cancers, as mesothelioma, ovary, and breast cancers cancer [337]. 
Nevertheless, overexpression of glypican is associated with hepatocellular carcinomas 
[342]. 
c) Secreted/ECM PGs 
Several PGs are secreted to the ECM (Fig. 6). These include the SLRPs that 
associate with collagen fibrils, the hyalectans that bind to HA, and the basement 
membrane PGs that are responsible for the basement membrane homeostasis. SLRPs 
are ubiquitous PGs, presenting relatively small core proteins (36-42 kDa). These PGs 
are subdivided in five different groups, based on evolutionary conservation, structural 
homology and chromosome organization [343]. Typically, these PG present a N- 
terminus CRD, four cysteine residues separated by a variable number of amino acids, 
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several leucine rich repeats (LRRs) and a C- terminus capping motif encompassing two 
LRR and the canonical “ear repeat” [344, 345]. LRRs are subunits of 24 amino acids with 
a characteristic pattern of hydrophobic residues, forming a short β-sheet. These repeats 
assemble into a curved, solenoid structure composed of several short β-sheets, 
connected by a turn and a more variable region[343]. SLRPs are able to interact with 
several ECM proteins by a LRR mediated process, where the inner side chains of the 
residues composing the β-sheets interact with specific proteins. According to the last 
review on these proteins classification [343, 344], SLRPs are organized into five distinct 
groups. 
SLRPs Group I includes decorin, biglycan, asporin and ECM-2. These present the 
typical CRD forming two intrachain disulphide bonds, the “ear repeat” between the last 
two LRRs, and can be substituted by CS or DS. Asporin lacks the typical peptide motif 
required for glycanation [346, 347]. GAG substitution seems to be tissue specific. 
Decorin and biglycan mostly present CS chains in bone, while in skin are substituted by 
DS [343]. Decorin is the model SLRP. its protein core is a Zn2+ metalloproteinase that 
binds to collagen α1(I) and helps maintain both intrafibrillar space in corneal collagen, 
essential for transparency, and mechanical coupling in tendon and skin [348]. Decorin 
interacts with fibrillar collagen in a periodic manner, forming a surface coat in fibril, 
which coat regulates proper fibril assembly and protects collagen from degradation, 
limiting MMPs access to cleavage sites. Asporin also binds to collagen I, and it 
competes with decorin for the same binding sites. However, decorin interacts with 
collagen through its LLR 7; whereas in asporin, these interactions are mediated by LRR 
10-12 [349]. 
SLRPs Group II members - lumican, fibromodulin, PRELP, Keratocan and 
osteoadherin - are typically substituted by KS or polylactosamine, an unsulphated form 
of KS, and present a tyrosine clusters at the amino end. Fibromodulin and lumican also 
associate with collagen, regulating its fibril assembly. These SLRPs interact with 
collagen fibrils through the same LRR 5-7, but only fibromodulin intervenes in the 
process of fibril maturation.  
SLRPs Group III comprises epiphycan, opticin and osteoglycin. These SLRPs 
present a relatively low number of LRRs and may exist as glycoproteins. Osteoglycin is 
typically substituted by KS, while epiphycan may present CS and DS substitutions. As 
for opticin, it does not present GAG chain.  
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SLRPs Groups IV and V, considered non canonical SLRPs, main distinctive 
features are the lack of “ear repeat” and the absence of GAG substitutions [344]. Group 
IV features chondroadherin, nyctolopin and the recently described tsukushi [350]. 
Chondroadherin presents a KS substitution, being the only member presenting a GAG 
chain. Nyctolopin, implicated in stationary night blindness, is the first GPI-anchored 
SLRP described [351]. Group V is composed by podocan and the highly homologous 
podocan-like protein 1. These SLRPs present a distinct amino end cysteine rich motif 
and 20 LRRs very similar to those of groups I and II [345].  
As mentioned, several SLRPs are associated with collagen assembly, and as such, 
mutations in these PGs are associated with skin and cartilage diseases and ocular 
defects. A particular asporin mutation, D14, is associated with high risk of osteoarthritis 
in Asian individuals [347], whereas mutations of lumican are associated with myopia 
[352], and alterations in keratocan cause cornea plana, a condition ultimately resulting in 
hypermetropia and astigmatism [353]. Decorin deficiency, for instance, is connected 
with enhanced skin fragility, and decorin truncated forms are associated to congenital 
dystrophy of the cornea [354]. 
Hyalectans are a small family of PGs family known for interacting with HA (Fig. 6) 
[236]. These high molecular weight PGs comprise aggrecan, neurocan, brevican, 
versican and neurocan. These CS substituted molecules are particularly abundant in 
cartilage and neural tissues [236]. These PGs, also known as lecticans, feature two 
globular regions, at C- and N- termini, interconnected by a structurally diverse central 
domain, presenting attachment sites for CS [355]. Such globular regions present several 
functional domains that promote and regulate several interactions. The N- terminal 
region presents the HA binding motif [356]. The amino end globular region, also known 
as G1 region, features an immunoglobulin-like loop and two link protein-like tandem 
repeats, also named proteoglycans tandem repeats (PTRs). The immunoglobulin-like 
loop presents two conserved Cys residues, while the PTRs present 4 conserved Cys. The 
PTR domain form a double loop stabilized by disulphide bonds between these residues 
[236]. The HA binding activity of these domains is dependent of a proper protein 
folding, and the presence of both PTRs, as a single PTR does not present significant HA 
binding [357]. In cartilage, the G1 region also presents the binding site for the cartilage 
link protein; this 50 kDa glycoprotein stabilizes the complex of aggrecan and HA [236].  
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Aggrecan presents an extra globular region (G2), containing two additional PTRs 
but without the immunoglobulin-like loop. The carboxyl end globular region (G3) 
comprises a C-type lectin domain flanked by two EGF-like repeats and a complement 
regulatory protein-like motif (CRP) [356]. These domains are also found in the some 
adhesion molecules, namely the selectin family, although organized in a distinct manner 
[358]. The C- terminus globular region interacts with simple sugars, as fucose, galactose 
or GlcNAc [359] [360, 361], and other GAGs [362] through the C-type lectin-like domain. 
The C-type lectin like domain also binds with tenascin-R, through interactions with 
tenascin-R FN repeats [361]. The lecticans central domain presents high variability in 
size and sequence. Brevican presents a 300 amino acids long sequence, versican splice 
variants can lack the entire central domain or present a 1700 amino acid long sequence. 
This domain presents all the potential CS-GAG chains attachment sites; aggrecan 
presents 120 sites, versican can be substituted at 20 sites, neurocan features seven 
attachment sites and brevican only presents three potential substitution sites [236].  
Lecticans are widely present in metazoa organisms. Aggrecan is the main PG of the 
cartilage, neurocan and brevican are the most abundant proteins of the central nervous 
system, and versican is present in most connective tissues [236, 355, 356]. Lecticans, as 
other ECM molecules, are subject of MMP cleavage, yielding new functional 
molecules. For example, the glial HA-binding protein is a 60 kDa fragment of versican 
[363]. Alterations in these proteoglycans turnover are associated with pathophysiological 
conditions. The abnormal degradation of aggrecan by a non-MMP enzyme is associated 
with the pathogenesis of osteoarthritis [364, 365]. Lecticans, mostly neurocan and 
brevican, are expressed in the central nervous system and regulate cell adhesion and 
migration, controlling and guiding axon growth [239, 366]. These PGs form a barrier to 
guide axon development and neural crest cell migration [367]. Deregulations in 
hyalectans synthesis and turnover have been associated with Alzheimer’s disease [368], 
prostate cancer [369] and vascular disease [370]. 
Basement membrane PGs interact and modulate the action of several growth 
factors, influencing processes like angiogenesis and keeping basement membrane 
homeostasis [371]. These HS substituted PGs influence cell adhesion, interact with cell 
surface receptors and regulate angiogenesis [372]. The best characterized basement 
membrane PGs are: the hybrid collagen PG from the multiplexin family, Collagen 
XVIII [373, 374]; the high molecular weight modular PG, perlecan [375, 376]; and the 
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neuromuscular junction PG, agrin [377]. These PGs have an especially active role in the 
modulation of angiogenesis; their GAG chains can either promote angiogenesis - 
binding growth factors and presenting them to cell surface receptors – or inhibit this 
process - restricting growth factor diffusion and inhibiting signalling [372]. Proteolytic 
cleavage of carboxyl end domains of these PGs can release new functional molecules 
with potent anti-angiogenic activity, as endostatin and endorepellin [63, 378, 379]. 
Collagen XVIII is a member of the multiplexin subfamily of collagens; the first 
evidence of its role as PG came from the presence of several Ser-Gly residues in NC 
domains [380]. These PGs plays a crucial role in eye development and ocular functions; 
animals deficient for collagen XVIII expression present iris disruption and degeneration 
of retinal epithelial cells [381, 382]. Alterations in the synthesis of collagen XVIII result 
in structural defects in the basement membrane; collagen null animals present basement 
membrane thickening [383], and collagen XVIII alterations in the choroid plexus 
basement membrane leads to  abnormal accumulation of cerebrospinal fluid in the 
ventricles of the brain, hydrocephalus pathology [384]. Collagen XVIII is widely 
distributed through vasculature basement membranes, but the absences or mutation of 
collagen XVIII is only associated with defects in the eye vasculature [385]. The lack of 
collagen XVIII, and consequent lack of endostatin, is associated with increasing of 
angiogenesis [386]; however, some reports also showed that the absence of this PG is 
connected with neovascularization and maintenance of vascular permeability [387]. 
Perlecan is one of the largest natural proteins, 470 kDa, and can reach 800 kDa when 
substituted with GAG chains [372]. This PG presents 46 functional domains organized in 
five modules; these domains, as well as GAG chains, interact with several basement 
membrane growth factors as FGF, vascular endothelial growth factor (VEGF) or 
platelet-derived growth factor (PDGF) [371]. Perlecan is present in the basement 
membrane of most epithelia and endothelia [388], especially vascular endothelia; but it is 
also present in avascular tissues like cartilage [389] or connective tissue stromas [390]. 
The presence of perlecan in the cell surface enables the interaction with cell receptors, 
as integrins, and the modulation of their ligands [388]; perlecan regulates the action of 
Hh and FGF during the synthesis of cartilage [376]. Perlecan is vital for the integrity of 
basement membranes; almost half of the animals deficient for perlecan die from 
haemorrhage in the pericardial cavity, this happens due to the deterioration of the 
basement membrane in regions of increased mechanical stress [391]. In humans, 
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mutations in perlecan lead to cartilage and brain defects and are associated with severe 
dwarfism [392]. In cancer, perlecan supports tumour blood vessels development [393]; 
deletion of perlecan or perlecan GAG chains leads to decreased tumour growth and 
angiogenesis [394]. Agrin is a modular PG that, similarly to perlecan and collagen 
XVIII, presents an anti-angiogenic carboxyl terminal module, endorepellin [379]. This 
PG is involved in the acetylcholine receptor clustering [395], being special relevant in 
neuromuscular junction [377]. Agrin is highly expressed in the brain, lungs and kidneys 
[396], especially in the blood vessels around these organs [397, 398]. Agrin I extremely 
important for the proper establishment of neuromuscular and immunological synapses 
[377, 398]; animals lacking agrin die neonatally due to respiratory failure from impaired 
diaphragm excitation [399]. This modular PG presents four splicing sites; a splice variant 
present a transmembrane domain at the amino end [371]. Altered distribution of agrin 
has been associated with Alzheimer’s disease [400, 401] and its presence in liver has been 
used as an angiogenesis marker [402]. 
Secreted Morphogens  
In higher eukaryotes, each cell must acquire positional information that specifies its 
relative position in tissues, organ and body. In embryonic development, or any other 
major tissue rearrangement, such information is delivered to the cell through proteins 
secreted to the ECM – morphogens [403]. These proteins are capable of both short-range 
contact-dependent signalling and long distance communication [404]. Morphogens 
control critical processes during embryogenesis, as patterning, differentiation, 
proliferation, and cell fate, and their malfunction underlies severe developmental defects 
and many types of cancer [405, 406].  
Several morphogen families are currently known, including Hedgehog (Hh), 
Wingless-Int (Wnt)1, and Bone Morphogenetic Protein (BMP). Each of these 
morphogens corresponds to signalling cascades, known to control specific processes, 
but sharing some degree of cross-talking, this way fine-tuning the processes together.  
                                                     
1
 The name Wnt was coined as a combination of Wg (wingless) and Int. The Wg gene had originally been identified as a segment 
polarity gene in D. melanogaster which functions during embryogenesis and adult limb formation. The INT genes were originally 
identified as vertebrate genes near several integration sites of mouse mammary tumor virus (MMTV). The Int-1 gene and the Wg 
gene were found to be homologous, with a common evolutionary origin evidenced by similar amino acid sequences of their encoded 
proteins. 
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Hedgehog family of morphogens comprises the original Hedgehog protein from 
Drosophila melanogaster (Rasp), and three members from vertebrates, the Sonic (Shh), 
the Indian (Ihh) and the Desert (Dhh) Hedgehog proteins. Shh is especially important in 
limb bud development, and notochord patterning. The bone and cartilage development 
are under the control of Ihh, which is partially redundant with Shh. Dhh mediates the 
germ cell development in the testis, as well as the peripheral nerve sheath formation 
[407]. Most information regarding these proteins processing and secretion is yet derived 
from the Hh from D. melanogaster Rasp and the vertebrate homologue Shh protein. 
The Hh morphogen is a highly post-translationally modified protein. It is translated 
as a 45 KDa precursor (Fig. 7), which undergoes intramolecular processing to yield a 
secreted 25 kDa C-terminal fragment (Hh-C), and a 20 kDa N-terminal fragment (Hh-
N) attached covalently to a cholesterol moiety in its C-terminal [408-412]. The 
cholesterol modification allows association of Hh-N with the cell membrane and is 
essential for proper Hh function and secretion [411, 412]. Actually, the cholesterol 
modification is indispensable to operate the nucleophilic attack that further allows 
transesterification-mediated cleavage of the peptide bond between two highly conserved 
amino acid residues, Cys-Phe. The Hh signal secreted to the ECM is further modified 
through palmitoylation of its N-terminal (Fig. 7) [411, 413]. In vitro studies show that this 
modification can be performed before or after the cholesterol attack [414]. The Hh 
palmitoylation is operated by the Hedgehog Acyltransferase (Hhat) from the MBOAT 
family of membrane bound O-acyl transferases [415]. On the other hand, the highly 
similar protein Hedgehog Acyltransferase-Like (Hhatl) regulates negatively Hh signal 
by competing with Hhat to bind the Hh ligand, rendering the palmitoylation impossible 
[416]. 
The secretion of processed Hh-N (Fig. 7), hereafter named simply as Hh, is 
mediated by the membrane-spanning Dispatched (Disp), a conserved protein with 
similarities to transmembrane transporters, that presents a SRR that interacts with the 
cholesterol moiety [417, 418]. In organisms lacking Disp, the secreting cells retain Hh 
and all its elicited responses are lost, except for the cell-cell communication mediated 
by the membrane-tethered Hh [417].  
The above mentioned lipid moieties are critical for Hh-N association with the 
membrane and secretion. In the absence of cholesterol modification, Hh does not 
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associate with cell membrane, which leads to an enhanced spreading of the Hh-N signal, 
and abnormal long-range signalling, originating severe development defects [419-421]. 
 
 
 
 
Figure 7. Hedgehog protein lipid modification and signalling. In Hh-producing cells, the Hh precursor protein 
undergoes processing, yielding a cholesterol-modified signalling domain and a processing domain that is 
ubiquitinated and directed for degradation. The molecule is further processed by the action of Hhat that transfers a 
palmitate to the amino end of the molecule; this step can be performed before or after the autoprocessing step. The 
mature hedgehog signal is directed for the plasma membrane and it is inserted in the lipid rafts. The transmembrane 
protein Dispatched helps the secretion of the signals as multimeric complexes, which are soluble and can be 
detected in the extracellular environment. Hh multimeric complex is likely the vehicle to be transported to Hh-
responsive cells to achieve long-range signalling, although the mechanism by which transport is achieved is 
unknown. The Hedgehog signal binds to the Patched transmembrane protein of the-responsive cell and relieves the 
Smo inhibition. This promotes the transcription of the Hedgehog response genes. Adapted from [422]. 
 
 
Nevertheless, Hh peptides associated with the membrane are only capable of juxtacrine 
signalling. The release of Hh-N to the ECM is indispensable for long-range signalling 
which is diffusional gradient-dependent (Fig. 7). After secretion, the Hh-N 
concentration gradient is mediated by several ECM macromolecules, namely HSPGs 
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and Hh-interacting protein (Hip). Embryos lacking the HS synthesizing enzymes from 
the EXT family do not present Hh migration across the tissues [423, 424]. Whereas Hip 
binds to Hh with high affinity and restricts its diffusion, regulating its action range [425]. 
The Hh peptide elicits a response when encounters a cell expressing the membrane 
receptor Patched (Ptch), a 12 span transmembrane protein with some homology to the 
bacterial RND transmembrane transporter family [403]. However, the transcriptional 
response to Hh depends on the activity of the seven-span membrane protein 
Smoothened (Smo) [426, 427]. The Ptch protein inhibits activation of Smo and 
subsequent downstream signalling (Fig .7). This process is not fully understood in 
mammals, but it has been characterized in D. melanogaster. In the absence of Hh 
ligand, the protein cubitus interruptus (Ci) is retained in the cytoplasm by the complex 
formed by Costal-2 (Cos2), Fused (Fu) and “Suppressor of Fused” protein (SuFu). The 
Ci protein is phosphorylated by protein kinase A (PKA), Glycogen synthase kinase 3 
beta (GSK3β) and casein kinase I (CKI), a process mediated by Cos2, and associates 
with the Slimb/βTrCP E3 ubiquitin ligase. The complex is directed to the proteasome, 
where Ci is processed to a repressor form (CiR), and represses the expression of Hh-
target genes [428]. Ultimately, the activation of the Hh elicited response depends on the 
inhibition of Ptch (Fig. 7). When Hh is present, the ligand binds to the two large 
extracellular domains of Ptch, and blocks the action of Ptch on Smo [429]. The Hh 
association with Ptch is enhanced and stabilized by the action of membrane tethered 
glypican [430], and by the “Cell adhesion molecule, down-regulated by oncogenes” 
(CDO) and “brother of CDO” (BOC) membrane proteins [431].  In D. melanogaster, the 
activation of Smo occurs by phosphorylation of 26 serine/threonine residues of its 
carboxyl end cytoplasmic tail, by PKA and CKI [432, 433]; however, none of these 
residues are conserved in mammals [434]. The activated Smo accumulates in the 
membrane, leading to an enhanced association with Cos2/Fu. The association with Smo 
inhibits the Cos2/Fu/Sufu mediated processing of Ci; the full-length protein enters the 
nucleus as a transcriptional activator (CiA) and promotes the expression of Hh-target 
genes [403, 428], including the genes coding for Ptch, Patched 2 (Ptch2), HIP1 and 
GLI1(vertebrate homologue of Ci) that participate directly in the pathway [435-437].  
In each tissue a specific sub-set of genes are activated. In the D. melanogaster wing 
development, Hh gradient promotes the differential activation of several genes, namely 
decapentaplegic (dpp), collier and engrailed [438]. Some studies show that the 
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activation of some genes require distinct ratios of CiA/CiR [439, 440]. Different 
concentration of Hh ligand might lead to distinct intracellular levels of Ci processing 
[441, 442], creating a Ci activity gradient that further increases the signalling gradient and 
enhances tissue patterning. Some studies show that the time of exposure to Hh ligand 
may be just as important [443-445]. All this information leads to the proposal of a model 
in which the Ci/GLI activity behaves as a component in the regulatory networks 
mediating patterning. Both the level and timing of Ci/GLI activity influence when and 
where genes are activated [446]. 
Hh signalling also induces the response from other signalling pathways, namely 
Wnt and BMP as referred above. The abnormal appearance of D. melanogaster larvae 
lacking Hh is the result of the loss of reciprocal feedback between cells expressing the 
Wnt family member Wingless (Wg) and Hh [447]. The reciprocal feedback helps to 
maintain the expression of these proteins along the anterior-posterior axis, guiding the 
embryo development. Similarly, in vertebrates limb development, a set of feedback 
signalling loops of Shh, BMP and Gremlin 1 (Grem1) regulate limb outgrowth and 
patterning, while the expression of Grem1 is stimulated by Shh, limiting the BMP 
signalling [448].  
Besides its role as a morphogen, Hh is also a very important player in the 
modulation of numerous tissue progenitor and stem cell populations [449]. In the central 
nervous system (CNS), Hh signalling is important in the regulation of adult neural stem 
cells, providing continuous supply of new neurons [450, 451]. However, in the 
developing cerebellum the Hh signalling elicit a different response. The Shh ligands 
secreted by Purkinje cells will promote the proliferation of granule cell precursors, and 
activate the expression of several stem cell and proliferative genes, including genes 
encoding MYC, cyclin D1, insulin-like growth factor 2 and BMI1 [452, 453]. Hh has also 
been associated with the maintenance of adult stem cells in several tissues, from the hair 
follicle to the haematopoietic system, but more importantly, it is involved in injury 
healing, modulating the injury-dependent regeneration of numerous organs, namely 
exocrine pancreas, prostate and bladder [449].  
The critical role of Hh signalling in the numerous developing tissues and organs is 
intimately connected with several severe congenital abnormalities that result from 
genetic defects in the pathway components [407]. Some defects are ligand-independent, 
including constitutive activation or repression of some pathway component; whereas 
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others are ligand-dependent, namely abnormal ligand secretion or diffusion. The 
heritable Gorlin’s syndrome belongs to the former; this pathology, also known as 
nevoid basal cell carcinoma syndrome, presents a mutation in the PTCH gene that 
blocks the Ptch-mediated Smo inhibition [454, 455]. Patients with this syndrome presence 
a high incidence of the skin cancer basal cell carcinoma and the cerebellum cancer 
medulloblastoma [407]. The abnormal production of Hh ligand by tumour cells 
themselves,[456] promoting proliferation and tumour growth [457]. Hh signalling may 
work in two different ways; the autocrine and juxtacrine Hh signalling may mediate 
communication and promote cell growth inside the tumour [458], but the tumour cells 
may also signal to the surrounding environment, which will then signal back and also 
promote cancer progression [459]. Some drugs that target the Hh production have been 
used to treat some ligand-dependent cancers [460]; however, the simple ligand inhibition 
does not completely blocks cell proliferation, suggesting a more complex signalling 
network promoting the tumour growth.  
Morphogens were subject of intense study in the last decade, however, there is still 
much to be understood. A recent review [407], summarized the current 10 great 
questions about Hh signalling and its physiological role. From the mechanism that 
allows Hh diffusion in tissues to the mechanism of Smo inhibition by Ptch or the tissue 
specific gene regulation after Hh elicitation, much needs to be unveiled until we have a 
clear picture of all the mechanisms and roles of Hh signalling and the putative influence 
of the other ECM components in this. 
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Microbial ECM – the slime of the slimy microbes 
Life forms come in all shapes and sizes, and microbes are surely counted among the 
smallest and simplest. Nevertheless, these “simple” organisms present a wider 
ecological distribution than other more complex life forms, being capable of surviving 
and growing in the presence of high concentrations of certain chemical compounds or 
extreme temperatures and pressures (reviewed in [461-463]). 
The term “microorganism” is commonly associated with simple unicellular entities 
swimming freely in watery environments, contaminating food, or causing disease. 
However, these solitary planktonic cells rarely exist in nature. Over 90% of all 
microorganisms on Earth live as multicellular communities [464-466], organized 
distinctly as biofilms [465], colonies [467, 468] and UV-induced stalks [469, 470]. These 
types of multicellular organization are common to bacteria, microalgae, protozoa and 
fungi (including yeasts), occurring more or less frequently according to environmental 
constraints. Such organized communities can be found in environments so diverse as 
mine sediments [471] and wastewater treatment plants [472, 473] or man-made equipment 
and facilities [474, 475]. While the occurrence of microbial colonization of medical 
devices or marine facilities equipment carries severe health and economic losses [476-
478], the development of these communities is actually helpful in several processes, like 
for example the microbial-enhanced recovery of minerals and oil, the bioremediation of 
soils, rivers and groundwater, or wastewater treatment [479, 480].  
Bacterial biofilms 
Bacteria, distributed across a wide range of ecological niches, form highly dense 
multicellular communities - biofilms [481]. Bacterial biofilms are heterogeneous 
communities embedded in a polysaccharide-rich ECM that mediates attachment to 
biotic and abiotic substrates [482]. But the multicellular aggregation of bacterial cells 
brings several advantages over the planktonic cell lifestyle; biofilm ECM provides 
surface adhesion, mechanical support, physical and chemical protection against 
environmental variations, while promoting cell-cell communication and enabling 
community-based gene regulation and metabolic cooperation [482]. Being a highly 
complex structure, the ECM provides physical protection for the cells against shear 
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forces or UV damage. Although this is still not known how, bacterial ECM also 
mediates cell-cell communication, since it enables biofilm gene expression 
synchronization [483]. As in mammals, it presents a high water retention capacity, 
keeping a stable hydration level against environmental variations, and retains several 
organic and inorganic compounds, providing a nutrient source and protecting against 
xenobiotics [484-486] [487, 488]. Furthermore, it apparently also is able to modulate 
extracellular enzymatic activity, and mediate horizontal transfer of genetic material [481, 
489, 490]. 
Bacterial biofilms development occurs in sequential steps of colonization, 
proliferation, and differentiation. Cellular adhesion to a biotic or abiotic substrate is the 
first step of bacterial colonization (Fig. 8 A). Planktonic cells interact with surfaces 
through the action of fibrillar adhesins or polysaccharides. Some of these molecules, 
like the fibrillar pilli or flagella, interact directly with the substratum, while others 
modulate the cell surface hydrophobic properties to enhance the interaction between the  
 
 
 
Figure 8. Bacterial biofilm formation and development. Planktonic cells attach to biotic and abiotic substrates 
through cell surface adhesins, after environmental variations (A). Cell motility and division lead to the formation 
of microcolonies, enabling cell-cell communication and metabolic synchronization (B). The differentiated 
community produces an ECM that supports and protects the developing biofilm (C). Under continuously changing 
environmental conditions, the biofilm further develops into a mature and highly differentiated community 
completely included in a protective ECM (D). Extracellular enzymes mediate the degradation of ECM 
biopolymers, leading to the release of planktonic cells that might colonize new substrates (E). Adapted from 
[491] and [492]. 
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cell and the biological or artificial surface [493]. These initial interactions are frequently 
non-specific and reversible. The permanent attachment depends of physical constraints, 
like surface roughness and shear stress of water or air against the surface, and non-
covalent binding forces, like electrostatic interactions and hydrogen bonds [465]. After a 
stable surface attachment, cells start proliferating and form microcolonies (Fig. 8 B). 
Cells presenting motile appendages may form microcolonies through agglomeration of  
several roaming cells [491]. The cells within the microcolony undergo differentiation 
and simultaneously initiate production and secretion of extracellular polymeric 
substances (EPS) that accumulate and form the ECM (Fig. 8 C). This secreted ECM 
enhances cell surface adhesion and intercellular cohesion, resulting in an irreversible 
attachment to the substrate. The onset of bacterial ECM production may occur upon 
diverse environmental insults, namely biotic stresses like competition or predation, 
nutrient availability or shear forces intensity [465, 481, 490]. In face of these 
environmental challenges, constant biopolymers production and secretion is maintained, 
until all the cells are embedded in ECM (Fig. 8 D). In bacterial biofilms, the ECM may 
account for over 90% of the total dry weight [494, 495].  
The bacterial ECM is composed of several biopolymers, viz. polysaccharides, 
proteins, lipids, extracellular DNA (eDNA) and humic substances [481]. The ECM 
composition is highly dependent on the microorganism and on the environmental causes 
that guided its development [465]. A mature biofilm presents an uneven distribution of 
cells, these being organized in layers and clusters supported and connected by the ECM. 
The three dimensional structure of a mature biofilm contains voids depleted of cells, 
cavities, channels, pores, filaments and other structures that mediate a two phase 
system: 1) a solid network of polymers enclosing bacterial cells, and 2) free interstitial 
water that conducts the nutrients flow and exerts physical pressure [488]. As the biofilm 
grows and becomes more complex, there is remodelling and recycling of several 
components, through the action of some secreted enzymes. These ECM degrading 
enzymes are therefore responsible for the remodelling of the biofilm and in ultimately 
the reutilization of polysaccharides and proteins as nutrient sources [481]. The action of 
these secreted proteins also enables the release of planktonic cells (Fig. 8 E), which can 
migrate and colonize new and sometimes completely different surfaces. 
The bacterial biofilms, as mentioned above, are composed of a wide range of 
biopolymers, each microorganism species, or even strain, producing and secreting a 
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different type of polysaccharides, proteins or eDNA [481]. The role of each component 
also seems to be species-dependent. Otherwise, the polysaccharide poly-N-acetyl-
glucosamine in Staphylococcus epidermidis, and some types of eDNA in its close 
relative S. aureus, play the same structural function in biofilms [496]. Extracellular 
polysaccharides, or exopolysaccharides, are the main class of biopolymers in bacterial 
biofilms [497, 498], comprising long molecules, linear or branched, with high molecular 
weight [481]. Some of these are composed by repetitions of a single monosaccharide, 
like the fructans and glucans from Streptococcus spp., or the cellulose from Escherichia 
coli 2 [499], while others result from the combinations of several different sugar units, 
e.g., the heteropolysaccharides from Proteobacteria [500]. The biochemical properties of 
these molecules depend on their overall charge and hydrophobicity. Several Gram-
negative bacteria present neutral or polyanionic exopolysaccharides, rich in uronic acids 
or ketal-linked pyruvates or more rarely sulphate [481], while in some Gram-positive 
strains is possible to detect exopolysaccharides primarily cationic, as the poly-N-acetyl 
glucosamine with partly deacetylated residues from S. aureus and S. epidermidis [464, 
495, 501]. The presence of several organic and inorganic substituents can change the 
physical and biochemical properties of polysaccharides. These molecules are frequently 
N- and O-acylated, presenting substitution with N-acetyl or O-succinyl groups [502, 503]. 
The production of polysaccharide is vital for proper biofilm development. In fact, 
strains that do not produce exopolysaccharides are unable to form a biofilm, even if they 
adhere to a substrate [504, 505]. However, some polysaccharides types are not 
fundamental structural elements of a biofilm although their presence changes the 
biofilm structure radically. Pseudomonas aeruginosa strains that colonize and produce 
biofilms in the lungs of patients with cystic fibrosis present a typical mucoid phenotype 
[506, 507]. These strains produce an increased amount of alginate, a polysaccharide 
composed by mannuronic acid and guluronic acid, that helps to sustain a more complex 
biofilm and plays an important role in the surface adhesion [508, 509]. 
Proteins are another very important component of bacterial biofilms. The molecules 
can even exceed the polysaccharide in a mass basis [497]. Biofilms have several 
extracellular enzymes, many of which are associated with the modification or 
                                                     
2
 Cellulose can be classified into plant cellulose and bacterial cellulose, both of which are naturally occurring. They have basically 
the same chemical nature, but they differ significantly as to the macromolecular properties and characteristics. In general, microbial 
cellulose is chemically more homogenous, containing no hemicellulose or lignin. It has higher water holding capacity, and greater 
tensile strength, resulting from a larger amount of polymerization and ultrafine network architecture. 
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degradation of their polymeric constituents, both water-soluble – proteins and 
polysaccharides - and water-insoluble - cellulose, chitin and lipids [481]. These enzymes 
are particularly important during starvation periods or for planktonic cells release, for 
which the remodelling and recycling of the ECM components are vital [510]. Actually, 
the release of planktonic cells is dependent on environmental changes, either the 
depletion of nutrients in the substrate where the biofilm is set, or the elsewhere-nutrient 
availability that will facilitate the colonization of new surfaces [510, 511]. In 
Actinobacillus actinomycetemcomitans biofilms, the cells secrete an N-acetyl-β-
hexosaminidase that mediates ECM/biofilm exopolysaccharides degradation and cell 
release [512]. These proteins are kept inside the biofilm by interactions with 
polysaccharide and other proteins, maintaining a dynamic turnover of ECM components 
and structure. In P. aeruginosa biofilms, alginate molecules interact with several 
enzymes. Such interactions keep the enzymes inside the biofilm and promote the 
biochemical activation of the biofilm constituents by the attached enzymes [513].  
Bacterial ECM enzymes target exopolysaccharides belonging to the biofilm of the 
producing bacteria as mentioned above, or otherwise degrade the polysaccharides 
produced by another bacteria [514]. Some of these proteins have industrial applications, 
namely in food and pharmaceutical industries [515, 516]. The growth inhibition effect of 
some these enzymes against other bacteria is frequently used to reduce food spoilage 
and improve shelf-life [517, 518]. One such example is the bacterial cell wall hydrolase 
family (BCWHs), enzymes that degrade peptidoglycan. Hydrolysis of peptidoglycan by 
BCHWs results in cell lysis, since this cross-linked cell wall component confers 
mechanical strength and resistance against external turgor pressure [519]. ECM secreted 
enzymes are also object of active studies in bacterial infection. They act as virulence 
factors in mammals and plant hosts, for the advantages they provide the infectious 
microorganism against the host defence system [520, 521]. 
Biofilms also present several non-enzymatic proteins that play a structural role, 
usually interacting with cell membranes or presenting carbohydrate-binding domains. 
Such proteins include lectin-like and biofilm-associated surface proteins (Bap), which 
help to establish a connection between the cell surface and the biofilm structure. In oral 
biofilms, the pathogen Streptococcus mutans secretes several glucan-binding proteins 
[522, 523]. P. aeruginosa also secretes some lectin-like proteins during biofilm 
formation, the galactose-specific lectin lecA and the fucose-specific lectin lecB [524, 
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525]. These lectin-like proteins mediate biofilm formation and stabilization. The 
selective inhibition of LecB hinders biofilm formation and promotes complete 
dispersion of established biofilms [526]. The protein CdrA, present in P. aeruginosa 
biofilms, is attached to the bacterial cell surface but interacts with several 
exopolysaccharides, namely Psl, anchoring the cells to the matrix. The shedded forms of 
these proteins interact directly with exopolysaccharides, cross-linking and reinforcing 
the biofilm network [527]. Other common biofilm constituents are amyloid proteins; 
these fibrous adhesins comprise several repeats of protein molecules forming a cross-β 
structure, in which the β-strands are perpendicular to the fibre axis. These proteins are 
involved in abiotic surfaces adhesion, and can also function as cytotoxins for host cells 
or other bacterial cells [528, 529]. In Bacillus subtilis biofilms, amyloid fibres provide 
structural integrity and bind the cells in the biofilm [530]. These proteins present a very 
ubiquitous distribution, being found in freshwater lakes, brackish water, drinking-water 
reservoirs or wastewater treatment plants [528, 529]. The presence of motility 
appendages, pilli or flagella, stabilizes the biofilm through interactions with other ECM 
components. In several bacterial biofilms, namely E. coli and Salmonella typhimurium, 
the presence of interactions between fimbriae and cellulose results in a rigid and 
hydrophobic ECM, whereas that the absence of these appendages results in a cellulose-
based fragile network [499]. 
The presence of eDNA is very frequent in bacterial biofilms; however, for some 
time the structural role of eDNA in biofilm ECM was not recognized, being accepted as 
residual material from lysed cells [481]. Evidence of its importance for biofilm integrity 
and structure has lately piled up [531-533]. The importance of eDNA in microbial 
aggregation was initially surveyed in bacteria from the genus Rhodovulum. These 
bacteria aggregate in flocs and produce an ECM composed of polysaccharides, proteins 
and nucleic acids. These aggregates were treated with degrading enzymes, selectively 
targeting polysaccharides, proteins or DNA. Surprisingly, only the action of nucleolytic 
enzymes resulted in deflocculation, the other treatments had no effect [534]. eDNA is 
also particularly important in the development of P. aeruginosa biofilms, where it acts 
as a structural connector [535], evidenced by the treatment with DNase inhibiting new 
biofilm formation and destabilizing mature biofilms [531, 536]. The amount, localization 
and role of eDNA in biofilms greatly differ between bacterial species. In S. aureus 
biofilms, eDNA is an important structural constituent present in high amounts and 
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forming a grid-like structure across the biofilm [537], whereas in the closely related S. 
epidermidis biofilms, eDNA is only a residual component [496]. In Haemophilus 
influenza biofilms, eDNA is organized in a dense network composed of fine strands that 
provides structural support to the microcolonies. Occasionally, thick rope-like strands of 
dsDNA, crossing over and through the channels that conduct water, bridge different 
parts of the densely populated bacterial biofilm [538].  
Gammaproteobacterium strain F8 presents a filamentous network of eDNA 
supporting its biofilms [489]. Some bacteria present eDNA identical to the genomic 
DNA, namely P. aeruginosa and P. putida, which can be used as a pool of genetic 
information and enable the horizontal transfer of genes [489], whereas others species, 
namely Gammaproteobacterium strain F8, present eDNA with particular properties, 
indicating that its biofilm eDNA is not simply released by lysed cells but undergo some 
specific modifications [537]. In S. epidermidis biofilms, eDNA is released by the action 
of an autolysin that promotes the controlled lysis of a particular subpopulation of cells, 
promoting biofilm formation of the remaining cells [539]. 
Most polymeric substances present in bacterial biofilms ECM are hydrophilic, as 
polysaccharides and DNA, but some species present highly hydrophobic components in 
their ECM. The production of hydrophobic biopolymers, both lipids and substituted 
polysaccharide, is frequently associated with adhesion, nutrient utilization or resistance 
to antibiotics. Several bacteria, including Thiobacillus ferrooxidans, produce energy 
from the oxidation of reduced sulphur compounds, colonizing and forming biofilms in 
mine sediments. These minerals, mainly pyrite, present high surface hydrophobicity and 
so, this bacteria biofilm is rich in lipopolysaccharides, presenting hydrophobic features 
and mediating the attachment to the surface of pyrite [540]. Serratia marcescens is a 
bacterium that colonizes lipid rich environments, namely gasoline or diesel fuel 
contaminations these bacteria secrete several lipids with surface-active properties, 
named “serrawettins”, that disperse hydrophobic substances and render them 
bioavailable [541]. These bacteria have biotechnological potential in bioremediation in 
oil spills [542].  
K. C. Marshall, one of the pioneers in biofilms research, defined biofilms as “stiff 
water” [481, 543]. Such statement reveals the importance of water for biofilms 
physiology. Biofilms ECM is a highly hydrated environment that provides the proper 
pH, temperature and molecules diffusion conditions for cells to survive. The ECM is 
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highly hygroscopic and retains water entropically, drying more slowly than its 
surroundings therefore protecting against desiccation. Desiccation reduces biofilm 
volume, concentrating the matrix and exposing new binding sites, promoting changes in 
molecules interactions and responses. As such, desiccation is one of the stimuli for 
bacteria to produce ECM [544, 545].  
The combination of different biopolymers, and their distinct interactions with 
water, makes the biofilm a highly complex structure. All these components contribute 
for the mechanical properties of biofilms. Cohesive and adhesive properties, mediated 
by polysaccharides, proteins and eDNA, are particularly important in ECM stability and 
biofilm resistance to physical and chemical removal [546]. The combined environmental 
conditions of shear stress, temperature and water availability, and interactions with 
multivalent inorganic ions, may reinforce the ECM network. Also the presence of more 
than one species of microorganism, a single bacterial species or a mixture of different 
bacteria and yeast/fungi, greatly influences the properties of biofilms. Biofilms from 
stable environments, like stagnant waters, are easily disrupted by low shear force as 
were not formed to resist such conditions. Otherwise, biofilms from the family 
Podostemaceae present high stability, rubber-like appearance, and colonize waterfall 
rocks [547]. A biofilm can reinforce the structure of its ECM to respond to mechanical 
insults by increasing biopolymers synthesis and secretion [548]. The biofilm ECM can 
act as a molecular sieve, sequestering cations, anions, and apolar particles. The 
biopolymers secreted during biofilm development and maturation contain a diversity of 
structural elements, uronic acids or amino sugars, that allow tight interactions with 
water phase compounds restricting access to the cells [549]. In activated sludge, 
hydrophobic compounds, as benzene or toluene, are retained by the biofilm ECM, 
whereas heavy metals, as Zn2+, Cd2+ or Ni2+, bind to cell walls of bacteria [550]. The 
molecular sieving provided by the biofilm ECM plays an important role in restricting 
the access of foreign substances to the cells, namely compounds that modulate biofilm 
structure and composition [551]. The role of biofilm biopolymers in antibiotics 
resistance is of particular interest. Bacteria producing biofilms produce chronic 
infections with high human and economic implications [552]. Biofilm response to 
xenobiotics is distinct of planktonic cells’. A bacterial biofilm comprises different 
metabolically and physiologically subpopulations, expressing high amounts of efflux 
drug pumps and presenting distinct susceptibility to drugs [484-486], and its ECM 
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interferes with diffusion rates of antibiotics [487, 488] and presents extracellular enzymes 
that may degrade them [553, 554]. 
Within bacterial communities the response to environmental stimuli, the metabolic 
synchronization, the aggregation in multicellular biofilms, the production of the 
extracellular biopolymers, and the release of DNA, are mediated by cell-cell 
communication [483]. The most studied bacterial communication mechanism is the 
quorum sensing (QS) [483, 555, 556], which regulates the expression of specific genes in 
correlation to population density [465]. Bacterial cells produce and secrete signalling 
molecules, named autoinducers, which diffuse and accumulate in the surrounding 
environment. The autoinducers accumulate until a specific critical concentration is 
reached. The larger the population producing the autoinducers is, the faster this 
concentration is reached. After reaching this threshold, the autoinducers interact with 
receptors on the cell surface or are imported into the cell and interact with receptors in 
the cytoplasm, which act as transcription factors and change the expression of genes 
[556, 557]. Several systems of bacterial QS are known, like the signalling through N-acyl-
homoserine lactone (AHL) system of Gram negative bacteria [558, 559], the modified 
oligopeptides from Gram positive bacteria [560, 561], and the autoinducer type II 
interspecific system [562-564]. 
The first and best-characterized QS system is the AHL-mediated communication in 
Vibrio fischeri [565-567], being the QS paradigm for communication in Gram negative 
bacteria [465, 483]. This QS system comprises two proteins, LuxI and LuxR, which 
regulate the expression of the Luciferase operon, responsible for the light production 
characteristic of this species. The protein LuxI is an autoinducer synthase that produces 
N-(3-oxohexanoyl)-L-homoserine lactone, requiring S-adenosylmethionine, whereas the 
LuxR is a cytoplasmic receptor that once activated, binds to DNA and initiates the 
transcription of the Luciferase genes [565, 568]. V. fischeri also recognizes and responds 
to N-octanoyl-L-homoserine lactone [569]. Similarly, P. aeruginosa also presents two 
AHL-based communication systems that regulate virulence and biofilm development 
[570, 571]. Two LuxI type synthases, LasI and RhlI, produce N-(3-oxododecanoyl)-L-
homoserine lactone and N-butyryl-L-homoserine lactone, respectively. These AHL 
inducers cross the membrane and interact with LasR and RhlR receptors, LuxR type 
transcription activators that activate specific genes and promote the phenotypic change 
[572-575]. Mutants on QS systems produce thinner and more densely populated biofilms, 
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while mutation of LasI produces abnormal and undifferentiated biofilms [576]. The 
lipopolysaccharides synthesis in A. ferrooxidans is regulated by the AfeI/AfeR system 
[577, 578]. Other Gram negative bacteria present AHL-mediated communication. In 
Pectobacterium carotovorum, QS communication mediates carbapenem antibiotic 
production [579], while in Agrobacterium tumefaciens regulates Ti plasmid conjugal 
transfer [580]. The multicellular aggregation of Serratia liquefaciens [581], as well as the 
virulence and production of exopolysaccharides in Pantoea stewartii [582] are also 
regulated by AHL-based systems. While the AHL system was a broad distribution in 
bacterial species, the sequence homology between LuxI type and LuxR type proteins is 
fairly low. Some species produce AHL degrading enzymes, while others produce small 
molecules that block the AHL. The former include oxireductases, AHL aminoacylases 
that cleave the amine bond and AHL lactonases that open the lactone ring [583, 584]. The 
latter include brominated furanones that bind to the active centre of LuxR type receptors 
and block the action of the AHL inducer [585, 586]. The production of quorum quenching 
molecules gives the producing bacteria competitive advantage, as it can inhibit biofilm 
development or genetic information exchange from other species. 
 In Gram positive bacteria, communication is carried out by modified oligopeptides 
that interact with membrane bound sensor histidine kinases. Typically, a newly 
synthesized pre-protein undergoes proteolytic cleavage and exported from the cell. In 
the extracellular milieu, these oligopeptides interact with the cell surface receptor, 
generating a signal that is communicated by several phosphorylated intermediates [560]. 
Such signals are highly specific; the chemical structure of the signal is defined by the 
amino acid sequence, which can be further modified to increase specificity, e.g., the 
formation of a thiolactone ring in the S. aureus oligopeptides [587]. Such high specificity 
allows distinct signalling between different strains of the same bacterial species. In S. 
aureus, several strains produce signalling peptides that able to cross-communicate with 
other strains. In several strains, the signal produced by a group of cells, stimulates the 
production of more of the same signal, while it inhibits the production of different 
signals. Arguably, these types of cross-strain communication could demonstrate 
cooperative behaviour and intraspecific competition [588]. 
The interspecific QS system is present in Gram positive and negative bacteria [562, 
589, 590]. This very simple system is based on the signal synthase LuxS, that produces 
4,5-dihydroxy-2,3- petanedione in chemical equilibrium with several furanones [591, 
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592], and in the LuxPC sensor that recognizes the signal and promotes the gene 
expression change [589]. Different species and strains are able to recognize different 
stereoisomers of the molecule and respond in distinct ways, while others respond in the 
same way to both chemical species. This lack of directionality in the promoted 
responses leads to an inefficient information transfer. 
Multicellular bacterial communities are remarkable structures in which unicellular 
microorganims organise a multicellular way of life. This complex life style provides 
improved nutrient supply and protection against environmental stresses, such as 
antibiotics. The cell-cell communication that undergoes within these communities and 
that allows metabolic synchronization and concerted responses is still little understood. 
Fungal biofilms 
Similarly to bacteria, yeast and other fungi organize themselves in multicellular 
aggregates embedded in a polymeric ECM [466]. In response to environmental insults 
fungal cells assemble into several structurally distinct communities – biofilms, colonies 
and stalks [467]. While most yeasts and fungi species are able to form some kind of 
multicellular community, biofilms are the most studied [495] mostly for their role in 
infection and pathogenesis. Adherence and colonization of inert surfaces from medical 
devices are important for clinically relevant fungal pathogens [593] and constitute a 
critical source of hospital-acquired infections. On the other hand, yeast and fungi 
infections usually proceed through adherence and colonization of mucosa. In 
immunosuppressed patients, serious infection progresses by overcoming the 
hematopoietic barrier and colonizing the blood stream causing systemic infection and 
eventual death [594, 595]. This is particularly so in patients receiving transplants, who are 
immunodepressed on purpose in order to lower the chances of organ rejection, as well 
as patients under medical-assisted life extension procedures, adding the 
immunodepression caused by HIV, cancer or other diseases [596]. Altogether, the 
numbers have reached a world-wide significant high impact with large associated costs 
on lives, health care systems and ultimately economy. The high tolerance of biofilms to 
antifungal drugs is yet another important issue to public health [597, 598].  
Some of these major offenders are fungal human commensals of mucosal surfaces 
and intestinal tract, like the fungus Aspergillus fumigatus or the yeasts Candida albicans 
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and Cryptococcus neoformans. The shift from commensality to pathogenicity is a very 
complex process that has been mostly addressed in the yeast C. albicans. 
a) The fungus Aspergillus fumigatus 
A. fumigatus is an opportunistic filamentous mould, being the second most common 
fungal infection found in hospitalized patients, after C. albicans [599]. This mould forms 
biofilms in both biotic and abiotic surfaces, through the germination of small spores 
called conidia. The conidia are easily dispersed through the air, remaining active in the 
atmosphere for long periods, and being frequently inhaled by humans [600]. In a healthy 
host, conidia are easily and quickly eliminated by the immune system. In 
immunodepressed patients, especially those with cystic fibrosis, these cells can cause a 
wide range of systemic problems, including severe pulmonary infections [601]. After the 
initial colonization, the conidia start differentiating and producing hyphae. During 
maturation, the mycelium continues to develop and the ECM accumulates until it 
envelops the entire biofilm [478, 602]. A. fumigatus infections can be subdivided 
according to their distinct hyphal organization [478] into (1) the aspergilloma, a tightly 
packed spheroid mass of hyphae that promotes localized infection of pre-existing 
parenchymal cavities or in chronically obstructed paranasal sinuses in the upper-
airways, and (2) the invasive aspergillosis, a widespread and multifocal invasion of host 
tissues leading to systemic infection. Such infections result in elevated mortality rates, 
over 50% [603]. The ECM has a particularly important role in these infectious processes. 
The presence of polysaccharides (galactomannan, α-1,3 glucan), melanin, proteins 
(major antigens and hydrophobins) and monosaccharides was described for agar-grown 
biofilm’s ECM of A. fumigatus [604]. Later studies in vivo showed differences between 
the ECM of lung aspergilloma and aspergillosis. Both hyphal aggregates presented 
galactomannan and galactosaminogalactan, but α-1,3 glucan was detected only in 
aspergilloma [478]. Additionally, components of the ECM interact with and sequester 
antifungal drugs, mainly azoles [605]. 
b) The yeast Cryptococcus neoformans 
The yeast C. neoformans is an encapsulated opportunistic yeast pathogen that 
colonizes the central nervous system of immunocompromised individuals, causing life-
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endangering meningoencephalitis [606]. Similarly to A. fumigatus, host colonization may 
happen by inhalation of air disperse small spores or planktonic cells, as it presents a 
very ubiquitous distribution [607, 608]. This pathogenic yeast is capable of colonizing 
several hosts, including plants [609, 610], protozoans [611], nematodes [612], insects [613, 
614], birds [615], and mammals, including house pets [616, 617] or humans [606]. 
Clinically, C. neoformans forms biofilms in ventricular shunts, peritoneal dialysis 
fistulas or cardiac valves [618, 619]. Similarly to other fungal and bacterial pathogens, 
cryptococcal biofilms are less susceptible to anti-fungal agents, as well as to host 
immune system [618, 619]. Cryptococcus spp. enhanced resistance to antifungals and 
virulence derives from the presence of an unusual polysaccharide capsule. This provides 
protection against phagocytosis and diminishes the effect of antimicrobial agents 
through these molecules sequestering and reduced diffusion [619, 620]. The capsule 
forms a dense, highly hydrated, gelatinous layer that prevents contact between cellular 
components and the host defences, avoiding antibody binding and subsequent activation 
of complement system [621]. Natural occurring Cryptococcus strains that present 
defective capsule production or no capsule at all are little virulent or avirulent [622, 623]. 
Studies on Cryptococcus biofilms are mostly performed in vitro, including 
adherence onto glass surfaces or wells of polystyrene plates [608, 618, 619, 624], and 
information on the capsule composition has been inferred based largely on analysis of 
shed exopolysaccharides that accumulate in culture supernatants [625]. The capsule is 
mainly formed by glucuronoxylomannan, galactoxylomannan and mannoproteins [626]. 
However, the role of these polysaccharides in the capsule structure is unknown. C. 
neoformans is also capable of synthesizing hyaluronan. The gene CPS1 encodes a 
hyaluronan synthase. The presence of this GAG in the capsule is extremely important 
for the yeast infection in vitro and in vivo, as strains lacking HA production are less 
pathogenic [627]. The capsule size depends on the environmental conditions, including 
host immune response; incubation with serum, increasing in CO2 concentration, iron 
deprivation and pH variations stimulate capsular components production and the 
enlargement of this structure [621, 628-631].  
c) The Candida yeast species 
The pathogenic species of the genus Candida are the major agents causing hospital-
acquired infections [632]. The most common species include C. glabrata and C. 
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parapsilosis but mostly C. albicans. C. albicans usually acts as a commensal of human 
skin, gastrointestinal tract, and vaginal and urinary mucosa. However, under favourable 
environmental conditions, this yeast behaviour shifts towards pathogenicity, causing 
several pathologies, namely stomatitis, thrush, nosocomial pneumonias and urinary 
tract-infections. Moreover, as the other fungi and yeasts, in immunocompromised 
patients, it provokes life-threatening systemic infections [633]. To study C. albicans 
biofilm formation several in vivo and in vitro models were developed, including several 
animal models, namely for venous catheters, oral and denture colonization; abiotic 
surfaces like polystyrene; or special apparatus that allow the control of all the different 
biofilm developmental phases like the Calgary biofilm device [477, 634-637].  
C. albicans biofilm development occurs in sequential steps of adherence, 
proliferation and ECM secretion (Fig. 9). In a natural occurring biofilm, these steps may 
happen simultaneously rather than sequentially, in different regions of the same cellular 
aggregate. This complex process is controlled by genes regulating (1) the morphological 
transition from yeast to hyphal form, (2) the production and response to QS molecules, 
and (3) the cell wall composition [638-643], while initiation is regulated by nutrient 
availability and cell-cell communication (Fig. 9 A). Most proteins involved in this step 
are involved in the regulation of the adherence to plastic or protein-coated surfaces. A 
group of cell wall proteins - adhesins - is responsible for the cell-cell and cell-substrate 
interactions. Adhesins include the Eap1, Hwp1 and the two closely Als1 and Als3. Eap1 
is the main adhesin involved in adherence to inert substrate It is a GPI anchored protein 
rich in serine and threonine that presents internal repeats of Trp-Pro-Cys-Leu, common 
in fungal surface proteins [644, 645]. The Ser and Thr residues are potential glycosylation 
sites [645]. The deletion of the EAP1 gene results in reduced adherence to polystyrene 
and defective biofilm formation, both in vivo and in vitro. Analogously, the 
heterologous expression of this protein in non-adherent S. cerevisiae strains promoted 
the adhesion to polystyrene [644, 646]. The role of the closely related adhesins Als1 and 
Als3 was unveiled through the phenotypical analysis of mutant strains for both 
adhesins, and non-adherent S. cerevisiae strains heterologously expressing these 
proteins. C. albicans mutant strains for these proteins were unable to produce biofilm in 
the surface of a catheter inoculated with the double mutant [647]. Expression of Als1 and 
Als3 in S. cerevisiae strains promoted the adherence of cells to several protein-coated 
substrates [648]. Eap1 and Als1 are expressed in both yeast-form and hyphal cells [649, 
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650]. Als3 is present exclusively in hyphae [649]. The expression of C. albicans adhesins 
is under the control of several transcription factors, which respond to QS signals and 
nutrient availability. These include Efg1, a transcription factor with a basic helix–loop–
helix motif and a homologue of S. cerevisiae Sok2 [651], and Yac1, a DYRK 
transcription factor family member [652, 653]. Efg1 is the major regulator of cell wall 
proteins expression [641, 654, 655], and Yac1 regulates the expression of several adhesins 
and initiation and maintenance of hyphal growth.  
Recently, a further signalling pathway regulating adherence was described, the 
Mating Factor Response pathway [656]. C. albicans a/a cells respond to α-factor by  
 
 
 
Figure 9. C. albicans biofilm development phases and regulatory proteins. Similarly to bacterial biofilms, 
adherence to the substrate is the first step in surface colonization and biofilm development (A). Cells propagate to 
form microcolonies, and start differentiation into pseudo- and true hyphae (B). As the biofilm matures, the 
extracellular matrix accumulates and the overall drug resistance increases (C). In the dispersal step, yeast-form 
cells are released to colonize the surrounding environment (D). Proteins and pathways involved in biofilm 
development are depicted; known pathway relationships (upper half) and proteins with known function in a 
specific step but not be connected to a known pathway (lower half) are represented. Dashed T-shaped bars indicate 
repression by an indirect mechanism. Adapted from [657]. 
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forming a biofilm. These responsive cells are unable to mate with α/α cells because they 
have not underwent the epigenetic transition from white, mating-incompetent, to 
opaque, mating-competent cells [658]. During biofilm formation, white cells present 
several upregulated genes, including the adhesin coding EAP1 and the PGA10, PBR1 
and CSH1 that are fundamental for the proper adherence of pheromone-induced 
biofilms [659]. 
While some external and internal factors may stimulate adherence and modulate 
gene expression, the process of adherence itself promotes changes in gene expression. 
Microarray comparative analysis between planktonic and adherent cells shows changes 
in gene expression around 30 minutes after the beginning of the process [660]. Even 
faster responses were reported, the adherence to glass modulates the expression of 
efflux pumps Cdr1 and Mdr1 just a few minutes after adhesion, promoting antifungal 
resistance in an early phase of biofilm development [661].  
The adherent cells start proliferating and clustering, beginning the yeast-to-hyphae 
transition (Fig. 9 B). These processes are mediated by cell-substrate and cell-cell 
adhesins [662]. The proteins Als3 and Hwp1 are the main adhesins in cell-cell adhesion. 
These proteins are complementary and interact to mediate intercellular adhesion [650, 
663]. Mutants for these adhesins are unable to form biofilms, but the mixture of C. 
albicans mutant strains, each lacking one of these adhesins, results in strong and dense 
biofilms [647]. This mutation complementation derives from the overexpression of Als3 
in an eap1Δ mutant strain, indicating these proteins probably have overlapping 
functions [664]. The expression of adhesins is regulated by several transcription factors, 
including Bcr1, a C2H2 zinc finger protein, and Tec1, a TEA/ATTS transcription factor 
family member. Bcr1 mediates cell-substrate adhesion, being fundamental for biofilm 
formation [642, 665-667], while Tec1 regulates the expression of several hyphal cell wall 
proteins, and is involved in the yeast-to-hyphae transition [668-670] and the white cells 
response to the pheromone signalling [671]. The bcr1Δ mutant strain is unable to form 
biofilms because of the lack of expression of the adhesins Als3 and Hwp1. The over-
expression of these proteins restores the capacity to develop biofilms, both in vivo and 
in vitro [642, 663].  
There are several genes know to be involved in the yeast-to hyphae transition and 
biofilm development. These include the genes GUP1, RBT2, HWP2, SUN41 and 
PGA10 all of which encoding proteins without fully characterized function. In 
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particular, the pleotropic gene GUP1 codes for an O-acyltransferase [415], which 
deletion results in defective hyphal and biofilm development and affects the strain 
virulence and antifungal resistance [633]. The simultaneous deletion of either RBT2 or 
HWP2 and HWP1 results in an increasingly defective adhesion phenotype, while the 
deletion of SUN41 and PGA10 genes increases the sensibility to cell wall inhibitors, 
indicating a potential role in cell wall architecture [672, 673].  
The development of microcolonies interconnected by hyphae leads to the 
production of a supportive and protective ECM (Fig. 9 C). The study of this ECM 
revealed the presence of carbohydrates, proteins, hexosamines, uronic acids and DNA 
[4, 674, 675]. A major component is the carbohydrate β-1,3 glucan. This molecule 
synthesis is significantly increased in biofilm cells and might play a role in antifungal 
resistance [676, 677]. A more detailed analysis of some the C. albicans biofilm 
components revealed an ECM exopolysaccharide composed of α-D-glucose and β-D-
glucose, α-D-mannose, α-L-rhamnose and N-acetyl glucosamine [678]. Yet, the 
molecular identification of most of the biofilm components has focused on proteins and 
was unveiled in proteomic surveys [679-681]. C. albicans biofilms ECM displays a large 
number of very diverse proteins included in the most diverse cellular processes: 
metabolic process, protein synthesis, folding and degradation, cell rescue, defence and 
virulence, and biogenesis of cellular components [679]. A sticking revelation was the 
presence of so many of supposedly intracellular-only proteins, such as the glycolytic 
enzymes Pgk1, Pfk2, Eno1, Fba1, Tdh3, Tpi1, Gpm1 and Hxk2. The abundant presence 
of these enzymes in the biofilm ECM overcame their hypothetic origin from lysis of 
dead cells in the biofilm, and opened the way to consider protein moonlighting [682, 
683]. 
Finally, and similarly to bacterial biofilms, C. albicans biofilms present eDNA, 
which appears to play a structural role in the fungal multicellular aggregates, since 
exogenously added DNA promotes biofilm growth and the addition of DNase resulted 
in the dissociation of the biofilm [675].  
Some environmental factors, namely water availability or the presence of certain 
chemicals, regulate the production of structural components of the biofilm ECM. The 
presence of ionic zinc is one of the best studied environmental inputs, seeming to 
negatively regulate ECM production [684]. The zinc responsive transcription factor Zap1 
activates the expression of Csh1 and Ifd6, and represses the expression of Gca1 and 
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Gca2 and Adh5. The mutant zapΔ forms biofilms with elevated production of β-1,3 
glucans in the ECM. The glucoamylases Gca1 and Gca2 might play a role in the β-1,3 
glucans hydrolysis, and the proteins Adh5, Csh1 and Ifd6 are involved in the synthesis 
of acyl- and aryl- alcohols, putatively acting as QS signals [684, 685]. The biofilm 
maturation, and the production of ECM components, both contribute to high-level 
resistance to antifungals. Several mechanisms underlie this resistance, namely (1) the 
upregulation of the drug efflux pumps genes CDR1, CDR2 and MDR1 early in biofilm 
development [686], (2) the reduced amount of membrane sterols and elevated expression 
of sterol synthesis proteins, comparatively to planktonic cells [660, 686-688], (3) the 
binding and sequestering of antifungal agents by the ECM β-1,3 glucans [676], and (4) 
the existence of subpopulations of persister cells, metabolically quiescent cells that 
resist to a range of drug concentrations otherwise lethal to planktonic cells [689, 690].  
The release of cells from biofilms occurs to allow colonization of new substrates or 
dissemination into the host tissues (Fig. 9 D). These cells are mainly yeast-form cells 
that present increased adherence and filamentous capacity, becoming highly virulent 
[691]. The regulation of this process is not yet fully understood, but the role of the 
transcription factors Ume6, Pes1 and Nrg1 was described. The overexpression of Ume6 
yielded lower levels of released cells, whereas overexpression of either Pes1 or Nrg1 
resulted in higher release of yeast-form cells [691, 692].  
The environmental inputs that regulate most of these processes are not yet fully 
characterized, but most of these surface colonization and biofilm formation mechanisms 
depend on cell-cell communication and behaviour synchronization. Similarly to 
bacteria, fungal pathogens present an auto-regulatory communication system [693, 694]. 
In C. neoformans, QS signalling is performed through a peptide-mediated mechanism. 
The signalling peptide is coded by the gene QSP1, under direct control of Gat201 DNA-
binding regulator, being translated as a larger precursor that undergoes proteolytic 
processing before being secreted. Both production and secretion-mediating are currently 
unknown [695, 696]. The Qsp1 peptide is important in overcoming the inhibition of 
growth at low culture density lag phase. However, only mutants for the repressor Tup1 
present an effect dependent on Qsp1 concentration [695]. In C. albicans biofilms, QS 
signalling is mediated by farnesol and tyrosol [639, 697]; farnesol is an intermediate in 
sterol biosynthesis, whereas tyrosol derives from aromatic amino acids biosynthetic 
pathway. The biosynthesis, as well as the secretion machinery remain uncharacterized 
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[693]. Farnesol regulates cell adherence (Fig. 9 A), increasing amounts of farnesol 
inhibited the cell adherence to substrates, yet it had no effect in biofilm development if 
presented after adhesion was in an advanced stage. An inhibitory effect on cell 
germination was also reported [698], farnesol might mediate yeast-form cells detachment 
and dissemination. Tyrosol-mediated signalling, in turn, influences the lag phase of 
diluted cultures of C. albicans, a microarray analysis showed that tyrosol induces the 
expression of genes involved in DNA replication [697]. However, tyrosol promoting 
effect cannot overcome farnesol inhibitory activity, being a secondary signalling system 
[699, 700]. Unlike in bacteria, where some systems have all intermediates characterized 
and the environmental and internal inputs identified, the QS communication in fungal 
species is still in its first steps. Much more research is needed to understand the full 
effects of QS in multicellular communities’ metabolism and behaviour, and to identify 
the mechanisms that activate or repress such communication. 
Saccharomyces cerevisiae 
S. cerevisiae is one of mankind oldest domestications, providing food and 
beverages since ancient times [701, 702]. One can think of S. cerevisiae as one of those 
friendly neighbours that always has the right tool for the job, or in this particular case, it 
is the right tool for the job. This yeast, useful in so many industrial and biotechnological 
applications, has also lent its many “talents” to biological and medical research, 
contributing with knowledge to understand several fundamental cellular processes, as 
cell cycle [703], providing tools for biomolecules production and manipulation [704, 705], 
and shedding light in some intricate disease processes as a model eukaryote [706-708].  
Similarly to other microorganisms, S. cerevisiae is capable of forming multicellular 
aggregates. Structured communities include flocs, the peculiar stalks, mats or biofilms, 
and, of course, colonies [467, 469, 709-711]. Flocs are industrially relevant aggregates of 
yeast cells, produced in response to environmental variations [712, 713]. However, 
arguably, this transitory behaviour in liquid growth might not be a true multicellular 
community. Most of the times, flocculation can be easily reverted by the action of 
EDTA or mannose [711, 714]. As such, the study of this microorganism growth on solid 
media provided the most important evidences on its ability to be more than an 
undifferentiated cluster of cells, including the production and secretion of a yet 
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uncharacterized ECM. As in the other organisms, this polymeric structure provides 
protection against external insults, interconnects yeast cells with each other mediating 
cell-cell communication, and offers an suitable environment for cellular survival [467]. 
Nevertheless S. cerevisiae multicellular aggregates received little attention for a long 
time. The widely spread biotechnological utilization of this yeast in liquid cultures, 
tightly connected to its fermentative capacity in batch, fed-batch or continuous culture, 
has diverted the attention from S. cerevisiae multicellularity-associated abilities. Quite 
surprisingly, in support of this omission, there are reports that claim this yeast being 
unable to excrete an extracellular matrix [713, 715].  
a) Yeast Stalks 
Yeast stalks were the first multicellular community that received detailed attention 
in the works of Engelberg and collaborators [469, 470]. These authors described the 
morphological structure, the three-dimensional organization, and assessed the 
physiological state of the composing cells. They reported the presence of upright, long 
and thin multicellular aggregates achieving a centimetre size scale, when yeast cells 
were inoculated in high percentage agar media and irradiated with UV light (Fig. 10 A). 
Highly dense lawns of cells (2x106 cells/plate) were exposed to UV radiation until 
99,95% of the cells were dead. The cells that accumulated in tiny pits formed by air 
bubbles in the agar surface were protected by the layers of cells above and survived. 
Under such conditions, the vast majority of the surviving colonies formed stalks. 
Several other species were able to produce stalks in these same conditions, including C. 
albicans and E. coli, which led the authors to suggest that a merely mechanical model 
was responsible for stalk formation. The surviving cells in contact with nutrients, in the 
bottom and the walls of the air bubble pit, started proliferating and the top layers of the 
colony were extruded the cellular mass through the pit hole, forming the stalk. 
However, this environmental and mechanical model was proved to be, at least, 
incomplete [470]. The same group reported the structural organization and cellular 
differentiation across the stalk, an inner core formed by vital yeast cells and spores, was 
enveloped by a physically separated outer shell composed mainly by dying or dead 
cells. The protective shell cells presented very thick cell walls, a large number of 
vesicles. The inner core was described as being composed of cells similar to colony 
cells but presenting several vesicles or fat bodies, and cells presenting 1-2 spores. The 
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spores-containing cells were present only in the top half of the inner core. The cell 
differentiation and structural organization presented by these aggregates goes against 
the initially described model of mere mechanical extrusion. The authors suggested the 
possibility of the cells differentiation occurring in a latter phase of development, after 
the initial stalk formation. The study of this multicellular aggregated halted after these 
first reports, and information regarding these structures supporting ECM, and its 
composition, is not currently available. The study of these peculiar structures may 
provide insight on early mechanisms of multicellular communities’ formation, and in 
the environmental and genetic driving vectors behind them. 
b) Yeast Mats/Biofilms 
Yeast mats, more recently referred as biofilms, are other structural organizations 
that have been receiving great attention [709, 710, 716-721]. Such aggregates were first 
described as multicellular communities grown on low-agar plates, presenting an 
“elaborated pattern” [709]. Yeast cells in a low-agar media (0.3%) for several days form  
 
 
Figure 10. S. cerevisiae multicellular communities. Microphotography of stalks [469](A); mat or biofilm(left 
panel) and detail of mat spokes (right panel) [709](B); and colony structure (left panel) and ECM (right panel) 
[722](C).  
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wide confluent mats, spreading radially until most of the area was covered. These 
communities are organized in two visually distinct populations: a central hub composed 
of a network of “cables”, emanating a bundle of spokes, and a rim of less organized 
cells (Fig. 10 B) [709]. The radial symmetry and the number of spokes were conserved 
under several conditions, indicating a putative programmed developmental event. 
The role of the mucin Flo11 was assessed in S. cerevisiae adhesion to plastic 
surfaces. Cells lacking FLO11 and its regulatory protein FLO8 showed poor adherence 
to plastic substrates. Flo11 is similar to the glycopeptidolipids (GPL) of Mycobacterium 
smegmatis, which depend on these proteins to display sliding motility3 [723, 724]. The 
similarity between Flo11 and the GPLs raised the question as to whether Flo11 might 
mediate biofilm formation and adhesion. The mutant flo11∆ lacked adherence to agar, 
and decreased Flo11 expression was detected in mutants for glucose responsive 
pathways, presenting blocked mat formation and alterations in adherence ability. 
Although Flo11 expression was found in both the rim and the hub cells, the mutant 
flo11∆ loses the ability to form confluent mats above described [710]. Additionally, high 
pH in the rim area decreased the Flo11 adhesion capacity and allows the detachment of 
these cells. The low adherence capacity of the rim cells might be fundamental for the 
colonization of new substrates, in response to changes in glucose levels across the mat. 
Moreover, under glucose limiting conditions, yeast cells were able to adhere and 
form a thin-layered biofilm in several plastic surfaces. Similarly to mat formation, the 
adhesion to plastic is dependent on glucose levels and the presence of Flo11. 
Another study analysed the molecular pathways that may regulate mat formation, 
performing whole-genome transcriptional profiling to compare cells growing as a mat 
and planktonic cells [716]. Gene disruptions of INO2, INO4, and OPI1 revealed that 
Opi1 has a significant effect on mat formation, not presenting spokes and showing a 
poorly developed hub, and INO2 and INO4 have minor effects. Given the important role 
of Flo11 and nutrient limitation conditions in mat formation, the Flo11 expression levels 
and invasive growth in an opi1∆ mutant strain were assessed. The mutant presented low 
levels of Flo11 expression and defective invasive capacity. Both phenotypes were 
dependent on the transcriptional activator Ino2p. These results indicate that Opi1 affects 
mat formation and invasive growth by participating in the regulation of FLO11. Later, 
                                                     
3
 Sliding motility is a form of surface motility of entire colonies obtained by expansive forces produced by the growing bacterial 
population in combination with cell surface physical properties of reduced friction between the cells and the substrate [723].  
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the presence of Flo11-independent regulatory mechanisms of mat formation was 
reported [719, 725]. Martineau and collaborators showed that the disruption of genes of 
the Hsp70 family molecular chaperones and nucleotide exchange factors resulted in 
defective mat formation, but do not interfered with Flo11 expression, localization or 
invasive growth. The effect of the chaperone system disruption in Flo11 folding or post-
translational modifications, such as O-glycosylation, cannot be discarded. Nonetheless, 
this was the first report of a Flo11 independent regulatory mechanism in mat 
development, as the previous reports always referred to mutations that decreased or 
abolished FLO11 expression, affecting invasive growth [709, 716]. 
Until recently, mat formation in low-agar media was studied separately from 
invasive growth since the softness of low-agar surface could not withstand the wash 
under running water. The latest work on mat formation reported conditions to enable the 
evaluation of both the development of the multicellular aggregate in the plate surface, 
and the invasive growth on agar [721]. This work showed that the same pathways 
regulate both processes, and that such mechanisms are two faces of the same response 
to environmental stimuli, regulating S. cerevisiae social behaviour. 
c) Yeast Colonies 
Colonies of S. cerevisiae or any other microorganism have been known and used 
since the dawn of Microbiology. They are recognized as multicellular communities, but 
were mostly considered just unorganized, unstructured lumps of cells. The study of the 
structural organization of these communities started barely a decade ago, when the first 
glimpse of its scaffolding infrastructure was first reported (Fig. 10 C) [722]. 
Interestingly, the first approaches to study colonies as a whole unveiled a cell-cell 
communication system that promoted a synchronized response to environmental signals 
[726-728]. Palková and her group showed that S. cerevisiae colonies exhibit a periodic 
behaviour, transitioning from an active growth “acidic” phase, to an “alkali” phase 
presenting transiently inhibited growth, and back to an “acidic” phase where growth is 
resumed. The transition from “acidic” phase to “alkali” is mediated by amino acid 
depletion, as assessed by the study of mutants in amino acid uptake that were unable to 
make the acidic-to-alkali transition and the transient changes in intracellular amino acid 
concentrations during this transition [728, 729]. During the “alkali” phase, ammonia is 
released and this volatile compound acts as a long-range signal between neighbouring 
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colonies. The ammonia produced by colonies in “alkali” phase induces the production 
of this volatile compound in the neighbouring colonies. The concentration of ammonia 
is especially higher in adjacent regions, where neighbouring colonies growth became 
concurrently inhibited. As the production of ammonia declines, cells resume growth and 
enter the next “acidic” phase. The authors suggested that the ammonia-mediated 
signalling helps synchronize the acid/alkali pulses of neighbour colonies and directs 
their growth to free space. The same group reported that, during colony development, 
some programmed cell death features were observed in an ammonia-dependent manner 
[730]. A volatile signal produced by aging colonies promotes differential cell death 
distribution across the colony, only in the colony centre. The remaining cells might 
utilize the released resources and survive for longer periods. The role of ammonia was 
further highlighted by the survival defect and cell fragility of cells mutant in the gene 
SOK2 [731]. Cells lacking this transcription factor are unable to produce ammonia. 
Genome-wide analysis on gene expression differences between sok2∆ and Wt colonies 
revealed that mutant colonies are not able to switch on the genes of adaptive 
metabolisms effectively, and displayed impaired amino acid metabolism and 
insufficient activation of genes for the putative ammonium exporter Ato. The 
differential expression of several genes during colony morphogenesis, including CCR4, 
PAM1, MEP3, ADE5,7 and CAT2, was also reported [732]. Concurrently, the absence of 
Mca1p metacaspase or Aif1p was shown not to prevent programmed cell death in yeast 
colonies [730], which occurs differentially according to cells position in the colony. 
The first exploration of S. cerevisiae colonies structure and composition was 
reported by Kuthan and his research group [722]. The authors analysed the colonies 
complex structure presented by wild strains and the progressive loss of this complexity 
during the process of laboratory “domestication”. The authors showed that the 
continuous growth under laboratory nutrient-rich conditions of nature isolated S. 
cerevisiae strains leads to the progressive decrease in secreted polymers that 
interconnect and support the colony. The wild strains presented a complex structure 
(Fig. 10 C), named fluffy by the authors, presenting intercellular fibrils and very rich in 
proteins and glycoproteins, whereas, the colonies grown under laboratory conditions 
were lean and structurally poor, presenting significantly less proteins and glycoproteins. 
The presence of long, pseudo-hyphae-like cells in the fluffy colonies was later reported 
by the same group [733].  
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The great influence of ECM production and the high expression of FLO11 and 
AQY1 in three-dimensional colony architecture were also emphasised. Similarly to 
mats, the adhesin Flo11, when present in high levels, could mediate cell–cell adhesion. 
Otherwise, the channel aquaporin Aqy1p can influence water permeability and the 
surface properties. The lack of FLO11 expression in the vast majority of laboratory 
strains due to a mutation in the Flo8 transcriptional activator [734], may be associated 
with the incapacity to produce a complex colony. All fluffy colonies presented high 
amounts of ECM (Fig. 10 C; right panel). The authors mention a method to extract the 
yeast from these colonies [722], but no detailed compositional study was ever reported. 
More recent works showed the importance of Flo11 to intercellular connections inside 
de colony, especially in the aerial parts and cavities architecture, and reinforced the 
predicted role of ECM in the protection of the colony, presenting low-permeability even 
to small molecules [735]. The presence of drug efflux pumps in the top layers of the 
mature colonies and elongated cells anchoring the community were also described in the 
same report. The latest study on S. cerevisiae colony structure and ECM composition 
focused on the metabolically distinct subpopulations of these communities [736]. The 
authors were able to identify two major subpopulations in a growing colony, U and L 
cells occupying the upper and lower colony regions, respectively. These subpopulations 
were distinct in cellular ultrastructure, physiology, gene expression, and metabolism and 
the authors suggested that metabolite exchange occurs between these different yeast cell 
types. The population closer to the substrate, L cells, displayed features of stressed and 
nutrient starved cells, presenting active degradative mechanisms to recycle cellular 
components. The upper subpopulation, U cells, presented an active metabolism 
controlled by TOR pathway, amino acid sensing systems and mitochondrial-mediated 
signalling; promoting adaptation to nutrient limitations and scavenging of L cells 
metabolites.  
The study of S. cerevisiae multicellular aggregates is still in its very early stages as 
compared to bacteria or fungal pathogens. The future developments will no doubt 
contribute to unveil the nature and roles of ECM in the radical change between cellular 
behaviour when alone or in a community, and understand the very roots of 
multicellularity in Eukaryotes, further allowing the use of yeast as a model also for 
higher eukaryotes ECM-related pathologies. 
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Objectives 
The yeast Saccharomyces cerevisiae is a well-known eukaryote that has provided 
crucial information in most cellular processes, contributing to understand other more 
complex organisms and their malfunctions. Also important is the role that this microbe 
plays in the food industry, as well as in so many biotechnological applications, 
contributing daily to the fulfilment of human needs. However, the multicellular 
communities formed by this microorganism are barely known, on one hand because 
traditionally a microorganism is by definition regarded a unicellular being, and in 
another hand because it actually presents some technical difficulties to assess the 
multicellular properties and behaviour. 
In this context, the primary objective of this thesis was to develop, and credit 
experimentally, the essential protocols that allow the assessment of the extracellular 
matrix produced by the yeast S. cerevisiae. The focus on the extracellular matrix 
derived from the recognition that in other more complex eukaryotes, ECM is in the 
centre of most of the fundamental biological processes controlling existence. Hence, the 
work dedicated to pioneer: 
I. the establishment of a reproducible methodology for the generation of a young 
yeast cells matt that allowed the retrieval of analysable amounts of ECM; 
II. the characterization of the proteins secreted by yeast to the ECM; and 
III. the characterization of the glycosidic constituents of the yeast ECM. 
For this purpose, we chose to use S. cerevisiae W303-1A strain, as well as the 
derived mutant strains deficient in genes encoding for the putative morphogen-
modifying enzymes, the Gup1p and Gup2p. These proteins are orthologous to high 
eukaryotes acyltransferases that modulate morphogens from the Hedgehog pathway, 
main players in ECM biological roles. Finally, and as additional preparation for future 
yeast ECM-related work, also the mammalian receptors of hyaluronic acid, a major 
regulator of ECM biophysical properties, were cloned into the same strains. 
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Abstract 
Multicellularity depends on a complex balance between the needs of individual 
cells and those of the organism. It is maintained by a tightly controlled communication 
network between cells mediated by the extracellular matrix (ECM) in which the cells 
are embedded. ECM provides tissues with a cell-supporting scaffold, mediating 
molecules diffusion and cell migration, and its components have an active role in each 
cell fate. Microorganisms like Saccharomyces cerevisiae are mostly regarded as 
unicellular organisms. However, they can form large communities – colonies, biofilms 
and stalks - in which cells display complex multicellular-type behavior. These 
communities function as proto-tissues: yeast cells organize hierarchically to form basic 
supra-cellular structures that maintain the group shape and actively promote its survival, 
while individual cells roles and fates become differentiated. We extracted S. cerevisiae 
ECM and characterized its proteome. More than 600 proteins were identified; most 
being ascribed to intracellular functions and localization and found extracellularly for 
the first time. This might indicate unexpected extensive moonlighting. The entire sets of 
enzymes from glycolysis and fermentation, as well as gluconeogenesis through 
glyoxylate cycle were highly represented, raising considerable reason for doubt as 
whether there is extracellular metabolism. Moreover, a large number of proteins 
associated with protein fate and remodeling were found. These included several proteins 
from the HSP70 family, and proteases, importantly, the exopeptidases Lap4, Dug1 and 
Ecm14, and the metalloproteinases Prd1, Ape2 and Zps1, sharing a functional zincin 
domain with higher Eukaryotes ECM metalloproteinases. The further presence of the 
broad signaling cross-talkers Bmh1 and Bmh2, as well as the homing endonuclease Vde 
that shares a Hedgehog/intein domain with the Hh morphogens from higher Eukaryotes, 
suggest that analogously to the tissues in these organisms, yeast ECM is mediating 
signaling events. 
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Introduction 
The yeast Saccharomyces cerevisiae is the most studied and best-known lower 
Eukaryote. As all microorganisms, it is mostly regarded as a unicellular organism. Yet, 
S. cerevisiae, as other yeasts, can form large multicellular communities: colonies, 
biofilms, and stalks [1]. All these are formed by extremely large numbers of cells, 
sustained by a scaffolding extracellular polymeric substance (EPS), forming a network 
of channels conducting water and nutrients to the cells farther from the surrounding 
medium [2-5]. This is accompanied by large differences in gene expression, metabolic 
performance between cells in different layers [4, 6-8], namely, the different biological 
behaviour of cells in what regards apoptosis and therefore cell fate [4, 6-8]. These 
observations suggest that yeast multicellular aggregates display multicellular-type 
behaviour and may therefore be regarded as proto-tissues. In tissues from higher 
Eukaryotes, cells are embedded in the extracellular matrix (ECM) that, besides 
providing these with a supporting scaffold, also mediates molecules diffusion and cell 
migration, and which components have an active role in each cell fate [9]. Identically, 
the existence of a microbial ECM in colonies and biofilms, frequently referred as 
extracellular polymeric substance (EPS), with active roles in the protection against 
xenobiotics and dissecation has been described in S. cerevisiae [4, 7], and C. albicans 
[10]. This encompasses a new conceptualization of microbial life, taking colonies and 
other multicellular structures as the simplest forms of multicellular organization, with 
tissue-like behaviour, ensuring spatial organization and group survival. 
The molecular characterization of the yeast ECM is still incipient. The ECM of S. 
cerevisiae colonies display large amounts of glycoproteins [2], namely the flocculin 
Flo11 [8], while C. albicans biofilms have been reported to contain proteins, sugars and 
DNA [11, 12]. Several proteins from carbon metabolism were identified, namely several 
glycolytic and fermentative enzymes, as well as members of the HSP70 family [13, 14].  
Our group developed a methodology to retrieve amounts of S. cerevisiae ECM 
large enough to be assessed in detail. In this work we report, for the first time to the best 
of our knowledge, the molecular characterization of yeast S. cerevisiae ECM proteome. 
We identified the proteins secreted in yeast ECM grown to homogenous overlay/mat, 
and compared these with the ones secreted in identical liquid media samples. 
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Importantly, most of the proteins identified are annotated to cellular compartments, and 
are now reported to appear extracellularly for the first time. Moreover, entire sets of 
main metabolic pathways were found, and identically to higher Eukaryotes’ ECM, a 
large number of chaperones and metalloproteinases were identified. This work 
contributes to the assertion of yeast ECM importance in the development of 
multicellular aggregates through a first comprehensive image of its molecular 
composition. 
Materials and Methods 
Strains and Media  
S. cerevisiae strain W303-1A (MATa; leu2-3; leu2-112; ura3-1; trp1-1; his3-11; 
his3-15; ade2-1; can1-100) was used in this work [15]. Cells were grown on rich 
medium, YPD (yeast extract 1%; peptone 2%; glucose 2%; adenine hemisulphate 
0.005%) on an orbital shaker, 200 rpm, at 30°C. Growth was monitored by optical 
density (OD) at 600 nm. Solid growth was performed in agarose (2%, w/v) 
supplemented YPDa plates. All ingredients percentages were calculated as weight per 
volume units.  
Yeast Overlay Development and Matrix Extraction 
The development of a uniform, ±3 mm thick homogenous yeast culture mat was 
obtained spreading evenly 1.5 ml of YPD batch cultures at OD600 1 in Ø 90 mm YPDa 
plates and incubating for 7 days at 30 °C [2]. The cellular biomass was gently swapped 
into a 50 ml Falcon tube. The suspension was washed with PBS buffer (NaCl 100 mM; 
KCl 2.7 mM; Na2HPO4.2H2O 10 mM; KH2PO4 2.0 mM; pH 7.4), supplemented with a 
protease inhibitor cocktail (PMSF 0.2 µg/ml; Aprotinin 0.32 µg/ml; Pepstatin 1 µg/ml; 
Leupeptin 1 µg/ml), and incubated for 10 min with constant rotation in a tube roller 
(SRT1; Stuart, Staffordshire, UK). The suspension, containing cells and ECM, was spun 
down for 10 min at 15,000 rpm and 4 °C in a Sigma 4-16K centrifuge (Sigma, Osterode, 
Germany). The supernatant was collected and freeze-dried. The proteins were 
precipitated using the chloroform/methanol protocol as before [16]. Overnight batch 
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cultures on liquid YPD with an air:liquid ratio of 2:1 were used as control, to assess the 
proteins from the extracellular growth medium. Cultures were centrifuged for 10 min at 
5000 rpm, and the supernatants collected and processed in the same way as the ECM 
samples. 
Cellular viability assessment  
Membrane integrity was assessed by cytometry as described before [17]. Briefly, 
cells were harvested and added 4 μg/ml PI (Sigma). After a 10 min incubation in the 
dark at room temperature, the samples were analysed in an Epics® XL™ (Beckman 
Coulter) flow cytometer.  
Proteomic analysis 
The SDS-PAGE was carried out in a 10% homogeneous gel [18]. Protein expression 
was analysed through Western Blot as described before [19]. Total protein extract (50 
µg) was brought up to 40 µl with MilliQ water and mixed with loading buffer 5X [18]. 
The samples were loaded and run at low voltage (25 V) until the migration front 
reached 2-3 mm above the resolving gel. Two dimensions electrophoresis (2DE) were 
performed as described before [20], with minor modifications. The samples were cup 
loaded in isoelectric focusing (IEF) dry strips (24 cm, pH 3-11 NL), and the IEF 
performed at 20 °C, according to the following program: 120 V for 1 h; 500 V for 2 h; 
500-1,000 V in gradient for 2 h; 1,000-5,000 V in gradient for 6 h; and 5,000 V for 10 
h. Second dimension SDS-PAGE were run on homogeneous polyacrylamide gel (12% 
T, 2.6% C). Gels were stained with Colloidal Coomassie Blue as before [21]. 
The bands containing protein total extract, as well as the chosen spots from the 
2DE, were excised and in-gel digested as described in the literature [22]. Samples were 
digested overnight at 37 °C with 12.5 ng/μl and 1 µg/20µg protein of sequencing grade 
trypsin (Roche Biochemicals), and in 25 mM ammonium bicarbonate (pH 8.5), for spots 
and bands, respectively. After digestion, the supernatant from the excised protein bands 
were analysed by LC-MS/MS and the spots assessed by MALDI-TOF.  
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Protein Identification  
LC-MS/MS  
The total extract samples (5 μl), in 0.1% formic acid for a final concentration of 1 
μg/μl, were loaded onto a C18-A1 ASY-Column 2 cm pre-column (Thermo Scientific) 
and then eluted onto a Biosphere C18 column (inner diameter 75 µm, 15 cm long, 3 µm 
particle size) (NanoSeparations). The proteins were separated using a gradient on a 
nanoEasy HPLC (Proxeon) coupled to a nanoelectrospray ion source (Proxeon), at a 
flow-rate of 250 nl/min. The mobile phase A consisted of 0.1% formic acid in 2% CAN 
and mobile phase B was 0.1% formic acid in 100% CAN. A solvent gradient was 
applied for 140 min, from 0% to 35% phase B. Mass spectra were acquired on the LTQ-
Orbitrap Velos (ThermoScientific) in the positive ion mode. Full-scan MS spectra (m/z 
400-1800) were acquired with a target value of 1,000,000 at a resolution of 30,000 at 
m/z 400 and the 15 most intense ions were selected for collision induced dissociation 
(CID) fragmentation in the LTQ with a target value of 10,000 and normalized collision 
energy of 38%. Precursor ion charge state screening, and monoisotopic precursor ion 
selection, were enabled. Singly charged ions and unassigned charge states were rejected. 
Dynamic exclusion was enabled with a repeat count of 1 and exclusion duration of 30 
ms. 
Proteome discoverer 1.2 with MASCOT 2.3 was used as search engine to search in 
the Uniprot/Swissprot (taxonomy Saccharomyces cerevisiae) database (7,798 
sequences). The search parameters used were the following: peptide tolerance - 10 ppm; 
fragment ion tolerance - 0.8 Da; missed cleavage sites - 2; fixed modification, 
carbamidomethyl cysteine and variable modifications, and methionine oxidation. 
Mascot ion score 20 and a 99% peptide confidence were set as filters. 
MALDI-TOF/TOF 
The supernatants from spots excised from 2DE gels were collected and 1 μl was 
spotted onto a MALDI target plate and allowed to air-dry at room temperature. 
Subsequently, 0.5 μl of α̣-cyano-4-hydroxytranscinnamic acid matrix (3 mg/ml in 50% 
(v/v) acetonitrile (Sigma Aldrich)) was added to the dried peptide digest spots, and 
allowed to air-dry again at room temperature. Analyses were performed in a 4800 Plus 
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MALDI TOF/TOF™ and Proteomics Analyzer (Applied Biosystems. MDS Sciex, 
Toronto, Canada), using 4000 Series Explorer™v 3.5 software (ABSciex). The 
instrument was operated in reflector mode, with an accelerating voltage of 20,000 V. 
All mass spectra were internally calibrated using peptides from the auto-digestion of the 
trypsin. The MS spectra of all the spotted fractions were acquired in positive reflector 
mode for peak selection (S/N>12). The suitable precursors for MS/MS sequencing 
analysis were selected, and fragmentation was carried out using the CID (atmospheric 
gas) on 1 Kv ion reflector mode, and precursor mass Windows +/− 4 Da. The plate 
model and default calibration were optimized for the MS-MS spectra processing.  
The search of peptides was performed in batch mode, using GPS Explorer v3.5 
software (ABSciex), 2.3 of MASCOT version (www.matrixscience.com), using the 
NCBInr database (date: 08052012; 17919084 sequences; 6150218869 residues). The 
MASCOT search parameters were: (1) species - S. cerevisiae, (2) allowed number of 
missed cleavages – 1, (3) fixed modification - carbamidomethyl cysteine, (4) variable 
modifications - methionine oxidation, (5) peptide tolerance - ±50 ppm for PMF and 80 
ppm for MSMS searches, (6) MS/MS tolerance - ±0.3 Da, and (7) peptide charge - +1. 
In all identified proteins, the probability score was p<0.05, i.e., greater than the one 
fixed by Mascot as significant. 
Western blot 
The western blot was performed as described before [19]. The blot was revealed 
using the peroxidase subtract 3,3’-diaminobenzidine (Sigma, UK). The rabbit anti-VDE 
antibody was kindly provided by Professor Yoshi Ohya (University of Tokyo, Japan). 
Results and Discussion 
Experimental Strategy 
Our approach to study the yeast ECM proteome started with the standardization of 
a methodology to multiply the cells into an homogenous overlay/mat of solid growth 
that can be reproducibly obtained, and that is manageable for the extraction of usable 
 THE PROTEOME OF S. CEREVISIAE ECM 
118 
amounts of ECM. Colonies are too small to handle in that sense. The cells in the mat 
were primarily separated from the surrounding ECM, and fractioned into analytical-
grade protein and sugar fractions. As control for the detection of proteins that 
correspond exclusively to the yeast ECM, we examined the secreted proteins during 
batch growth in identical liquid medium (Table 1). 
Cells were inoculated so as to fill a whole Petri dish, thus providing a cellular 
environment similar to a colony [23, 24] yet greatly increasing the yield in biomass. The 
development of a thick homogenous mat was achieved after 7 days, similarly to other 
reports [2, 23]. Outer layers of cells from yeast colonies are usually composed of dying 
cells [25]. A similar observation was reported in S. cerevisiae stalks [26]. The viability of 
the cells during this growth process was followed by cytometry (not shown). The results 
indicated that in the 7 days-mat, ±15% of the cells were dead or presenting 
compromised membrane integrity. As much as the existence of dead cells may be 
natural in vivo, eventually contributing to colony or biofilm regular life, the presence of 
dead cells debris in the ECM samples affects the variety and number of intracellular 
molecules identified. Therefore, to avoid that intracellular, plasma membrane and cell 
wall proteins are unduly released into the ECM, a mild non-enzymatic method was 
chosen to separate and extract the ECM components. To achieve this, cells were gently 
emulsionized in PBS buffer and centrifuged. The protein fraction was obtained with a 
protein precipitation protocol known to remove most salts and detergents [16], The use 
of this protocol was particularly important to avoid interference of buffer salts in the 
downstream analysis by polyacrylamide gel-based electrophoresis (2DE and SDS-
PAGE) and liquid chromatography coupled with tandem mass spectrometry (LC-
MS/MS).  
Proteins Identification 
The ECM protein extracts were analysed and compared with batch cultures 
extracellular medium. The range of protein separation obtained by a large size 2DE was 
complemented by further using LC-MS/MS. The first encompassed 17 - 120 KDa and 4 
- 10 pI proteins. The second allowed the separation of proteins from 3 - 430 KDa and 
3.88 - 11.36 pI [20]. The extracts were also preliminarily assessed through SDS-PAGE, 
comparing the total protein extract against the proteins secreted during solid and liquid 
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growth (Fig. 1 A). The ECM extract band pattern was clearly different from both total 
protein and liquid grown samples. The 2DE were identical in 4 independent assays (Fig. 
1 B), reinforcing the reproducibility of the ECM extraction methods. With both 
approaches 693 proteins were unequivocally identified (Table 2). These proteins belong 
to very diverse pathways, mechanisms and structures. The ECM thus emerges as a 
dynamic and rich environment, with high molecular diversity. The majority of the 
proteins identified are ascribed to intracellular compartments in databases. In fact, only 
106 were already annotated to the cell surface, cell wall and/or plasma membrane 
(Table 2), whereas 27 have no ascribed  
 
Figure 1. SDS-PAGE and Two-dimensions electrophoretic (2DE) separation of the Yeast ECM proteome. The SDS-
PAGE analysis (A) of total protein extract (1), ECM proteome (2), and liquid growth secreted proteins (3) reveal 
three distinct profiles. The ECM proteome presents a different band pattern from both (1) and (2). The intensity of 
some bands indicates that the ECM is enriched in some protein species. The 2DE (B) revealed the presence of several 
glycolytic enzymes, as well as stress response. Some of these proteins should present post-translational modifications, 
as the predicted pI is different from the experimental determined pI. 
 
 
location. Nevertheless, some of the supposedly intracellular proteins were already 
reported to appear in the cell surface, namely several of the glycolytic/ fermentation 
enzymes [20, 27]. Actually, in yeasts, proteins unconventional localization appears to be 
more common than thought [28], and might correspond to moonlighting proteins for 
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their unexpected roles, although this designation has been mainly applied to proteins of 
higher Eukaryotes [29]. A good example of such a protein is S. cerevisiae enolase [30] 
that was also identified in yeast ECM in the present work. 
The subcellular localization-related information is often generated using 
fluorescence-tagged proteins in liquid grown cells [31, 32], although non-tagged proteins 
may localize differently [33, 34]. Additionally, also different cultivation conditions 
interfere with protein localization [35]. Computer assisted analysis of protein sequences 
to predict subcellular location and secretion based on the recognition of signal peptides 
can be surpassed by the biological mechanism. Most proteins in eukaryotic cells are 
targeted to the membrane and extracellular space through a tightly regulated process, 
the canonical Endoplasmic Reticulum (ER)/ Golgi-dependent secretory pathway [36]. 
However, some proteins are secreted through unconventional mechanisms [28, 37, 38], 
that mediate the transfer for the extracellular space of two kinds of proteins, (i) those 
that do not have a recognized signal sequence, and (ii) those presenting the signal 
peptide, but suffering modifications during the trafficking being diverted from the 
classical secretory mechanism [37]. Therefore the realization that many proteins actual 
path during their lifetime is mostly unknown [28]. 
Functional Classification and ECM Relevant Families 
From the yeast ECM 693 proteins (Table 2), 630 have known or predicted roles 
spread by a wide range of functional groups, while 63 are presently either 
uncharacterized ORFs or have no attributed function (Fig. 2). From these functional 
groups, metabolism and protein fate account for 46% of the ECM proteins. Moreover, 
almost 19% accounts for processes of cellular response, including stress response (Fig. 
2). 
Metabolism 
The carbon metabolism group includes all the enzymes necessary to accomplish 
glycolysis and alcoholic fermentation, as well as the gluconeogenic 
phosphoenolpyruvate carboxykinase Pck1 (Table 2). Furthermore, the enzymes Aco1, 
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Cit1, Mls1, Mdh1, Idh1, Icl2, Idh2 and Idp24 from either or both the glyoxylate and 
TCA cycles were also found (Table 2). Besides carbon, the metabolism of amino acids, 
nucleotides and lipids are also represented (Table 2). 
The presence of a whole metabolic pathway in biofilms had already been suggested 
to occur in C. albicans [13]. Besides, several glycolytic enzymes (Tdh3, Eno1/2, Pgk1, 
Pyk1 and Fba15) were localized to the cell surface [22, 39]. These proteins may be 
moonlighters. Tdh3 was detected in the outermost layer of the C. albicans cell wall and 
suggested to act as fibronectin and laminin-binding protein [40], mediating this yeast 
adhesion to tissues during pathogenic invasion. Accordingly, Tdh3 is found 
overexpressed C. albicans biofilms, being suggested to be implicated in their 
development [13]. On the other hand, based on results from the ICL1 deletion mutant, 
the glyoxylate cycle has been suggested as mandatory for C. albicans virulence [41], 
although its enzymes were never reported to appear extracellularly. The glyoxylate 
cycle is used in yeasts for gluconeogenesis from fatty acids. Glyoxylate and acetyl-CoA 
are ultimately converted into phosphoenolpyruvate, which is the product of Pck1, the 
first enzyme in gluconeogenesis, which is also present in yeast ECM.  
S. cerevisiae is Crabtree positive. It preferably utilizes high amounts of glucose to 
form ethanol, even in the presence of oxygen [42]. Glucose exerts repression on the 
genes that enable the consumption of alternative carbon sources, such as ethanol [43]. 
These include a number of genes involved in mitochondrial and peroxisomal functions. 
The presence in the yeast ECM of proteins which genes are known to be in vivo under 
glucose repression, like Pck1, Mls1 and Icl2, could suggest that the yeast cells mat 
generated two types of cellular population, one using glucose in the growth medium, 
and the other putatively feeding on the ethanol generated by the first. In colonies of S. 
cerevisiae, there has been reference to the existence of two sub populations of cells 
metabolically diverse, promoting nutrients flow inside the colony [44]. Identically, C. 
albicans biofilms display sub-populations of morphologically and metabolically distinct 
cells [45]. In liquid grown yeasts, where there is unrestricted access to nutrients, some of 
these glycolytic enzymes were also reported at the cell surface [20, 21, 27]. At this stage 
we can only speculate what the true function of these proteins in the ECM might be, 
                                                     
4 Aco1 – aconitase; Cit1 - citrate synthase; Mls1 – malate synthase; Mdh1 – malate dehydrogenase; Icl2 – isocitrate liase; 
Idh1/ Idh2/ Idp2– isocitrate dehydrogenases. 
5 Tdh3 - glyceraldehyde-3-phosphate dehydrogenase; Eno1/2 – enolase; Pgk1 - 3-phosphoglycerate kinase; Pyk1 - Pyruvate 
kinase; Fba1 - Fructose 1,6-bisphosphate aldolase. 
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namely, whether there is extracellular metabolism as the finding of complete pathways 
might suggest.  
 
 
Figure 2. Functional distribution of the proteins from S. cerevisiae extracellular matrix. 
 
Protein fate 
Of all S. cerevisiae ECM proteins, 147 are involved in the synthesis, folding and 
degradation of other proteins (Fig. 2; Table 2). These include the proteins from the 
HSP70 family, Ssa1/2/3/4, Ssb1, Ssc1, Sse1/2 and Kar2, and the proteases, Lap4, Dug1, 
Ecm14, Ape2, Prd1 and Zps1. The HSP70 family includes chaperones that are 
responsible for the folding and membrane translocation of other proteins [46]. In 
particular, Ssa1 and Ssa2 are implicated in the biosynthesis and assembly of the cell 
wall [47]. These two proteins, as well as Ssb2 and Sse1 were previously reported to be 
present in the cell surface in both S. cerevisiae and C. albicans [20, 21, 27].  
In mammalian ECM, metalloproteinases ensure constant remodelling of the 
glycoproteins [48]. Yeasts do not have a group of recognized metalloproteinases. 
Nevertheless, from the proteases found in S. cerevisiae ECM, Lap4 is a Zn-
metalloproteinase, Dug1 is a metallo-di-peptidase, Ecm14 is a Zn-carboxipeptidase, 
Prd1 is a metalloendopeptidase, and Ape2 is an aminopeptidase. Lap4, Dug1 and 
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Ecm14 share the functional domain Zn–dependent exopeptidase, therefore belonging to 
the same Zn-dependent exopeptidases superfamily (53187), which includes another 11 
yeast members not found in the ECM survey. On the other hand, Prd1 and Ape2 both 
have a functional zincin domain. This domain is also present in another protein 
identified in yeast ECM with unknown function, Zps1. Prd1, Ape2 and Zps1, together 
with 6 other yeast proteins not found in the ECM survey, belong to the Metalloproteases 
("zincins") superfamily (55486) that includes, importantly, mammalian ECM 
metalloproteinases [49]. In higher Eukaryotes, ECM demands for constant remodelling. 
Analogously, we suggest that such a function in S. cerevisiae ECM is performed by the 
hereby-identified metalloproteinases Lap4, Dug1 and Ecm14 from the Zn-dependent 
exopeptidases superfamily, and Prd1, Ape2 and Zps1 from the metalloproteases 
("zincins") superfamily, as well as the HSP70 chaperones Ssa1/2/3/4, Ssb1, Ssc1, 
Sse1/2 and Kar2.  
Once considering the parallelism between yeast and higher Eukaryotes ECM, we 
should expect to find a protein able to perform the structural roles of collagen and 
proteoglycans. Springer and co-workers [50] showed that the pathogenic yeast 
Cryptococcus gattii formed extensive extracellular fibrils sensitive to cytoskeleton 
protein inhibitors [50]. Also in S. cerevisiae, inter-cellular filaments were reported in 3 
weeks starved colonies [51], although there was no reference as to their molecular 
nature. In the present survey, actin (Act1) was well represented (Table 2), and tubulin 
(Tub2) was also found although in trace amounts (Table 2).  
Cellular response 
From the group of proteins that were ascertained to the broad designation of 
Cellular Response, the presence of ROS-related proteins, the signalling Bmh1 and 
Bmh2, and the Subunit A of the V1 domain of the vacuolar ATPase Tfp1 stand out. 
Response to oxidative stress is another function well represented in the yeast ECM 
through the presence of Sod1 and Sod2, Ctt1, Trx1 and Trx2 and Trr16. These enzymes 
are involved in the response to several reactive oxygen species (ROS), namely 
superoxide and both hydrogen and organic peroxides. Cells deficient in SOD1 grow 
poorly in liquid media [52], yet, both these and the ∆sod2 mutants keep producing 
                                                     
6
 Sod1 / Sod2 – superoxide dismutase; Ctt1 – catalase; Trx1 / Trx2 – thioredoxin; Trr1 - thioredoxin reductase. 
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colonies identically to Wt. This could indicate that the response to oxidative stress is not 
working as such in a multicellular environment. In accordance, Cap and co-workers [53] 
showed that colonies lifespan depends more on the maintenance of cellular metabolic 
differentiation, and Sod2 is necessary for this differentiation, since the deletion of this 
gene affects cell ageing and viability across the whole colony [53].  
The Bmh1 and Bmh2 found in yeast ECM are also known as the 14-3-3 proteins. 
They are transversal to a large number of signalling pathways. These include the TOR 
pathway and retrograde response, HOG, PKC and Ras, pathways as well as the chitin 
synthesis control [54, 55]. In S. cerevisiae the double deletion of these two genes is lethal 
[56]. Bmh1 and Bmh2 have been observed in the cell surface of both S. cerevisiae and 
C. albicans [20, 22, 27]. The presence of such broad cross talking controllers of signalling 
in the yeast ECM suggests that, identically to higher Eukaryotes, signalling events occur 
through the matrix, therefore implying cell-to-cell communication. 
Tfp1 is the designation of the ORF that actually encodes for two proteins, the 
vacuolar membrane ATPase Vma1, and the intein homing endonuclease Vde, also 
known as PI-SceI. In the present survey, the peptides that originated the identification of 
Tfp1 correspond to three different parts of this ORF, two inside the Vma1 sequence (in 
the beginning and in the end of the protein), and the other inside the Vde sequence. This 
means that the yeast ECM may actually harbour either or all Tfp1, Vma1 and Vde.  
The presence of the Vde protein in the ECM was further surveyed by Western Blot 
with a rabbit anti-Vde antibody. This antibody is capable of recognizing Vde before and 
after the auto-excision process, yielding several molecular size bands. Tfp1 has 120 
kDa, Vma1 70 kDa and Vde 50 kDa [57]. In the total cell protein extract (including all 
the intracellular proteins), a thick band of 50 kDa (Fig. 3, lane 1, arrow head) indicated 
the presence of large amounts of Vde. Additionally, this sample also presents the 
predicted higher and lower molecular weight intermediates of 90 kDa, 80 kDa, 40 kDa 
and 30 kDa corresponding to Vde+Vma1-C’, Vde+Vma1-N’, Vma1-C’and Vma1-N’ 
respectively (Fig. 3, lane 1, arrows). This is in agreement with the intracellular 
processing mechanism of Tfp1 to yield Vma1 and Vde [57]. However, the lower 
molecular weight intermediates visible in lane 1 are absent from ECM protein sample 
(Fig. 3, lane 2), as well as from lane 3 which shows residual amounts of Vde secreted 
during liquid growth (Fig. 3, lane 3). In view of these results, the presence of this 
protein in the ECM seems to occur through a specific mechanism, as the lower 
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molecular weight bands should result from misprocessed proteins during intein 
excision. As such, the presence of just the intein (50 kDa band) and some higher 
molecular weight intermediates suggests that only the correctly processed forms are 
secreted, indicating the presence of some kind of regulatory mechanism.  
 
 
Figure 3. Yeast intein Vde presence assessed through Western Blot. The intein Vde was present in all 
tested conditions, total cell protein extract (1), ECM proteome (2) and liquid growth secreted proteins 
(3). The antibody detected and bound the main 50 kDa form (arrow head), as well as all the higher 
molecular weight intermediates forms and the miscleaved smaller peptides (arrows). The ECM extract 
presented both the mains 50 kDa protein and the higher intermediates, but completely lacked the smaller 
size peptides. Only the 50 kDa protein was above detection level in (3). 
 
 
The Vde is the only recognized intein from S. cerevisiae proteome, and belongs to 
the Hedgehog/intein (Hint) domain superfamily 51294. This superfamily includes the 
self-splicing Hedgehog (Hh) proteins from higher Eukaryotes. The Hh proteins 
command crucial events during embryogenesis and wound healing, namely cellular 
differentiation, patterning and migration [58]. The pathway operates on a cell-to-cell 
signalling basis. The signalling Hh protein diffuses through the ECM generating a 
molecular gradient according to proximity [59]. Considering that S. cerevisiae colonies 
and C. albicans biofilms display sub-populations of metabolically, molecularly and 
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morphologically differentiated cells [10, 44], it would not be surprising if a Hedgehog-
like pathway could operate through yeast ECM. The proteins that modify the Hh 
secreted signal in numerous high Eukaryotes, Hhat and Hhatl, are orthologous to the S. 
cerevisiae MBOAT O-acyltransferases Gup1 [60] and Gup2 [61-63] and C. albicans 
Gup1 [64]. The putative presence of Tfp1, Vma1 and/or Vde in the yeast ECM, along 
with the Bmh1 and Bmh2, is a strong indicator that broad signalling events implicating 
cell-to-cell communication might operate in a Hedgehog pathway-like manner in yeast 
ECM. 
Conclusions 
The acknowledgement of the existence of structural organization, and differential 
expression of genes with concomitant metabolic and morphological specialization 
across a yeast colonies, biofilms or stalks, suggests that yeasts have a complex 
multicellular behaviour. The existence of an extracellular matrix that, in analogy to the 
higher Eukaryotes, may operate as scaffold but also actively contribute to this behaviour 
agrees with the suggested complexity. The present work presents the first identification 
of the proteome of S. cerevisiae ECM.  
It stands out the presence of sets of intracellular enzymes covering whole metabolic 
pathways, glycolysis and gluconeogenesis through the glyoxylate cycle. Although some 
of these enzymes have been previously described as moonlight proteins, the presence of 
entire pathway enzyme sets generates doubts as whether these might actually be 
metabolically active in the yeast ECM. Additionally, the simultaneous presence of 
glycolytic and glucose repressible enzymes could derive from two metabolically distinct 
sub-populations of cells coexisting in the multicellular aggregates. This would also be 
compatible with the extracellular presence of proteins from oxidative stress response 
that have been associated with cellular differentiation and ageing in yeast colonies. 
Furthermore, from the proteins identified, it also stands out the presence in S. cerevisiae 
ECM of chaperones and metalloproteinases that could be active on protein remodelling, 
identically to the metalloproteinases from higher Eukaryotes ECM. Further extending 
this parallel, broad signalling events could originate from the diffusion of proteins found 
in yeast ECM, able to control many pathways and to possibly also command 
differentiation and spatial distribution events. By this work, a door is opened to deepen 
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the understanding of yeast extracellular matrix as a model for multicellular life, taking 
yeast colonies, biofilms, or other types of large aggregates like the overlays used in this 
work as tissue-like communities. 
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Abstract 
In a multicellular organism, the extracellular matrix (ECM) provides a cell-
supporting scaffold and helps maintaining the biophysical integrity of tissues and 
organs, at the same time playing crucial roles in cellular communication and signalling, 
implicating in spatial organization, motility and differentiation. Similarly, the presence 
of an ECM-like extracellular polymeric substance is known to support and protect 
bacterial and fungal multicellular aggregates such as biofilms or colonies. However, the 
roles and composition of this microbial ECM are still poorly understood. In the present 
work, we report a protocol for obtaining a homogenous mat of young cells of 
Saccharomyces cerevisiae and from this the extraction and separation into analytical 
purity of the main molecular fractions of yeast ECM. The analysis of the glycosidic 
fraction by anion exchange chromatography, diaminopropane agarose and 
polyacrylamide electrophoresis, suggests the presence of two well-defined low 
molecular weight polysaccharides. The mass spectrometry data indicates that these are 
composed of glucose, galactose, mannose and uronic acids. Our results also suggest the 
presence of possible sulphate substitution, given the metachromatic shift of DMMB and 
toluidine blue, as well as the anticoagulant effect variably displayed by the ECM 
extracts of some yeast mutant strains. These results pioneer the study of yeast surface 
glycomics beyond the cell wall, opening a whole range of unsolved questions for the 
future, and positioning S. cerevisiae as a possible model for the study of eukaryotic 
ECM. 
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Introduction 
In a multicellular organism, the maintenance of the homeostatic balance required 
for regular function ultimately depends on the extracellular matrix (ECM) where cells 
are embedded. The ECM provides a cell-supporting scaffold and helps maintaining the 
biophysical integrity of tissues and organs. ECM is under constant remodelling, 
changing rigidity, porosity and spatial disposition, therefore orienting cell movement 
and tissue growing [1, 2]. Moreover, the diffusion of molecules from cell to cell depends 
on ECM, that in this way influences directly the availability of signalling effectors of all 
kinds, including growth factors and hormones [3, 4], playing crucial roles in all tissue 
rearrangements [5].  
Mammalian ECM presents a great number of functional molecules, biochemically 
and biophysically diverse, including proteins, glycoproteins, glycosaminoglycans 
(GAGs), and proteoglycans (PGs). PGs are vital structural and signalling molecules 
composed of a core protein with one or more covalently attached GAGs [6, 7], which can 
be a single GAG, as decorin [8], or several units of different GAGs, as versican and 
aggrecan [9, 10]. GAGs are linear heteropolysaccharides consisting of repeating 
disaccharide units, composed of a hexosamine (glucosamine or galactosamine, 
frequently N-substituted) and a hexuronic acid (glucuronic acid or iduronic acid). 
Exceptionally, in keratan sulphate, N-acetyl-glucosamine associates with galactose 
instead. GAGs are generally multi-sulphated, with the exception of hyaluronan [6, 7, 11-
13]. In mammals, a few PGs are secreted to the extracellular space, like the large 
molecular weight aggrecan, or the small leucine-rich PGs [14-16]. Some are membrane 
tethered, through a glycosylphosphatidylinositol anchor, like glypican, or by a 
membrane spanning protein core, as syndecan [7, 17]. A high molecular diversity arises 
from the different combinations of PGs protein cores with one or more types of GAGs, 
eventually leading to a wide variety of biological roles. As such, disturbances in PGs 
synthesis and turnover lead to severe pathologies [5]. Moreover, important medical 
properties were also reported for some ECM components. Heparin for example, 
presents anti-thrombotic, anti-coagulant, anti-inflammatory and anti-metastatic 
properties [18-20].  
The presence of ECM-like extracellular polymeric substances, is known to support 
and protect multicellular bacterial and fungal aggregates [21-27]. Saccharomyces 
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cerevisiae yeast cells are able to form complex multicellular aggregates: stalk-like 
structures [28, 29], mats/biofilms [30, 31] and colonies [27, 32]. These last display a high 
level of cellular organization [27, 33-35], and an ECM-like glycosidic substance [27, 35] 
involved in the conduction of nutrients to the top layers of cells [27], while providing 
protection against xenobiotics [35], and dissecation [32]. Within a colony, 
physiologically different subpopulations are present [36], a substantial part of which is in 
a non-dividing and quiescent state [37, 38]. Like in mammals, these cells present 
condensed chromosomes [39] and unreplicated genomes [40], with low rates of 
translation [41, 42], getting most of their energy from respiration [43]. A genomic 
analysis showed that different genes are expressed accordingly with the area that the 
cell occupies in the colony. In fact, even apoptosis is coordinated differently within the 
same colony [34, 44, 45].  
The complex chemical nature of the microbial ECM has been poorly assessed [46, 
47]. In Candida albicans biofilms, ECM was shown to contain proteins, 
polysaccharides, and DNA [48-50]. In S. cerevisiae, some preliminary data showed the 
existence of glycoproteins [27] [35]. A more recent work showed ECM to be highly 
glycosylated, and highlighted the presence of high amounts of secreted Flo11p [35].  
In the present work, a protocol was devised to obtain a young homogenous mat-
type growth of S. cerevisiae, and separate the ECM main glycosidic fraction to 
analytical purity allowing chemical analysis of its components. This revealed the 
presence of two low molecular weight polysaccharides, basically composed of glucose, 
mannose, galactose and uronic acid. The metachromatic shift induced by the ECM 
extracts, as well as the anticoagulant activity showed by some yeast strains ECM, 
suggests the further presence of sulphate groups in S. cerevisiae ECM polysaccharides. 
Although the chemical nature of the glycosidic bonds, and the macromolecular structure 
of the polysaccharides are still under study, this work pioneers the acknowledgement of 
S. cerevisiae ECM polysaccharides main components and their complexity. 
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Materials and Methods 
Strains and Media  
S. cerevisiae strains used in this work are listed in Table 1. Liquid batch cultures 
were done on YPD (yeast extract 1%; peptone 2%; glucose 2%; adenine hemisulphate 
0.005%) on an orbital shaker (200 rpm), at 30 ºC and an air: liquid ratio of 2:1. Growth 
was monitored by measuring OD at 600 nm. Yeast mat development was obtained on 
YPD supplemented with 2% electrophoretic grade agarose instead of agar (YPDa). All 
media constituents are expressed in weight /volume percentages. 
 
Yeast mat development and ECM extraction 
The development of a uniform yeast culture overlay/mat was obtained spreading 
evenly 1.5 ml of YPD batch cultures at OD600=1 in Ø 90 mm YPDa plates and 
incubating for 7 days at 30 °C. The cellular overlay was carefully removed from the 
plates into a 50 ml Falcon tube, suspended in PBS buffer and homogenised for 10 min 
with constant gentle rotation in a tube roller (SRT1, Stuart, UK). The suspension, 
containing cells and ECM, was then spun down for 10 min at 10,000 rpm and 4 °C 
(Sigma4-16K, Germany). The supernatant, containing the water-soluble ECM, was 
collected and freeze-dried (Christ Alpha 2-4 Christ LDC-1m, B.Braun, Germany). 
 
Table 1. S. cerevisiae strains used in the present study. 
Strain Genotypes Origin 
W303-1A MATaleu2-3 leu2-112 ura3-1 trp1-1 his3-11 his3-15 ade2-1 can1-100 [51] 
BHY54 Isogenic to W303-1A but gup1::His5+ [52] 
Cly5 Isogenic to W303-1A but gup2::KanMX [52] 
Cly3 Isogenic to W303-1A but gup1::His5+gup2::KanMX [52] 
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Protein fraction collection and Western Blot 
The ECM protein sample was collected and treated as described before (Ch. 3). The 
proteins were separated in a 10% PAGE and blotted in a PVDF membrane and probed 
with Concanavalin-A – Horseradish Peroxidase conjugate as previously described [27]. 
Polysaccharide Precipitation and Fractionation 
The lyophilized supernatant was resuspended in digesting buffer (0.1 M sodium 
acetate; 5 mM EDTA; 5 mM cysteine; pH 5.5) in a proportion of 20 ml for each 1 g of 
lyophilized supernatant. Double-crystalized papain was added to the mixture (10 
mg/ml) and incubated at 60 °C overnight. The mixture was centrifuged (3,000 rpm for 
10 min at room temperature), and the clear supernatant was collected. The recovery of 
yeast ECM polysaccharides was achieved through ethanol precipitation. Three volumes 
of ethanol (95-99% v/v) were added to the supernatant and incubated overnight at 4 ºC. 
The precipitate was collected by centrifugation, 10 min at 3,000 rpm, and left to 
evaporate the residual ethanol. An aliquot of the resulting pellet was resuspended in 
deionised water and stored at 4 ºC for (1) electrophoretic analysis and (2) evaluation of 
total sugar content, by the reaction of phenol-sulphuric acid with hexoses [53], (3) 
presence of hexuronic acids, through carbazole method [54], and (4) metachromatic shift 
of 1,9-dimethylmethylene blue (DMMB), indicative of chemically substituted 
polysaccharides [55]. Another aliquot of the ethanol-precipitated pellet (∼20 mg) was 
resuspended in 1 ml MilliQ water, filtered through a syringe filter (0.22 µm) for 
analysis in a FPLC system (Pharmacia Biotech, Sweden). The filtered sample was 
applied to a Hitrap Q-XL-FPLC column, equilibrated with elution buffer (20 mM Tris-
HCl; pH 8.6). The glycosaminoglycans were eluted by a linear gradient of 0–3.0M NaCl 
(10 ml) at a flow rate of 0.50 ml/min. Fractions of 0.5 ml were collected and hexuronic 
acid [54], and total sugars [53] were quantified. Additionally, sulphated polysaccharides 
were also assessed [55]. The fractions comprising the peaks detected were collected and 
dialysed against MilliQ water for 48 hours and subsequently freeze dried. 
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Sugar Fraction Chemical Analysis  
a) Mass Spectrometry 
The ratio of monosaccharides in the extract of yeast ECM was determined by 
GC/MS, analysing the corresponding alditol acetate derivatives, according to the 
previously described method [56]. Briefly, the samples were briefly hydrolysed with 
trifluoroacetic acid at 100° C for 4 h. The monosaccharides released were converted 
into alditol acetate by successive reduction with NaBH4 and acetylation with Ac2O 
pyridine, allowing identification by GC/MS. The samples were analysed by GC-MS 
system (Shimadzu QP2010 Plus, Japan) equipped with a Restek RTX-5MS column. 
Ultrapure helium (99.999%) was used as the carrier gas at a constant flow of 1.0 
ml/min. The oven temperature was programmed to increase from 110 °C to 260 °C in a 
70 min period. The ion-source temperature was 200 °C and the interface temperature 
was 230 ºC.  
b) GAG Agarose Gel Electrophoresis 
ECM total polysaccharide, as well as the respective fractions, were submitted to 
agarose gel electrophoresis as described previously [13]. Briefly, about 1.5 µg of the 
sample was applied to a 0.5% agarose gel in a buffer composed of 50 mM 1,3-
diaminopropane acetate (pH 9.0), and run for 1 h at 100 V. As standard, a mixture of 
GAGs, containing chondroitin sulphate, dermatan sulphate, and heparan sulphate (1.5 
µg of each) was used. The GAGs were fixed with aqueous 0.1% cetyl-
trimethylammonium bromide solution (Cetavlon®), allowed to dry, and stained with 
0.1% toluidine blue in acetic acid/ethanol/water (0.1:5:5, v/v/v).  
c) GAG PAGE 
PAGE was used to estimate the MW of polysaccharide molecules. Samples (10 µg) 
were applied to a 1-mm-thick 6% polyacrylamide gel in 3X PAGE running buffer (60 
mM Tris-HCl; pH 8.6), and run at 100 V. The gel was stained with 0.1% toluidine blue 
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in 1% acetic acid. After staining, the gel was washed overnight in 1% acetic acid. The 
molecular mass markers were dextran sulphate 8 (average MW 8,000 Da), chondroitin-
4-sulphate (average MW 36,000 Da), and dextran sulphate 100 (average MW 100,000 
Da). 
Anticoagulant Action Measured by Activated Partial Thromboplastin 
Time (aPTT)  
Activated partial thromboplastin clotting time assays were carried out incubating at 
37°C for 1 min, 100 μl of human plasma with 10 μl of the yeast ECM polysaccharide 
sample. As a control, the incubation was performed with a solution standard of heparin 
(50µg/ml). Subsequently, 100 μl of cephalin were added, and the mixtures re-incubated 
for 2 min, after which 100 μl of CaCl2 (0.25 M) were added and the clotting time 
recorded in a coagulometer (KC4A, Amelung) [57]. 
Results and Discussion 
S. cerevisiae polysaccharides in the ECM 
The extraction and characterization of yeast ECM protein fraction was recently 
described by our group (Ch. 3). In this work we applied a complementary methodology 
to extract considerable amounts of polysaccharides from yeast ECM. The production of 
a S. cerevisiae young cells mat and extraction of the correspondent ECM (Faria-Oliveira 
et al., submitted), was combined with a widely used protocol to recover and identify the 
polysaccharides of mammalian ECM [57]. The ECM total extracts, containing both 
proteins and sugars, were treated with a broad range proteinase, double crystalized 
papain, to eliminate all protein residues, as described before for higher eukaryotes 
tissues [57]. Then the polysaccharides were recovered by ethanol precipitation [57]. This 
approach yields a pure sugar fraction that allows chemical downstream analyses aimed 
at the characterization of the ECM polysaccharide components. 
The yeast ECM total polysaccharides were initially characterized by mass 
spectrometry (Fig. 1). The results indicate that the polysaccharides present are mainly 
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composed by glucose (52%), mannose (44%), and galactose (4%). The presence of such 
monomers suggests that these ECM polysaccharides might be similar to the glucans 
and/or mannans present in yeast and fungi cell walls. In part, this is in concert with the 
studies on C. albicans biofilms, which revealed the presence of several polysaccharides: 
β-1,3 glucan, a major biofilm component presenting a putative role in antifungal 
resistance [58], and a polysaccharide composed of α-D-glucose and β-D-glucose, α-D- 
 
 
Figure 1. Yeast polysaccharides composition. Mass spectrometry of the ECM glycosidic constituents: the 
presence of glucose, mannose and galactose was revealed. The retention times and main mass-to-charge ratios for 
each monomer are included in the table. 
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mannose, α-L-rhamnose and N-acetyl glucosamine [25]. Nevertheless, the presence of 
galactose on S. cerevisiae ECM hints for the presence of more unconventional 
carbohydrates, as some galactoglycans described for algae and ascidians [59, 60]. 
ECM polysaccharides present chemical substitution 
Samples of the ECM papain-treated total polysaccharide extract induced 
metachromasia in both DMMB and toluidine blue dyes, and tested positive for the 
presence of uronic acids through the carbazole method (not shown). The induction of 
metachromasia is frequent in chemically substituted polysaccharides, namely the highly 
sulphated glycosaminoglycans from higher eukaryotes ECM [61], whereas, 
polysaccharides rich in uronic acids are common in both high eukaryotes and bacteria 
ECM [6, 24].  
These same samples were submitted to PAGE, and their components separated 
according to the molecular weight. ECM papain-treated total polysaccharide extract 
presented two distinct polydisperse bands (Fig. 2A, black arrows), the more abundant 
band showing low molecular weight (<8 kDa), and a lighter band showing an average 
size of 35-40 kDa. The abundant low molecular weight band might be composed by 
oligosaccharides, with just some disaccharide units, putatively associated with protein 
cores, similarly to what happens with the higher eukaryotes PGs. To test this 
hypothesis, we analysed the glycosylation level of the ECM proteins with 
Concanavalin-A (Fig. 2B), which recognizes glycosyl and mannosyl groups. The results 
(Fig. 2B) showed that the ECM protein extract presented a highly glycosylated pattern. 
Several intense bands were detected and could be easily attributed to protein bands on 
the SDS- PAGE. The indication of several polysaccharides in the yeast ECM 
composition led to the samples fractionation in an anionic exchange column (Fig. 3A) 
and analysis by diaminopropane agarose (Fig. 3B).  
The ECM papain-treated total polysaccharides were loaded in the column and a 
NaCl gradient (0-3M) was used to separate the differently charged molecules. Fractions 
(0.5 ml) were collected and each tested once more for metachromasia, uronic acids, as 
well as total sugars. The fractionation of the yeast ECM extract yielded two major sugar 
peaks that tested positive for uronic acid, presenting as well metachromasia in DMMB 
 
 YEAST ECM POLYSACCHARIDES 
143 
 
 
Figure 2. Yeast ECM molecular size and association to proteins. (A) The molecular weight assessment revealed 
two components presenting distinct sizes (arrows): one fraction weighing less than 8 kDa, and another component 
in small amounts with an average weight of 35-40 kDa. (B) The yeast ECM revealed a wide range of glycosylated 
proteins, particularly a highly glycosylated band (arrow). STD – GAG standards: DexS100 - Dextran Sulphate 
MW 100,000; CS4 – Chondroitin-4-Sulphate MW 36,000; DexS8 – Dextran Sulphate MW 8,000. CCB – 
Colloidal Coomassie Blue staining; Con-A-HRP – Concanavalin-A - Horseradish Peroxidase conjugate. 
 
 
(Fig. 3A). This indicates that two compounds were differentially eluted by the NaCl 
gradient. The presence of metachromasia in ECM polysaccharides is mostly associated 
with the presence of sulphate groups [6], however, metachromasia may also be induced 
by a wide range of polyanions [62-64]. These later compounds, also known as 
chromotropes, include polyphosphates, polyacrylates, polysulphates, carboxylated 
polysaccharides, and include some proteins and nucleic acids as well [62]. While some 
of these compounds may be present in the yeast ECM and therefore induce the 
metachromatic shift, the chromatographic fractionation revealed a “clean” profile (Fig. 
3A), which suggests the presence of just two major compounds. The compounds 
constituting these two peaks also tested positive for the presence of some type of uronic 
acid (Fig. 3A). Accordingly, glucuronic and iduronic acids are common on in higher 
eukaryotes ECM [6], and the presence of mannuronic and guluronic acid was already 
reported in Pseudomonas aeruginosa biofilms [24]. The fractions composing each of the 
two major peaks were collected (P1 and P2) and submitted to electrophoretic analysis  
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Figure 3. Chromatographic fractionation and electrophoretic profiles of yeast polysaccharides. The total ECM 
sample was submitted to anionic exchange fractionation and yielded two main compounds fraction P1 and P2 (A). 
The same sample was analysed through diaminopropane agarose electrophoresis before the FPLC fractionation (PC), 
together with fractions P1 and P2 (B). STD – GAG standard (see Materials and Methods).. 
 
 
(Fig. 3B). The diaminopropane agarose electrophoresis is a powerful tool to separate 
compounds with different degrees of chemical substitution, usually sulphated 
polysaccharides [65]. The charged molecules have high affinity for the diaminopropane 
matrix in the agarose gel. The higher is the affinity/charge of the migrating compound, 
the shorter is the migration path. The pre-chromatography sample (PC), as well as the 
fractions composing the two peaks (P1 and P2), were submitted to this electrophoretic 
separation (Fig. 3B). The PC sample presented two clearly distinct bands; two 
metachromatic compounds migrated similarly to chondroitin sulphate (CS) and heparan 
sulphate (HS), putatively presenting a chemical substitution degree similar to these 
GAGs. These two compounds were efficiently separated through FPLC (Fig. 3B), even 
though a little more dispersion is visible. Similarly to other reports using both FPLC 
fractionation and 1,3- diaminopropane agarose electrophoresis for GAG analysis [61], 
the first eluted ECM component (P1) matched the shortest migration in the agarose 
electrophoresis. These two fractions might be the same molecule with different degrees 
of chemical substitution, or more likely two different molecules. The latter is supported 
by the molecular weight assessment in PAGE (Fig. 2A). 
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Anticoagulant activity displayed by yeast substituted-polysaccharides 
Several studies showed the importance of sulphate substitution in the anticoagulant 
effect of heparin [66], as well as of DS [67], or tunicates analogues [13, 18, 57]. Therefore, 
assessing the yeast ECM components for anti-coagulant properties may be an indirect 
way of confirming this type of residue substitution in ECM polysaccharides. This was 
done using the same ECM total extracts above tested. The yeast putative morphogens 
Gup1p and Gup2p were previously described to interfere with cell wall and plasma 
membrane composition and function [68-70], including wall polysaccharide assembly, 
lipid metabolism, and rafts and GPI anchors integrity. The role of Gup1 in the colony 
morphology, as well as in invasive and filamentous growth, was also reported in C. 
albicans [70]. Therefore, the glycosidic fraction of the ECM extracted form Wt was 
compared to the one from these genes single and double mutant strains (Fig. 4). As a 
control, bovine heparin anticoagulant action was used.  
 
 
 
Figure 4. Anticoagulant effect of yeast ECM extracts. Anticoagulant effect of ECM extracts from several yeast 
strains. Yeast Wt was compared to the mutant strains defective in the putative morphogens Gup1p and Gup2p, 
known to interfere with cell wall and plasma membrane composition and functions [68-70], including rafts and GPI 
anchors integrity, as well as in colony morphology, and invasive and filamentous growth [70]. These strains were 
assessed for their ECM polysaccharides chemical substitution through the aPTT test. The differences in 
anticoagulant effect represent an indirect measurement of the presence of sulphate groups. Heparin (50µg/ml) was 
used as control. UA- Uronic acid concentration. 
 YEAST ECM POLYSACCHARIDES 
146 
ECM papain-treated total polysaccharide extracts from several yeast strains (Table 
1) were tested for anticoagulant properties. The double mutant gup1Δgup2Δ extract 
presented the highest anticoagulant effect (Fig. 4). Given the role of sulphation pattern 
and degree in anticoagulant effect of mammalian heparin and ascidian analogues [18], 
the effect displayed by this mutant suggests that the disruption of these genes influences 
the chemical substitution present on the ECM polysaccharides, supposedly increasing 
sulphation. These results suggest that some sulphate substitution is present in the 
polysaccharides, but also that a dynamic substitution pattern regulated by genetic 
elements is observed. The nature of the chemical substitution in the yeast ECM is 
currently being examined using tools with higher analytic power, including the 
methylation analysis of such compounds and NMR. 
Conclusions 
This work presents the first report on the nature of S. cerevisiae ECM 
polysaccharides. Hints on the presence of uronic acids, besides the common sugars of 
glucose, mannose and galactose, indicate that yeast ECM polysaccharides are complex 
molecules. Our results also suggest the presence of sulphate substitution in the yeast 
ECM, given the metachromatic shift of DMMB and toluidine blue, as well as the 
anticoagulant effect displayed by the mutants ECM extract. However, as mentioned 
before, several chemical groups may induce the metachromasia of DMMB and toluidine 
blue, and the presence of classic sulphotransferases, as well as the chemical 
intermediates, has not been so far reported in S. cerevisiae. These results pioneer the 
study of yeast surface glycomics beyond the cell wall, opening a whole range of 
unsolved questions for the future, and positioning S. cerevisiae as a possible model for 
the study of eukaryotic ECM. 
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Abstract 
The study of yeast colonies extracellular matrix (ECM) structure, composition and 
properties is still in an early stage. In order to better understand the mechanisms 
underlying the ECM assembly and maintenance, we assessed the multicellular 
aggregates formed by cells lacking the pleiotropic gene GUP1, known to affect cellular 
processes so diverse as cell wall and plasma membrane composition and organization, 
cytoskeleton assembly, or apoptosis. The mass spectrometry analysis of the ECM 
proteome revealed that the mutant’s presented less 106 proteins than the Wt. The 
common proteins were assessed for differences between strains through the highly 
sensitive DIGE methodology. A total of 56 proteins were present in statistically 
different amounts. Seven spots presented a 2-fold increase in abundance in the mutant, 
whereas eight were more abundant in the Wt. Both the absent and differentially present 
proteins belong mainly to the functional classes: carbon metabolism, cellular rescue and 
defence, protein fate, and cellular organization. The absence of such proteins concurs 
with several of the known phenotypes of gup1Δ, namely the impaired response to stress 
and diminished ability to utilize non-fermentable carbon sources. Nevertheless, we 
cannot overlook the possibility that all or most of these protein are moonlighting, i.e., 
performing completely new functions in the ECM, its maintenance and biological 
activity. Similarly, the absence of Gup1 also has a high impact in the polysaccharide 
components of the ECM. The mutant presents a low molecular weight oligosaccharide, 
but lacks the 35-40 kDa polysaccharide also observed in the Wt. Additionally, the 
deletion of GUP1 severely compromised the synthesis and/or chemical substitution of 
the ECM polysaccharides. The unveiling of Gup1 and Gup2 roles in the ECM 
composition, structure and chemical properties will certainly contribute for the 
understanding of the S. cerevisiae multicellular lifestyle. 
  
THE EFFECT OF THE DELETION OF GUP1 GENE 
ON YEAST ECM COMPOSITION 
157 
GUP1 – A Jack of all trades, a master of none 
Saccharomyces cerevisiae was the first eukaryote with the genome fully sequenced 
[1]. The next step was the annotation of all 6000 potential protein-encoding genes. 
Presently, 85% of these have their proteins and biological function described [2]. 
However, the complete annotation of the remaining 15% coding ORFs is probably the 
most difficult part. Some of the remaining unannotated genes are pleiotropic, with 
effects in apparently unrelated phenotypical traits, which turn very difficult the 
unveiling of their biological role. GUP1, named after glycerol uptake protein 1, gene is 
one such case. 
GUP1, and its close homologue GUP2, according to sequence similarity and 
conserved domains, encode transmembrane-spanning proteins that belong to the 
membrane-bound O-acyltransferase (MBOAT) superfamily [3] [4, 5]. However, Gup1 
was initially reported to have a role in S. cerevisiae glycerol active uptake [6]. The 
defective growth of cells lacking GUP1 gene in both glycerol based media and glucose-
based media supplemented with high amounts of salt, suggested a putative function 
relating to the glycerol transport across the membrane. Moreover, the deletion of GUP1 
in a mutant deficient in glycerol consumption and dissimilation, through the mutation of 
the GUT1 (glycerol kinase) and GPD1 (glycerol 3P dehydrogenase), impaired glycerol 
uptake. However, other mutant combinations involving the deletion of GUP1 were still 
able to actively take up glycerol [7]. Additionally, the expression of both GUP1 and 
GUP2 did not match glycerol transport regulation [8]. 
The Gup1p localization was predicted to be in the plasma membrane due to the 
putative existence of 10-12 transmembrane domains [6]. In the study by Blève and his 
collaborators [9], Gup1 protein was tagged with the green fluorescent protein (GFP) and 
its subcellular localization was found to be the plasma membrane, but also the 
endoplasmic reticulum (ER). Experiments of cellular fractionation by Hölst and 
collaborators [6] identically showed possible multiple localizations of Gup1p, in the 
plasma membrane, in the ER and in the mitochondrion [6]. The immuno-electron 
microscopy analysis [9] suggested that Gup1 presents a carboxyl end cytoplasmic tail, 
and an amino end extended to the periplasmic space. The mechanism of Gup1-GFP 
proper localization and its removal from the membrane was analysed in a collection of 
yeast lacking genes in specific steps of the secretory and endocytic pathways, 
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highlighting the role of Sec6 and End3 in, respectively, the plasma membrane 
localization and turnover of this protein [9]. Shortly after, the transmembrane spanning 
Stl1 was beyond doubt recognized as the active glycerol/H+ symporter [10]. The role of 
Gup1p in the regulation of the Stl1 glycerol symporter, that justifies the glycerol 
transport-related phenotypes [6], is not at expression level [10]. Rather, the absence of 
Gup1 affects the proper localization and activity of ATPase, and therefore the resulting 
proton motive force [11]. Considering that the glycerol transporter is a symport with 
protons, this might be the cause affecting Stl1 activity. Nevertheless, the hypothesis was 
never tested in other H+ symporters. 
A considerable amount of the information available for Gup1 derives from the 
survey of gup1Δ phenotypes. In view of their large amount and diversity, Gup1 function 
remains elusive. From genome-wide surveys it was possible to identify that Gup1 
influences anaerobic sterol uptake [12], cytoskeleton polarization and bud side selection 
pattern [13, 14], telomeres length [15], secretory/ endocytic pathway performance [16], as 
well as arsenic [17] and imatinib resistance [18]. The role of Gup1 in the integrity and 
composition of the plasma membrane and cell wall was also reported [4]. In gup1Δ an 
increase in total triglycerides and diacylglycerol and concomitant decrease in 
phospholipids percentage was reported, implying Gup1 in the maintenance of the 
membrane lipids. Moreover, Ferreira and collaborators (2006) [19] reported a wide array 
of altered cell wall phenotypes in gup1Δ cells. Cells lacking GUP1 presented increased 
amounts of chitin and β1,3-glucans and decreased amounts of mannoproteins. The 
mutant cell wall was also loose and more easily extractable. Cells presented altered 
morphology and exhibited increased sensitivity to weak acids, detergents, caffeine, cell 
wall degrading enzymes, and heat. The mutant cells also displayed and increased 
sedimentation/aggregation phenotype. 
According to Bosson and collaborators [20, 21] the role of Gup1 relies in the 
remodelling of glycosylphosphatidylinositol (GPI) anchors, both in S. cerevisiae and in 
the fungus Trypanosoma brucei. S. cerevisiae GPI anchors have two different lipid 
moieties, ceramides and diacylglycerol. These lipids are introduced by remodelling of 
the primary GPI lipid, during which C16- and C18- diacylglycerol are modified or 
replaced. The authors analysed the lipid moieties of GPI anchored proteins in thin layer 
chromatography (TLC) and reported that gup1Δ cells presented a high accumulation of 
primary anchors. The mutant cells seemed to perform a different remodelling on the 
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GPI anchors. The analysis of Gas1, a very well-known diacylglycerol GPI-anchored 
protein, revealed that in Wt cells most of the protein was detergent resistant, whereas 
the Gas1 from gup1Δ cells were detergent soluble. In view of these results, the authors 
suggested that Gup1 perform the acylation on sn-2 position of GPI anchors. Other 
reports supporting the role of GUP1 on the remodelling of GPI anchored are available 
[22-25]. Nevertheless, the existence of a GPI remodelling branch independent of Gup1 
was suggested by Ferreira and co-workers [11] and recently confirmed [26], indicates 
that the role of Gup1 in that regard might not actually be the suggested acylation on sn-2 
position of GPI anchors [20, 21]. 
The gup1Δ elicits changes in plasma membrane lipid composition [4], and cell wall 
components amounts [19], as well as GPI anchors [20, 21], and cytoskeleton polarization 
[13]. This prompted the study of the role of Gup1 in the integrity of lipid order 
microdomains, lipid rafts. The sphingolipid-sterol-ordered domains integrity/assembly 
is disrupted by the deletion of GUP1 [11]. The cells lacking GUP1 yield 40% less 
Detergent Resistant Membrane domains (DRMs) than the Wt cells. Moreover, the 
mutant DRMs presented fewer proteins, namely the plasma membrane H+-ATPase 
Pma1 and the GPI-anchored Gas1 [11].  
The gup1Δ mutant showed altered lipid metabolism [11], as cells lacking Gup1 
presented increased resistance to several ergosterol synthesis inhibitors targeting 
different biosynthetic steps, and increased sensitivity to some sphingolipid biosynthesis 
inhibitors. But perhaps more important is the role of Gup1 in the maintenance of the 
structural integrity and maintenance of lipid rafts. Their analysis through staining with 
the fluorescent dye filipin, showed in Wt cells a typical patched distribution, as well as 
the presence of some of these microdomains in some intracellular membranes, whereas 
in the strain lacking Gup1, the cells presented an unusual uniform distribution with 
occasional patches in some cells. The deregulation of lipid rafts integrity may cause the 
otherwise reported phenotypes on GPI-anchoring [20] and cytoskeleton polarization [13]. 
More recent works also implied the role of Gup1 in mechanisms of programed cell 
death [27, 28], however, each suggests opposite roles for this O-acyltransferase. Li and 
collaborators [27] analysed the effect of calorie restriction in the lifespan of S. cerevisiae 
and tried to identify related mutants with similar effects on life span. Typically, life span 
in yeast is studied in two distinct manners: replicative lifespan (RLS), measuring the 
number of yeast cell divisions before senescence; and chronological lifespan (CLS), that 
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measures the length of time cells remain viable in the post-diauxic and stationary phases 
[29, 30]. Calorie restriction has a positive effect in both CLS and RLS. The gup1Δ cells 
presented especially extended CLS and RLS. Actually, GUP1 disruption increased 
RLS, in particular under calorie restriction. On the other hand, the analysis of cell 
viability in stationary phase showed that the disruption of GUP1 extends CLS beyond 
Wt cells, but not compared to Wt cells under calorie restriction. This way, the Gup1p 
appears to have an effect over replicative life span rather than over chronological life 
span. The increase in extension of RLS in cells lacking Gup1 is prevented by the 
disruption of cytochrome c1 gene, CYT1.  
On the other hand, ∆gup1 cells, when challenged with conditions of acetic acid-
inducing programmed cell death (PCD) [31], were unable to undergo proper apoptosis 
and died by necrosis, presenting shorter CLS [28]. The authors analysed several typical 
apoptosis markers, namely plasma membrane integrity and mitochondrial membrane 
potential, phosphatidylserine externalization and chromatin condensation. The Wt cells 
progressively followed the typical hallmarks of PCD, while the gup1Δ mutant presented 
faster loss of membrane integrity, the presence of abnormal chromatin condensation and 
multiple nuclei, and a high percentage of necrotic cells. However, mitochondrial 
membrane potential decreased similarly in both the mutant and the Wt. Additionally, the 
authors also showed that ∆gup1 is highly sensitive to acetic acid [28], in agreement with 
the previous report of sensitivity against weak acids [19].  
The differences between the reports of Li and collaborators [27] and Tulha and 
collaborators [28], may be due to different genetic backgrounds of yeast strains, BY4742 
vs. W303-1A, or to distinct experimental procedures. Both performed the measurement 
of CLS in minimal media supplemented with auxotrophic elements, however, Li and 
collaborators [27] supplemented the media with 4 times more auxotrophic requirements 
than Tulha and collaborators [28], which may alter the mutant nitrogen metabolism and 
cause different responses. 
The role of Gup1 was also studied in the pathogenic yeast C. albicans. Similarly to 
what happens in S. cerevisiae, Ferreira and collaborators [32] reported that the C. 
albicans gup1Δ null mutant displayed altered sensitivity to specific ergosterol 
biosynthesis inhibitors [11], and disruption of lipid rafts [11]. More importantly, they also 
reported the loss of virulence and yeast-to-hyphal transition in cells lacking CaGup1. 
The disruption reduces the virulence factors of C. albicans: the gup1Δ strain is unable to 
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form true hyphae, to adhere, to invade different substrates and to form biofilms. 
Concurrently, this strain presents aberrant colony morphology and absence of 
filamentous growth in the colony periphery [32]. The mutant colonies presented a more 
complex architecture than Wt, with a radial pattern and no filamentous growth around 
the colony.  
Gup1 and Gup2 are highly conserved genes, with orthologues in many organisms 
[5, 33]. Presently, a search in databases can easily yield more than 150 putative 
orthologues in yeasts, fungi, mammals, insects, fish, nematodes, and even plants. 
Namely, Gup1 and Gup2 orthologues are recognized in mouse (Mus musculus) [33], rat 
(Rattus novergicus) [34] and man [35]; the bony fish Danio rerio [36], the frogs Xenopus 
laevis and X. tropicalis [37], the higher plant Zea mays [38], the alga Dunaliella 
tertiolecta [39], and the parasite Trypanosoma cruzi [40]. Otherwise, in the fly D. 
melanogaster [41] and the nematode Caenorhabditis elegans [42], only a orthologue for 
Gup1 is present, whereas in several fungi, namely the basidiomycete Puccinia graminis 
[43], and the yeast C. albicans [44], only the Gup1 orthologue is described. 
All these proteins putatively belong to the MBOAT family for possessing the 
correspondent conserved domain. All the Gup2-similar proteins present the conserved 
His412 residue in the active centre of the acyltransferases from this family, whereas 
only S. cerevisiae Gup1 maintains this residue [3]. All the remaining Gup1-similar 
proteins do not possess this residue. 
In line with this high similarity, the Gup1 orthologue from mouse (Mus musculus), 
MmGup1, was shown to be responsible for the negative regulation of the palmitoylation 
of the secreted Sonic Hedgehog (Shh) protein from the morphogenic Hedgehog (Hh) 
pathway [33]. In high eukaryotes, several morphogenic processes are regulated through 
secreted proteins that function as long distance signals, namely Hh and Wnt (see 
Chapter 1). For the proper secretion and extracellular diffusion of the Hh signalling 
proteins, these undergo several post-translational modifications, including the 
attachment of a cholesterol molecule to the carboxyl end, and the palmitoylation of the 
amino end. This is mediated by a specific acyl transferase, Hhat (Hedgehog Acyl 
Transferase). Actually, mouse Hhat is 27% similar to the yeast Gup2p. MmGup1 
instead is 26% similar to yeast Gup1p, and is presently known by the designation of 
Hhatl (Hedgehog Acyl Transferase Like protein). Hhatl (MmGup1) and Hhat 
(MmGup2) differ in which Hhatl does not present the conserved His residue in the 
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active centre typical of the MBOATs O-acyl transferases, and conserved in yeast Gup1 
and Gup2, and is therefore unable to execute the transfer of a palmitate group. Hhatl and 
Hhat compete for binding Shh signal, and the inhibition of the palmitoylation can 
preclude secretion of the Shh signal, and block Hh signalling altogether. 
Several attempts are under way to complement the yeast ∆gup1, ∆gup2 and double 
mutants with the orthologous genes from mouse, man and fly (Ch. 6). A successful 
complementation, single trial, was obtained using MmGup1 in C. albicans gup1Δ- cells 
(personal communication from Ferreira, C.). This yielded partial complementation of 
the above mentioned morphogenic defects of hyphae formation and invasive growth, 
suggesting that a putative morphogenic pathway, similar to the mammalian Hedgehog, 
could be present in yeast.  
In view of the putative involvement of the Gup proteins in morphogenic processes, 
it became likely that their absence could affect the yeast extracellular matrix formation 
in some way. The study of the effects of deletion of GUP1 on the structure and 
composition of multicellular aggregates might contribute for unveiling its roles on 
cellular metabolism, and at the same time provide important hints on the ECM structural 
organization and metabolic mechanisms. 
Materials and Methods 
Strains and Media  
S. cerevisiae strains W303-1A (MATa; leu2-3; leu2-112; ura3-1; trp1-1; his3-11; 
his3-15; ade2-1; can1-100) and BHY54 (isogenic to W303-1A but gup1::HIS5+) were 
used in this work [6, 45]. Cells were grown on rich medium, YPDA (1% yeast extract; 
2% peptone; 2% glucose; 0.005% adenine hemisulphate) on an orbital shaker, 200 rpm, 
at 30 °C. Growth was monitored by optical density (OD) at 600 nm. Cells were 
maintained in solid YPDA medium supplemented with agarose (2% (w/v)), grown at 30 
°C for 48 h and kept at 4 °C up to 5 days. All ingredients percentages were calculated as 
weight per volume units. 
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Yeast ECM production, extraction and fractionation 
a) Yeast ECM production and extraction  
The development of the yeast cell mat and the ECM extraction were performed as 
described previously (Ch. 3 and 4). For differential gel electrophoresis, four separate 
batch cultures per strain were treated independently up to the ECM extraction step and 
freeze drying.  
b) Sugar precipitation and Gel electrophoresis 
The polysaccharides precipitation and recovery, the as well as the 1,3-
diaminopropane acetate and polyacrylamide gel electrophoresis were performed as 
described previously (Ch. 3). 
 
c) Protein precipitation and recovery 
The freeze dried extracts were resuspended in MilliQ water (just enough to 
completely solubilize the overlay components). The proteins were precipitated using the 
chloroform/methanol protocol [46]. The protein pellets were left at room temperature to 
evaporate the remaining methanol, and resuspended in DIGE compatible buffer (30 mM 
Tris at pH 8.9; 7 M urea; 2 M thiourea; 2% (w/v) CHAPS). Protein was quantified with 
Bio-Rad Protein Assay (Bio-Rad, Richmond, CA, USA) as recommended by the 
manufacturer.  
Protein Labelling 
Four biological replicates were used for the Wt and mutant strain, thus generating 
eight individual samples Proteins in each sample were fluorescently labelled with Cy 
dye derivatives according to the scheme in Table 1 as described before [47]. Labelling 
was done according to manufacturer instructions (GE Healthcare Life Sciences, USA). 
Briefly, the protein sample (50 μg) was labelled with 400 pmol of Cy dye in 1 μl of 
anhydrous N,N-dimethylformamide (DMF, Sigma). The mixture as was incubated on 
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ice for 30 min of incubation, in the dark. The reaction was stopped with the addition of 
lysine (10 mM), and a second incubation of 10 min on ice in the dark. 
 
 
Table 1. Experimental design indicating the CyDye labelling in each of the four replicates for each condition 
(indicated as “1-4”) and the samples that are mixed in each of the gels 1 to 4. 
 Cy5 Cy3 Cy2 
Gel 1 Wt (1) gup1Δ (4) Internal standard 
Gel 2 Wt (2) gup1Δ (1) Internal standard 
Gel 3 gup1Δ (2) Wt (3) Internal standard 
Gel 4 gup1Δ (3) Wt (4) Internal standard 
 
Two-Dimensional Differential Gel Electrophoresis (DIGE) 
The DIGE was performed using GE Healthcare reagents and equipment. Labelled 
samples were combined as in Table 1. Dye swaps were performed to avoid dye-
dependent differences. Each gel contained a pair of Cy3 and Cy5 labelled samples, 
corresponding to the Wt and Δgup1 mutant, and a Cy2 labelled pooled standard, a 
mixture of equal amounts of all the samples used for each DIGE experiment. To each 
mixture, an equal volume of 2x hydratation buffer (7 M urea, 2 M thiourea, 4% (w/v) 
CHAPS, 2% (w/v) dithiothreitol (DTT), 4% (v/v) pharmalytes at pH 3-11) was added 
for the cup loading process. 
For first dimension, 24 cm IPG strips in the pH range of 3-11 were used. The strips 
were previously hydrated overnight with 7 M urea, 2 M thiourea, 4% (w/v) CHAPS, 
100 mM DeStreak, and 2% (v/v) pharmalytes at pH 4-7. Isoelectric focusing was 
performed at 20º C using the following program: 120 V for 1 h, 500 V for 2 h, 500-1000 
V for 2 h, 1000-5000 V for 6 h, and 5000 V for 10 h. Subsequently, strips were 
equilibrated for 12 min in reducing solution (6 M urea, 50 mM Tris-HCl at pH 6.8, 30% 
(v/v) glycerol, 2% (w/v) SDS, and 2% (w/v) DTT) and then for 5 min in alkylating 
solution (6 M urea, 50 mM Tris-HCl at pH 6.8, 30% (v/v) glycerol, 2% (w/v) SDS, and 
2.5% (w/v) iodoacetamide). The second-dimension SDS-PAGE was run on 
homogeneous 10% T and 2.6% C polyacrylamide gels casted in low-fluorescent glass 
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plates. Electrophoresis was carried out in the dark at 20 ºC, with a potency of 2 W/gel 
for 18 h, using an Ettan-Dalt six unit. 
Image acquisition and DIGE analysis 
Proteins were visualized using a Typhoon 9400™ scanner (GE Healthcare) with 
CyDye filters. For the Cy3, Cy5 and Cy2 image acquisition, the 532 nm/580 nm, 633 
nm/670 nm and 488 nm/520 nm excitation/emission wavelengths were used, 
respectively, and 100 µm as pixel size. Image analysis was carried out with DeCyder™ 
differential analysis software v6.5 (GE Healthcare). The Differential In-gel Analysis 
(DIA) module was used to assign spot boundaries and to calculate parameters such as 
normalized spot volumes. Inter-gel variability was corrected by matching and 
normalization of the internal standard spot maps in the biological variance analysis 
(BVA) module. The internal standard image gel with the greatest number of spots was 
used as a master gel. Comparisons between Wt and Δgup1 mutant were carried out 
using average ratio and unpaired Student’s t-test. In order to reduce the false positive, 
False Discovery Rate was applied [48]. Protein spots were considered as differentially 
present with statistical significance between the extracts under comparison, if 
presenting: (1) a 1,5-fold difference in the average ratio; and (2) a p value less than 
0.05. Principal Component Analyses (PCA), Hierarchical Cluster Analysis (HCA) were 
performed using the DeCyder Extended Data Analysis (EDA) module on the group of 
spots identified as significantly changed. Based on collective comparison of expression 
patterns from the set of proteins, these multivariate analyses clustered the individual 
Cy3- and Cy5-labeled samples.  
Colloidal Coomassie Blue Staining and Protein Digestion and 
Identification 
The procedures for gel staining and protein digestion and identification were 
performed as described previously (Ch. 2). 
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Results and Discussion 
Deletion of GUP1 affects ECM composition and complexity  
Compared analysis of ∆gup1 and Wt ECM proteome by LC-MS/MS 
The analysis of the gup1Δ total ECM proteins, as well as the proteins secreted 
during liquid growth, was performed through liquid chromatography coupled with mass 
spectrometry as described for the Wt samples (Ch. 2). This methodology allowed an in-
depth analysis of the effects on GUP1 deletion on the ECM proteome. 
a) Comparative identification of the proteins secreted during liquid batch culturing 
The analysis of the proteins secreted by mutant cells gup1Δ grown in liquid batch 
cultures had previously been briefly assessed [11]. The results now obtained confirmed 
the mutant secretes substantially more proteins than the Wt in identical conditions (Fig. 
1 A), respectively 311 against 80 (Table S3). From these, 68 were common to both 
strains (Table S3). The gup1Δ samples presented a great number of surface proteins, 
including cell wall and plasma membrane proteins. These include plasma membrane 
integral proteins as Pma1, and glycosylphosphatidylinositol-anchored proteins, namely 
several members of the Gas family that are crucial for the cell wall remodelling. Gas1 
had already been identified as one of the major proteins secreted by the mutant [11]. 
Both Gas1 and Pma1 are usual markers of lipid rafts integrity. The abnormally high 
release to the extracellular medium of these proteins, as well as Pir1, Pir2 and Pir3 
required for cell wall organization and maintenance, is in agreement with the 
compromised membrane and cell wall composition and structure reported for the gup1Δ 
mutant cells [4, 11, 19, 20]. 
The gup1Δ samples also presented a high number of proteins intervening in the 
carbon metabolism (Table S3), namely Eno1 (enolase), Fba1 (fructose-1,6-
bisphosphatase) or Tpi1 (triosephosphate isomerase). While these proteins were already 
reported in the cell surface of other yeast strains during liquid growth [49, 50], they were 
never reported to actually appear in the extracellular medium, and were absent from the 
Wt sample in identical conditions. Additionally, a great number of proteins associated 
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with lipid synthesis, ergosterol and fatty acids metabolism, was also present in the 
gup1Δ mutant ECM sample (Table S3). Whether the unintended release of proteins 
belonging to the Erg and Fas families might contribute to the altered composition of the 
mutant plasma membrane, or might be the cause of such defective condition, is still not 
fully understood. 
b) Comparative identification of the proteins secreted to the yeast ECM 
In opposition to liquid batch cultures, mutant cells mats secreted 15% less proteins to 
their ECM than Wt (Fig. 1 B), respectively 587 against 693 (Table S4). From these, 406 
were common to both strains (Table S4). As occurs in the liquid growth, the mutant 
ECM comprises a great number of proteins involved in the cell wall remodelling that 
were not found in the Wt ECM. It includes the homologous GPI-anchored proteins 
Dcw1 and Dfg1, putative mannosidases required for cell wall biosynthesis, the Utr2, 
Kre6 and Krt2 proteins, involved in the biosynthesis of β-glucans, the Pir1 and Pir2 
proteins, involved in the stabilization of the cell wall, or the GPI-anchored protease 
Yps1, required for the cell wall growth and maintenance (Table S4). 
 
 
 
 
Figure 1. Venn charts of the distribution of identified proteins. Proteins released during growth on liquid media (A), 
and during the ECM development (B). Overlapping area represent proteins common to both samples. 
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The proteins absent in the mutant ECM that were identified in Wt (Ch. 2) comprise 
several functional classes: carbon metabolism, cell rescue and defence, protein fate and 
cellular organization. In fact, the Wt ECM presented all the proteins composing the 
glycolysis, gluconeogenesis and glyoxylate cycle (Ch. 2). However, the mutant is 
lacking some pivotal proteins that play crucial roles in the regulation of these pathways, 
namely the Fbp1 (fructose-1,6-bisphosphatase) and Pyc2 (pyruvate carboxylase).  
Fbp1 protein is the key regulatory protein of gluconeogenesis [51], and it is under 
tight glucose regulation [52]. A recent report [53] shows that the addition of glucose to 
starved cells performing gluconeogenesis leads to the degradation of both intracellular 
and extracellular Fbp1, suggesting that the protein might be performing the same role in 
the cell surface. The absence of this protein in the ECM might suggest that a glucose 
repression could still be in place, which is not in accordance with the outside presence 
of other glucose repressed proteins like Pck1 (phosphoenolpyruvate carboxykinase) and 
Mls1 (malate synthase). More plausibly, the apparent absence of relation between the 
physiology of the cell and the extracellular appearance of these proteins, suggests they 
might have distinct roles once outside the cell.  
Pyc2 protein is responsible for the conversion of pyruvate to oxaloacetate that 
initiates the gluconeogenesis, but also plays a role in the tricarboxylic acid (TCA) and 
glyoxylate cycles [54, 55]. Evidence of this protein presence in the cell surface is 
available in the pathogenic yeast C. albicans [56], but this is the first report in S. 
cerevisiae. These results show a class difference between the ECM protein lot of mutant 
and Wt that corresponds to the absence of the gluconeogenic enzymes, the physiological 
significance of which remains for the moment obscure.  
The gup1Δ ECM is also lacking the presence of pyruvate decarboxylase isoforms 
Pdc5 and Pdc6. These proteins are involved in the glucose fermentation into ethanol, 
and their expression is usually repressed by the presence of another isoform, Pdc1 [57, 
58]. However, the presence of the three isoforms was detected in the Wt sample (Ch. 2), 
suggesting the presence of subpopulations with distinct expression patterns. However, 
that expression heterogeneity is absent in the mutant ECM, which might be indicative of 
a loss of differentiation/specialization with the yeast colony. 
Another large set of proteins are absent from the gup1Δ ECM sample, the ones 
involved on the metabolism of intermediates of the TCA cycle. This includes the Acs1, 
Pda1 and Pdx1 from the Acetyl-CoA biosynthesis, and the Gor1, Kgd1, Lsc3 and Sdh2 
THE EFFECT OF THE DELETION OF GUP1 GENE 
ON YEAST ECM COMPOSITION 
169 
enzymes responsible for the glyoxylate, α-ketoglutarate, succinyl-CoA and succinate 
metabolism, respectively. The effect of the absence of these proteins on the yeast ECM 
function and structure is unknown.  
A great reduction in the proteins performing roles of cellular organization was also 
observed. The gup1Δ ECM samples do not present several proteins involved in the 
cytoskeleton organization, namely the tubulin encoding Tub2, the Arc19, Arc35, Arp2, 
Ent2 and Ent3 proteins involved in the assembly of actin cortical patches, or Rvs161 or 
VPS that modulate the cytoskeleton assembly. All these were present in Wt ECM (Ch. 
2). Considering that ∆gup1 has altered cytoskeleton and bud-site selection [13], one 
cannot avoid considering the possibility that there might be some relation. Actually, the 
actin (Act1) protein present in both Wt and mutant ECM samples, might play some 
structural role in ECM edification, similarly to what happens in Staphylococcus gatii, 
which extracellular filaments that are sensitive to cytoskeleton protein inhibitors [59]. 
Nevertheless, no other known cytoskeleton proteins able to interact with and reinforce 
actin were found. 
The gup1Δ ECM also presents considerable less number of proteins from stress 
response and secretory pathway. Several proteins associated with the vacuole 
acidification, namely the ATPase isoforms Vma7 and Vma6, as well as its V0 subunit 
Vph1, are absent from the mutant ECM. Following an identical rationale as above for 
cytoskeleton phenotypes, this might relate to the abnormal vacuolar morphology 
described for gup1Δ cells [60]. Similarly, proteins associated with oxidative stress 
response and glutathione metabolism, namely Ctt1, Ecm4, Ecm38 and Gto1, could not 
be detected in the mutant ECM, again ultimately implicating in gup1Δ mutant altered 
oxidative stress response that results in cell death [28].  
Another functional class that is substantially diminished in the gup1Δ ECM is the 
one of protein fate, especially protein degradation. Several proteins involved in 
ubiquitination and sumoylation, namely Fub1, Aos1, Pib1 and several members of the 
Rpn family, and that direct proteins from degradation are absent from the mutant 
sample. Similarly, proteins involved in the folding of other proteins are also missing 
from the mutant ECM, especially the chaperone Cct3 that is involved in the assembly of 
actin and tubulin filaments.  
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Compared analysis of ∆gup1 and Wt ECM protein abundance by DIGE 
In order to confirm and better characterize the differences in ECM protein secretion 
caused by GUP1 deletion on the secretion of proteins to the ECM, we further submitted 
the same samples to DIGE. This highly sensitive technique allowed us the direct 
comparison of both mutant and Wt samples in the same gel. At the same time it 
demonstrated the robustness of the ECM extraction and fractionation methodologies. 
The preparatory SDS-PAGE (Fig. 2 A) was followed by 2D DIGE technique, 
which enables the use of a unique experimental design that eliminates the inter-gel 
comparison bias. A crucial characteristic of this technique is the presence of the internal 
standard labelled with Cy2 dye, which is formed by equal amounts of all samples, and is 
included in all gels, allowing the normalization of measured fluorescence. In order to 
avoid dye-dependent variations, namely labelling efficiency and fluorescence emission, 
half of the samples from each strain ECM protein fraction were labelled with Cy3 dye, 
and the other half was labelled with Cy5 dye (Table 1). This allowed to eliminate most 
of the inherent variation between the gels, and allowed a statistically validated analysis, 
the four gels acting as independent replicates.  
The proteomic profile, analysed in the DeCyder Software, revealed an average of 
1400 spots per sample, which include all the protein isoforms present. The biological 
variation analysis matched a total of 1200 spots that were present in every sample. This 
spot set was used to study the proteins that are differentially abundant in the ECM of the 
Wt and gup1Δ ECM samples. A total of 56 protein spots presented significant different 
(p<0.05) abundance variation 1.5-fold or greater between the two strains. The mutant 
strain presented 28 spots with increased abundance, and 28 spots that were significantly 
less abundant than in the Wt. Among these 56 protein spots, the 15 protein spots 
presenting an abundance variation of 2-fold or greater between the two strains were 
excised from 2D GE gels staining with CCB, subjected to tryptic digestion, and the 
resulting peptides analysed by mass spectrometry (Table 1). Seven spots presented a 2-
fold increased abundance in the mutant sample, and 8 were more abundant in the Wt 
sample (Table 2). 
A pattern analysis was performed to assess the differential abundance of proteins in 
the several replicates and validate the reproducibility of the extraction methodology 
(Fig. 3). The Principal Component Analysis displays the two principal components that 
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distinguish the two largest sources of variation within the data set. The data sets from 
the four replicates were grouped together with the first component (PC1) in the loading 
plot (Fig. 3 A; top panel), showing that the samples present a low variance within the 
same strain. The score plot show that eight protein are more present in the Wt, while 
seven are more abundant in the mutant (Fig. 3 A, lower panel). Next, the similarities of 
protein abundance between samples was analysed through the Hierarchical Clustering 
Analysis (Fig. 3 B). As expected, the samples formed two main clusters, one including 
all the Wt replicates and other including all the gup1Δ replicates. The variations 
between each replicate are displayed as and abundance matrix, represented in a 
standardized logarithmic scale of abundance ranging from -0.5 (green) to +0.5 (red).  
 
Figure 2. Electrophoretic separation of the ECM proteins. Preparatory one-dimensional analysis (A) of the Wt (lane 1) 
and gup1Δ (lane 2) samples. Two-dimensional DIGE analysis (B) and identification of the protein spots whose 
abundance varied 2-fold or more and present p < 0.05. 
 
 
The proteins present in higher abundance in the gup1Δ mutant were mainly 
associated with cell wall assembly and maintenance: Gas1 β-1,3 (glucanosyltransferase) 
[61], Exg1 (exo-1,3-beta-glucanase) [62], Bgl2 (endo-beta-1,3-glucanase) [63], and Sod1 
(superoxide dismutase) [64]. As predicted [11], the most secreted protein by the mutant 
cells to the ECM was Gas1, presenting an increase of abundance more than 8-fold 
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greater than the Wt ECM. Both Exg1 and Bgl2 proteins were previously described in 
the cell surface [49]. From these, only Exg1 was reported in the extracellular region [65], 
but the presence of Bgl2 in the extracellular space is predicted through bioinformatics 
approaches [66]. Sod1 was also found in increased amounts in the mutant ECM. The 
presence of this protein in the cell surface of S. cerevisiae, where it plays a role in the 
cell wall maintenance, was already described [49, 50, 64]. As mentioned above, the 
altered membrane and cell wall composition and structure is most certainly associated 
with an unintended release of surface proteins. The function performed by these 
proteins in the ECM is still unknown. Nevertheless, increased amounts of cell wall 
remodelling enzymes in the extracellular space might affect the structure of the wall 
periphery but also of ECM, through the modification of the structural components or 
interference with their normal turnover. 
 
 
 
Figure 3. Unsupervised multivariate analysis of data from the 2D DIGE experiment. (A) PCA loading and score  
(bottom) plots show the clustering of the eight individual Cy3- and Cy5-labeled DIGE spot maps and the subset of 
proteins whose ratios varied 2-fold or more and in which p < 0.05 respectively, in the two principle components. (B) 
Hierarchical clustering settings are Pearson distance measurements and average linkage. The dendrogram of eight 
individual spot maps clustering is shown at the top, and that of individual proteins is shown on the left, with relative 
expression values being displayed in a heat map. 
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Two uncharacterized proteins, Hmf1 and Ypl225w, were also identified. These two 
proteins were not sufficiently resolved in the 2D electrophoresis and were identified 
from the same spot (Fig. 1 B), being difficult to assess if both or only one are affected 
by the GUP1 deletion. Finally, the protein spots nº 127 and nº 800 were not identified, 
as it was not possible to extract enough protein to perform an unequivocal identity 
assignment. 
On the other hand, the proteins that were significantly less present in the mutant 
ECM can be ascribed to several functional processes: metabolism of ethanol (Ald4 and 
Adh2) and Acetyl-CoA (Cit1 and Pdb1), protein folding and targeting (Hsp60 and 
Hri1), and maintenance of mitochondrial DNA (Ilv5). A partial overlap of the functional 
classes of proteins absent, and the proteins significantly reduced, can be observed in the 
mutant ECM. The most striking difference between the Wt and mutant ECM proteins 
relies in the many enzymes from carbon metabolism absent of significantly less 
represented, namely from ethanol metabolism. 
In addition to the alcohol dehydrogenases Adh4 and Adh6 that are absent, which 
are responsible for the formation of several alcohols [67, 68], the gup1∆ sample presents 
only residual amounts of another isoform, Adh2 (Table 2). This enzyme is glucose 
repressible and catalyses the conversion of ethanol to aldehyde, i.e. the initial step in the 
utilization of ethanol as a carbon source [69]. Accordingly, the gup1∆ ECM lacks the 
aldehyde dehydrogenase Ald4 and presents reduced amounts of the isoform Ald2, 
which catalyse the next step in ethanol consumption [70]. A role in the detoxification of 
harmful aldehydes was also reported for these enzymes [71]. This suggests that, inside 
Wt multicellular aggregates, two metabolically distinct subpopulations might coexist, 
one fermenting the glucose present in the media and the other respiring the ethanol and 
glycerol produced by the first. The data now obtained for the gup1Δ multicellular 
aggregates, suggests this metabolic differentiation is partially lost or significantly 
reduced by GUP1 deletion. 
Another group of proteins that are significantly altered in the mutant ECM are the 
proteins responsible for the Acetyl-Co-A metabolism. The gup1Δ sample presents low 
amounts of Pdb1 (Table 1), and completely lacks Pda1. These two proteins comprise the 
subunit E1 of the pyruvate dehydrogenase, responsible for the conversion of pyruvate to 
acetyl-CoA [72]. The abundance of the citrate synthase Cit1 in the mutant sample is also 
significantly decreased (Table 2). Being the rate-limiting enzyme of the TCA cycle, this 
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enzyme is responsible for the condensation of acetyl-CoA and oxaloacetate into citrate 
[73]. The function of such proteins in the ECM is still unknown. The presence of 
complete pathways may suggest that some part of the metabolic steps could be 
performed outside the cell. Proteins involved in the maturation and targeting of other 
proteins, Hsp60 and Hri1 (Table 2), are also significantly decreased in the ECM of 
gup1Δ colonies. The protein Hri1 is a protein of unknown function that interacts with 
the broad protein kinase Hrr25 [74], and that is associated with the protein targeting to 
the membrane. On the other hand, the chaperone Hsp60 is vital for the cell survival, 
cells lacking the gene encoding for this protein are unviable [75]. Hsp60 is a 
mitochondrial chaperone involved in the de novo folding of mitochondrial proteins and 
respiration complexes assembly [76]. The two isoforms Hsp60 detected were the 
proteins whose abundance in the ECM most decreased with the deletion of GUP1 (-3.73 
and -4.38 fold). The presence of this Hsp60 in the ECM raises high expectations as to a 
possible role in the maintenance of protein function and extracellular metabolism.  
Finally, the acetohydroxy acid reductoisomerase Ilv5 is also significantly less 
abundant in the mutant sample (Table 2). Intracellularly, this protein is responsible for 
the mitochondrial DNA maintenance [77], and is involved in the biosynthesis of 
branched-chain amino acids, like leucine, isoleucine, and valine [78]. In spite that in the 
present work the presence of DNA in the yeast ECM was not assessed, it most probably 
exists (see Ch. 1). Given Ilv5 DNA-binding properties, the presence of proteins 
involved in DNA modification are not unexpected. 
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Table 2. Summary of the differentially present proteins. Statistical analysis, Identification data and 3D representation of the spots. 
Master 
number 
Protein 
Name Mr pI 
gup1∆/Wt 
Wt gup1∆ Score N Mass Matched 
MS/MS MS/MS 
ion 
score 
Sequence 
coverage t-test Avg 
ratio mass ion 
26 Gas1 60343 4,46 0,0077 8,33 
 
59 47 - - 21 
127 127 - - 0,023 5,73 
 
- - - - - 
954 Bgl2 34325 4,16 0,0065 3,51 
 
62 9 - - 40 
800 800 - - 0,0065 3 
 
- - - - - 
518 Exg1 51735 4,57 0,011 2,79 
 
66 13 - - 24 
1239 Sod1 15959 5,62 0,025 2,11 
 
83 8 - - 77 
1274 YPL225w 17491 5,24 0,029 2,01 
 
190 - 
1257.673; 59; 
45 
1.951.892 75 
1274 Hmf1 14011 5,28 0,029 2,01 
 
119 - 
1133.593; 40; 
62 
1.304.658 34 
880 Pdb1 40086 5,23 0,023 -2,01 
 
78 10 - - 37 
744 Ilv5 44512 9,83 0,023 -2,33 
 
163 19 - - 45 
1048 Hri1 27541 5,1 0,0077 -2,37 
 
71 8 - - 51 
455 Ald4 56973 6,31 0,044 -2,38 
 
102 15 - - 30 
687 Adh2 37165 6,26 0,023 -2,62 
 
66 10 - - 35 
599 Cit1 53384 8,23 0,023 -2,85 
 
53 9 - - 24 
345 Hsp60 60999 5,23 0,0068 -3,73 
 
91 14 - - 31 
346 Hsp60 60999 5,23 0,0077 -4,38 
 
113 16 - - 34 
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Deletion of GUP1 induces differences on polysaccharides of the ECM 
The ECM polysaccharides from cells lacking Gup1 were analysed as described for 
the Wt strain (Ch. 3). The polysaccharides were recovered through ethanol precipitation 
and analysed in both agarose and acrylamide electrophoresis (Fig. 3). The 
polysaccharides extracted from gup1Δ ECM were remarkably different from the Wt 
(Ch. 3). Furthermore, the 1,3-diaminopropane agarose electrophoresis showed that the 
deletion of GUP1 possibly induces a loss of complexity in the polysaccharides from the 
ECM (Fig. 3 A). The sample from Wt ECM polysaccharides clearly presents two 
metachromatic compounds, one of which close to the control chondroitin sulphate, 
while in the gup1Δ sample, only one band close to this last was observed. Different 
migration patterns in 1,3-diaminopropane agarose electrophoresis occur due to 
differences in the degree of sulphation, which increases towards the start point of the 
run. Therefore, the lack of Gup1 either affects the synthesis of a core compound, or the 
chemical substitution, originating a compound that does not induce metachromasia. The 
further molecular weight separation of compounds by PAGE (Fig. 3 B) yielded a similar 
result. The samples from gup1Δ mutants presented a single polydisperse band in the 5-8 
kDa range (arrow), compared to wt in which samples a further 35-40 kDa was present 
(arrows). This suggests that the Gup1 protein might play a role in the production, 
secretion and/or processing of such compounds. 
In the literature, several reports show that gup1Δ mutant cells presented altered 
plasma membrane and cell wall composition and integrity [4, 19], compromised lipid 
metabolism and lipid rafts integrity [11]. These phenotypes might influence the efficient 
production and secretion of ECM components. Nevertheless, the putative role of Gup1 
in chemical substitution of ECM polysaccharides cannot be discarded. The protein 
analysis revealed that several polysaccharide modifying or degrading enzymes are 
released to the yeast ECM that may alter the ECM polysaccharides, namely the exo-1,3-
beta-glucanase Exg2, a chitin trans-glycosylase involved in the β-glucan processing, as 
well as the putative mannosidases Dcw1 and Dfg5 (Table S4). Moreover, the double 
mutant disrupted in both GUP1 and its close homologue 
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Figure 4. Electrophoretic profiles of Wt and gup1Δ ECM polysaccharides. The 1,3-diaminopropane acetate agarose 
(A) and polyacrylamide (B) electrophoresis shows that the deletion of GUP1 induces the loss of the 35-40 kDa 
chemically substituted polysaccharide present in the Wt ECM. 
 
 
GUP2 produced ECM polysaccharides that showed anticoagulant properties, inducing 
an extended activated partial thromboplastin time (shown in Ch. 3). Bearing in mind 
that Wt sample induced metachromasia, and is chemically substituted, while not 
presenting anticoagulant properties, it is possible to consider that the two Gup proteins 
are most likely intervening together with the regulation of the polysaccharide 
modification.  
In the future, the utilization of other staining systems may also prove helpful. The 
Stain All dye detects acidic compounds, being able to stain both hyaluronan and 
sulphated glycosaminoglycans [79, 80].  
Conclusions 
The yeast ECM is a dynamic environment that is greatly influenced by the cells 
physiological state. The deletion of the pleiotropic GUP1 gene introduced profound 
changes in the cell physiology and structure. Therefore, it is not unexpected that the 
ECM components are altered by GUP1 and GUP2 deletions. Moreover, the putative 
morphogenic aptitude of the Gup proteins, stressed by the similarity with the Hedgehog 
acyltransferases, suggests as much. 
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Alterations in both protein identities and abundances were observed, a great number 
of proteins were absent, and the remaining proteins were in significantly different 
amounts. The careful analysis of the functions performed by these proteins inside the 
cell might give some indications as to their functions on the ECM. Nevertheless, we 
cannot overlook the possibility that all or most of these proteins are actually 
moonlighting, i.e., performing completely new functions in the ECM. Furthermore, the 
deletion of GUP1 severely compromised the synthesis and/or chemical substitution of 
the ECM polysaccharides, disappearance the polysaccharide of higher molecular 
weight.  
A whole new range of unanswered questions arose from this work. Further 
unveiling the Gup1 and Gup2 roles in the ECM composition, structure and chemical 
properties, will certainly contribute for the understanding of the S. cerevisiae 
multicellular lifestyle.  
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Abstract 
In higher Eukaryotes, at tissue level, major events like patterning during 
embryogenesis or remodelling during wound healing, are regulated by molecules named 
morphogens. These molecules comprise several families, including the Hedgehog (Hh) 
signalling pathway. The Hh signal is a long-range signal transmitted from one cell to the 
other through the ECM. It is translated into a precursor protein that undergoes extensive 
post-translational modifications, including palmitoylation of the amino end. The protein 
that palmytoylates the Hh signal (Hhat Hedgehog acyltransferase) is similar to yeast 
Gup2, while the negative inhibitor of this modification (Hhatl Hedgehog 
acyltransferase-like) is recognizably similar to yeast Gup1. In view of the high 
conservation of these proteins in the most diverse organisms, from man to plants, 
insects and nematodes, the complementation of the GUP mutants with the Gup1 and 
Gup2 orthologues from mouse, man and fly was attempted. The constructions involved 
transformation of the ∆gup1 and ∆gup2 and ∆gup1∆gup2 mutants with the mouse 
mmGUP1/HHATL, the human HHAT and HHATL and the fly RASP. The preliminary 
complementation assays under stress that highly impairs the growth of these mutants 
did not yield phenotype reversion. Further assays will show whether the proteins are 
expressing correctly, and whether a change of expression system will be needed. 
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Higher eukaryotes Gup- like acyltranferases 
Saccharomyces cerevisiae presents several orthologues of human genes, a great 
number of which are associated with diseases [1-3]. Yeast models of protein-misfolding 
disorders are allowing a better understanding of disease underlying mechanisms [4], and 
identification of compounds with potential therapeutic effect. Namely, studies in 
spongiform encephalopathies are being conducted in S. cerevisiae due to the presence of 
proteins that behave like mammalian prions [5]. These proteins (PrPC), consisting 
mainly by α-helices in their native form, can be founded in a misfolded prion-like form 
(PrPSc), which develops pathological aggregates, due to their capacity to catalyse the 
transformation of all other endogenous proteins into an identical, pathological, form[6]. 
The identification of specific drugs that solubilize the protein aggregates and reduce its 
toxic effect is the main objective [5]. Similarly, alterations in the mechanisms of protein 
folding, accumulation and sorting underlying diseases like Huntington, Parkinson or 
Alzheimer’s [7]. S. cerevisiae helped shed some light on the basis of malfunction of 
misfolded proteins removal processes, or protein sorting, as well as on the role of 
oxidative stress, thus contributing for the understanding of numerous neurodegenerative 
diseases [7-10]. Moreover, yeast has also provided information regarding human 
mitochondrial disorders like Leigh syndrome. The respiratory chain defects, metabolism 
regulation or abnormal modifications of mitochondrial DNA are some of the subjects 
studied in S. cerevisiae [11]. Additionally, yeast has been giving a great deal of help to 
uncover the function of many mammalian proteins through their successful 
heterologous expression [12]. When these proteins are human this is frequently 
designated as yeast humanization. The other way around is less frequent, but may also 
happen. For example, several oncogenes were firstly known in mammalian models, and 
subsequently identified in yeast, where their functions have been shown to be rather 
similar to the ones in the original organism. This is the case of the RAS1 and RAS2 
oncogenes [1].  
GUP1 and its close homologue GUP2 were initially identified as participants of the 
glycerol active transport mechanism [13]. Later, GUP1 has been implicated in several 
critical cellular mechanisms: plasma membrane and cell wall composition and integrity 
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[14, 15]; cytoskeleton polarization and bud side selection pattern [16, 17]; telomeres 
length [18]; lipid metabolism and lipid rafts integrity [19]; anaerobic sterol uptake [20]; 
secretory/endocytic pathway [21], GPI-anchor remodelling [22, 23]; and programmed cell 
death [24, 25]. Studies on the pathogenic yeast Candida albicans additionally showed 
that the disruption of CaGUP1 reduces the virulence, since the gup1Δ strain is unable to 
form true hyphae, to adhere and to invade to different substrates and to form biofilms. 
Similarly to what happens in S. cerevisiae, the cells lacking CaGUP1 displayed altered 
sensitivity to specific ergosterol biosynthesis inhibitors [19], and distribution of lipid 
rafts [19]. 
Both Gup1 and Gup2 are members of the MBOAT family of membrane bound O-
acyltransferases [14]. These two proteins share a high degree of similarity with each 
other (53% of identity between sequences) and with the other members of the same 
family from yeast [14, 26]. Moreover, they also share a high degree of similarity with 
proteins from other eukaryotic organisms, namely other yeasts and fungi, but 
importantly, from high eukaryotes, like the fly, the mouse and man [14, 27] (Fig. 1).In 
these last cases, the fact that the Gup-similar proteins were identified as regulators of 
the Hedgehog pathway [28], yielded the nomenclature by which Gup1 orthologues from 
high eukaryotes are known, Hhat (Hedgehog Acyl Transferase) for Gup2, and Hhatl 
(Hedgehog Acyl Transferase-Like) for Gup1. Hhat is responsible for the palmitoylation 
of the Sonic Hedgehog, while Hhatl competes with Hhat to inhibits its function, this 
way greatly diminishing Sonic hedgehog extracellular mobility and compromising 
signalling proper course [28]. Unpublished results from our group (kindly supplied by C. 
Ferreira) show that the mouse Hhatl can partially complement the phenotypes generated 
by gup1∆ deletion in C. albicans, namely hyphae production and invasive growth. The 
complementation of the morphology phenotypes raises the question of whether yeast 
might possess a morphogenic signalling pathway equivalent to Hedgehog from high 
eukaryotes. Therefore, the functional complementation of gup1∆ and gup2∆ mutations 
in S. cerevisiae by the high eukaryotic orthologues was attempted. 
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hsHHATL         -------------MGIKTALP-----------------AAELGLYSLVLSGALAYAG-RGLLEASQDGAHRKAFRESVRPGWEYIGRKMD  
mmHHATL         -------------MGIKTALP-----------------AAELGLYSLVLSGALAYAG-RGLLEASQDGAHRKAFRESVRPGWEYLGRKMD 
yeastGUP1       MSLISILSPLITSEGLDSRIKPSPKKDASTTTKPSLWKTTEFKFYYIAFLVVVPLMFYAGLQASSPENPNYARYERLLSQGWLFG-RKVD 
                              *:.: :                  ::*: :* :.:  .:.     **  :* :..:   :.. :  ** :  **:* 
 
hsHHATL         VADFEWVMWFTSFRNVIIFALSGHVLFAKLCTMVAPKLRSWMYAVYGALAVMGTMGPWYLLLLLGHCVGLYVASLLG--QPWLCLGLGLA 
mmHHATL         VADFEWVMWFTNFRNVIVFALSGHVLFAKLCTMVAPQLRSWMYAVYGVLAVVGTMGPWYLLLLLGHCMVLYVASLLG--QRWLCLALGLA 
yeastGUP1       NSDSQYRFFRDNFALLSVLMLV-HTSIKRIVLYSTNITKLRFDLIFGLIFLVAAHGVNSIRILAHMLILYAIAHVLKNFRRIATISIWIY 
                 :* :: ::  .*  : :: *  *. : ::    :   :  :  ::* : ::.: *   : :*    :   :* :*   :    :.: :             
 
hsHHATL         SLASFKMDP-LISWQSGFVTGTFDLQEVLFHGGS-------SFTVLRCTSFALES---------------------------------CA 
mmHHATL         SLASFKVDP-GISWQSGFVTGTFDLQDVLFHGGS-------SFTVLRCTSFALES---------------------------------CA 
yeastGUP1       GISTLFINDNFRAYPFGNICSFLSPLDHWYRGIIPRWDVFFNFTLLRVLSYNLDFLERWENLQKKKSPSYESKEAKSAILLNERARLTAA 
                .:::: ::    ::  * : . :.  :  ::*         .**:**  *: *:                                  .* 
 
hsHHATL         HPDRHYSLADLLKYNFYLPFFFFGPIMTFDRFHAQVSQVEPVRREGELWHIRAQAGLSVVAIMAVDIFFHFFYILTIPSDLKFANRLPDS 
mmHHATL         HPDRRYSLADLLKYNFYLPFFFFGPIMTFDRFHAQVSQ-EPVRPEGELWHIQAQAGLSAAAIVAVDVFFHFFYILTIPSDLKFASRLPDS 
yeastGUP1       HPIQDYSLMNYIAYVTYTPLFIAGPIITFNDYVYQSKHTLPSIN---FKFIFYYAVRFVIALLSMEFILHFLHVVAISKTKAWENDTP-F 
                ** : *** : : *  * *:*: ***:**: :  * .:  *      : .*   *   . *:::::.::**:::::*..   : .  *                
 
hsHHATL         ALAGLAYSNLVYDWVKAAVLFGVVNTVACLDHLDPPQ-PPKCITALYVFAETH--FDRGINDWLCKYVYNHIGGEHSAVIPELAATVATF 
mmHHATL         ALAGLAYSNLVYDWVKAAVLFGVVNTVARLDHLDPPQ-PPKCITALYVFGETH--FDRGINDWLCKYVYDHIGGDHSTVIPELAASVATF 
yeastGUP1       QISMIGLFNLNIIWLKLLIPWRLFRLWALLDGIDTPENMIRCVDNNYSSLAFWRAWHRSYNKWVVRYIYIPLGGSKNRVL----TSLAVF 
                 :: :.  **   *:*  : : :..  * ** :*.*:   :*:   *        :.*. *.*: :*:*  :**.:. *:    :::*.* 
 
hsHHATL         AITTLWLGPCDIVYLWSFLNCFGLNFELWMQKLAEWGPLARIEASLSVQMSRRVRALFGAMNFWAIIMYNLVSLNSLKFTELVARRLLLT 
mmHHATL         VVTTLWLGPCDIVYLWSVLNCFGLNFELWVQKLAERGPLAQIEARLSEQMSRRVRALCGAVNFWAIIMYNLVSLNSLEFTELVARRLILT 
yeastGUP1       SFVAIWHDIELKLLLWGWLIVLFLLPEIFATQIFS--------HYTDAVWYRHVCAVGAVFNIWVMMIANLFGF----CLGSDGTKKLLS 
                 ..::* .    : **. *  : *  *:: :: .           .    *:* *: ...*:*.::: **..:         . : :*: 
hsHHATL         GFPQTTLSILFVTYCGVQLVKERERTLALEEEQKQDKEKPE- 504 
mmHHATL         GFPQTTLAVLFVTYCGVQLVKERERSLALEEEQRQDREKLE- 503 
yeastGUP1       DMFCTVSGFKFVILASVSLFIAVQIMFEIREEEKRHGIYLKC 560 
                .:  *. .. **  ..*.*.   :  : :.**:::.    : 
B 
hsHHAT          ----------------------------------------------------------------MLPRWELALYLLASLGFHFYSFYEVY 
mmHHAT          ----------------------------------------------------------------MLPGWELTLCLLVSLGFHFRSFYEVY 
dmRASP          --------------------------------------------------------MSRLPDRSLLTRCEIFVYFGVYIAYIVVGLYKIY  
yeastGUP2       MSMLRIWSCIVHFFSVQALDSRIKPDIEFKRRQRIFINSSKEENGSSSSAVTVTRNPVLSSNSPSPPLWNTWEFRLYYLAFTVVVPFMIK 
                                                                                  .  :        :.: .   : :       
 
hsHHAT          KVSREHEEELDQEFELETDTLFGGLKKDATDFEWSFWMEWGK--QWLVWLLLGHMVVSQMATLLARKHRPWILMLYGMWACWCVLGTP-- 
mmHHAT          KVSREHEEELDQEFELEMDTLFGGLKKDPTDFEWNFWMEWGK--RRLVWLFIGHMAVSQLATLLTKKHRPWIVMVYGMWACWCVLGAP-- 
dmRASP          GLR--DHIVKEAKFQFPEGWSLYPFSQRRRDDSNDELENFGD--FIVSFWPFYLLHVAVQGFIRWKRPRLQCLGFIGVCALALSVNLD-- 
yeastGUP2       AALATSSESNPNYYKFSGLLAHGWILGRKVDNSDPQYRFFRSNFFLLAILILLQIILKKVFVKFSKIPKTKFDFACGLVFVCFMYGINSV 
                             :::        :     * .      : .    :    :  : :        :  :       *:       .     
 
hsHHAT          -GVAMVLLHTTIS--FCVAQFRSQLLTWLCSLLLLSTLRLQG---------VEEVKRRWYKTENEYYLLQFTLTVRCLYYTSFSLELCWQ 
mmHHAT          -GVVMVLLHSTIA--FCVAQFRSVLLSWLCSLLLLSTLRLQS---------VEEVKRRWYKTENEYYLLQFTLTVRCLYYTSFSLELCRQ 
dmRASP          -WSSMVLLVTLIASYYIVSLLSLKFLVWLLSAGWILCINVMQ---------KNVWWTDRVG-YTEYVLVIVTMSWSVLRGCSYSLSKIGA 
yeastGUP2       KLFTHAFIFFTLAHSLKRKRLIAAFAIWSYGIFTLFINQKMKNLPFNNIAIILSPMDQWYKGIVPRWDFFFNFTLLRLLSYSMDFLERWH 
                     .::   ::       :   :  *  .   :   .                             . ..::   *   * .:          
 
hsHHAT          QLPAAST--------------------------------------------SYSFPWMLAYVFYYPVLHNGPILSFSEFIKQMQQQEHDS 
mmHHAT          PPSAQPTPSAQG--------------------------------------ASHSYPWLLTYVFYYPVFHNGPILNFPEFFRQMQQPELNS 
dmRASP          KQEDLTR---------------------------------------------YSLVQYLGYAMYFPCLTYGPIISYQRFAARREDEVQNW 
yeastGUP2       EQLSRQPSIDYDDRRPEFRKSLSGSTLQTIYESGKNVLEEKERLVAEHHIQDYNFINFIAYITYAPLFLVGPIITFNDYLYQSENKLPSL 
                                                                    :.    : *  * * :  ***:.:  :  : ::   . 
             
hsHHAT          LKASLCVLALGLGRLLCWWWLAELMAHLMYMHAIYSSIPLLETVS-CWTLGGLALAQVLFFYVKYLVLFGVPALLMRLDGLTPPA-LPRC 
mmHHAT          LQHSLCIVAKGLGRLLCWWWLAELMVHLMYMHALYSSAPLLESVS-CWTLGGLALAQVLFFYVKYLVLFGVPALLMRLDGLTPPP-LPRC 
dmRASP          LG-----FVGGVLRSAIWWLVMQCALHYFYIHYMSRDVRMVEMMDSVFWQHSAGYFMGQFFFLYYVVTYGLGIAFAVQDGIPAPN-RPRC 
yeastGUP2       TKKN---IGFYALKVFSSLLLMEIILHYIYVGAIARTKAWNNDTP--LQQAMIALFNLNIMYLKLLIPWRLFRLWAMVDGIDAPENMLRC 
                       .     :      : :   * :*:  :       :           .     : :::  :: : :     **: .*    ** 
 
hsHHAT          VSTMFSFTGMWRYFDVGLHNFLIRYVYIPVGGSQHGLLGTLFSTAMTFAFVSYWHGGYDYLWCWAALNWLGVTVENGVRRLVETPCIQDS 
mmHHAT          VSTMFSFTGMWRYFDVGLHNFLIRYVYIPL------------------------------------------------------------ 
dmRASP          IGRIHFYSDMWKYFDEGLYEFLFQNIYAELCGKRSSAAAKFGATALTFAFVFVWHGCYTYVLIWSILNFLCLAAEKVFKTFTAMPEYQRW 
yeastGUP2       VDNNYSTVGFWRAWHTSFNKWVIRYIYVPFGGSNN----KILTSFAVFSFVAIWHDIQLRVLFWGWLTVLLLLGETYITN---------C 
                :.  .   .:*: :. .: ::::: :*  . 
 
hsHHAT          LARYFSPQARRRFHAALASCSTSMLILSNLV-FLGGNEVGKTYWNRIFIQGWPWVTLSVLGFLYCYSHVGIAWAQTYATD------- 
mmHHAT          LARHLSPQAHHRLHALLAACSTSMLILFNLV-FLGGIQVGKTYWNRIFLQAAFR--------------------------------- 
dmRASP          TQRHLGAVGAQRLYAMLATQLFIPAAFSNVY-FIGGQEIGDFLMRGAYLSGVGNYVALCFCSYCFFQCSELLLTKSDGRSKTKTF-- 
yeastGUP2       FSRYRFRSWYRFVCGIGAAINICMMMIINVYGFCLGAEGTKLLLKGIFNNSHSPEFLTAVMVSLFIAVQVMFEIREEEKRHGINLKC 
                  *:      : . .  *:       : *:  *  * :  .   .  : ..         
 
Figure 1. Alignments of the S. cerevisiae Gup1 protein with its orthologues from H. sapiens and M. musculus 
(mouse)(A); and Gup2 protein with its orthologues from D. melanogaster (fly) and H. sapiens (B).  
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Materials and Methods 
Strains and growth conditions 
S. cerevisiae strains used in the present work are listed in Table 1. Plasmid cloning 
and propagation was performed in the Escherichia coli strain XL1Blue (endA1 gyrA96 
(nalR) thi-1 recA1 relA1 lac glnV44 F'[::Tn10proAB+lacIqΔ(lacZ)M15] hsdR17(rK-
mK
+)).Yeast batch cultures were grown aerobically in minimal medium YNBD (0.67 % 
yeast nitrogen base and 2 % glucose). Incubation was performed at 30 °C, 200 rpm, 
orbital shaking and air/liquid ratio 2:1. Wt and mutant strains maintenance was done on 
solid rich medium YPD (1% yeast extract; 2% peptone; 2% glucose and 2 %agar), and 
the transformed strains were kept in solid minimal medium (with 2% agar), grown at 30 
ºC for 48 h and kept at 4 ºC up to five days. Bacterial strains were grown in LB (2 % 
tryptone; 0.5 % yeast extract; 0.5 % NaCl; pH 7.2), at 37 °C, 200 rpm, orbital shaking, 
The maintenance of positive transformants was done in solid LB medium (with 2% 
agar), grown at 37 ºC overnight and kept at 4 ºC up to five days.  
Dropout tests were performed from mid-exponential YNBD cultures containing 
approximately 1×106 cells/ml. Ten-fold serial dilutions were then made, and 5 μl of 
each suspension was applied on YNB medium supplemented with 2% glucose or 2% 
glycerol, and 2% glucose supplemented with 50 mM CaCl2, 200 µg/ml rapamycin, 50 
mM Congo Red, 0.01% SDS, 1 M sorbitol and 0.01% SDS + 1 M sorbitol. Results were 
scored after 48h of incubation at 30 °C, unless mentioned otherwise. 
All ingredients percentages were calculated as weight per volume units. Amino 
acids and antibiotics supplementation were done according to strains auxotrophic 
markers and plasmid maintenance needs.  
Plasmid constructions 
The cloning and expression of the higher eukaryotes cDNAs was carried out using 
the plasmid p426GPD. This multi-copy plasmid presents the strong GPD promoter and 
the URA3 gene for auxotrophic selection [29]. The Drosophila melanogaster RASP 
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cDNA, also known as dmGUP2, was provided already cloned in this vector with the 
HindIII/XhoI restriction sites (kindly supplied by F. Grieco from the Instituto di Scienze 
Delle Produzioni Alimentari, Lecce, Italy). The Mus musculus HHATL cDNA, referred 
as mmgup1, presented an eGFP tag and it was cloned in another plasmid [28]. This was 
kindly supplied by Y. Abe from the Keio University, Tokyo, Japan. The gene from 
pGup1-eGFP was digested with BamHI and BglII and the fragment was recovered with 
a GenElute Gel Extraction Kit (Sigma). The fragment was inserted in a BamHI digested 
p426GPD plasmid; proper orientation was evaluated through EcoRI digestion. The 
digestion of a correct oriented gene originated to 2 fragments: 7800 bp (plasmid + 1430 
bp mmGUP1) and 250 bp (250 bp mmGUP1). The human cDNAs from HHAT and 
 
 
 
 
HHATL, respectively hsGUP2 and hsGUP1, were inserted in a pDonor Gateway 
system® plasmid [31] and supplied by the Human ORFeome Collection of the Dana 
Table 1. S. cerevisiae strains used in the present study. 
Strain Genotypes Origin 
W303-1A MATaleu2-3 leu2-112 ura3-1 trp1-1 his3-11 his3-15 ade2-1 can1-100 [30] 
BHY54 Isogenic to W303-1A but gup1::His5+ [13] 
Cly5 Isogenic to W303-1A but gup2::KanMX [13] 
Cly3 Isogenic to W303-1A but gup1::His5+gup2::KanMX [13] 
FFOY011 Isogenic to BHY54 but transformed with p426GPD+mmGUP1 This study. 
FFOY012 Isogenic to BHY54 but transformed with p426GPD+hsGUP1 This study. 
FFOY021 Isogenic to Cly5 but transformed with p426GPD+dmGUP2 This study. 
FFOY022 Isogenic to Cly5 but transformed with p426GPD+hsGUP2 This study. 
FFOY121 Isogenic to Cly3 but transformed with p426GPD+mmGUP1 This study. 
FFOY122 Isogenic to Cly3 but transformed with p426GPD+hsGUP1 This study. 
FFOY123 Isogenic to Cly3 but transformed with p426GPD+dmGUP2 This study. 
FFOY124 Isogenic to Cly3 but transformed with p426GPD+hsGUP2 This study. 
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Faber Cancer Institute, University of Harvard, USA. These genes were PCR isolated 
with specific primers (Table 2). The primers were designed to include the HindIII and 
XhoI restriction sites to enable the cloning in the plasmid p426GPD.The genes were 
inserted in the p426GPD plasmid through the action of a T4 ligase (Roche). 
 
 
 
Transformation and DNA manipulation 
Escherichia coli cells were transformed with a CaCl2/heat shock-based protocol 
[32]. Cells were incubated in LB medium supplemented with ampicillin (100 µg/ml) for 
selection. Positive transformants were grown overnight and the presence of the desired 
plasmid was assessed through miniprep and digestion with restriction endonucleases. 
Positive transformants were used to plasmid storage and propagation. S. cerevisiae cells 
were transformed using the lithium acetate methodology [32]. Transformants were 
selected through incubation in minimal medium without uracil. 
Table 2. Primers used in PCR reactions. 
Primer Sequence 
hsGUP1_fw 5’-GCG AAG CTT ATG GGC ATC AAG ACA GCA TTG CC -3’ 
hsGUP1_rv 5’- GCG CTC GAG CTC CGG CTT CTC TTT GTC CTG C-3’ 
mmGUP1_fw 5’- ATA AAG CTT GCC ATG GGC ATC AAG ACA GC-3’ 
mmGUP1_rv 5’-ATA GGA TCC CTC CAG CTT CTC TCT GTC CTG-3’ 
hsGUP2_fw 5’- GCG AAG CTT ATG CTG CCC CGA TGG GAA CT-3’ 
hsGUP2_rv 5’- GCG CTC GAG GTC CGT GGC GTA GGT CTG GG-3’ 
dmGUP2_fw 5’-ATA AAG CTT CCA AAT CGG TGG TGT AGT G-3’ 
dmGUP2_rv 5’-CGC CGC GGA TCC ATA TAC AAT TAT ATA TTT-3’ 
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Results and Discussion 
Stress response and functional complementation 
The S. cerevisiae GUP1and 2 mutants were complemented according to the 
following scheme: 
 
 Ø plasmid dmRASP mmHHATL hsHHATL hsHHAT 
gup1∆ X  X X  
gup2∆ X X   X 
gup1∆gup2∆ X X X X X 
 
The transformants were submitted to phenotypic tests according to the results 
previously obtained in S. cerevisiae [15].The transformants were incubated in glucose 
and glycerol, and submitted to several types of stress, including high temperature (37 
ºC), cell wall perturbing agents (SDS and Congo Red), signalling pathways disturbing 
compounds (50 mM CaCl2 and 200 µg/ml rapamycin), osmotic pressure (1 M sorbitol), 
as well as remediation of 1 M of Sorbitol through the combination of 0,01% SDS[15]. 
The Wt strain, as well as the gup1∆, gup2∆ and gup1∆gup2∆ mutants, responded to 
these tests similarly to previously [15]. The transformants on the other hand, did not 
complement the mutants phenotypes under the conditions tested (Fig. 1, 2 and 3). 
In fact, it is possible to observe a discrete loss of fitness in all the strains harbouring 
plasmids. These were assessed for the plasmid presence through growth in solid 
minimal media supplemented with the auxotrophic needs except uracil (not shown). All 
strains were able to grow as expected in supplemented YNB, but, surprisingly, lost the 
ability to grow on this selective medium after one passage. Therefore, the presence of 
the plasmid was thereafter checked by PCR, using the primers in Table 2. Nonetheless, 
the expression of the heterologous proteins was not assessed through Western Blot, as 
there were no available antibodies. Although these have been recently commercialized 
(see https://www.scbt.com/pt/), raising a whole new range of possibilities, they have not 
yet been tested in yeast. 
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The successful complementation of Δgup1 mutant achieved in C. albicans by 
mmHHATL cDNA above referenced was obtained using the p414GPD. This expression 
plasmid belongs to the same vector family as p426, but it is a low-copy plasmid, and 
presents the tryptophan auxotrophic marker instead of uracil. In what regards these 
markers, both have recorded low level of reversal, and should present similar selective 
strength [33]. Identically, the presence of the strong constitutive GPD promoter on both 
cloning vectors should result in similar levels of expression for each plasmid copy. 
 
Figure 1. Functional complementation of gup1∆ mutation by mouse and human acyltransferase-like genes. Ten-fold 
serial dilutions of cells were spotted in minimal media with 2% glucose at 30 ºC (Column A) or at 37 ºC (Column B) 
and 2% glycerol at 30 ºC (Column C), or 2% glucose supplemented with 50 mM CaCl2 (Column D), 200µg/mL 
Rapamycin (Column E), 50 mM Congo Red (Column F), 0.01% SDS (Column G), 1 M Sorbitol (Column H) and 
0.01% SDS + 1 M Sorbitol (Column I).  
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It is known that a high number of plasmids might lead to the expression of 
saturating levels of heterologous protein inside the cells, triggering the proteolytic 
degradation of the protein of interest [34], which might be responsible for the lack of 
complementation and putatively of expression. However, the differences in growth 
conditions may also play a role. The minimal media and auxotrophic requirements limit 
the growth of the 
 
 
Figure 2. Functional complementation of gup2∆ mutation by fly and human acyltransferase genes. Ten-fold serial 
dilutions of cells were spotted in minimal media with 2% glucose at 30 ºC (Column A) or at 37 ºC (Column B) and 2% 
glycerol at 30 ºC (Column C), or 2% glucose supplemented with 50 mM CaCl2 (Column D), 200µg/mL Rapamycin 
(Column E), 50 mM Congo Red  (Column F), 0.01% SDS (Column G), 1 M Sorbitol (Column H) and 0.01% SDS + 1 
M Sorbitol (Column I). 
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colonies, yielding less biomass than rich media in the same conditions. Hence, if only a 
mild or partial functional complementation is occurring, it could be masked by fewer 
colonies observed in the minimal media. 
Still, the strains made available in this pioneering work will be further studied. 
They will be used to confirm the expression of the heterologous proteins using the 
antibodies presently available commercially against Rasp, mmHhatl, hsHhatl and 
hsHhat. If necessary the constructions will be shifted to low copy number plasmids for a 
new phenotypic check. Additionally, several drugs have been described as targeting 
components of the Hh pathway, namely exo-cyclopamine that selectively inhibits the 
Smoothened protein and interferes with the patterning during development [35]. The 
effects of such compounds that target proteins downstream of the Hh signalling 
pathway should overlap, at least partially, with the effects of mutations in the yeast 
acyltransferases, giving important hints about the cell-cell communication mediated by 
the putative yeast pathway.  
All the available information in the components of Hh pathway in mammals, and 
the available tools for the treatment of Hh-related disorders may become powerful tools 
to uncover the function of yeast Gup1 and Gup2 proteins, and the putative extracellular 
signalling pathway. 
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Figure 3. Functional complementation of gup1∆gup2∆ mutation by fly, mouse and human acyltransferase genes. 
Ten-fold serial dilutions of cells were spotted in minimal media with 2% glucose at 30 ºC (Column A) or at 37 ºC 
(Column B) and 2% glycerol at 30 ºC (Column C), or 2% glucose supplemented with 50 mM CaCl2 (Column D), 
200µg/mL Rapamycin (Column E), 50 mM Congo Red (Column F), 0.01% SDS (Column G), 1 M Sorbitol 
(Column H) and 0.01% SDS + 1 M Sorbitol (Column I). 
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Abstract 
Hyaluronan (HA) is a non-sulphated glycosaminoglycan (GAG) present in the 
extracellular matrix (ECM) of the higher Eukaryotes, regulating major cellular 
processes as apoptosis, angiogenesis or cell migration and proliferation. HA is present 
in the ECM in a wide range of biologically active sizes, which modulate the biophysical 
and biochemical properties of tissues. This GAG intervenes in several signalling 
pathways through its receptors CD44 and RHAM. Several microorganisms produce 
proteins involved in the metabolism of HA, namely Candida albicans and 
Streptococcus spp., which are associated with infection/colonization processes. The 
effects of different size HA in S. cerevisiae were assessed in W303-1A strains 
heterologously expressing the HA receptors, CD44 and HMMR. The engineered strains 
were subjected during cultivation to the presence of HA with 2 to 1000 kDa. The HA of 
higher molecular weights produced a mild effect on growth parameters of CD44 and 
HMMR expressing strains. However, in accordance with the literature the strain 
expressing CD44 presented a high growth reduction in the presence of 50 kDa HA. 
These results suggest that the receptors are functional in the cell, and the cellular 
machinery to respond to HA stimuli is fairly conserved. The further testing of S. 
cerevisiae strains expressing the HA receptors will provide crucial information on the 
role of yeast interactions with high molecular weight polysaccharides, and the role of 
those interactions on several cellular processes, namely differentiation and invasive 
growth. 
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Hyaluronan and hyaladherins 
Hyaluronan (HA) is one of the most important components of the extracellular 
matrix (ECM) of high eukaryotes, and it plays several structural and metabolic roles in 
the ECM [1]. Its average molecular weight ranges from 1 to 5 million Daltons, and it is 
composed of a homogenous linear repetition of the dimmer [glucuronic acid (β1,3) /N-
acetyl- glucosamine (β1,4)][2]. This glycosaminoglycan is not attached to a peptide, and 
its synthesis is performed in the plasma membrane by opposition to the Golgi apparatus 
as the remaining glycosaminoglycans [3]. Also, the new residues are added to the 
reducing end of the chain, whereas in the case of the other glycosaminoglycans the 
addition occurs at the non-reducing end [4]. Moreover, the hyaluronan synthase, aside 
from being capable of establish both β-1,3 and β-1,4 linkages, is also responsible for the 
exportation of the newly synthesized chain to the extracellular space through a pore 
constituted by the enzyme itself [5]. 
HA regulates and intervenes in several important intracellular pathways [6] through 
the numerous and disparate biological-relevant molecular sizes, resulting from very 
dynamic and controlled processes of synthesis and degradation/ turnover [1, 3, 6].These 
different size molecules interact with specific receptors, hyaladherins, promoting signal 
transduction and HA internalization [7]. The hyaladherins, namely HMMR 
(Hyaluronan-Mediated Motility Receptor, also known in the literature as RHAMM, 
Receptor for Hyaluronan-Mediated Motility) and CD44, present several different 
isoforms, resulting from alternative splicing, that interact with different HA molecular 
sizes and control cell migration, aggregation and proliferation [6]. Being present in the 
cell surface and in intracellular compartments, these receptors may perform a role in the 
information flow between the cell genome and the extracellular environment [3].  
The lack of information on yeast ECM and the presence of enzymes related to HA 
turnover in yeast and bacteria, namely Candida albicans and Streptococcus spp. [8-11], 
prompted the study of HA and its metabolism in S. cerevisiae. The growth of yeast 
strains expressing cDNAs from the human hyaladherins HMMR and CD44 was 
differently affected by the presence of several HA molecular sizes. This study allows us 
to infer the possibility of potential conserved pathways to integrate HA receptors 
signals, a probable result of glycosaminoglycans presence in yeast ECM. 
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Materials and Methods 
Strains and growth conditions 
S. cerevisiae strains used in the present work are listed in Table 1. Plasmid cloning 
and propagation was performed in the Escherichia coli strain XL1Blue (endA1 gyrA96 
(nalR) thi-1 recA1 relA1 lac glnV44 F'[::Tn10proAB+lacIqΔ(lacZ)M15] 
hsdR17(rKmK+)).Yeast batch cultures were grown aerobically in minimal medium 
YNBD (0.67 % yeast nitrogen base; 2 % glucose). Incubation was performed at 30 °C, 
200 rpm, orbital shaking and air/liquid ratio 2:1. Wt and mutant strains maintenance 
was done on solid rich medium YPD (1% yeast extract; 2% peptone; 2% glucose; 2 
%agar) and transformants strains were kept in solid minimal medium (with 2% agar), 
grown at 30 ºC for 48h and kept at 4 ºC up to five days. Bacterial strains were grown in 
LB (2 % tryptone; 0.5 % yeast extract; 0.5 % NaCl; pH 7.2), at 37 °C, 200 rpm, orbital 
shaking. The maintenance of positive transformants was done in solid LB medium (with 
2% agar), grown at 37ºC overnight and kept at 4ºC up to five days.  
The growth assays in the presence of 0.1% HA were performed in 96 well plates. 
Cells from mid-exponential YNBD cultures were collected through centrifugation and 
resuspended in fresh YNBD (OD600nm=0.5). The cells were diluted to an initial OD of 
0.05 (200µl of suspension per well), and incubated in the presence of HA (2, 10, 200, 
1000 kDa), at 30ºC with orbital shaking for 10h. Growth was monitored 
spectrophotometrically every hour at 600 nm in a SpectraMax microplate reader 
(Molecular Devices). Data represents the average of three independent experiments. 
 
 
Table 1. S. cerevisiae strains used in the present study. 
Strain Genotypes Origin 
W303-1A MATaleu2-3 leu2-112 ura3-1 trp1-1 his3-11 his3-15 ade2-1 can1-100 [12] 
FFOY000 Isogenic to W303-1A but transformed with empty p426GPD This study. 
FFOY001 Isogenic to  W303-1A  but transformed with p426GPD+CD44 This study. 
FFOY002 Isogenic to  W303-1A but transformed with p426GPD+HMMR This study. 
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All ingredients were calculated as weight per volume units. Amino acids and 
antibiotics supplementation were done according to strains auxotrophic markers and 
plasmid maintenance needs. 
Plasmid constructions 
The cloning and expression of the HA receptors was carried out using the plasmid 
p426GPD. This multi-copy plasmid presents the strong GPD promoter and the URA3 
gene for auxotrophic selection [13].  
The cDNAs from human CD44 and HMMR were received in a pDonor Gateway 
system® plasmid [14]. These genes were PCR isolated with specific primers (Table 2). 
The primers were designed to include the HindIII and XhoI restriction sites for the 
CD44 gene, and the HindIII and SpeI for the HMMR gene, to enable the cloning in the 
plasmid p426GPD. The cDNAs were inserted in the p426GPD plasmid through the 
action of a T4 ligase (Roche). 
 
 
Transformation and DNA manipulation 
E. coli cells were transformed with a CaCl2/heat shock-based protocol [15]. Cells 
were incubated in LB medium supplemented with ampicillin (100 µg/ml) for selection. 
Positive transformants were grown overnight and the presence of the desired plasmid 
was assessed through miniprep and digestion with restriction endonucleases. Positive 
transformants were used to plasmid storage and propagation. S. cerevisiae cells were 
Table 2. Primers used in PCR reactions. 
Primer Sequence 
hsCD44_fw 5’-GCGAAGCTTATGGACAAGTTTTGGTGGCA-3’ 
hsCD44_rv 5’- GCGCTCGAGCACCCCAATCTTCATGTCCACATTGTGC-3’ 
hsHMMR_fw 5’- GCGACTAGTATGTCCTTTCCTAAGGCGCCC-3’ 
hsHMMR_rv 5’- GCGCTCGAGCTTCCATGATTCTTGACACTCCATA-3’ 
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transformed using the lithium acetate methodology [15]. Transformants were selected 
through incubation in minimal medium without uracil. 
Results and Discussion 
Hyaladherins expression and growth defects 
In order to assess the effect of HA in S. cerevisiae expressing HA specific 
receptors, the cloning of the genes coding for these proteins was performed in the multi-
copy plasmid p426GPD. As before (Chapter 6), these cDNAs originated from the Dana 
Farber Human ORFeome Collection, and were retrieved from the Gateway system-
based plasmids through PCR with specific primers (Table 2). The p426GPD plasmid 
containing the cDNAs encoding for the HA receptors were transformed into the W303-
1A yeast strain. The strains were assessed for the plasmid presence through growth in 
uracil-less selective medium (not shown). The strains were able to grow in 
supplemented YNB after the transformation, and identically to what happened with the 
construction from Chapter 6, after a passage in YPD, the strains were no longer able to 
grow on YNB lacking uracil (not shown). As mentioned before (Chapter 6), the plasmid 
stability in the transformants was an issue, impossible to assess by Western Blotting. 
Some transformants did not respond to HA, but presented enhanced adherence to agar 
(not shown). Only transformants that responded to HA were selected to proceed with 
the tests. 
The several strains were grown in selective medium in the presence of 0.1% HA 
from a wide range of molecular sizes: ≈2, 10, 50, 200 and 1000 kDa (Fig. 4). Each 
culture growth was followed throughout exponential and post-diauxic phases. As 
control, the strains were incubated without HA (Fig. 4 A). Results showed that the 
CD44 and the HMMR expressing yeast strains presented identical performance. 
Moreover, in the presence of the HA lower molecular weights (≈2 kDa and 10 kDa) 
(Fig. 4 B, C), growth was basically indistinguishable from the control cultures in the 
absence of HA (Fig. 4 A). The low HA MW, in the present conditions, namely HA 
concentration, did not produce a growth phenotype. 
Otherwise, the HA higher molecular weights (200 and 1000 kDa) (Fig. 4 E, F), 
produced a mild effect on lag phase which increased to 2 h time, as well as on μg that  
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Figure 1. Hyaluronan influence on cell growth in the yeast strains expressing CD44 and HMMR. Growth curves in 
YNB alone (A), or supplemented with 0.1% HA ≈2 kDa (B), 10 kDa (C), 50 kDa (D), 200 kDa (E) and 1000 kDa (F). 
Strains: W303-1A ( ), W303-1A p426GPD ( ), W303-1Ap426GPD-CD44 ( ) and W303-1A p426GPD-
HMMR ( ). 
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was 0.14 h-1 and 0.18 h-1 in CD44 and HMMR expressing strains respectively, that is, 
40% and 20% slower as compared to 0.23 h-1from both control strains in the same 
growth conditions. An identically mild effect was observed in biomass achieved 
entering stationary phase. The fact that this effect was not too afar in both the CD44 and 
the HMMR expressing strains could arguably be due to a non-specific inhibition caused 
by the increase in osmotic stress derived from the presence of the very high MW HA, 
which has high water retention ability and/or the high viscosity of these media. Finally, 
0.1% 50 kDa HA had the most effect (Fig. 4 D), affecting especially the CD44 
expressing strain. These cells presented a decreased in growth, being exponential phase 
μg 0.11 h-1, ±70% lower than all the other strains (HMMR - 0.40 h-1, empty plasmid - 
0.35h-1, and Wt- 0.37 h-1) (Fig. 4 D).  
These results are quite preliminary. No WB was possible to confirm the expression 
of the two proteins in yeast cells. Nevertheless, the different response of each strain to 
the several HA concentrations suggests that the proteins are functionally expressed. 
Actually, the growth sensitivity of the CD44 expressing strain to 50 kDa HA is 
somehow expected since this receptor in mammalian cells presents high affinity for HA 
in the range of 30-40 kDa MW [16]. Moreover, other HA concentrations were not tested. 
Although that would not be possible to perform for the higher MW because of the limits 
of solubility and/or exceptional viscosity of the media, it cannot be disregarded that for 
the smaller MW effects could be observed in other range of concentrations. 
Additionally, it is known that the physiological state of the cell, namely glucose 
metabolism, or other environmental factors, may affect HA turnover if not the response 
to HA [3, 17].  
The S. cerevisiae strains humanized by expressing the hyaluronan receptors will be 
further assessed, hopefully becoming a tool for the study of the roles and effects of 
hyaluronan in yeast cell response and yeast ECM production and characteristics. 
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General discussion 
The yeast Saccharomyces cerevisiae, as all microbes, is generally regarded as a 
unicellular organism. The biotechnological applications of this yeast mostly relying on 
liquid batch, fed-batch or continuous cultures contributed to strengthen that concept. 
Essentially, microbes are regarded as unicellular because they do not form enduring and 
self-complying multicellular aggregates like higher organisms. However, in nature, the 
existence of planktonic cells is transitory. Actually, microorganisms live more 
frequently in spontaneously forming macroscopic aggregates of many cells that easily 
could be considered as proto-tissues. They present differentiated and specialized cells [1, 
2], spatially organized into functional structures [3, 4], coordinated by complex 
communications systems [5, 6], and supported by a complex extracellular matrix (ECM) 
[7-10]. The ECM is a crucial structure for the development of multicellularity. It 
provides protection against environmental variations and stresses, and acts as a scaffold 
for the three-dimensional organization of cells [11, 12]. Evidence of the presence of this 
type of structure supporting the life of S. cerevisiae within colonies emerged barely a 
decade ago [4]. Since then, new information from S. cerevisiae, as well as knowledge 
gathered from other microorganisms, including bacteria, has been accumulating [2-4, 13-
22]. However, the identity of most protein and sugars basic components supporting this 
life-style, as well as their biological roles, are still unknown, although complexity is 
expected in view of the 3D spatial organization of wild type yeasts colonies [4, 19]. 
Hence, the work developed under the scope of this thesis aimed to provide a first 
systematic insight in the composition and molecular characterization of yeast ECM 
components. 
The inexistence of a robust methodology for the extraction and fractionation into 
chemical purity of yeast ECM to enable the identification of the major components from 
different chemical families was not available. The extraction of the protein fraction of 
the colonies ECM had already been described, but only a very preliminary analysis by 
SDS PAGE was presented [4, 19], therefore raising doubts as to the feasibility of the 
correspondent protocol for proteomic approaches. A more in-depth analysis, based in 
powerful methodologies, was a requirement to initiate the systematic study of the yeast 
mat ECM proteins and their biological roles. In this work a methodology was devised to 
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(1) reproducibly obtain young yeast cells grown into homogenous mats; (2) extract the 
ECM and (3) fractionate the ECM into analytical-grade protein and sugar fractions. 
The high throughput mass spectrometry analysis of the proteins in the yeast ECM 
identified an unsuspected large number and diversity of proteins, most of which usually 
assigned to the cytoplasm or intracellular organelles. These proteins were empirically 
organized into the following classes: control of cellular organization, cell rescue and 
defence, DNA/RNA maintenance, protein fate and components metabolism. The cell 
integrity assessment showed that in a 7 days grown-mat, 10-15% of cells had 
compromised plasma membrane. The lysis of some cells during the development of the 
mat is inevitable, and certainly contributes to increase the number and/or amount of 
intracellular proteins that were found. As much as it may theoretically be desirable to 
avoid, one cannot discard the notion that the actual existence of intracellular contents 
from lysed cells might be important for the mat or biofilm development. The role of 
such proteins is for the moment unknown. They might contribute to the scaffolding of 
the ECM, to the formation of signalling gradients, or simply to act as a nutrient source. 
However, some of these proteins have already been reported in the cell surface, namely 
glycolytic enzymes [23-25]. In another yeast, Candida albicans, the same proteins were 
shown to present a completely different function [26, 27], and therefore nicknamed 
moonlighting proteins [28, 29]. Moreover, a large number of proteins associated with 
protein fate and remodeling were found. These included several proteins from the 
HSP70 family, and proteases, importantly, the exopeptidases Lap4, Dug1 and Ecm14, 
and the metalloproteinases Prd1, Ape2 and Zps1, sharing a functional zincin domain 
with higher Eukaryotes ECM metalloproteinases.  
The information regarding the ECM sugar fraction available in the literature [4, 19] 
was considerably smaller than the protein-related data. The methodologies underlying 
polysaccharides characterization are not very common and present a considerable 
degree of difficulty and uncertainty. The information available on yeast ECM 
polysaccharides was reduced to the acknowledgement of the present of glycoproteins [4, 
19], and the sugar monomers composing a exopolysaccharide in C. albicans 
biofilms[30]. Our methodology allowed obtaining a sugar rich fraction that once treated 
with a broad range proteinase, yielded a sugar fraction with high purity. The mass 
spectrometry analysis revealed the presence of glucose, mannose and galactose, 
suggesting the presence of polysaccharides similar to the glucans and/or mannans 
 GENERAL DISCUSSION 
219 
present in yeast and fungi cell walls [31], or to the galactoglycans described for algae 
and ascidians [32, 33]. The presence of uronic acids was also observed in the yeast ECM 
sample, whose occurrence is frequent in the ECM of both high Eukaryotes [34], and 
microbial biofilms [35]. The electrophoretic and chromatographic separation revealed 
the existence of two distinct polysaccharides, a low molecular weight oligosaccharide, 
and a 35-40 kDa polysaccharide. Both these compounds presented chemical 
substitution, as indicated by the metachromatic shift induced in dimethymethylene blue 
and toluidine blue dyes. The putative existence of sulphate groups in the yeast ECM led 
to the analysis of the anticoagulant activity of several ECM samples from different 
yeasts strains. A particular strain, mutant for both GUP1 and GUP1 genes, presented a 
relatively high anticoagulant activity, which was not observed in Wt cells. Given the 
role of sulphation pattern in anticoagulant effect [36], the chemical substitution detected 
in the yeast ECM is mostly likely sulphate groups. However, several other chemical 
groups may induce the metachromatic shift of the analysed dyes, and the presence of 
classic sulphotransferases, as well as the chemical intermediates, has not been so far 
reported in S. cerevisiae. The nature of the chemical substitution in the yeast ECM 
polysaccharides, as well as its macromolecular structure, is currently being examined 
using tools with higher analytic power, including the methylation analysis of such 
compounds and NMR. 
The GUP1 gene is a very pleiotropic gene that influences a great deal of cellular 
processes, from plasma membrane and cell wall composition and organization to 
cytoskeleton assembly [37-42]. In C. albicans, the disruption of this gene resulted in 
changes in colony morphology, and loss of invasive growth capacity and hyphae 
formation [43]. The effects of the deletion of GUP1 gene in the composition of yeast 
ECM were assessed, providing a more in-depth perspective of the ECM structural 
organization and metabolic mechanisms. Alterations in both protein identities and 
abundances were observed, a great number of proteins were absent and the remaining 
proteins amounts were significantly different. The deletion of GUP1 made disappear 
from the yeast ECM mainly proteins associated with the carbon metabolism, cell rescue 
and defence, protein fate and cellular organization. The functions of these proteins in 
the ECM are still unknown. The deletion of GUP1 additionally had a profound impact 
in the composition of the ECM sugar fraction, through the disappearance of the higher 
molecular weight polysaccharide that was detected in the Wt sample, or alternative 
 GENERAL DISCUSSION 
220 
elimination of the sulphation and subsequent loss of metachromasia. The GUP1 effects 
on the ECM shows that its structure is very dynamic, and that it is under the tight 
control of the cells composing the aggregate. The possible relation between the ECM 
molecular composition and the phenotypes observed previously in this mutant (lipids, 
rafts [40], wall[39], cytoskeleton [38], life span and death [41, 42], invasiveness and 
differentiation [43]) point to the biological roles known to higher Eukaryotes ECM. 
In higher Eukaryotes, tissue patterning and remodelling during embryogenesis or 
wound healing are regulated by molecules named Morphogens [44]. These molecules 
comprise several families, including the Hedgehog (Hh), Wnt or the Bone 
Morphogenetic Protein (BMP) [45-47]. The Hh signal is translated into a precursor 
protein that undergoes auto-excision and extensive post-translational modifications, 
including the addition of cholesterol and palmitate to the protein extremities [47]. The 
palmitoylation of Hh is the role of a membrane bound O-acyltransferase known as the 
Hedgehog acyltransferase (Hhat) [48]. Another protein, Hedgehog acyltransferases-like 
(Hhatl) competes for the Hh molecule and negatively regulates the process [49]. These 
proteins are similar to, respectively, Gup2 and Gup1. The high homology between yeast 
Gup1 and Hhatl, and Gup2 and Hhat, suggests the presence of a signalling pathway 
equivalent to the morphogenic Hedgehog pathway, mediated by a modified protein 
extracellular bound signal. Unpublished results from our group, showed that the Hhatl 
from mouse is capable of functionally complement the GUP1 deletion in C. albicans. 
This led to the engineering the yeast mutants defective on either or both GUP1 and 
GUP2 by expressing the fly, human and mouse orthologues. This strain set was 
preliminarily assessed in stress conditions known to produce severe phenotypic changes 
in cells lacking Gup1, and the functional complementation evaluated. The different 
strains did not present reversion of the mutant phenotype. The assessment of protein 
expression through WB, as well as the trial of alternative expression systems, will be 
continued in the future. 
Finally, as an additional preparation for future yeast ECM-related work, also the 
mammalian receptors of hyaluronic acid (HA), CD44 and HMMR, were cloned into the 
yeast S. cerevisiae. Several microorganisms produce proteins involved in the 
metabolism of HA, mostly human pathogens [50-52]. The presence of such proteins in 
yeast and bacteria, as well as the lack of information regarding yeast ECM prompted the 
study of HA and its metabolism in S. cerevisiae. The engineered strains were subjected 
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to the presence during cultivation of HA from 2 to 1000 kDa. Nevertheless, the presence 
of these HA higher molecular weights (produced a mild effect on lag phase, as well as 
on μg that was 40% and 20% slower in CD44 and HMMR expressing strains, 
respectively.  However, in accordance with the literature [53], the strain expressing 
CD44 presented a high growth reduction in the presence of 50 kDa HA. These results 
suggest that the receptors are functional in the cell, and the cellular machinery to 
respond to HA stimuli is fairly conserved. The further testing of S. cerevisiae strains 
expressing the hyaluronan receptors will provide crucial information on the role of yeast 
interactions with high molecular weight polysaccharides, and the role of those 
interactions on several cellular processes, namely differentiation and invasive growth. 
The study of the multicellular life-style of the yeast S. cerevisiae is still very recent. 
The knowledge on the ECM composition, organization and metabolism is still reduced. 
The methodology described in this work is able to provide large amounts of yeast ECM, 
in a simple and reproducible manner, allowing the analysis of both the protein and sugar 
components. So far, the study of the yeast ECM was limited due to the low amount of 
starting materials. Our methodology will help to overcome this limitation. The 
establishment of standardized inoculation, growing conditions, and ECM extraction 
procedures, ensures reproducibility, which became patent in the results obtained using 
highly sensitive techniques, namely DIGE. Several independent replicates were 
analysed and shown to behave similarly.  
The present work is innovative and ground breaking since (1) this is the first time 
that a detailed survey on the identity of the proteins secreted during growth in a yeast 
multicellular aggregate is presented, and (2) this is the first time a more in-depth 
approach into the polysaccharide composition of the correspondent glycosidic fraction 
is obtained. Moreover, this work contributed with the first description of the effect of 
the deletion of genes involved in several cellular processes in the development of the 
yeast ECM, identifying the proteins affected positively and negatively by the mutation. 
Finally, this work is also a pioneer for suggesting the possibility of polysaccharide 
chemical substitution, this way adding to the complexity of yeast ECM. Overall, this 
work contributes with a large step to give the future insight of the multicellular life-style 
of S. cerevisiae. 
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Table S1. Proteins secreted during liquid growth by S. cerevisiae W303-1A cells. 
Accession Protein Coverage # PSMs # Peptides # AAs MW [kDa] calc. pI Score 
Q04951 SCW10 32,65 35 10 389 40,4 4,65 1398,20 
P53334 SCW4 31,61 31 10 386 40,1 4,83 1072,14 
P00445 SOD1 55,84 35 8 154 15,8 6,00 1021,79 
P38288 TOS1 17,80 23 5 455 48,0 4,67 972,76 
P23776 EXG1 40,40 25 12 448 51,3 4,75 799,49 
P17967 PDI1 30,08 22 11 522 58,2 4,53 770,07 
P42835 EGT2 8,55 15 5 1041 108,5 4,82 755,08 
P00925 ENO2 40,05 18 11 437 46,9 6,00 694,00 
Q12408 NPC2 22,54 24 3 173 19,1 4,44 591,44 
P00044 CYC1 32,11 17 3 109 12,2 9,42 583,90 
P15703 BGL2 23,32 15 6 313 34,1 4,51 571,11 
A7A003 UTH1 16,30 15 5 362 36,7 4,79 415,10 
P0CG63 UBI4 40,68 14 4 381 42,8 7,58 378,33 
P35842 PHO11 13,28 9 5 467 52,7 5,17 367,21 
P40472 RPL10 16,81 11 4 476 48,2 4,60 359,16 
P06169 PDC1 14,03 8 6 563 61,5 6,19 312,63 
P00359 TDH3 22,89 9 6 332 35,7 6,96 306,08 
P53616 SUN4 11,90 8 2 420 43,4 4,36 296,34 
P02994 TEF1 8,73 10 4 458 50,0 9,04 271,49 
B5VL27 CIS3 11,56 10 3 225 23,0 4,68 249,94 
P00560 PGK1 21,15 10 8 416 44,7 7,61 246,64 
P36110 PRY2 5,17 8 1 329 33,8 4,60 218,62 
P00729 PRC1 12,97 8 6 532 59,8 4,73 185,14 
P00549 PYK1 11,20 6 5 500 54,5 7,68 181,40 
P26263 PDC6 5,33 4 2 563 61,5 6,19 170,63 
P12709 PGI1 4,69 7 2 554 61,3 6,46 167,72 
P10592 SSA2 8,29 4 3 639 69,4 5,06 136,17 
Q05902 ECM38 7,58 5 3 660 73,1 5,88 129,25 
P60010 ACT1 9,87 5 3 375 41,7 5,68 125,61 
P16474 KAR2 4,69 5 3 682 74,4 4,93 124,36 
P25296 CNB1 10,86 4 2 175 19,6 4,55 122,03 
P22146 GAS1 9,12 4 3 559 59,5 4,67 108,20 
P06367 RPS14A 24,82 4 3 137 14,5 10,73 99,61 
P02365 RPS6A 13,56 2 2 236 27,0 10,45 96,75 
P00330 ADH1 2,30 3 1 348 36,8 6,68 95,82 
P17076 RPL8A 7,42 3 2 256 28,1 10,04 95,27 
P11484 SSB1 5,22 3 3 613 66,6 5,44 93,39 
P04456 RPL25 9,15 1 1 142 15,7 10,11 90,63 
P38013 AHP1 11,36 1 1 176 19,1 5,16 89,71 
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Accession Protein Coverage # PSMs # Peptides # AAs MW [kDa] calc. pI Score 
A6ZL22 ECM33 3,50 3 1 429 43,7 4,91 87,41 
P35271 RPS18A 7,53 4 1 146 17,0 10,27 86,76 
P17079 RPL12A 14,55 3 2 165 17,8 9,41 79,28 
P38836 ECM14 3,49 2 1 430 49,8 5,30 77,69 
P32603 SPR1 2,25 3 1 445 51,8 5,81 75,35 
Q12335 PST2 7,58 2 1 198 21,0 5,73 72,17 
P05317 RPP0 3,53 2 1 312 33,7 4,83 69,26 
P26783 RPS5 6,67 1 1 225 25,0 8,59 68,78 
P29029 CTS1 1,78 2 1 562 59,0 4,55 67,79 
Q08108 PLB3 1,75 2 1 686 75,0 5,03 65,86 
P00950 GPM1 8,91 2 2 247 27,6 8,84 64,82 
P07267 PEP4 2,22 2 1 405 44,5 4,84 61,50 
P00635 PHO5 3,43 2 2 467 52,8 4,83 60,66 
P38011 ASC1 3,76 2 1 319 34,8 6,24 60,28 
P41805 RPL10 4,98 2 1 221 25,3 10,02 59,72 
P04807 HXK2 3,50 1 1 486 53,9 5,30 57,22 
P40213 RPS16A 8,39 1 1 143 15,8 10,26 56,08 
P15108 HSC82 1,28 2 1 705 80,8 4,83 55,06 
P25349 YCP4 3,24 2 1 247 26,3 8,19 55,05 
P00175 CYB2 2,20 2 1 591 65,5 8,41 52,48 
P19882 HSP60 2,10 1 1 572 60,7 5,31 51,84 
P14904 LAP4 1,95 1 1 514 57,1 5,83 51,49 
P25443 RPS2 4,33 2 1 254 27,4 10,43 48,96 
P05750 RPS3 5,42 1 1 240 26,5 9,41 46,27 
P47143 ADO1 3,53 1 1 340 36,3 5,16 45,08 
P05739 RPL6B 8,52 1 1 176 20,0 10,08 42,34 
P39931 SSP120 5,13 1 1 234 27,3 5,11 41,16 
P22803 TRX2 11,54 1 1 104 11,2 4,93 38,63 
P26786 RPS7A 7,37 1 1 190 21,6 9,83 37,46 
P54115 ALD6 2,20 1 1 500 54,4 5,44 37,04 
P26782 RPS24A 6,67 1 1 135 15,3 10,51 35,89 
P05737 RPL7A 3,69 1 1 244 27,6 10,15 35,24 
P0C2H6 RPL27A 10,29 1 1 136 15,5 10,36 33,09 
P05753 RPS4A 3,83 1 1 261 29,4 10,08 32,65 
P05743 RPL26A 6,30 1 1 127 14,2 10,58 31,51 
P06168 ILV5 2,53 1 1 395 44,3 9,04 27,85 
Q12074 SPE3 4,44 1 1 293 33,3 5,53 27,81 
Q03558 OYE2 2,75 1 1 400 45,0 6,57 26,80 
P28319 CWP1 4,60 1 1 239 24,3 4,67 25,30 
P32589 SSE1 1,44 1 1 693 77,3 5,22 24,96 
P48589 RPS12 13,29 1 1 143 15,5 4,73 20,36 
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Table S2. Proteins from S. cerevisiae W303-A extracellular matrix. 
Accession Protein Coverage # PSMs # Peptides # AAs MW [kDa] calc. pI Score 
P00924 ENO1 62,70 305 20 437 46,8 6,62 10412,91 
P00925 ENO2 67,28 281 21 437 46,9 6,00 10025,98 
P53334 SCW4 46,63 278 12 386 40,1 4,83 9452,71 
P00359 TDH3 74,10 221 20 332 35,7 6,96 7415,04 
P14540 FBA1 54,32 169 12 359 39,6 5,78 5530,25 
P10591 SSA1 54,98 162 24 642 69,6 5,11 4923,62 
P38013 AHP1 76,14 125 8 176 19,1 5,16 4717,40 
P15703 BGL2 59,74 152 11 313 34,1 4,51 4558,72 
P10592 SSA2 57,12 148 23 639 69,4 5,06 4239,94 
P00560 PGK1 68,27 138 23 416 44,7 7,61 3638,17 
P00360 TDH1 71,08 125 21 332 35,7 8,28 3610,70 
P00549 PYK1 62,80 122 23 500 54,5 7,68 3226,01 
P06169 PDC1 54,71 109 22 563 61,5 6,19 3021,53 
P00358 TDH2 54,52 97 17 332 35,8 6,96 2885,88 
P38288 TOS1 23,52 107 6 455 48,0 4,67 2811,27 
P12709 PGI1 51,44 81 19 554 61,3 6,46 2746,63 
P23776 EXG1 59,38 85 16 448 51,3 4,75 2615,98 
P00942 TPI1 81,45 83 13 248 26,8 6,01 2371,82 
P02829 HSP82 42,45 77 26 709 81,4 4,91 2186,28 
P15992 HSP26 66,82 66 10 214 23,9 5,53 2181,80 
P15108 HSC82 43,97 77 27 705 80,8 4,83 2175,96 
Q04951 SCW10 43,44 67 12 389 40,4 4,65 2111,81 
P31539 HSP104 41,63 74 30 908 102,0 5,45 1961,32 
P09435 SSA3 50,39 72 23 649 70,5 5,17 1909,38 
P53252 PIL1 51,03 41 12 339 38,3 4,63 1721,15 
Q12230 LSP1 43,99 38 12 341 38,0 4,70 1511,81 
P00830 ATP2 46,97 51 16 511 54,8 5,71 1502,95 
P46367 ALD4 60,50 58 23 519 56,7 6,74 1494,66 
P11484 SSB1 44,05 48 17 613 66,6 5,44 1447,13 
A7A003 UTH1 26,24 37 6 362 36,7 4,79 1447,06 
P00890 CIT1 41,96 51 15 479 53,3 8,29 1425,57 
P42835 EGT2 13,74 39 8 1041 108,5 4,82 1359,54 
P02994 TEF1 43,89 48 13 458 50,0 9,04 1358,73 
P0CX10 ERR1 48,28 39 13 437 47,3 5,29 1346,42 
P22202 SSA4 38,47 53 17 642 69,6 5,14 1344,40 
P60010 ACT1 49,33 51 13 375 41,7 5,68 1328,07 
P32324 EFT1 38,24 45 22 842 93,2 6,32 1313,92 
P17967 PDI1 33,33 36 13 522 58,2 4,53 1311,36 
P09624 LPD1 50,10 45 18 499 54,0 8,03 1308,86 
P04806 HXK1 50,93 46 16 485 53,7 5,45 1307,31 
P53912 YNL134C 51,86 47 11 376 41,1 6,21 1275,46 
P40472 SIM1 23,11 35 7 476 48,2 4,60 1250,50 
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Accession Protein Coverage # PSMs # Peptides # AAs MW [kDa] calc. pI Score 
P07257 QCR2 63,04 39 17 368 40,5 7,96 1172,81 
P17505 MDH1 65,57 42 14 334 35,6 8,47 1155,69 
Q04432 HSP31 62,03 39 10 237 25,7 5,50 1138,91 
P00950 GPM1 65,99 45 12 247 27,6 8,84 1125,13 
P34760 TSA1 72,45 44 10 196 21,6 5,14 1108,43 
P26263 PDC6 34,64 35 15 563 61,5 6,19 1057,44 
Q12363 WTM1 49,43 38 14 437 48,4 5,36 1045,15 
P22803 TRX2 73,08 31 6 104 11,2 4,93 1037,86 
P19882 HSP60 37,59 38 17 572 60,7 5,31 1036,47 
P05694 MET6 33,77 39 18 767 85,8 6,47 1030,13 
P39708 GDH3 41,36 33 14 457 49,6 5,47 969,03 
P37012 PGM2 49,91 43 20 569 63,0 6,62 931,42 
P29311 BMH1 50,94 36 11 267 30,1 4,88 928,41 
Q12512 ZPS1 48,19 32 8 249 27,5 5,02 928,35 
P48589 RPS12 28,67 23 3 143 15,5 4,73 841,07 
P17709 GLK1 28,80 28 10 500 55,3 6,19 838,52 
P34730 BMH2 49,82 35 11 273 31,0 4,88 824,90 
P15019 TAL1 46,27 29 13 335 37,0 6,43 813,60 
P07262 GDH1 33,70 25 12 454 49,5 5,69 803,97 
P41921 GLR1 38,72 28 11 483 53,4 7,83 781,98 
P09938 RNR2 34,34 24 11 399 46,1 5,25 779,80 
P00330 ADH1 52,30 33 14 348 36,8 6,68 772,50 
P15705 STI1 34,47 27 17 589 66,2 5,59 766,54 
P38715 GRE3 44,04 25 11 327 37,1 7,08 755,48 
P54114 ALD3 38,34 29 15 506 55,4 5,76 752,51 
Q06494 YPR127W 53,33 24 13 345 38,6 5,99 742,34 
Q07653 HBT1 19,22 21 12 1046 113,5 6,38 735,79 
P17255 TFP1 18,39 26 15 1071 118,6 6,16 731,32 
P07267 PEP4 28,64 23 8 405 44,5 4,84 719,05 
A6ZRW6 MLS1 35,56 31 13 554 62,8 7,03 711,76 
P04840 POR1 68,55 29 15 283 30,4 7,93 710,71 
A6ZTT5 ADH4 36,39 25 9 382 41,1 6,28 705,25 
P38720 GND1 31,08 26 11 489 53,5 6,64 705,12 
P16474 KAR2 29,47 35 17 682 74,4 4,93 700,23 
P35842 PHO11 24,41 21 9 467 52,7 5,17 697,79 
P14904 LAP4 38,33 28 13 514 57,1 5,83 683,95 
P16861 PFK1 22,19 29 17 987 107,9 6,39 652,65 
P12398 SSC1 26,61 28 14 654 70,6 5,59 635,89 
P53184 PNC1 38,43 19 5 216 25,0 6,27 634,16 
P37291 SHM2 25,80 24 11 469 52,2 7,43 627,93 
Q03558 OYE2 27,75 23 9 400 45,0 6,57 626,75 
P22146 GAS1 15,74 20 7 559 59,5 4,67 626,29 
Q01574 ACS1 22,30 22 12 713 79,1 6,62 619,30 
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Accession Protein Coverage # PSMs # Peptides # AAs MW [kDa] calc. pI Score 
P38804 RTC3 52,25 18 5 111 12,0 5,07 618,00 
P53228 NQM1 52,25 29 13 333 37,2 6,38 617,89 
P00331 ADH2 48,56 25 12 348 36,7 6,74 607,44 
Q12408 NPC2 25,43 35 4 173 19,1 4,44 604,85 
P49723 RNR4 46,96 26 13 345 40,0 5,21 600,62 
P54070 KTR6 33,63 23 11 446 52,1 5,50 597,27 
Q08108 PLB3 18,51 25 10 686 75,0 5,03 595,45 
P53319 GND2 28,05 20 10 492 53,9 7,30 586,24 
P10963 PCK1 21,49 20 8 549 60,9 6,34 577,12 
P07251 ATP1 29,36 24 12 545 58,6 9,04 574,18 
P46955 NCA3 16,32 15 5 337 35,4 4,46 572,71 
P53753 DSE4 8,77 19 7 1117 121,0 4,53 553,08 
A6ZZG1 PIR3 49,16 15 5 415 41,5 5,74 549,97 
P47771 ALD2 32,81 23 13 506 55,2 5,60 547,47 
P26783 RPS5 28,89 13 4 225 25,0 8,59 541,24 
P00817 IPP1 43,90 18 10 287 32,3 5,58 534,30 
P32590 SSE2 25,25 22 15 693 77,6 5,63 530,84 
P36139 PET10 18,02 14 4 283 31,2 8,16 526,91 
P32589 SSE1 21,50 25 13 693 77,3 5,22 520,73 
P16120 THR4 32,49 21 12 514 57,4 5,64 513,22 
P46655 GUS1 22,03 21 12 708 80,8 7,53 511,48 
P16140 VMA2 27,85 19 11 517 57,7 5,07 509,36 
P19414 ACO1 14,52 22 9 778 85,3 8,07 503,98 
P28240 ICL2 29,80 20 11 557 62,4 6,42 503,26 
Q07551 YDL124W 37,18 18 9 312 35,5 6,19 497,66 
P40185 MMF1 74,48 18 7 145 15,9 9,28 496,98 
P09620 KEX1 16,87 17 9 729 82,2 4,56 496,62 
P32316 ACH1 30,80 21 11 526 58,7 6,79 495,58 
P23301 HYP2 30,57 15 4 157 17,1 4,96 489,82 
A6ZQJ1 TIF1 31,65 14 9 395 44,7 5,12 489,55 
P23285 CPR2 47,32 21 7 205 22,8 6,13 488,74 
P16467 PDC5 11,72 15 5 563 61,9 6,43 486,58 
P22217 TRX1 58,25 13 5 103 11,2 4,93 479,78 
Q03048 COF1 38,46 15 4 143 15,9 5,20 479,09 
P00445 SOD1 59,09 17 6 154 15,8 6,00 463,38 
Q08911 FDH1 30,59 16 9 376 41,7 6,47 461,21 
P04807 HXK2 23,05 16 7 486 53,9 5,30 456,13 
P33315 TKL2 19,97 17 9 681 75,0 6,14 453,75 
P04802 DPS1 24,78 17 11 557 63,5 6,58 453,19 
Q08969 GRE1 29,17 11 3 168 19,0 4,77 452,89 
P16547 OM45 30,03 17 10 393 44,6 8,59 450,11 
P25694 CDC48 10,30 17 6 835 91,9 4,94 448,03 
Q00055 GPD1 26,09 15 7 391 42,8 5,47 441,80 
 232 
Accession Protein Coverage # PSMs # Peptides # AAs MW [kDa] calc. pI Score 
P14065 GCY1 45,19 21 10 312 35,1 7,99 440,96 
P00729 PRC1 27,63 23 12 532 59,8 4,73 438,89 
P32454 APE2 12,61 18 10 952 107,7 8,03 430,14 
P27809 KRE1 31,00 21 9 442 51,4 5,40 428,03 
P14832 CPR1 38,89 19 5 162 17,4 7,44 426,51 
Q03104 MSC1 22,22 13 9 513 59,6 7,58 424,54 
P06168 ILV5 32,66 18 10 395 44,3 9,04 412,07 
P28834 IDH1 41,94 18 11 360 39,3 9,00 409,55 
Q12068 GRE2 17,25 15 5 342 38,1 6,15 408,21 
P33416 HSP78 10,85 14 7 811 91,3 8,05 407,45 
P05750 RPS3 37,50 16 7 240 26,5 9,41 400,69 
P41939 IDP2 30,34 15 11 412 46,5 6,19 396,76 
P29509 TRR1 43,57 12 7 319 34,2 5,94 393,07 
P0CG63 UBI4 56,43 15 4 381 42,8 7,58 391,84 
P24031 PHO3 16,70 15 6 467 52,7 4,63 390,77 
P40531 GVP36 42,33 13 9 326 36,6 4,97 376,66 
P07991 CAR2 34,91 13 10 424 46,1 6,95 374,58 
P32861 UGP1 12,42 12 5 499 56,0 7,44 371,58 
P36110 PRY2 9,73 12 2 329 33,8 4,60 370,91 
P41338 ERG10 21,36 13 7 398 41,7 7,39 368,55 
P38616 YGP1 16,67 18 5 354 37,3 5,44 364,86 
P36008 TEF4 12,62 10 4 412 46,5 7,87 360,06 
P41816 OYE3 27,00 19 10 400 44,9 5,60 358,74 
P11076 ARF1 40,33 13 6 181 20,5 7,34 347,77 
P49090 ASN2 17,66 13 8 572 64,6 5,87 342,19 
P49089 ASN1 19,76 16 9 572 64,4 6,11 336,09 
Q04792 GAD1 18,80 12 8 585 65,9 6,62 335,22 
Q00764 TPS1 14,14 11 5 495 56,1 6,09 334,82 
P00447 SOD2 57,94 14 7 233 25,8 8,48 331,07 
P39931 SSP120 32,05 12 6 234 27,3 5,11 327,46 
P28241 IDH2 36,59 17 9 369 39,7 8,69 326,93 
P06115 CTT1 22,95 18 10 562 64,5 6,54 326,62 
Q04409 EMI2 16,80 13 6 500 55,9 6,27 326,55 
Q12303 YPS3 21,06 12 6 508 54,5 8,69 325,29 
A6ZV70 CTT1 23,84 19 10 562 64,5 6,54 322,71 
P29547 CAM1 23,61 15 7 415 47,1 8,38 321,18 
A6ZZH2 MCR1 24,83 16 6 302 34,1 8,65 320,54 
P08524 ERG20 23,01 10 6 352 40,5 5,47 318,52 
P29029 CTS1 5,87 11 3 562 59,0 4,55 309,27 
P34227 PRX1 31,03 12 7 261 29,5 8,87 307,56 
P40165 YNL200C 31,30 10 5 246 27,5 8,29 303,65 
P38115 ARA1 38,08 11 9 344 38,9 5,96 302,18 
P04076 ARG4 19,22 13 8 463 52,0 5,73 301,47 
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Accession Protein Coverage # PSMs # Peptides # AAs MW [kDa] calc. pI Score 
P00724 SUC2 12,78 12 6 532 60,6 4,75 300,83 
B5VL27 CIS3 11,56 13 3 225 23,0 4,68 299,74 
P11412 ZWF1 25,35 16 10 505 57,5 6,30 299,07 
O74302 YDR261C-C 27,50 13 7 440 49,0 7,62 298,33 
Q12335 PST2 39,90 12 4 198 21,0 5,73 292,72 
P07256 COR1 18,82 9 6 457 50,2 7,30 291,42 
P06106 MET17 17,57 13 7 444 48,6 6,43 289,93 
P25294 SIS1 30,40 12 8 352 37,6 9,03 286,13 
Q05911 ADE13 19,29 14 7 482 54,5 6,43 284,67 
P53978 HEF3 2,59 8 2 1044 115,8 6,23 283,79 
P32582 CYS4 25,05 12 9 507 56,0 6,70 277,14 
P38011 ASC1 20,06 10 5 319 34,8 6,24 275,17 
P26321 RPL5 30,98 8 5 297 33,7 6,83 274,62 
P25375 PRD1 7,58 7 4 712 81,9 5,80 271,68 
P38069 MNN2 11,56 7 5 597 67,7 6,27 268,61 
P31116 HOM6 32,87 10 7 359 38,5 7,44 267,14 
P07274 PFY1 34,13 11 3 126 13,7 5,80 264,90 
P05317 RPP0 19,55 8 4 312 33,7 4,83 264,38 
P22515 UBA1 15,82 14 11 1024 114,2 5,11 262,06 
P35691 TMA19 20,96 7 3 167 18,7 4,56 261,67 
P28319 CWP1 29,29 11 5 239 24,3 4,67 260,42 
Q04304 YMR090W 44,93 11 7 227 24,9 5,80 258,69 
P06738 GPH1 10,53 13 7 902 103,2 5,62 256,97 
P10659 SAM1 25,39 9 7 382 41,8 5,22 255,29 
P32327 PYC2 6,44 9 5 1180 130,1 6,51 254,64 
P41940 MPG1 21,88 12 5 361 39,5 6,34 253,44 
Q12428 PDH1 20,35 9 7 516 57,6 9,07 252,83 
P41277 GPP1 34,40 9 6 250 27,9 5,55 252,39 
P39954 SAH1 17,37 9 6 449 49,1 6,24 250,75 
P13663 HOM2 21,92 12 6 365 39,5 6,73 248,81 
P00635 PHO5 20,56 16 7 467 52,8 4,83 244,82 
Q05016 YMR226C 16,48 8 3 267 29,1 6,81 243,31 
P22943 HSP12 34,86 7 3 109 11,7 5,38 242,78 
B3LT19 RPS0B 39,68 12 7 252 27,9 4,75 242,17 
P18239 AAC2 21,38 7 5 318 34,4 9,79 240,22 
A6ZLF4 SDS24 11,95 8 4 527 57,2 8,91 239,92 
P00044 CYC1 32,11 10 3 109 12,2 9,42 239,70 
P54838 DAK1 20,38 12 8 584 62,2 5,41 239,42 
P53616 SUN4 19,05 7 3 420 43,4 4,36 234,73 
P53301 CRH1 10,65 9 5 507 52,7 4,65 226,54 
P25349 YCP4 23,89 7 3 247 26,3 8,19 225,21 
P26637 CDC60 8,07 10 7 1090 124,1 5,85 224,95 
P23254 TKL1 16,32 10 7 680 73,8 7,01 222,95 
 234 
Accession Protein Coverage # PSMs # Peptides # AAs MW [kDa] calc. pI Score 
P48016 ATH1 5,95 11 6 1211 136,8 5,43 222,28 
P38230 ZTA1 18,26 7 5 334 37,0 8,73 221,44 
P43616 DUG1 4,16 3 1 481 52,8 5,67 220,53 
P22203 VMA4 27,47 8 5 233 26,5 5,36 220,24 
Q08193 GAS5 13,22 10 5 484 51,8 4,64 220,01 
P07284 SES1 13,85 7 4 462 53,3 6,09 219,72 
P02365 RPS6A 13,56 6 2 236 27,0 10,45 217,08 
P54115 ALD6 20,60 10 8 500 54,4 5,44 216,77 
P21954 IDP1 16,12 7 6 428 48,2 8,76 214,82 
P38009 ADE17 21,11 10 9 592 65,2 6,55 210,95 
P36010 YNK1 47,71 12 6 153 17,2 8,60 209,47 
Q12331 YDR262W 23,90 8 5 272 30,6 5,41 206,92 
P40510 SER33 13,22 8 5 469 51,2 6,42 206,92 
A6ZRK4 LAP3 21,12 9 7 483 55,5 8,75 206,62 
P40893 REE1 24,75 6 4 198 22,0 6,39 206,56 
P38067 UGA2 9,26 5 2 497 54,2 6,65 206,32 
P47143 ADO1 26,18 10 5 340 36,3 5,16 205,11 
P35271 RPS18A 26,71 7 4 146 17,0 10,27 203,76 
P38836 ECM14 16,98 10 5 430 49,8 5,30 203,46 
P54113 ADE16 15,74 8 7 591 65,2 6,55 203,34 
Q3E841 YNR034W-A 40,82 4 3 98 10,8 8,97 198,78 
P36046 MIA40 3,97 3 1 403 44,5 4,56 196,37 
P19358 SAM2 18,49 8 6 384 42,2 5,38 194,45 
P00431 CCP1 15,51 5 4 361 40,3 6,38 192,06 
A6ZRW8 SCY_4679 5,59 4 3 644 74,1 6,71 191,60 
P43635 CIT3 10,70 9 4 486 53,8 8,59 189,36 
P12695 PDA2 13,90 8 5 482 51,8 7,80 186,95 
P25296 CNB1 6,86 5 1 175 19,6 4,55 186,03 
P23638 PRE9 13,57 7 3 258 28,7 5,22 184,82 
P05756 RPS13 15,89 5 2 151 17,0 10,43 184,31 
P26786 RPS7A 26,32 5 3 190 21,6 9,83 181,99 
Q05902 ECM38 10,15 7 5 660 73,1 5,88 179,66 
P17695 GRX2 25,17 7 3 143 15,9 7,28 179,47 
P04147 PAB1 9,19 5 4 577 64,3 5,97 178,46 
P38764 RPN1 7,05 7 6 993 109,4 4,63 178,15 
P39721 AIM29 12,60 8 2 246 27,1 6,28 175,91 
P23542 AAT2 18,42 7 6 418 46,0 8,32 174,73 
P23641 MIR1 12,22 4 3 311 32,8 9,31 167,64 
P0C0W1 RPS22A 12,31 3 1 130 14,6 9,94 166,74 
A6ZYI0 ADK1 28,38 8 5 222 24,2 6,70 166,38 
P39676 YHB1 7,27 4 2 399 44,6 6,28 164,30 
P07244 ADE5,7 5,74 5 3 802 86,0 5,27 162,19 
P06208 LEU4 9,53 6 5 619 68,4 6,01 161,78 
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P38131 KTR4 12,93 9 5 464 54,5 4,84 156,58 
P38891 BAT1 17,30 8 5 393 43,6 8,91 156,12 
P19262 KGD2 12,10 7 5 463 50,4 8,85 156,01 
P31373 CYS3 17,26 6 4 394 42,5 6,54 155,77 
P25373 GRX1 39,09 7 3 110 12,4 5,06 153,93 
P39101 CAJ1 6,91 4 2 391 44,8 5,80 153,05 
P40213 RPS16A 18,88 4 2 143 15,8 10,26 153,01 
P35719 MRP8 14,61 4 3 219 25,1 4,79 152,27 
P13130 SPS100 13,50 7 2 326 34,2 5,41 151,82 
P32471 EFB1 39,81 8 5 206 22,6 4,45 151,68 
P53598 LSC1 20,06 7 4 329 35,0 8,46 150,91 
P47176 BAT2 13,56 8 4 376 41,6 7,30 150,06 
P40582 GTT1 18,80 5 4 234 26,8 6,65 149,00 
P54839 ERG13 7,33 4 3 491 55,0 8,16 148,87 
P32445 RIM1 34,81 5 4 135 15,4 8,34 148,63 
Q04902 SNO4 17,30 6 3 237 26,0 8,07 148,10 
P32614 FRD1 7,87 5 3 470 50,8 6,33 141,91 
P07143 CYT1 9,39 5 2 309 34,0 8,12 141,30 
P17079 RPL12A 21,82 5 3 165 17,8 9,41 141,16 
P38707 DED81 4,69 3 2 554 62,2 5,85 141,13 
P38841 YHR138C 45,61 7 4 114 12,7 5,06 140,63 
Q06151 DCS1 7,71 4 2 350 40,7 6,25 140,57 
P16862 PFK2 7,61 7 6 959 104,6 6,67 140,36 
P32775 GLC3 9,38 8 7 704 81,1 6,16 138,63 
P14306 TFS1 21,00 5 3 219 24,3 6,54 138,59 
P04801 THS1 4,09 6 3 734 84,5 7,03 138,39 
P38788 SSZ1 16,91 7 6 538 58,2 5,05 137,87 
P07245 ADE3 8,14 7 6 946 102,1 6,84 137,68 
P41805 RPL10 18,10 3 2 221 25,3 10,02 137,31 
P17555 SRV2 7,98 5 3 526 57,5 5,64 136,50 
P43590 YFR006W 9,35 4 3 535 61,7 6,16 135,24 
Q12449 AHA1 19,43 5 5 350 39,4 7,47 132,92 
P08417 FUM1 7,79 5 3 488 53,1 8,25 132,62 
Q06703 CDA2 9,29 4 2 312 35,7 5,38 132,37 
P17649 UGA1 16,14 6 5 471 52,9 6,80 132,13 
P40054 SER3 10,87 5 4 469 51,2 5,57 131,38 
P32835 GSP1 21,92 6 4 219 24,8 6,55 130,52 
P02557 TUB2 10,94 6 3 457 50,9 4,75 130,06 
P33297 RPT5 9,68 4 3 434 48,2 5,06 129,91 
P25293 NAP1 19,42 9 5 417 47,9 4,34 129,00 
P43593 UBP6 6,81 4 3 499 57,1 7,14 128,03 
P09232 PRB1 8,50 7 5 635 69,6 6,39 127,62 
Q08971 YPL225W 15,07 3 2 146 17,4 5,30 127,29 
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P22133 MDH2 19,89 6 4 377 40,7 6,90 127,18 
A6ZRM0 ADE12 17,55 8 7 433 48,2 8,35 127,03 
P40513 MAM33 13,91 3 2 266 30,1 4,58 125,85 
P0C0W9 RPL11A 12,64 3 2 174 19,7 9,92 125,79 
P07283 SEC53 36,22 10 9 254 29,0 5,24 124,79 
P19097 FAS2 2,81 5 3 1887 206,8 5,44 124,45 
P25659 FUB1 9,60 3 2 250 26,7 5,02 123,24 
Q04947 RTN1 5,76 2 1 295 32,9 8,98 122,55 
A6ZY20 PST1 10,59 4 3 444 45,8 9,19 121,74 
P07263 HTS1 4,40 5 2 546 59,9 7,71 121,47 
Q03161 YMR099C 20,20 6 5 297 33,9 6,13 120,57 
P38701 RPS20 31,40 4 4 121 13,9 9,52 120,28 
P00498 HIS1 13,47 5 3 297 32,2 6,15 119,54 
P32191 GUT2 5,70 8 4 649 72,3 7,90 119,07 
P39005 KRE9 13,77 5 2 276 30,0 9,20 118,80 
Q12458 YPR1 12,50 6 3 312 34,7 7,12 116,37 
P53090 ARO8 7,00 5 3 500 56,1 6,01 115,47 
Q03655 GAS3 6,49 4 3 524 56,8 4,79 114,93 
P07278 BCY1 12,02 5 4 416 47,2 7,94 114,28 
P07806 VAS1 3,89 5 4 1104 125,7 6,96 114,03 
P22768 ARG1 10,95 7 4 420 46,9 5,62 113,93 
A6ZS33 SCY_4744 3,87 2 2 671 77,3 6,58 113,38 
P38137 PCS60 9,76 6 4 543 60,5 9,20 112,50 
Q12118 SGT2 8,96 4 2 346 37,2 4,79 110,74 
P36105 RPL14A 13,77 4 2 138 15,2 10,93 110,58 
P13517 CAP2 12,54 4 3 287 32,6 4,72 109,79 
P25491 YDJ1 14,43 5 4 409 44,6 6,30 109,27 
P21242 PRE10 8,68 4 2 288 31,5 5,19 108,95 
P14120 RPL30 29,52 6 2 105 11,4 9,80 108,50 
P10664 RPL4A 12,43 4 3 362 39,1 10,64 108,48 
Q04336 YMR196W 5,06 4 4 1088 126,5 5,45 107,46 
P40302 PRE5 23,50 5 4 234 25,6 7,39 106,88 
Q05506 YDR341C 7,74 6 5 607 69,5 6,79 106,55 
P20967 KGD1 5,92 5 4 1014 114,3 7,21 105,73 
Q12447 PAA1 11,52 5 2 191 21,9 5,82 105,71 
P48015 GCV1 5,25 4 2 400 44,4 8,84 105,43 
P40495 LYS12 14,56 4 4 371 40,0 8,02 105,38 
P01120 RAS2 13,04 3 3 322 34,7 7,27 104,64 
P10869 HOM3 5,69 5 3 527 58,1 6,67 104,10 
P07560 SEC4 27,44 6 4 215 23,5 7,09 103,48 
P33330 SER1 5,82 3 2 395 43,4 6,54 102,13 
P38624 PRE3 18,60 5 4 215 23,5 5,90 101,68 
P21243 SCL1 13,49 3 3 252 28,0 6,24 100,67 
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P41911 GPD2 5,23 3 2 440 49,4 7,09 100,35 
P05737 RPL7A 15,98 4 3 244 27,6 10,15 99,90 
P38077 ATP3 19,29 6 3 311 34,3 9,31 99,81 
P06780 RHO1 16,27 5 3 209 23,1 6,23 99,26 
P07275 PUT2 5,22 4 2 575 64,4 7,01 99,10 
P32603 SPR1 2,25 3 1 445 51,8 5,81 98,93 
P13298 URA5 16,81 5 3 226 24,6 6,05 98,33 
P17076 RPL8A 8,20 3 2 256 28,1 10,04 97,98 
P29952 PMI40 4,90 2 1 429 48,2 5,99 97,91 
P32366 VMA6 8,41 3 2 345 39,8 4,60 97,53 
A6ZL22 ECM33 5,83 4 2 429 43,7 4,91 94,70 
Q03940 RVB1 4,75 4 2 463 50,4 5,87 93,97 
P16550 APA1 8,72 3 2 321 36,5 5,02 92,60 
P05744 RPL33A 31,78 5 3 107 12,1 11,08 92,17 
B3LRI4 RGI1 19,25 3 2 161 19,0 6,18 92,14 
P06367 RPS14A 17,52 4 2 137 14,5 10,73 92,14 
Q12123 DCS2 12,46 5 4 353 40,9 6,64 92,00 
P07280 RPS19A 6,25 2 1 144 15,9 9,61 91,82 
P04456 RPL25 9,15 1 1 142 15,7 10,11 91,59 
P53312 LSC2 10,54 5 4 427 46,9 7,47 91,44 
P05626 ATP4 12,30 3 2 244 26,9 9,13 91,03 
P39990 SNU13 19,05 2 1 126 13,6 7,85 90,27 
Q12122 LYS21 10,00 4 4 440 48,6 6,30 89,71 
Q01939 RPT6 6,17 3 2 405 45,2 9,01 89,64 
P08067 RIP1 9,77 3 2 215 23,3 8,07 89,19 
P40581 HYR1 7,98 2 1 163 18,6 8,19 89,19 
P22855 AMS1 2,12 2 2 1083 124,4 7,25 88,98 
P21576 VPS1 1,70 2 1 704 78,7 7,91 88,82 
P52290 DIA3 7,05 4 3 468 53,0 5,53 88,23 
P24280 SEC14 10,86 4 3 304 34,9 5,49 87,86 
P32419 MDH3 11,66 3 2 343 37,2 9,20 87,57 
P35189 TAF12 6,56 2 1 244 27,4 5,29 87,54 
Q99258 RIB3 11,06 4 2 208 22,6 5,78 86,38 
P0C2I0 RPL20A 18,02 5 3 172 20,4 10,30 86,15 
P53189 SCW11 8,30 3 3 542 56,4 4,48 85,21 
P36059 YKL151C 15,13 6 4 337 37,3 7,55 84,99 
P53691 CPR6 7,82 4 2 371 42,0 6,16 84,63 
P46672 ARC1 22,07 6 5 376 42,1 7,88 84,63 
P40037 HMF1 30,23 4 3 129 13,9 5,41 84,61 
P54837 ERV25 7,58 1 1 211 24,1 5,52 84,39 
P33327 GDH2 2,01 3 2 1092 124,3 5,73 84,31 
P53130 GPG1 21,43 3 2 126 14,9 4,75 82,93 
P32381 ARP2 4,09 5 2 391 44,0 5,78 82,55 
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P30656 PRE2 9,41 3 2 287 31,6 6,23 82,21 
P05755 RPS9B 15,90 4 4 195 22,3 10,10 82,20 
P00931 TRP5 3,68 3 2 707 76,6 6,51 82,08 
P38910 HSP10 19,81 3 2 106 11,4 9,00 81,48 
P00045 CYC7 19,47 5 2 113 12,5 9,58 81,13 
P23724 PRE7 13,28 3 3 241 26,9 6,07 79,59 
P00175 CYB2 7,78 4 2 591 65,5 8,41 77,88 
P25372 TRX3 14,96 3 2 127 14,4 8,90 77,58 
P40168 YNL195C 12,64 3 3 261 28,3 6,46 77,30 
A6ZWD3 DBP1 4,21 3 2 617 67,9 8,62 77,08 
P25443 RPS2 10,24 6 2 254 27,4 10,43 76,60 
P53622 COP1 1,67 3 1 1201 135,5 5,99 76,50 
P05739 RPL6B 8,52 4 1 176 20,0 10,08 75,60 
Q12377 RPN6 5,30 2 2 434 49,7 6,28 75,44 
P20081 FPR1 30,70 2 2 114 12,2 6,04 75,21 
P20459 SUI2 8,88 3 2 304 34,7 5,02 75,03 
P40029 MXR1 10,87 3 2 184 21,1 6,99 74,43 
P15625 FRS2 12,92 3 3 503 57,5 5,78 74,06 
P47096 BNA1 5,65 3 1 177 20,2 5,78 73,69 
P25572 YCL042W 7,56 3 1 119 13,4 10,56 73,06 
P32598 GLC7 6,73 4 2 312 35,9 5,49 72,56 
P26782 RPS24A 14,81 3 2 135 15,3 10,51 72,40 
P40471 AYR1 5,39 1 1 297 32,8 9,16 71,56 
Q03102 YML131W 4,66 1 1 365 40,0 8,13 71,37 
P47137 YJR096W 17,38 5 3 282 32,3 6,93 71,01 
P32599 SAC6 10,44 5 5 642 71,7 5,48 70,97 
P33299 RPT1 2,78 1 1 467 52,0 5,47 70,55 
P14843 ARO3 3,51 2 1 370 41,0 7,39 70,54 
P15873 POL30 7,75 3 2 258 28,9 4,59 70,05 
P32449 ARO4 10,27 3 3 370 39,7 6,95 69,42 
Q12513 TMA17 7,33 2 1 150 16,8 4,73 68,46 
P40509 SEC28 7,43 1 1 296 33,8 4,55 68,06 
Q06263 VTA1 9,70 3 2 330 37,3 4,63 67,73 
Q96VH4 HBN1 13,99 2 1 193 21,0 6,95 67,69 
P15624 FRS1 3,19 4 2 595 67,3 5,78 67,48 
P01095 PBI2 16,00 2 1 75 8,6 6,80 66,91 
P36421 TYS1 3,81 1 1 394 44,0 8,44 66,70 
A6ZXP4 SUB2 3,36 2 1 446 50,2 5,52 66,29 
P25087 ERG6 4,44 1 1 383 43,4 5,77 65,89 
P14747 CMP2 4,64 3 2 604 68,5 6,35 65,52 
A6ZPE5 NOP58 3,33 2 1 511 56,9 8,94 65,01 
Q12177 YLL056C 4,36 1 1 298 32,1 7,15 63,35 
P46784 RPS10B 13,33 3 1 105 12,7 9,07 63,30 
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P27472 GSY2 1,13 2 1 705 80,0 6,35 63,00 
Q03148 SNZ1 9,76 3 3 297 31,8 5,58 62,97 
Q02046 MTD1 5,94 3 2 320 36,2 6,99 62,34 
P32642 GRX4 3,28 2 1 244 27,5 4,65 62,31 
P05736 RPL2A 19,29 3 3 254 27,4 11,11 62,22 
P06105 SCP160 1,39 3 1 1222 134,7 5,85 62,07 
P38934 BFR1 5,74 2 2 470 54,6 9,19 62,00 
A6ZRR2 MDG1 7,38 2 2 366 40,3 5,80 61,77 
Q12434 RDI1 8,91 1 1 202 23,1 6,04 61,67 
P39958 GDI1 10,20 4 4 451 51,2 5,99 61,65 
P32499 NUP2 2,36 1 1 720 77,8 7,20 61,20 
P38219 OLA1 8,63 4 3 394 44,1 7,43 61,04 
P05753 RPS4A 10,34 4 3 261 29,4 10,08 60,80 
A6ZPQ6 MPM1 17,06 3 3 252 28,5 5,92 60,60 
P42936 YGR201C 5,78 1 1 225 26,3 5,55 60,58 
P32473 PDB1 12,84 3 3 366 40,0 5,30 60,18 
P11491 PHO8 2,65 2 1 566 63,0 5,59 60,08 
P08019 SGA1 2,00 1 1 549 61,4 5,07 59,83 
P38886 RPN10 7,84 2 1 268 29,7 4,82 59,64 
Q07505 YDL086W 4,76 1 1 273 30,8 6,34 59,36 
P32379 PUP2 9,23 2 2 260 28,6 4,73 59,27 
P33298 RPT3 7,24 2 2 428 47,9 5,53 58,41 
Q06142 KAP95 1,74 1 1 861 94,7 4,64 58,32 
P18961 YPK2 1,33 3 1 677 76,6 7,65 58,31 
P38427 TSL1 2,82 2 2 1098 122,9 6,64 57,78 
P47117 ARP3 4,90 2 2 449 49,5 5,80 57,57 
Q12464 RVB2 4,46 4 2 471 51,6 5,31 57,46 
P30624 FAA1 3,29 4 2 700 77,8 7,62 57,45 
P05030 PMA1 2,29 2 2 918 99,6 5,11 56,92 
P38081 YBR056W 2,40 1 1 501 57,8 6,46 56,49 
P38972 ADE6 1,18 2 1 1358 148,8 5,27 56,43 
P49435 APT1 12,83 2 1 187 20,6 5,10 56,41 
Q12460 NOP56 3,97 2 2 504 56,8 8,90 56,31 
P38129 TAF5 3,26 2 1 798 88,9 7,40 56,18 
P13134 KEX2 1,23 3 1 814 89,9 4,98 55,87 
P47068 BBC1 0,95 2 1 1157 128,2 5,26 55,03 
P38911 FPR3 2,68 2 1 411 46,5 4,46 54,59 
P01123 YPT1 10,68 2 2 206 23,2 5,33 54,41 
P16521 YEF3 4,31 5 3 1044 115,9 6,05 54,27 
Q04458 HFD1 4,32 2 2 532 59,9 6,76 53,17 
P10080 SBP1 3,74 2 1 294 33,0 5,66 53,16 
P31383 TPD3 3,78 1 1 635 70,9 4,72 52,66 
P50107 GLO1 3,07 1 1 326 37,2 6,84 52,51 
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P0C0V8 RPS21A 26,44 3 2 87 9,7 6,06 52,38 
P30402 URA10 7,93 3 2 227 24,8 8,51 52,28 
P19454 CKA2 4,42 2 1 339 39,4 8,53 51,94 
B3LLZ8 SPG4 20,87 2 2 115 13,2 6,80 51,89 
P43639 CKB1 3,60 1 1 278 32,2 4,61 51,65 
P16387 PDA1 2,62 2 1 420 46,3 8,10 51,63 
Q06651 PIB1 6,64 2 1 286 32,7 5,88 51,59 
P23639 PRE8 11,20 3 2 250 27,1 5,72 51,27 
P34251 YKL107W 9,39 2 2 309 34,5 6,58 51,17 
Q12277 RRP42 5,66 1 1 265 29,0 5,45 49,59 
Q04491 SEC13 14,81 3 3 297 33,0 5,73 49,51 
P54885 PRO2 3,51 2 1 456 49,7 5,59 49,32 
A6ZX97 AIM6 3,59 1 1 390 44,4 5,59 49,29 
Q08723 RPN8 3,55 1 1 338 38,3 5,64 49,10 
P36047 SDS22 15,98 3 3 338 38,9 5,52 49,07 
P10622 RPP1B 15,09 1 1 106 10,7 4,01 49,04 
Q02753 RPL21A 11,25 2 2 160 18,2 10,39 48,91 
P46992 YJL171C 4,29 2 1 396 42,9 5,06 48,64 
P22141 PRE1 12,63 2 2 198 22,5 6,23 48,48 
P38235 YBR053C 3,35 2 1 358 40,3 5,06 48,37 
P22137 CHC1 2,18 2 2 1653 187,1 5,24 48,05 
P15303 SEC23 1,30 1 1 768 85,3 5,66 47,87 
P50095 IMD3 5,93 2 2 523 56,5 7,40 47,83 
P09201 FBP1 9,48 2 2 348 38,2 6,01 47,82 
P43588 RPN11 7,52 3 2 306 34,4 6,19 47,64 
Q01560 NPL3 5,31 1 1 414 45,4 5,54 47,63 
P37302 APE3 7,45 3 3 537 60,1 5,31 46,96 
P04449 RPL24A 5,16 2 1 155 17,6 11,28 46,33 
A6ZT99 EGD2 15,52 2 2 174 18,7 4,94 46,31 
Q06624 AOS1 7,20 1 1 347 39,2 5,12 46,17 
P38755 OSH7 1,83 2 1 437 49,8 7,23 45,84 
Q06336 GGA1 1,97 1 1 557 62,3 5,62 45,57 
P02407 RPS17A 8,82 1 1 136 15,8 10,51 45,56 
P47037 SMC3 0,89 2 1 1230 141,2 5,81 45,06 
P47160 ENT3 2,45 2 1 408 45,1 4,84 45,05 
P38088 GRS1 3,77 2 2 690 78,1 6,52 44,67 
P31412 VMA5 8,67 3 3 392 44,2 6,67 44,48 
P09457 ATP5 5,19 2 1 212 22,8 9,57 44,37 
P02293 HBT1 11,45 1 1 131 14,2 10,10 44,27 
P11745 RNA1 1,97 2 1 407 45,8 4,61 43,84 
P32340 NDI1 2,14 1 1 513 57,2 9,44 43,63 
P48240 MTR3 5,60 2 1 250 27,6 4,98 43,52 
P16451 PDX1 2,68 2 1 410 45,3 5,73 43,46 
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P40075 SCS2 5,74 1 1 244 26,9 4,89 42,99 
P38892 CRG1 3,44 2 1 291 33,8 6,00 42,98 
P02309 HHF1 17,48 2 2 103 11,4 11,36 42,91 
P20606 SAR1 5,79 2 1 190 21,4 5,38 42,45 
P40009 YND1 3,02 1 1 630 71,8 6,24 42,06 
P0C0X0 RPS28B 17,91 2 1 67 7,6 10,78 42,04 
P53860 PDR1 7,69 2 2 351 40,7 7,96 41,83 
P25619 HSP30 3,01 1 1 332 37,0 5,21 41,71 
P32074 SEC21 2,35 1 1 935 104,8 5,12 41,33 
P27616 ADE1 3,92 1 1 306 34,6 5,95 41,13 
P48837 NUP57 2,22 1 1 541 57,5 9,58 40,93 
Q04062 RPN9 3,05 2 1 393 45,8 5,78 40,74 
P17423 THR1 5,04 2 2 357 38,7 5,41 40,65 
B3RHI0 HRI1 4,92 1 1 244 27,5 5,21 40,07 
P40215 NDE1 1,61 1 1 560 62,7 9,28 39,72 
P36156 ECM4 6,49 1 1 370 43,2 6,89 39,22 
P32527 ZUO1 5,77 2 2 433 49,0 8,25 39,07 
P38071 ETR1 2,63 3 1 380 42,0 9,00 38,91 
P36017 VPS21 10,48 2 2 210 23,1 5,33 38,90 
P43555 EMP47 2,70 1 1 445 50,3 5,97 38,69 
P53303 ZPR1 2,67 1 1 486 55,0 4,86 38,48 
Q12207 NCE102 5,78 1 1 173 19,0 9,39 38,37 
P42884 AAD14 2,39 2 1 376 42,0 6,74 38,35 
A6ZQF6 ATG27 4,43 1 1 271 30,2 5,77 38,32 
Q08977 YPL260W 2,54 1 1 551 62,7 5,12 38,19 
P03962 URA3 4,49 1 1 267 29,2 7,36 37,62 
A6ZWL1 EGD1 19,11 1 1 157 17,0 6,55 37,41 
P28777 ARO2 8,24 2 2 376 40,8 7,80 37,30 
P27466 CMK1 2,24 1 1 446 50,3 6,11 37,29 
P0C2H6 RPL27A 10,29 1 1 136 15,5 10,36 37,05 
P32911 SUI1 13,89 1 1 108 12,3 7,97 36,71 
P08536 MET3 4,70 1 1 511 57,7 5,82 36,67 
Q06505 SPN1 2,93 2 1 410 46,1 7,52 36,14 
P53731 ARC35 5,26 2 2 342 39,5 6,81 35,89 
A6ZLG8 OM14 19,40 1 1 134 14,6 8,75 35,62 
P02406 RPL28 16,11 3 2 149 16,7 10,62 35,38 
Q02933 RNY1 6,45 3 2 434 50,1 8,05 35,22 
P36521 MRPL11 4,82 1 1 249 28,5 9,70 35,21 
P38114 TBS1 0,64 2 1 1094 126,8 5,43 35,18 
P07342 ILV2 1,02 2 1 687 74,9 8,51 35,14 
Q12250 RPN5 2,47 1 1 445 51,7 6,13 34,52 
P25605 ILV6 6,80 1 1 309 34,0 6,52 34,41 
P35997 RPS27A 19,51 1 1 82 8,9 9,14 34,24 
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P34167 TIF3 1,83 2 1 436 48,5 5,29 34,17 
P32377 MVD1 3,28 2 1 396 44,1 5,76 34,12 
P05743 RPL26A 12,60 2 2 127 14,2 10,58 33,68 
P38109 YBR139W 3,35 1 1 508 57,6 5,31 33,67 
Q06205 FPR4 2,04 1 1 392 43,9 4,69 33,61 
P30822 CRM1 0,92 1 1 1084 124,0 5,48 33,53 
P32337 PSE1 2,02 1 1 1089 121,0 4,74 33,43 
Q02821 SRP1 2,03 1 1 542 60,4 4,91 33,37 
P40303 PRE6 4,33 2 1 254 28,4 7,36 33,36 
P27796 POT1 3,12 1 1 417 44,7 7,61 33,29 
Q01976 YSA1 6,49 1 1 231 26,1 6,38 33,05 
A6ZN26 NIP1 2,71 1 1 812 93,2 5,00 33,04 
P38264 PHO88 7,45 1 1 188 21,1 9,19 32,99 
P04046 ADE4 2,16 1 1 510 56,7 6,28 32,48 
Q12402 YOP1 4,44 1 1 180 20,3 9,03 32,23 
P38840 ARO9 1,95 1 1 513 58,5 5,52 32,10 
A6ZN14 LIP1 4,00 1 1 150 17,2 6,67 32,06 
B3LI04 SPG1 11,58 1 1 95 10,5 8,46 32,04 
P30657 PRE4 3,38 1 1 266 29,4 5,99 32,00 
Q03690 CLU1 0,94 1 1 1277 145,1 6,39 31,88 
P40069 KAP123 1,53 1 1 1113 122,5 4,63 31,79 
P48239 GTO1 3,09 1 1 356 41,3 8,84 31,61 
P47018 MTC1 3,35 1 1 478 53,4 4,59 31,17 
P53315 SOL4 5,88 2 1 255 28,4 5,35 31,09 
P00128 QCR7 17,32 2 2 127 14,6 5,88 31,05 
P38708 YHR020W 3,05 2 2 688 77,3 6,40 31,01 
Q12305 YOR285W 21,58 2 2 139 15,4 6,38 30,92 
P15496 IDI1 4,51 1 1 288 33,3 4,98 30,61 
Q03761 TAF12 4,64 1 1 539 61,0 9,55 30,61 
B3LSS7 SOL3 13,65 2 2 249 27,8 5,50 30,54 
P32288 GLN1 4,86 1 1 370 41,7 6,34 30,51 
Q05785 ENT2 1,63 1 1 613 71,8 5,47 30,43 
P38273 CCZ1 1,56 2 1 704 80,7 5,26 30,43 
O14467 MBF1 7,95 1 1 151 16,4 10,61 30,28 
P35176 CPR5 4,44 1 1 225 25,3 5,60 30,21 
P39077 CCT3 2,25 1 1 534 58,8 6,11 30,07 
P07149 FAS1 1,02 1 1 2051 228,5 5,92 30,02 
P53008 CWH41 1,44 1 1 833 96,4 5,07 29,96 
P32329 YPS1 1,58 2 1 569 60,0 4,89 29,93 
Q07454 YDL073W 0,81 1 1 984 113,8 7,94 29,91 
Q12074 SPE3 4,44 1 1 293 33,3 5,53 29,87 
Q12125 GET4 3,85 2 1 312 36,3 5,20 29,86 
P05318 RPP1A 20,75 1 1 106 10,9 3,88 29,79 
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P52488 UBA2 1,42 2 1 636 71,2 5,14 29,43 
B3LLS9 EIS1 1,66 2 1 843 93,3 6,34 29,24 
P38882 UTP9 1,22 2 1 575 65,2 4,86 29,14 
B3LGZ3 GET3 4,52 1 1 354 39,3 5,00 29,13 
P20485 CKI1 1,20 1 1 582 66,3 5,67 29,01 
P43123 UAP1 2,94 1 1 477 53,4 7,42 28,88 
Q03435 NHP10 5,42 1 1 203 23,8 7,87 28,85 
P38795 QNS1 2,52 1 1 714 80,6 6,54 28,75 
P33204 ARC19 4,68 1 1 171 19,9 5,40 28,30 
P49954 NIT3 4,47 1 1 291 32,5 7,55 28,15 
P32891 DLD1 1,87 1 1 587 65,3 6,83 28,12 
Q07648 DTD1 7,33 1 1 150 16,7 7,42 28,12 
P36015 YKT6 5,00 1 1 200 22,7 5,69 27,97 
A6ZP88 CLP1 2,47 1 1 445 50,2 5,87 27,68 
Q00362 CDC55 4,75 1 1 526 59,6 6,39 27,64 
Q07629 YDL218W 3,15 1 1 317 34,4 8,00 27,37 
P40363 YJL068C 6,69 2 2 299 33,9 6,71 27,12 
P41811 SEC27 1,12 1 1 889 99,4 4,74 27,00 
P14126 RPL3 3,88 1 1 387 43,7 10,29 26,74 
P00937 TRP3 2,48 1 1 484 53,5 6,92 26,69 
P47035 NET1 0,93 2 1 1189 128,5 7,80 26,62 
Q12329 HSP42 4,27 1 1 375 42,8 5,08 26,44 
P33734 HIS7 1,99 1 1 552 61,0 5,49 26,40 
A6ZRI9 RTC4 2,74 1 1 401 46,1 7,14 26,33 
Q02895 YPL088W 3,51 1 1 342 39,7 7,31 26,24 
O43137 YBR085C-A 14,12 1 1 85 9,4 5,35 26,23 
P05738 RPL9A 10,47 2 2 191 21,6 9,73 26,18 
P38913 FAD1 2,94 1 1 306 35,5 5,30 26,13 
A6ZP58 AIM41 3,78 1 1 185 21,2 9,60 25,81 
Q02785 PDR12 0,46 1 1 1511 171,0 6,84 25,81 
P07260 TIF45 12,21 2 2 213 24,2 5,49 25,75 
P50086 NAS6 4,39 1 1 228 25,6 6,44 25,53 
P32588 PUB1 1,99 1 1 453 50,7 5,11 25,48 
P41920 YRB1 3,48 1 1 201 22,9 6,10 25,45 
Q04178 HPT1 4,98 1 1 221 25,2 5,69 25,42 
P43619 BNA6 2,71 1 1 295 32,3 5,85 25,19 
P21801 SDH2 5,26 1 1 266 30,2 8,82 25,16 
P15454 GUK1 10,70 2 2 187 20,6 7,18 25,11 
P32356 NTH1 1,07 1 1 751 85,8 7,77 25,06 
P53905 LSM7 6,96 1 1 115 13,0 9,31 24,78 
P25567 SRO9 4,61 1 1 434 48,0 8,90 24,70 
P40825 ALA1 0,92 1 1 983 110,0 5,71 24,67 
O13546 YLR232W 7,83 1 1 115 12,2 6,51 24,61 
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Q02948 VPS30 1,26 1 1 557 63,2 5,07 24,56 
P15274 AMD1 1,23 1 1 810 93,2 6,61 24,46 
P04911 HTA1 6,82 1 1 132 14,0 10,67 24,46 
P47130 CSN12 3,55 1 1 423 49,5 9,17 24,27 
Q06103 RPN7 2,33 1 1 429 48,9 5,25 23,99 
P53049 YOR1 0,74 1 1 1477 166,6 7,68 23,96 
P14742 GFA1 3,07 1 1 717 80,0 6,43 23,93 
P38821 APE4 2,86 1 1 490 54,1 7,02 23,73 
Q08446 SGT1 2,53 1 1 395 44,8 6,49 23,59 
Q08245 ZEO1 11,50 1 1 113 12,6 5,43 23,47 
P25343 RVS161 4,91 1 1 265 30,2 6,62 23,44 
P38912 TIF11 7,19 1 1 153 17,4 4,83 23,31 
P39984 HAT2 2,24 1 1 401 45,0 4,84 23,21 
Q03976 RSM24 3,76 1 1 319 37,4 9,23 23,18 
P53981 YNL010W 4,15 1 1 241 27,5 5,45 23,14 
P47032 PRY1 3,34 1 1 299 30,6 4,63 23,13 
P15646 NOP1 4,28 1 1 327 34,4 10,24 23,11 
P38234 RFS1 4,29 1 1 210 22,9 5,29 23,09 
P07264 LEU1 2,18 1 1 779 85,7 5,90 23,07 
P53289 RTS3 2,66 1 1 263 29,2 9,98 22,98 
Q04894 ADH6 2,22 1 1 360 39,6 6,74 22,94 
P32563 VPH1 1,19 1 1 840 95,5 5,48 22,91 
P39726 GCV3 8,24 1 1 170 18,8 4,73 22,87 
P53839 GOR1 3,43 1 1 350 38,8 6,34 22,82 
P16649 TUP1 0,98 1 1 713 78,3 5,68 22,81 
P11978 SIR4 0,81 1 1 1358 152,0 9,00 22,71 
P53155 YGL082W 1,84 1 1 381 43,3 6,27 22,70 
P32565 RPN2 1,16 1 1 945 104,2 6,18 22,49 
P12904 SNF4 3,73 1 1 322 36,4 5,78 22,43 
Q06554 IRC20 0,45 1 1 1556 180,2 6,54 22,15 
P32804 ZRT1 6,12 1 1 376 41,6 5,81 22,11 
Q06096 COG4 1,05 1 1 861 98,6 6,10 22,11 
P53969 SAM50 1,45 1 1 484 54,4 8,51 22,08 
Q05080 HOF1 1,05 1 1 669 76,2 9,07 21,93 
P38249 TIF32 0,93 1 1 964 110,3 6,30 21,83 
P40482 SEC24 0,86 1 1 926 103,6 6,23 21,68 
P09436 ILS1 1,31 1 1 1072 122,9 6,06 21,57 
Q08968 FMP40 2,62 1 1 688 78,3 5,44 21,29 
P53141 MLC1 5,37 1 1 149 16,4 4,73 21,13 
P27476 NSR1 2,66 1 1 414 44,5 4,93 21,10 
P12612 TCP1 3,04 1 1 559 60,4 6,49 21,08 
P0C5L5 YBR191W-A 25,00 1 1 24 3,1 10,55 21,07 
P40580 IRC24 3,04 1 1 263 28,8 6,37 21,02 
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P40477 NUP159 0,82 1 1 1460 158,8 4,83 20,92 
P38811 TRA1 0,37 1 1 3744 432,9 6,55 20,84 
P38887 YHR202W 1,99 1 1 602 69,0 6,23 20,72 
P39743 RVS167 1,87 1 1 482 52,7 6,01 20,69 
P50942 INP52 1,69 1 1 1183 133,2 8,63 20,69 
P32457 CDC39 1,92 1 1 520 60,0 5,48 20,68 
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Table S3. Proteins secreted during liquid growth by S. cerevisiae W303-1A gup1Δ cells. 
Accession Protein Coverage # PSMs # Peptides # AAs MW [kDa] calc. pI Score 
P40472 SIM1 37,61 265 9 476 48,2 4,60 12468,33 
P53334 SCW4 36,01 130 10 386 40,1 4,83 4968,56 
P15703 BGL2 57,51 133 10 313 34,1 4,51 4239,87 
P00925 ENO2 71,40 128 20 437 46,9 6,00 4131,25 
P00924 ENO1 59,95 113 16 437 46,8 6,62 3676,89 
P38288 TOS1 35,38 120 8 455 48,0 4,67 3606,71 
P28319 CWP1 42,26 66 9 239 24,3 4,67 2699,88 
Q12408 NPC2 44,51 122 6 173 19,1 4,44 2311,12 
Q04951 SCW10 45,50 70 13 389 40,4 4,65 1974,18 
P42835 EGT2 12,39 38 6 1041 108,5 4,82 1783,29 
P23776 EXG1 57,37 58 16 448 51,3 4,75 1730,79 
P22146 GAS1 21,47 58 9 559 59,5 4,67 1728,31 
P06169 PDC1 35,88 56 13 563 61,5 6,19 1631,39 
P53753 DSE4 14,32 40 8 1117 121,0 4,53 1488,32 
P00560 PGK1 49,76 43 15 416 44,7 7,61 1257,74 
P00549 PYK1 46,40 48 17 500 54,5 7,68 1208,25 
P00359 TDH3 39,46 39 8 332 35,7 6,96 1196,61 
Q12303 YPS3 25,00 36 8 508 54,5 8,69 989,45 
P11484 SSB1 29,69 25 11 613 66,6 5,44 935,75 
P14540 FBA1 39,00 26 7 359 39,6 5,78 887,01 
A6ZY20 PST1 14,41 26 4 444 45,8 9,19 843,74 
P15108 HSC82 29,65 30 15 705 80,8 4,83 830,30 
P53616 SUN4 34,76 28 6 420 43,4 4,36 823,87 
P32324 EFT1 25,77 25 13 842 93,2 6,32 799,33 
P00942 TPI1 56,45 34 9 248 26,8 6,01 792,74 
P10596 SUC4 11,28 26 6 532 60,5 4,88 790,58 
P12709 PGI1 5,42 16 2 554 61,3 6,46 744,88 
P05694 MET6 28,55 34 17 767 85,8 6,47 743,04 
A6ZL22 ECM33 9,79 28 5 429 43,7 4,91 724,36 
B3LQU1 PIR3 8,79 21 2 307 31,2 5,66 632,44 
P02829 HSP82 23,55 24 13 709 81,4 4,91 600,58 
P02994 TEF1 31,44 27 9 458 50,0 9,04 586,99 
P24031 PHO3 24,84 19 6 467 52,7 4,63 573,87 
P39105 PLB1 15,21 24 8 664 71,6 4,73 561,01 
P00358 TDH2 39,16 23 8 332 35,8 6,96 557,81 
A7A003 UTH1 26,24 22 6 362 36,7 4,79 549,11 
P16521 YEF3 13,98 20 9 1044 115,9 6,05 549,00 
P36110 PRY2 12,77 19 3 329 33,8 4,60 548,68 
P06787 CMD1 29,93 10 3 147 16,1 4,30 539,76 
P07267 PEP4 27,16 18 8 405 44,5 4,84 517,72 
P00445 SOD1 35,06 15 4 154 15,8 6,00 516,38 
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P00830 ATP2 21,72 14 8 511 54,8 5,71 495,17 
P39954 SAH1 19,60 17 6 449 49,1 6,24 465,61 
P46992 YJL171C 14,65 12 3 396 42,9 5,06 460,30 
P48589 RPS12 13,29 11 1 143 15,5 4,73 458,88 
P26321 RPL5 33,33 13 5 297 33,7 6,83 445,85 
P32334 MSB2 2,30 12 2 1306 133,0 4,22 432,42 
Q08193 GAS5 10,54 11 3 484 51,8 4,64 421,26 
P38616 YGP1 22,88 15 5 354 37,3 5,44 411,60 
P00330 ADH1 20,98 21 7 348 36,8 6,68 400,20 
Q08108 PLB3 12,39 12 6 686 75,0 5,03 394,10 
P05750 RPS3 24,58 11 4 240 26,5 9,41 380,33 
P10664 RPL4A 26,24 13 5 362 39,1 10,64 358,84 
P15019 TAL1 14,63 6 3 335 37,0 6,43 358,80 
P34760 TSA1 28,06 10 4 196 21,6 5,14 347,88 
P26783 RPS5 19,11 8 2 225 25,0 8,59 333,82 
P12630 BAR1 8,52 13 3 587 63,7 4,78 330,79 
P00360 TDH1 27,11 10 6 332 35,7 8,28 329,70 
B5VL27 CIS3 11,56 15 3 225 23,0 4,68 321,49 
P38013 AHP1 28,98 12 2 176 19,1 5,16 320,79 
P04807 HXK2 19,75 11 5 486 53,9 5,30 319,20 
P08067 RIP1 18,60 9 4 215 23,3 8,07 315,94 
P00950 GPM1 51,82 19 8 247 27,6 8,84 313,80 
P26786 RPS7A 36,32 11 4 190 21,6 9,83 304,23 
P10592 SSA2 21,60 15 8 639 69,4 5,06 296,04 
P07262 GDH1 14,10 12 5 454 49,5 5,69 295,79 
Q03655 GAS3 18,13 11 6 524 56,8 4,79 289,95 
P36105 RPL14A 21,74 7 2 138 15,2 10,93 285,96 
P10591 SSA1 17,91 11 7 642 69,6 5,11 273,08 
P07251 ATP1 12,66 12 6 545 58,6 9,04 271,37 
P41805 RPL10 18,10 7 2 221 25,3 10,02 269,56 
P29453 RPL8B 31,64 9 6 256 28,1 10,02 259,23 
P02365 RPS6A 25,42 9 4 236 27,0 10,45 257,59 
P39676 YHB1 26,82 10 5 399 44,6 6,28 255,36 
P05754 RPS8A 13,50 7 2 200 22,5 10,67 247,92 
P23301 HYP2 30,57 9 3 157 17,1 4,96 238,53 
P05737 RPL7A 21,72 9 4 244 27,6 10,15 236,80 
P00890 CIT1 18,37 9 5 479 53,3 8,29 236,65 
P19358 SAM2 20,31 7 5 384 42,2 5,38 236,32 
P25694 CDC48 7,19 9 4 835 91,9 4,94 234,17 
P38720 GND1 11,04 10 4 489 53,5 6,64 230,94 
P17079 RPL12A 16,97 7 2 165 17,8 9,41 226,60 
P05030 PMA1 6,97 6 3 918 99,6 5,11 225,56 
P05759 RPS31 36,18 12 6 152 17,2 9,86 220,93 
P25443 RPS2 5,91 6 1 254 27,4 10,43 215,94 
Q03048 COF1 28,67 6 3 143 15,9 5,20 210,42 
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A6ZQJ1 TIF1 16,46 5 4 395 44,7 5,12 209,70 
P17967 PDI1 5,17 5 2 522 58,2 4,53 206,77 
P14120 RPL30 45,71 7 3 105 11,4 9,80 203,29 
P05739 RPL6B 19,32 9 3 176 20,0 10,08 202,88 
P53301 CRH1 6,31 9 3 507 52,7 4,65 202,41 
P36008 TEF4 9,71 5 3 412 46,5 7,87 201,47 
P53379 MKC7 8,39 8 3 596 64,2 4,75 200,08 
O13547 CCW14 17,65 3 2 238 23,3 5,94 198,51 
P07149 FAS1 4,49 11 7 2051 228,5 5,92 192,98 
B3LI22 RPS0A 21,43 8 3 252 28,0 4,72 192,58 
P52911 EXG2 7,65 7 4 562 63,5 5,38 189,80 
P41940 MPG1 7,20 6 2 361 39,5 6,34 186,80 
P00044 CYC1 17,43 6 2 109 12,2 9,42 185,54 
P35691 TMA19 20,96 5 3 167 18,7 4,56 184,49 
P40213 RPS16A 28,67 6 3 143 15,8 10,26 184,43 
P29311 BMH1 15,73 6 2 267 30,1 4,88 175,58 
P11986 INO1 14,82 7 5 533 59,6 5,92 173,54 
P06106 MET17 20,72 8 6 444 48,6 6,43 171,29 
P41338 ERG10 12,81 7 4 398 41,7 7,39 170,91 
P02293 HBT1 11,45 3 1 131 14,2 10,10 168,82 
P07279 RPL18A 11,29 4 2 186 20,6 11,71 165,64 
B5VL26 HSP150 5,94 9 2 303 30,5 5,59 162,65 
P18239 AAC2 13,84 7 4 318 34,4 9,79 159,52 
P32827 RPS23A 7,59 3 1 145 16,0 10,73 157,51 
P05753 RPS4A 15,33 8 3 261 29,4 10,08 156,33 
P26782 RPS24A 22,96 7 5 135 15,3 10,51 155,28 
P31373 CYS3 16,50 6 3 394 42,5 6,54 155,24 
P05317 RPP0 19,55 7 4 312 33,7 4,83 155,06 
P0C0W1 RPS22A 30,00 6 3 130 14,6 9,94 151,84 
P14904 LAP4 5,25 4 2 514 57,1 5,83 149,81 
P54115 ALD6 5,40 4 2 500 54,4 5,44 149,57 
P61830 HHT1 23,53 2 1 136 15,3 11,43 148,70 
P22217 TRX1 35,92 4 3 103 11,2 4,93 147,30 
P00729 PRC1 13,72 8 5 532 59,8 4,73 140,95 
P07280 RPS19A 25,69 7 3 144 15,9 9,61 140,19 
Q00955 FAS3 4,39 10 8 2233 250,2 6,28 139,08 
A6ZZG0 PIR1 5,28 7 2 341 34,6 6,55 138,78 
P23641 MIR1 9,97 6 3 311 32,8 9,31 129,53 
P32329 YPS1 7,38 6 2 569 60,0 4,89 128,45 
P05756 RPS13 30,46 8 4 151 17,0 10,43 128,40 
P40185 MMF1 17,93 3 2 145 15,9 9,28 128,25 
Q12118 SGT2 4,91 5 1 346 37,2 4,79 127,30 
P14832 CPR1 13,58 6 2 162 17,4 7,44 126,27 
P04801 THS1 2,45 4 2 734 84,5 7,03 124,71 
Q06549 CDD1 39,44 5 4 142 15,5 7,17 116,46 
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P0C2H8 RPL31A 23,89 4 2 113 12,9 9,99 114,69 
P22203 VMA4 12,02 3 2 233 26,5 5,36 112,67 
A6ZTT5 ADH4 4,45 2 1 382 41,1 6,28 112,53 
Q12335 PST2 7,58 4 1 198 21,0 5,73 111,74 
P25371 ADP1 2,48 4 2 1049 117,2 5,16 110,28 
P17255 TFP1 5,60 5 4 1071 118,6 6,16 109,49 
P16120 THR4 10,89 4 4 514 57,4 5,64 106,34 
P00447 SOD2 18,88 4 3 233 25,8 8,48 105,18 
P05736 RPL2A 16,14 3 2 254 27,4 11,11 105,04 
P49167 RPL38 8,97 3 1 78 8,8 10,93 104,24 
P05748 RPL15A 20,10 6 4 204 24,4 11,39 103,98 
P09624 LPD1 8,82 4 3 499 54,0 8,03 102,94 
P04456 RPL25 9,15 2 1 142 15,7 10,11 101,08 
A6ZPE5 NOP58 3,33 3 1 511 56,9 8,94 100,94 
P07259 URA2 1,85 6 4 2214 244,9 5,83 99,51 
P17505 MDH1 13,47 4 3 334 35,6 8,47 99,46 
P10622 RPP1B 15,09 3 1 106 10,7 4,01 99,09 
P0C0V8 RPS21A 11,49 3 1 87 9,7 6,06 98,50 
P02400 RPP2B 42,73 3 3 110 11,0 4,15 98,40 
P39976 DLD3 12,10 5 3 496 55,2 6,89 97,69 
P05735 RPL18A 4,76 2 1 189 21,7 11,36 97,03 
P32589 SSE1 5,63 5 3 693 77,3 5,22 96,22 
P35271 RPS18A 9,59 4 2 146 17,0 10,27 96,10 
P38841 YHR138C 24,56 5 2 114 12,7 5,06 95,73 
P41277 GPP1 11,20 3 2 250 27,9 5,55 95,53 
Q05016 YMR226C 6,37 2 1 267 29,1 6,81 93,02 
P11076 ARF1 10,50 4 2 181 20,5 7,34 92,94 
P19097 FAS2 2,23 3 2 1887 206,8 5,44 92,89 
P40106 GPP2 20,00 3 2 250 27,8 6,16 92,71 
P04449 RPL24A 14,19 4 2 155 17,6 11,28 91,70 
P02309 HHF1 17,48 3 2 103 11,4 11,36 91,00 
P28240 ICL2 5,03 3 2 557 62,4 6,42 90,47 
P53189 SCW11 5,72 3 2 542 56,4 4,48 89,52 
P05744 RPL33A 7,48 4 1 107 12,1 11,08 89,11 
P32582 CYS4 8,48 3 3 507 56,0 6,70 87,77 
P02406 RPL28 12,08 5 2 149 16,7 10,62 87,74 
Q07551 YDL124W 8,33 3 2 312 35,5 6,19 82,63 
Q03558 OYE2 11,50 5 3 400 45,0 6,57 82,20 
P32642 GRX4 3,28 3 1 244 27,5 4,65 81,89 
P23254 TKL1 9,56 4 4 680 73,8 7,01 80,73 
P16140 VMA2 2,71 2 1 517 57,7 5,07 79,27 
P05318 RPP1A 20,75 3 1 106 10,9 3,88 79,13 
P04911 HTA1 24,24 3 2 132 14,0 10,67 78,36 
P25087 ERG6 3,39 1 1 383 43,4 5,77 76,65 
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P08524 ERG20 4,83 4 2 352 40,5 5,47 76,31 
P49090 ASN2 10,84 3 3 572 64,6 5,87 76,27 
Q96VH4 HBN1 13,99 2 1 193 21,0 6,95 75,78 
P29029 CTS1 4,45 3 2 562 59,0 4,55 75,61 
P31787 ACB1 39,08 5 2 87 10,1 4,92 75,29 
P16861 PFK1 7,19 4 4 987 107,9 6,39 74,41 
P17709 GLK1 5,20 3 2 500 55,3 6,19 74,16 
P02407 RPS17A 10,29 3 1 136 15,8 10,51 74,07 
P38804 RTC3 15,32 3 1 111 12,0 5,07 71,38 
P14126 RPL3 9,04 5 3 387 43,7 10,29 70,86 
P11412 ZWF1 1,98 2 1 505 57,5 6,30 70,47 
P26781 RPS11A 6,41 2 1 156 17,7 10,78 69,47 
P29509 TRR1 3,76 2 1 319 34,2 5,94 69,38 
B3LLJ2 RPS1B 6,27 4 2 255 28,8 10,02 67,95 
P38836 ECM14 6,51 2 2 430 49,8 5,30 66,59 
P00817 IPP1 13,94 2 2 287 32,3 5,58 66,25 
P35997 RPS27A 19,51 2 1 82 8,9 9,14 66,17 
P19882 HSP60 5,07 3 2 572 60,7 5,31 65,75 
P39741 RPL35A 9,17 2 1 120 13,9 10,58 65,61 
P0C2H6 RPL27A 28,68 3 3 136 15,5 10,36 65,23 
P07246 ADH3 2,13 2 1 375 40,3 8,43 64,87 
P16474 KAR2 6,01 3 3 682 74,4 4,93 64,70 
P53090 ARO8 2,00 2 1 500 56,1 6,01 64,21 
P05755 RPS9B 8,72 3 2 195 22,3 10,10 63,92 
P36139 PET10 3,89 1 1 283 31,2 8,16 59,67 
P0C2I0 RPL20A 8,14 1 1 172 20,4 10,30 59,07 
P15873 POL30 4,26 2 1 258 28,9 4,59 58,70 
P22943 HSP12 10,09 2 1 109 11,7 5,38 58,25 
P25349 YCP4 8,91 2 2 247 26,3 8,19 57,99 
P06168 ILV5 5,57 3 2 395 44,3 9,04 57,81 
P32471 EFB1 22,33 3 2 206 22,6 4,45 57,80 
P05319 RPP2A 10,38 2 1 106 10,7 4,04 57,27 
P38011 ASC1 5,64 2 1 319 34,8 6,24 56,82 
P25296 CNB1 4,00 3 1 175 19,6 4,55 56,46 
P32449 ARO4 3,51 2 1 370 39,7 6,95 55,97 
P05740 RPL17A 14,13 2 2 184 20,5 10,92 54,43 
P49089 ASN1 5,07 3 2 572 64,4 6,11 54,21 
P46367 ALD4 5,97 2 2 519 56,7 6,74 53,25 
P07265 MAL62 4,28 4 2 584 68,1 5,81 50,55 
P52910 ACS2 4,25 2 2 683 75,4 6,68 48,74 
Q12447 PAA1 6,81 1 1 191 21,9 5,82 48,10 
P22803 TRX2 35,58 3 3 104 11,2 4,93 47,82 
Q99258 RIB3 11,06 2 2 208 22,6 5,78 47,81 
P31116 HOM6 3,34 2 1 359 38,5 7,44 46,46 
Q08822 CIR2 2,22 1 1 631 69,6 7,83 46,23 
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P40054 SER3 3,20 1 1 469 51,2 5,57 45,98 
P32891 DLD1 2,56 2 1 587 65,3 6,83 45,96 
P53252 PIL1 5,90 3 2 339 38,3 4,63 43,91 
P02557 TUB2 2,19 2 1 457 50,9 4,75 43,90 
Q12127 CCW12 12,78 2 1 133 13,0 4,64 43,80 
P04840 POR1 4,59 1 1 283 30,4 7,93 43,63 
P40069 KAP123 1,53 1 1 1113 122,5 4,63 43,56 
P46784 RPS10B 13,33 2 1 105 12,7 9,07 43,49 
P40212 RPL13B 13,07 2 1 199 22,5 11,08 43,25 
P54070 KTR6 4,04 3 2 446 52,1 5,50 42,80 
Q12460 NOP56 2,18 1 1 504 56,8 8,90 42,23 
P39938 RPS26A 7,56 1 1 119 13,5 10,76 42,15 
Q06325 YPS7 2,85 1 1 596 64,5 4,96 41,92 
P47037 SMC3 0,89 2 1 1230 141,2 5,81 40,97 
P00498 HIS1 2,36 2 1 297 32,2 6,15 40,33 
P54839 ERG13 4,07 2 2 491 55,0 8,16 40,33 
P32590 SSE2 3,61 3 2 693 77,6 5,63 40,13 
P53030 RPL1A 5,07 2 1 217 24,5 9,72 39,98 
P03962 URA3 4,49 1 1 267 29,2 7,36 39,63 
P53289 RTS3 2,66 2 1 263 29,2 9,98 39,59 
P07257 QCR2 4,35 1 1 368 40,5 7,96 39,04 
P07342 ILV2 1,02 1 1 687 74,9 8,51 38,85 
P26637 CDC60 1,65 2 2 1090 124,1 5,85 38,68 
P38701 RPS20 9,92 1 1 121 13,9 9,52 38,55 
Q02979 GDE1 0,57 3 1 1223 137,9 6,79 38,54 
Q3E7Z5 YIL002W-A 14,49 1 1 69 7,7 4,67 38,03 
P22137 CHC1 1,51 2 2 1653 187,1 5,24 36,44 
P41057 RPS29A 19,64 1 1 56 6,7 10,27 36,30 
P32835 GSP1 11,42 3 2 219 24,8 6,55 36,11 
Q01560 NPL3 5,31 1 1 414 45,4 5,54 35,86 
P05738 RPL9A 7,85 2 1 191 21,6 9,73 35,63 
A6ZX97 AIM6 3,59 1 1 390 44,4 5,59 35,03 
P60010 ACT1 5,87 2 2 375 41,7 5,68 34,93 
P48570 LYS20 5,37 2 2 428 47,1 7,27 34,63 
Q03674 PLB2 3,26 1 1 706 75,4 4,70 34,13 
Q12680 GLT1 0,33 2 1 2145 238,0 6,58 33,76 
P07260 TIF45 2,82 3 1 213 24,2 5,49 33,51 
P0C0X0 RPS28B 17,91 1 1 67 7,6 10,78 33,26 
P49723 RNR4 10,43 2 2 345 40,0 5,21 33,08 
P07283 SEC53 5,51 2 2 254 29,0 5,24 33,01 
P36010 YNK1 5,88 1 1 153 17,2 8,60 32,74 
P15992 HSP26 7,48 1 1 214 23,9 5,53 32,07 
P09938 RNR2 3,01 1 1 399 46,1 5,25 31,65 
P0C5L5 YBR191W-A 25,00 2 1 24 3,1 10,55 31,58 
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P40513 MAM33 10,15 2 2 266 30,1 4,58 31,33 
P04802 DPS1 1,62 2 1 557 63,5 6,58 30,92 
P04451 RPL24A 5,84 1 1 137 14,5 10,33 30,66 
P33775 PMT1 3,30 1 1 817 92,6 6,68 30,25 
P34167 TIF3 2,52 1 1 436 48,5 5,29 30,24 
P33331 NTF2 17,60 1 1 125 14,4 4,70 29,98 
P41921 GLR1 2,90 1 1 483 53,4 7,83 29,88 
A6ZZH2 MCR1 5,30 2 2 302 34,1 8,65 29,63 
A7A024 OAF3 0,81 1 1 863 101,8 6,96 29,36 
Q12306 SMT3 6,93 1 1 101 11,6 5,02 28,68 
P25846 MSH1 0,83 1 1 959 109,3 8,73 28,41 
P11745 RNA1 1,97 1 1 407 45,8 4,61 27,94 
P38882 UTP9 1,22 2 1 575 65,2 4,86 27,60 
P25572 YCL042W 7,56 1 1 119 13,4 10,56 27,56 
P47035 NET1 0,93 1 1 1189 128,5 7,80 27,33 
P39077 CCT3 1,50 1 1 534 58,8 6,11 27,13 
P39968 VAC8 1,38 2 1 578 63,2 5,14 27,07 
A6ZZ25 TIF35 4,38 1 1 274 30,5 6,81 26,86 
P27614 CPS1 2,26 1 1 576 64,6 5,53 26,82 
Q08300 YOL159C 7,02 1 1 171 19,6 4,45 26,00 
P38788 SSZ1 1,67 1 1 538 58,2 5,05 25,99 
P13298 URA5 6,64 1 1 226 24,6 6,05 25,77 
P27476 NSR1 2,17 1 1 414 44,5 4,93 25,71 
P53278 YGR130C 0,98 1 1 816 92,6 5,03 25,70 
Q02794 STD1 2,70 1 1 444 50,2 8,98 25,51 
P32466 HXT3 4,06 1 1 567 62,5 7,08 25,42 
P07274 PFY1 11,11 1 1 126 13,7 5,80 25,23 
P38273 CCZ1 1,56 1 1 704 80,7 5,26 25,19 
Q05902 ECM38 1,52 1 1 660 73,1 5,88 25,17 
P32074 SEC21 1,93 1 1 935 104,8 5,12 25,00 
P26785 RPL16B 7,07 2 2 198 22,2 10,55 24,75 
P10869 HOM3 2,09 1 1 527 58,1 6,67 24,58 
P38114 TBS1 0,64 1 1 1094 126,8 5,43 24,26 
P37012 PGM2 1,58 1 1 569 63,0 6,62 24,25 
Q02753 RPL21A 6,88 1 1 160 18,2 10,39 24,07 
P46655 GUS1 1,13 1 1 708 80,8 7,53 24,04 
P00410 COX2 7,97 1 1 251 28,5 4,58 23,86 
P20051 URA4 2,20 1 1 364 40,3 6,54 23,60 
P17695 GRX2 9,79 1 1 143 15,9 7,28 22,88 
P13663 HOM2 3,84 1 1 365 39,5 6,73 22,65 
P37291 SHM2 2,99 1 1 469 52,2 7,43 22,53 
P22768 ARG1 4,52 1 1 420 46,9 5,62 22,27 
P08964 MYO1 0,36 1 1 1928 223,5 6,40 22,13 
P28707 SBA1 5,09 1 1 216 24,1 4,59 21,47 
P38625 GUA1 2,86 1 1 525 58,4 6,49 20,33 
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P22515 UBA1 1,95 1 1 1024 114,2 5,11 20,18 
Q03361 JIP4 0,80 1 1 876 98,6 9,57 20,03 
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Table S4. Proteins from S. cerevisiae W303-1A gup1Δ extracellular matrix. 
Accession Protein Coverage # PSMs # Peptides # AAs MW [kDa] calc. pI Score 
P00942 TPI1 81,85 331 17 248 26,8 6,01 10008,87 
P0CG63 UBI4 61,68 261 5 381 42,8 7,58 9226,87 
P15703 BGL2 58,15 305 11 313 34,1 4,51 8874,51 
P00925 ENO2 74,60 228 26 437 46,9 6,00 7250,28 
P00359 TDH3 73,19 213 15 332 35,7 6,96 7205,30 
P00924 ENO1 69,79 212 23 437 46,8 6,62 6606,57 
P28240 ICL2 60,50 185 24 557 62,4 6,42 5548,13 
P22146 GAS1 21,65 192 11 559 59,5 4,67 5324,49 
P38013 AHP1 85,80 140 10 176 19,1 5,16 5012,38 
P34760 TSA1 82,65 177 12 196 21,6 5,14 4971,22 
P09624 LPD1 73,35 170 28 499 54,0 8,03 4736,74 
P49089 ASN1 70,63 167 31 572 64,4 6,11 4696,46 
P00560 PGK1 76,20 189 27 416 44,7 7,61 4550,29 
P00549 PYK1 73,80 166 31 500 54,5 7,68 4496,47 
P00830 ATP2 72,21 149 26 511 54,8 5,71 4331,32 
P00358 TDH2 48,80 122 12 332 35,8 6,96 4173,84 
P00360 TDH1 49,10 89 13 332 35,7 8,28 3455,51 
P49090 ASN2 70,28 117 28 572 64,6 5,87 3376,05 
P17255 TFP1 22,60 132 19 1071 118,6 6,16 3107,60 
P10591 SSA1 62,62 108 30 642 69,6 5,11 3047,31 
P23776 EXG1 66,96 93 19 448 51,3 4,75 2972,04 
P47143 ADO1 72,94 98 15 340 36,3 5,16 2900,13 
P37302 APE3 41,15 114 14 537 60,1 5,31 2555,84 
P06169 PDC1 65,90 94 25 563 61,5 6,19 2531,04 
P38288 TOS1 40,00 91 9 455 48,0 4,67 2516,57 
P07262 GDH1 67,18 69 21 454 49,5 5,69 2449,33 
P40472 SIM1 30,04 64 8 476 48,2 4,60 2240,70 
P10592 SSA2 55,87 88 26 639 69,4 5,06 2221,73 
P29509 TRR1 65,20 61 13 319 34,2 5,94 2221,50 
P15019 TAL1 57,61 67 18 335 37,0 6,43 2193,12 
P00890 CIT1 47,60 81 19 479 53,3 8,29 2126,16 
P38115 ARA1 66,57 73 18 344 38,9 5,96 2020,09 
P07267 PEP4 48,64 65 13 405 44,5 4,84 2014,64 
P17505 MDH1 72,46 69 16 334 35,6 8,47 1975,78 
P53912 YNL134C 63,03 65 14 376 41,1 6,21 1872,57 
P22803 TRX2 80,77 64 7 104 11,2 4,93 1859,39 
P07257 QCR2 69,84 56 20 368 40,5 7,96 1848,45 
P07274 PFY1 68,25 87 4 126 13,7 5,80 1800,03 
P41338 ERG10 52,76 60 16 398 41,7 7,39 1748,53 
P07251 ATP1 39,82 53 15 545 58,6 9,04 1699,49 
P39708 GDH3 57,99 53 18 457 49,6 5,47 1682,95 
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P40185 MMF1 82,76 63 9 145 15,9 9,28 1655,37 
P00447 SOD2 65,24 46 7 233 25,8 8,48 1643,40 
P00950 GPM1 69,64 63 14 247 27,6 8,84 1568,68 
P12709 PGI1 44,22 45 16 554 61,3 6,46 1560,46 
P43590 YFR006W 41,87 46 16 535 61,7 6,16 1550,96 
Q03655 GAS3 41,03 48 15 524 56,8 4,79 1505,32 
P00445 SOD1 81,82 47 10 154 15,8 6,00 1470,61 
P28319 CWP1 38,08 40 8 239 24,3 4,67 1456,95 
P41921 GLR1 59,01 60 20 483 53,4 7,83 1443,61 
P14540 FBA1 50,14 43 10 359 39,6 5,78 1437,95 
Q12363 WTM1 55,84 53 19 437 48,4 5,36 1424,40 
P38616 YGP1 30,23 58 7 354 37,3 5,44 1383,15 
P46367 ALD4 57,80 50 21 519 56,7 6,74 1379,41 
Q07505 YDL086W 64,47 41 12 273 30,8 6,34 1368,06 
Q04432 HSP31 83,54 40 13 237 25,7 5,50 1349,53 
P38804 RTC3 67,57 43 7 111 12,0 5,07 1294,25 
P15108 HSC82 28,37 42 15 705 80,8 4,83 1263,06 
P14904 LAP4 48,64 45 17 514 57,1 5,83 1253,69 
P00498 HIS1 55,89 44 12 297 32,2 6,15 1250,24 
P46992 YJL171C 23,99 31 6 396 42,9 5,06 1242,38 
P16120 THR4 40,47 33 13 514 57,4 5,64 1179,87 
P38720 GND1 49,69 43 18 489 53,5 6,64 1131,59 
P32445 RIM1 56,30 40 7 135 15,4 8,34 1127,45 
P38715 GRE3 62,69 41 19 327 37,1 7,08 1118,46 
P05694 MET6 44,85 51 24 767 85,8 6,47 1108,27 
P21954 IDP1 53,27 42 20 428 48,2 8,76 1097,24 
P02829 HSP82 28,21 38 15 709 81,4 4,91 1081,49 
P00729 PRC1 41,54 45 14 532 59,8 4,73 1066,27 
P38836 ECM14 41,86 39 13 430 49,8 5,30 1064,22 
P53753 DSE4 14,32 33 8 1117 121,0 4,53 1058,03 
Q03048 COF1 72,03 31 6 143 15,9 5,20 1049,08 
P39721 AIM29 70,73 34 12 246 27,1 6,28 1043,96 
Q08193 GAS5 23,97 31 8 484 51,8 4,64 1025,53 
P00431 CCP1 54,29 40 16 361 40,3 6,38 1023,27 
P04807 HXK2 40,95 42 14 486 53,9 5,30 1015,51 
P24031 PHO3 37,04 36 11 467 52,7 4,63 992,46 
P39105 PLB1 17,02 42 10 664 71,6 4,73 977,67 
P40513 MAM33 37,22 35 8 266 30,1 4,58 958,45 
P39954 SAH1 40,76 36 15 449 49,1 6,24 955,50 
P27614 CPS1 42,36 44 20 576 64,6 5,53 949,60 
P33331 NTF2 88,00 33 6 125 14,4 4,70 935,38 
P53301 CRH1 19,72 25 11 507 52,7 4,65 867,25 
P11412 ZWF1 42,97 30 15 505 57,5 6,30 867,07 
P00817 IPP1 63,76 28 12 287 32,3 5,58 865,40 
P09232 PRB1 25,20 31 10 635 69,6 6,39 857,29 
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P28834 IDH1 50,56 39 13 360 39,3 9,00 855,06 
Q02933 RNY1 50,69 30 15 434 50,1 8,05 842,48 
P22217 TRX1 80,58 27 8 103 11,2 4,93 841,76 
P38891 BAT1 54,20 35 13 393 43,6 8,91 823,06 
P25605 ILV6 35,60 29 9 309 34,0 6,52 818,69 
P02309 HHF1 41,75 33 5 103 11,4 11,36 805,74 
P29311 BMH1 48,31 30 10 267 30,1 4,88 794,46 
P09938 RNR2 36,59 28 10 399 46,1 5,25 782,49 
P14832 CPR1 46,30 29 7 162 17,4 7,44 777,50 
P31539 HSP104 23,79 34 15 908 102,0 5,45 736,74 
B5VL27 CIS3 8,00 54 2 225 23,0 4,68 720,99 
P02293 HBT1 34,35 23 5 131 14,2 10,10 712,95 
P32324 EFT1 16,51 22 12 842 93,2 6,32 702,28 
P07275 PUT2 26,78 22 11 575 64,4 7,01 701,95 
Q03558 OYE2 46,25 29 12 400 45,0 6,57 698,09 
P49723 RNR4 36,52 24 9 345 40,0 5,21 682,85 
P23301 HYP2 48,41 20 5 157 17,1 4,96 675,80 
P54115 ALD6 47,00 30 17 500 54,4 5,44 671,37 
P14065 GCY1 48,40 26 10 312 35,1 7,99 665,95 
P53334 SCW4 24,35 20 7 386 40,1 4,83 660,49 
Q08971 YPL225W 57,53 23 8 146 17,4 5,30 652,25 
B3LLV5 ARG7 30,16 22 11 441 47,8 7,14 637,81 
P13130 SPS100 14,11 23 3 326 34,2 5,41 637,17 
P19414 ACO1 28,53 28 15 778 85,3 8,07 634,52 
P25373 GRX1 74,55 18 6 110 12,4 5,06 631,77 
P38816 TRR2 34,21 15 6 342 37,1 6,87 627,55 
P13663 HOM2 39,45 26 11 365 39,5 6,73 624,30 
P53228 NQM1 42,04 21 10 333 37,2 6,38 618,70 
P15873 POL30 58,14 21 11 258 28,9 4,59 617,12 
Q05016 YMR226C 69,29 27 13 267 29,1 6,81 609,48 
Q99258 RIB3 74,04 29 12 208 22,6 5,78 606,16 
A6ZL22 ECM33 9,79 24 5 429 43,7 4,91 602,03 
P15992 HSP26 50,93 21 7 214 23,9 5,53 588,09 
P39726 GCV3 34,71 14 5 170 18,8 4,73 583,99 
P36015 YKT6 60,00 25 10 200 22,7 5,69 582,41 
P40303 PRE6 62,60 25 9 254 28,4 7,36 578,44 
Q08245 ZEO1 50,44 27 9 113 12,6 5,43 578,27 
P00044 CYC1 34,86 17 5 109 12,2 9,42 574,47 
P22943 HSP12 36,70 16 4 109 11,7 5,38 571,59 
P28241 IDH2 29,54 21 7 369 39,7 8,69 571,18 
P34730 BMH2 47,25 26 10 273 31,0 4,88 562,43 
A6ZY20 PST1 14,86 17 6 444 45,8 9,19 562,04 
P50095 IMD3 18,55 14 6 523 56,5 7,40 557,44 
P41939 IDP2 26,70 22 9 412 46,5 6,19 555,57 
P43616 DUG1 15,80 13 4 481 52,8 5,67 551,11 
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P00635 PHO5 30,41 22 9 467 52,8 4,83 550,50 
P36110 PRY2 12,77 18 3 329 33,8 4,60 549,32 
P47176 BAT2 32,71 23 8 376 41,6 7,30 547,59 
P22202 SSA4 18,54 29 10 642 69,6 5,14 520,63 
P36010 YNK1 61,44 21 8 153 17,2 8,60 519,96 
P04806 HXK1 29,69 15 9 485 53,7 5,45 519,21 
A7A003 UTH1 26,24 21 6 362 36,7 4,79 504,18 
P13298 URA5 42,04 16 6 226 24,6 6,05 503,30 
P38145 RIB5 42,44 16 8 238 26,2 5,17 494,04 
P09435 SSA3 12,17 25 7 649 70,5 5,17 493,72 
P40302 PRE5 35,47 16 6 234 25,6 7,39 485,18 
P17709 GLK1 17,40 17 6 500 55,3 6,19 484,68 
Q02895 YPL088W 27,19 21 9 342 39,7 7,31 480,60 
P21243 SCL1 46,03 18 10 252 28,0 6,24 480,20 
P06168 ILV5 32,15 17 9 395 44,3 9,04 474,41 
P32454 APE2 12,50 13 9 952 107,7 8,03 472,47 
P53184 PNC1 62,50 19 7 216 25,0 6,27 465,20 
O13547 CCW14 18,07 14 4 238 23,3 5,94 464,54 
P32891 DLD1 23,17 17 10 587 65,3 6,83 462,29 
B3RHI0 HRI1 41,80 15 8 244 27,5 5,21 454,30 
E7KS00 HRI1 41,80 15 8 244 27,5 5,21 454,30 
A6ZYI0 ADK1 41,44 16 7 222 24,2 6,70 450,56 
P23638 PRE9 34,88 11 8 258 28,7 5,22 447,29 
P31787 ACB1 67,82 19 6 87 10,1 4,92 428,33 
Q06252 YLR179C  47,26 17 6 201 22,1 4,94 425,07 
Q06494 YPR127W 29,57 16 8 345 38,6 5,99 420,39 
Q04951 SCW10 30,85 14 9 389 40,4 4,65 419,17 
P40029 MXR1 35,33 12 5 184 21,1 6,99 418,61 
P40893 REE1 43,94 15 6 198 22,0 6,39 418,12 
P06208 LEU4 31,66 16 12 619 68,4 6,01 409,76 
B3LSS7 SOL3 44,58 17 7 249 27,8 5,50 393,72 
P32377 MVD1 35,10 13 8 396 44,1 5,76 389,91 
P53982 IDP3 12,38 12 5 420 47,8 9,22 385,30 
P12398 SSC1 11,62 14 6 654 70,6 5,59 384,13 
P32471 EFB1 50,49 17 5 206 22,6 4,45 383,56 
P48016 ATH1 10,98 17 10 1211 136,8 5,43 379,80 
P40165 YNL200C 27,24 12 4 246 27,5 8,29 376,50 
Q12458 YPR1 51,60 18 11 312 34,7 7,12 376,07 
P40037 HMF1 59,69 16 7 129 13,9 5,41 373,86 
P17555 SRV2 7,03 8 3 526 57,5 5,64 368,97 
B3LQU1 PIR3 8,79 12 2 307 31,2 5,66 366,55 
P17695 GRX2 44,06 12 5 143 15,9 7,28 366,05 
P17967 PDI1 21,46 13 7 522 58,2 4,53 364,41 
P32582 CYS4 16,37 10 5 507 56,0 6,70 363,35 
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B3LRI4 RGI1 36,02 12 3 161 19,0 6,18 361,19 
P25372 TRX3 59,06 17 7 127 14,4 8,90 357,80 
P02994 TEF1 24,45 21 8 458 50,0 9,04 357,37 
Q06151 DCS1 19,14 11 5 350 40,7 6,25 354,79 
Q12434 RDI1 40,59 15 5 202 23,1 6,04 353,40 
P04911 HTA1 29,55 13 3 132 14,0 10,67 351,75 
P25451 PUP3 39,51 10 6 205 22,6 5,15 351,72 
P53252 PIL1 30,68 9 7 339 38,3 4,63 349,95 
P08524 ERG20 42,61 12 9 352 40,5 5,47 346,73 
P11484 SSB1 17,29 12 8 613 66,6 5,44 339,70 
P08679 CIT2 6,96 9 2 460 51,4 6,38 334,74 
P38841 YHR138C 54,39 14 7 114 12,7 5,06 332,28 
Q12123 DCS2 22,10 13 6 353 40,9 6,64 323,38 
P0CX10 ERR1 14,19 10 4 437 47,3 5,29 321,33 
P19882 HSP60 26,22 17 11 572 60,7 5,31 319,38 
Q04902 SNO4 19,83 9 3 237 26,0 8,07 316,71 
Q07551 YDL124W 49,68 18 10 312 35,5 6,19 313,91 
P23254 TKL1 24,26 19 11 680 73,8 7,01 311,82 
Q03161 YMR099C 36,70 16 9 297 33,9 6,13 310,91 
P35691 TMA19 27,54 9 4 167 18,7 4,56 307,96 
P31116 HOM6 37,33 13 7 359 38,5 7,44 305,63 
P32379 PUP2 36,54 11 7 260 28,6 4,73 302,57 
P38081 YBR056W 24,95 11 9 501 57,8 6,46 300,51 
Q12305 YOR285W 42,45 13 4 139 15,4 6,38 297,71 
Q04341 MIC14 11,57 8 1 121 13,9 5,63 295,04 
Q04304 YMR090W 45,81 15 7 227 24,9 5,80 293,44 
A6ZQJ1 TIF1 20,51 10 6 395 44,7 5,12 292,55 
P43577 GNA1 50,94 12 5 159 18,1 5,24 292,25 
Q12306 SMT3 46,53 11 4 101 11,6 5,02 291,79 
Q12230 LSP1 25,51 14 8 341 38,0 4,70 287,92 
P61830 HHT1 28,68 6 2 136 15,3 11,43 281,68 
Q99312 ISN1 20,00 13 7 450 51,3 5,43 275,65 
Q12513 TMA17 23,33 6 3 150 16,8 4,73 274,49 
P53616 SUN4 13,57 8 3 420 43,4 4,36 273,59 
P04840 POR1 36,04 9 7 283 30,4 7,93 271,57 
P27882 ERV1 26,98 12 4 189 21,6 8,21 266,68 
P29952 PMI40 20,75 9 6 429 48,2 5,99 266,53 
P23542 AAT2 43,06 14 10 418 46,0 8,32 262,83 
P54839 ERG13 22,81 12 7 491 55,0 8,16 262,39 
O43137 YBR085C-A 41,18 9 3 85 9,4 5,35 262,23 
P38707 DED81 9,57 8 4 554 62,2 5,85 262,19 
P36008 TEF4 10,68 6 3 412 46,5 7,87 258,61 
P32329 YPS1 7,38 13 2 569 60,0 4,89 258,23 
P41277 GPP1 30,40 9 5 250 27,9 5,55 256,07 
P38817 GGA2 9,74 9 4 585 64,3 6,49 251,92 
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A6ZRW6 MLS1 25,99 15 10 554 62,8 7,03 251,72 
P38624 PRE3 36,28 9 5 215 23,5 5,90 250,68 
P10963 PCK1 18,76 8 6 549 60,9 6,34 250,40 
Q07648 DTD1 20,00 10 3 150 16,7 7,42 249,48 
B3LHB3 AIM6 27,95 10 6 390 44,3 5,71 243,71 
P21242 PRE10 11,46 7 3 288 31,5 5,19 242,22 
P00724 SUC2 12,22 8 6 532 60,6 4,75 241,32 
P15705 STI1 12,56 8 5 589 66,2 5,59 240,76 
Q05911 ADE13 25,52 14 9 482 54,5 6,43 236,60 
P32334 MSB2 2,30 7 2 1306 133,0 4,22 229,79 
P39926 SSO2 16,61 9 4 295 33,7 4,91 229,43 
Q03629 YML079W 46,27 9 5 201 22,4 5,40 228,63 
P07256 COR1 21,44 11 7 457 50,2 7,30 225,59 
Q06178 NMA1 12,97 9 4 401 45,8 6,90 222,12 
P15891 ABP1 6,76 8 3 592 65,5 4,68 221,93 
P00330 ADH1 22,13 12 7 348 36,8 6,68 221,60 
Q12118 SGT2 25,43 10 6 346 37,2 4,79 221,30 
P30657 PRE4 16,54 5 3 266 29,4 5,99 220,23 
P53141 MLC1 37,58 8 4 149 16,4 4,73 217,86 
P48606 RBL2 44,34 8 4 106 12,4 5,10 217,01 
Q05031 DFG5 13,10 5 4 458 50,5 4,75 209,35 
P35842 PHO11 13,28 7 4 467 52,7 5,17 208,50 
P54838 DAK1 13,87 7 5 584 62,2 5,41 206,31 
P22133 MDH2 26,79 8 6 377 40,7 6,90 204,52 
P60010 ACT1 17,87 8 4 375 41,7 5,68 202,35 
P00175 CYB2 14,21 7 5 591 65,5 8,41 201,53 
P00331 ADH2 22,70 10 6 348 36,7 6,74 201,32 
P17536 TPM1 25,63 7 4 199 23,5 4,61 200,16 
P02400 RPP2B 33,64 7 3 110 11,0 4,15 197,93 
P07283 SEC53 16,14 10 5 254 29,0 5,24 196,69 
P53622 COP1 1,67 4 1 1201 135,5 5,99 193,91 
P53204 NMA2 21,01 10 5 395 44,9 5,90 193,62 
P52911 EXG2 14,06 9 7 562 63,5 5,38 189,45 
P23639 PRE8 34,00 10 6 250 27,1 5,72 189,32 
P00045 CYC7 27,43 6 3 113 12,5 9,58 186,95 
P36059 YKL151C 28,78 11 7 337 37,3 7,55 186,94 
P14843 ARO3 20,81 8 5 370 41,0 7,39 186,13 
Q04178 HPT1 31,22 11 5 221 25,2 5,69 183,05 
P22768 ARG1 16,43 9 5 420 46,9 5,62 181,30 
P47123 MOG1 23,39 5 3 218 24,3 4,68 180,99 
P16474 KAR2 11,14 13 6 682 74,4 4,93 180,69 
P54114 ALD3 18,38 6 6 506 55,4 5,76 180,60 
Q12449 AHA1 15,71 8 5 350 39,4 7,47 179,22 
P32449 ARO4 15,95 6 4 370 39,7 6,95 178,72 
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A6ZPE5 NOP58 8,41 6 3 511 56,9 8,94 175,84 
P20081 FPR1 41,23 6 3 114 12,2 6,04 175,78 
P29453 RPL8B 17,97 6 3 256 28,1 10,02 175,09 
P01095 PBI2 72,00 10 6 75 8,6 6,80 174,49 
P26783 RPS5 19,11 3 2 225 25,0 8,59 172,30 
P53090 ARO8 11,60 7 4 500 56,1 6,01 172,20 
P05739 RPL6B 14,20 7 2 176 20,0 10,08 171,85 
P53889 FMP41 18,53 6 3 259 28,8 8,62 171,74 
P46655 GUS1 11,30 9 6 708 80,8 7,53 170,49 
P37012 PGM2 8,44 7 4 569 63,0 6,62 169,29 
P17649 UGA1 17,41 7 5 471 52,9 6,80 168,90 
P14306 TFS1 26,48 7 4 219 24,3 6,54 168,72 
Q12447 PAA1 11,52 4 2 191 21,9 5,82 168,17 
P52893 ALT1 14,86 8 4 592 66,4 7,02 166,60 
P16547 OM45 18,83 8 6 393 44,6 8,59 165,84 
P28707 SBA1 26,39 9 4 216 24,1 4,59 165,72 
A6ZT99 EGD2 16,67 6 2 174 18,7 4,94 165,42 
Q12303 YPS3 12,99 6 4 508 54,5 8,69 164,80 
P36139 PET10 9,54 3 2 283 31,2 8,16 164,64 
P05319 RPP2A 39,62 5 3 106 10,7 4,04 162,21 
P40531 GVP36 32,52 8 6 326 36,6 4,97 161,98 
P39979 HPA3 16,20 10 3 179 20,7 7,59 158,81 
P48015 GCV1 23,75 6 5 400 44,4 8,84 158,63 
P38281 APD1 25,95 11 5 316 35,7 7,18 158,05 
Q08911 FDH1 18,62 6 4 376 41,7 6,47 155,85 
P22203 VMA4 18,45 5 3 233 26,5 5,36 155,76 
P28272 URA1 22,61 6 3 314 34,8 6,05 153,87 
P06106 MET17 9,91 6 4 444 48,6 6,43 152,16 
Q12074 SPE3 17,75 6 4 293 33,3 5,53 149,98 
P49435 APT1 12,83 3 2 187 20,6 5,10 149,14 
P23724 PRE7 19,50 7 3 241 26,9 6,07 147,46 
Q03104 MSC1 8,58 5 3 513 59,6 7,58 146,53 
Q3E841 YNR034W-
A 
52,04 5 4 98 10,8 8,97 146,41 
Q04344 HNT1 46,20 9 5 158 17,7 6,95 144,78 
P40581 HYR1 19,63 5 2 163 18,6 8,19 141,60 
P25694 CDC48 6,23 6 3 835 91,9 4,94 140,06 
P48589 RPS12 13,29 3 1 143 15,5 4,73 136,70 
P38235 YBR053C 20,39 6 5 358 40,3 5,06 134,53 
P32614 FRD1 6,38 8 2 470 50,8 6,33 133,94 
P17423 THR1 19,05 7 5 357 38,7 5,41 132,85 
P34216 EDE1 3,19 4 3 1381 150,7 4,72 131,87 
Q00055 GPD1 15,60 6 4 391 42,8 5,47 130,23 
P32469 DPH5 12,33 5 2 300 33,8 4,92 129,96 
Q12314 YOR021C 26,76 5 4 213 24,7 5,07 129,72 
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P40075 SCS2 18,85 4 3 244 26,9 4,89 125,72 
P05749 RPL22A 32,23 3 2 121 13,7 6,14 125,47 
P19097 FAS2 1,64 2 1 1887 206,8 5,44 122,66 
P38821 APE4 15,92 7 6 490 54,1 7,02 122,00 
B5VL26 HSP150 5,94 6 2 303 30,5 5,59 121,68 
P07244 ADE5,7 8,48 4 3 802 86,0 5,27 121,57 
P53095 DSD1 7,48 4 3 428 47,8 7,59 120,59 
P31373 CYS3 15,23 6 3 394 42,5 6,54 119,31 
P29029 CTS1 4,45 3 2 562 59,0 4,55 118,15 
P50107 GLO1 3,07 2 1 326 37,2 6,84 117,36 
P36091 DCW1 5,35 4 2 449 49,5 4,67 116,16 
P06738 GPH1 7,43 8 5 902 103,2 5,62 115,90 
P42938 TDA10 15,52 3 3 290 33,3 5,41 114,78 
Q06892 POS5 6,28 3 2 414 46,2 8,97 114,56 
P32861 UGP1 9,62 5 4 499 56,0 7,44 110,64 
P25043 PUP1 12,26 2 1 261 28,3 6,61 110,49 
A6ZRW1 NMA111 2,21 4 2 997 110,8 5,96 109,02 
P47117 ARP3 2,45 2 1 449 49,5 5,80 108,86 
P08466 NUC1 21,28 7 5 329 37,2 8,78 108,31 
P39676 YHB1 18,55 3 3 399 44,6 6,28 108,16 
P38067 UGA2 4,23 2 1 497 54,2 6,65 107,09 
P36154 AIM29 24,52 4 3 155 18,4 6,40 106,86 
P53314 CPD1 5,02 2 1 239 26,7 7,47 106,09 
P25036 YSP3 3,14 2 1 478 52,1 5,43 105,76 
P32486 KRE6 3,89 3 2 720 80,1 4,69 103,89 
P12630 BAR1 10,56 7 4 587 63,7 4,78 102,82 
Q01976 YSA1 11,69 3 2 231 26,1 6,38 101,46 
P12695 PDA2 6,64 5 3 482 51,8 7,80 100,94 
P39990 SNU13 25,40 3 2 126 13,6 7,85 100,88 
P43635 CIT3 3,91 3 1 486 53,8 8,59 100,49 
Q05926 GRX8 10,09 2 1 109 12,5 7,99 99,29 
A6ZZG0 PIR1 5,28 6 2 341 34,6 6,55 98,64 
Q03103 ERO1 2,31 2 1 563 65,0 5,68 98,40 
O13297 CET1 10,38 6 3 549 61,8 5,60 98,09 
Q12068 GRE2 16,37 4 4 342 38,1 6,15 96,70 
A6ZRM0 ADE12 8,08 4 3 433 48,2 8,35 96,50 
P15454 GUK1 22,99 4 3 187 20,6 7,18 94,82 
P47018 MTC1 7,53 4 3 478 53,4 4,59 93,92 
P48510 DSK2 11,53 4 2 373 39,3 4,96 93,74 
P35195 ECM15 56,73 8 2 104 11,5 6,68 93,67 
P07245 ADE3 5,81 4 3 946 102,1 6,84 92,27 
P50861 RIB4 9,47 4 1 169 18,5 6,54 92,17 
P36105 RPL14A 7,97 2 1 138 15,2 10,93 90,43 
P38886 RPN10 7,09 1 1 268 29,7 4,82 90,24 
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P32642 GRX4 3,28 3 1 244 27,5 4,65 89,86 
P27810 KTR1 17,30 7 5 393 46,0 6,68 88,93 
P47039 BNA3 11,26 6 3 444 50,1 6,57 87,93 
P32589 SSE1 7,22 4 4 693 77,3 5,22 87,16 
Q06991 PUN1 6,84 3 1 263 29,2 8,51 85,97 
P40509 SEC28 8,78 3 2 296 33,8 4,55 84,93 
P05318 RPP1A 20,75 2 1 106 10,9 3,88 84,51 
Q08220 GSH2 5,09 3 2 491 55,8 5,66 84,16 
Q05979 BNA5 11,48 3 3 453 51,0 5,29 83,96 
P18562 FUR1 25,00 4 4 216 24,6 5,74 82,39 
P41805 RPL10 4,98 2 1 221 25,3 10,02 81,71 
P38197 YBL036C 29,57 7 6 257 29,1 6,43 81,66 
A6ZQF6 ATG27 6,64 1 1 271 30,2 5,77 80,02 
P22141 PRE1 19,70 4 3 198 22,5 6,23 79,95 
P25719 CPR3 18,68 3 3 182 19,9 8,70 79,49 
P07991 CAR2 5,66 2 2 424 46,1 6,95 79,28 
P43567 AGX1 16,88 5 4 385 41,9 8,00 77,92 
P02365 RPS6A 6,36 2 1 236 27,0 10,45 77,91 
P24280 SEC14 6,91 4 2 304 34,9 5,49 77,46 
P38137 PCS60 5,34 4 2 543 60,5 9,20 75,75 
P48439 OST3 6,86 4 2 350 39,5 8,48 75,48 
P37291 SHM2 2,99 2 1 469 52,2 7,43 75,42 
P07215 CUP1-1 31,15 2 1 61 6,6 5,91 74,51 
Q12692 HTZ1 12,69 3 2 134 14,3 10,65 74,40 
Q04409 EMI2 5,20 4 2 500 55,9 6,27 74,23 
P07284 SES1 12,99 5 4 462 53,3 6,09 74,15 
P04449 RPL24A 10,97 3 2 155 17,6 11,28 73,93 
P32603 SPR1 2,25 2 1 445 51,8 5,81 72,55 
P04456 RPL25 9,15 1 1 142 15,7 10,11 72,24 
P40495 LYS12 4,58 1 1 371 40,0 8,02 71,75 
P30656 PRE2 8,01 2 2 287 31,6 6,23 69,01 
P22434 PDE1 5,69 2 2 369 42,0 6,13 68,72 
Q96VH4 HBN1 13,99 2 1 193 21,0 6,95 68,58 
P46681 DLD2 12,64 5 4 530 59,2 6,13 68,38 
P05740 RPL17A 8,70 2 1 184 20,5 10,92 68,19 
P05373 HEM2 10,53 3 3 342 37,7 6,14 66,81 
P32590 SSE2 5,19 3 3 693 77,6 5,63 65,86 
P16862 PFK2 1,88 1 1 959 104,6 6,67 65,70 
P47120 LIA1 10,46 3 2 325 36,1 4,87 65,67 
P46672 ARC1 9,84 2 2 376 42,1 7,88 65,56 
P47085 YJR008W 5,62 1 1 338 38,5 6,84 65,53 
P39976 DLD3 5,65 2 1 496 55,2 6,89 65,47 
Q12428 PDH1 4,84 2 2 516 57,6 9,07 65,21 
P32473 PDB1 7,38 4 2 366 40,0 5,30 64,69 
P06780 RHO1 9,09 3 2 209 23,1 6,23 64,55 
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P07280 RPS19A 6,25 2 1 144 15,9 9,61 64,19 
P54113 ADE16 3,05 2 1 591 65,2 6,55 64,00 
P39101 CAJ1 4,35 1 1 391 44,8 5,80 63,76 
P06787 CMD1 25,17 2 2 147 16,1 4,30 63,13 
P53598 LSC1 4,26 1 1 329 35,0 8,46 60,76 
P53853 VPS75 7,20 2 2 264 30,6 4,75 59,94 
P22855 AMS1 3,05 4 3 1083 124,4 7,25 59,44 
P32316 ACH1 5,51 1 1 526 58,7 6,79 58,91 
P53860 PDR1 11,68 5 4 351 40,7 7,96 58,20 
P0C0W1 RPS22A 12,31 1 1 130 14,6 9,94 58,02 
P32463 ACP1 12,80 2 1 125 13,9 4,97 57,17 
P25375 PRD1 1,54 1 1 712 81,9 5,80 57,02 
P32074 SEC21 2,35 2 1 935 104,8 5,12 56,74 
P38075 PDX3 15,35 2 2 228 26,9 7,49 56,06 
P33317 DUT1 8,16 1 1 147 15,3 7,25 56,06 
P53332 CAB4 8,20 3 2 305 34,3 6,32 55,98 
P26782 RPS24A 13,33 3 2 135 15,3 10,51 55,35 
P32775 GLC1 2,56 2 2 704 81,1 6,16 54,69 
P32835 GSP1 16,44 5 3 219 24,8 6,55 53,92 
Q08108 PLB3 3,35 2 2 686 75,0 5,03 53,72 
Q08977 YPL260W 1,81 1 1 551 62,7 5,12 53,41 
P40202 CCS1 6,02 1 1 249 27,3 6,67 53,24 
P38636 ATX1 23,29 2 1 73 8,2 8,44 53,01 
P01094 PAI3 39,71 3 2 68 7,7 7,40 52,82 
P10622 RPP1B 15,09 1 1 106 10,7 4,01 52,59 
P38911 FPR3 2,68 1 1 411 46,5 4,46 52,47 
Q04371 YMR027W 3,62 3 2 470 54,1 5,64 52,30 
P38109 YBR139W 8,86 2 2 508 57,6 5,31 51,81 
P53044 UFD1 6,37 4 2 361 39,8 6,21 51,34 
P38972 ADE6 1,18 2 1 1358 148,8 5,27 51,22 
P37292 SHM1 2,86 2 1 490 53,7 8,72 50,13 
P38131 KTR4 2,16 2 1 464 54,5 4,84 50,03 
P47068 BBC1 1,04 2 1 1157 128,2 5,26 49,94 
P39003 HXT6 4,04 1 1 570 62,7 7,75 49,28 
P50086 NAS6 4,39 2 1 228 25,6 6,44 48,92 
P40363 YJL068C 7,36 3 2 299 33,9 6,71 48,84 
P40414 TPM2 8,70 1 1 161 19,1 4,51 48,75 
P11632 NHP6A 13,98 1 1 93 10,8 9,76 48,55 
P05750 RPS3 7,08 2 1 240 26,5 9,41 48,09 
Q12408 NPC2 6,36 3 1 173 19,1 4,44 47,69 
P40213 RPS16A 8,39 1 1 143 15,8 10,26 47,61 
P53315 SOL4 5,88 2 1 255 28,4 5,35 47,58 
P39743 RVS167 2,28 1 1 482 52,7 6,01 47,56 
Q04013 YHM2 2,55 2 1 314 34,2 9,88 47,56 
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Q12329 HSP42 2,93 1 1 375 42,8 5,08 47,52 
P05735 RPL18A 4,76 1 1 189 21,7 11,36 47,28 
P38773 DOG2 8,54 4 2 246 27,1 5,74 47,21 
P53600 RET3 14,29 2 2 189 21,7 5,16 46,81 
P35127 YUH1 6,36 1 1 236 26,4 4,56 46,69 
P40212 RPL13B 5,53 2 1 199 22,5 11,08 46,66 
P0C0W9 RPL11A 8,05 1 1 174 19,7 9,92 46,50 
P32527 ZUO1 8,31 2 2 433 49,0 8,25 46,35 
Q03674 PLB2 4,82 3 2 706 75,4 4,70 46,05 
A6ZRK4 LAP3 6,42 3 2 483 55,5 8,75 45,93 
P00427 COX6 12,84 1 1 148 17,3 6,05 45,48 
P35176 CPR5 27,11 5 4 225 25,3 5,60 45,22 
P43321 SMD3 8,91 2 1 101 11,2 9,99 44,46 
Q08647 PUS7 2,07 1 1 676 77,0 7,80 44,45 
P13517 CAP2 8,01 2 2 287 32,6 4,72 44,39 
P27616 ADE1 9,48 3 3 306 34,6 5,95 43,89 
P38922 HRB1 2,64 1 1 454 52,1 7,59 43,89 
P04802 DPS1 3,59 2 2 557 63,5 6,58 43,46 
Q06325 YPS7 4,36 3 2 596 64,5 4,96 43,41 
P39522 ILV3 2,05 1 1 585 62,8 7,83 43,41 
P43619 BNA6 13,56 2 2 295 32,3 5,85 43,28 
Q12012 YOR289W 3,98 1 1 251 29,1 8,34 43,03 
Q99321 DDP1 18,09 2 2 188 21,6 8,15 42,90 
P35271 RPS18A 11,64 3 2 146 17,0 10,27 42,40 
Q12031 ICL2 1,57 2 1 575 64,9 7,56 42,25 
P40518 ARC15 7,14 2 1 154 17,1 5,31 41,94 
P32599 SAC6 2,49 2 1 642 71,7 5,48 41,82 
P32191 GUT2 1,23 1 1 649 72,3 7,90 41,73 
P06367 RPS14A 9,49 1 1 137 14,5 10,73 41,48 
P33330 SER1 2,53 1 1 395 43,4 6,54 41,48 
Q08412 CUE5 9,49 2 2 411 46,8 4,81 41,01 
Q12335 PST2 15,66 1 1 198 21,0 5,73 40,70 
P40093 YER156C 2,96 1 1 338 38,2 7,49 40,60 
P06786 TOP2 0,98 1 1 1428 164,1 7,03 40,40 
Q12165 ATP16 12,50 1 1 160 17,0 6,55 39,80 
Q04792 GAD1 1,88 1 1 585 65,9 6,62 39,75 
P39940 RSP5 3,09 2 2 809 91,8 6,70 39,53 
Q06217 SMD2 7,27 2 1 110 12,8 9,16 39,29 
Q06625 GDB1 1,76 2 2 1536 174,9 5,77 39,10 
P32623 UTR2 5,57 2 2 467 49,9 4,78 38,65 
P53691 CPR6 3,50 1 1 371 42,0 6,16 38,50 
P08417 FUM1 2,66 1 1 488 53,1 8,25 38,49 
P27809 KRE1 3,85 2 1 442 51,4 5,40 37,88 
Q04638 ITT1 1,51 2 1 464 54,1 5,55 37,80 
P32787 MGM101 10,41 2 2 269 30,1 9,32 37,38 
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P40582 GTT1 5,13 1 1 234 26,8 6,65 37,16 
P38910 HSP10 10,38 1 1 106 11,4 9,00 37,05 
A6ZZH2 MCR1 5,30 2 2 302 34,1 8,65 37,00 
P06101 CDC37 8,70 3 3 506 58,3 5,06 36,63 
P47037 SMC3 0,89 2 1 1230 141,2 5,81 36,04 
P05030 PMA1 2,18 1 1 918 99,6 5,11 35,97 
P16140 VMA2 2,71 1 1 517 57,7 5,07 35,67 
P32368 SAC1 2,89 1 1 623 71,1 7,71 35,35 
P54070 KTR6 1,79 2 1 446 52,1 5,50 34,59 
P53189 SCW11 2,40 2 1 542 56,4 4,48 34,22 
P39015 STM1 4,76 2 1 273 30,0 9,66 33,91 
P02406 RPL28 6,71 2 2 149 16,7 10,62 33,72 
P14120 RPL30 18,10 2 1 105 11,4 9,80 33,69 
P32472 FPR2 7,41 1 1 135 14,5 5,50 33,22 
P46680 AIP1 3,09 2 2 615 67,3 5,59 32,99 
P16861 PFK1 0,91 1 1 987 107,9 6,39 32,93 
A6ZV70 CTT1 2,67 1 1 562 64,5 6,54 32,72 
P38011 ASC1 2,82 1 1 319 34,8 6,24 32,58 
P20051 URA4 5,77 3 2 364 40,3 6,54 32,11 
P38777 FSH1 7,82 1 1 243 27,3 6,35 32,01 
P28777 ARO2 5,59 1 1 376 40,8 7,80 31,90 
P0CW40 IMA3 1,70 1 1 589 68,7 5,59 31,74 
P29547 CAM1 2,65 1 1 415 47,1 8,38 31,60 
P53299 TIM13 10,48 2 1 105 11,3 8,16 31,58 
A6ZUT6 PXR1 2,58 2 1 271 31,4 9,86 31,54 
A6ZS33 SCY_4744 1,19 1 1 671 77,3 6,58 31,47 
P19262 KGD2 1,94 2 1 463 50,4 8,85 30,83 
A6ZT54 CRP1 2,58 1 1 465 51,1 7,34 30,78 
P25654 YCR090C  3,85 1 1 182 20,7 4,88 30,73 
P19358 SAM2 2,08 1 1 384 42,2 5,38 30,66 
P53163 MNP1 5,67 1 1 194 20,6 9,19 30,16 
P33416 HSP78 1,23 1 1 811 91,3 8,05 30,07 
P11745 RNA1 1,97 1 1 407 45,8 4,61 30,06 
P04076 ARG4 6,70 2 2 463 52,0 5,73 29,98 
P25491 YDJ1 3,42 1 1 409 44,6 6,30 29,89 
P32867 SSO1 8,62 2 2 290 33,1 5,30 29,59 
P32558 SPT16 1,35 1 1 1035 118,6 5,10 29,28 
Q99288 DET1 4,49 1 1 334 39,1 7,34 29,10 
Q12287 COX17 18,84 2 1 69 8,1 4,92 28,24 
P00812 CAR1 2,40 1 1 333 35,6 5,64 28,01 
P32914 SPT4 14,71 1 1 102 11,2 5,12 28,00 
P42884 AAD14 2,39 1 1 376 42,0 6,74 27,78 
P49954 NIT3 4,47 1 1 291 32,5 7,55 27,71 
P0C2H6 RPL27A 5,15 1 1 136 15,5 10,36 27,54 
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P53303 ZPR1 2,06 1 1 486 55,0 4,86 27,54 
P05626 ATP4 6,15 1 1 244 26,9 9,13 27,50 
P32917 STE5 1,09 1 1 917 102,7 5,45 27,31 
P25332 RBK1 3,00 1 1 333 36,9 5,29 27,30 
Q04212 ARA2 2,69 1 1 335 38,2 5,57 27,16 
P25294 SIS1 3,98 1 1 352 37,6 9,03 27,10 
Q6Q546 HUB1 16,44 1 1 73 8,3 6,54 27,08 
Q06549 CDD1 6,34 1 1 142 15,5 7,17 26,92 
P43569 CAF16 3,11 1 1 289 33,1 6,65 26,92 
P32447 ASF1 7,89 1 1 279 31,6 3,99 26,82 
A6ZVM6 CBR1 7,39 2 1 284 31,4 8,78 26,72 
P25443 RPS2 5,91 1 1 254 27,4 10,43 26,51 
A6ZNU5 RKI1 5,43 1 1 258 28,2 5,92 26,17 
Q05778 PBA1 7,61 1 1 276 30,7 4,81 26,13 
P28273 OXP1 1,09 1 1 1286 140,3 6,77 26,02 
P46969 RPE1 2,94 1 1 238 26,0 6,28 25,98 
P38071 ETR1 2,37 1 1 380 42,0 9,00 25,96 
P34227 PRX1 3,83 1 1 261 29,5 8,87 25,92 
P05737 RPL7A 8,61 1 1 244 27,6 10,15 25,83 
A5Z2X5 YPR010C-A 22,22 1 1 72 7,9 8,73 25,55 
P05748 RPL15A 6,86 1 1 204 24,4 11,39 25,45 
P41920 YRB1 3,48 1 1 201 22,9 6,10 25,31 
P05736 RPL2A 4,72 1 1 254 27,4 11,11 25,25 
P11978 SIR4 0,81 1 1 1358 152,0 9,00 25,03 
P41697 BUD6 1,40 1 1 788 88,8 7,78 24,76 
Q12247 FYV7 5,96 1 1 151 18,2 10,26 24,40 
P25293 NAP1 5,76 1 1 417 47,9 4,34 24,37 
P11914 MAS2 1,45 1 1 482 53,3 6,34 24,35 
P10869 HOM3 2,09 1 1 527 58,1 6,67 24,19 
Q05788 PNP1 4,50 1 1 311 33,7 7,27 24,06 
O14455 RPL36B 7,00 1 1 100 11,1 11,59 23,80 
P53981 YNL010W 4,15 1 1 241 27,5 5,45 23,78 
P33315 TKL2 1,76 1 1 681 75,0 6,14 23,21 
P14747 CMP2 1,82 1 1 604 68,5 6,35 23,21 
P38041 BOI1 0,92 1 1 980 109,2 9,10 23,05 
P22082 SNF2 0,65 1 1 1703 193,9 7,01 22,95 
P47075 VTC4 1,25 1 1 721 83,1 6,83 22,92 
Q04869 YMR315W 5,44 1 1 349 38,2 6,62 22,79 
P33734 HIS7 1,99 1 1 552 61,0 5,49 22,78 
Q04947 RTN1 4,07 1 1 295 32,9 8,98 22,77 
P38283 SLI15 1,29 1 1 698 79,1 9,92 22,69 
P36126 SPO14 0,36 1 1 1683 195,1 7,59 22,49 
P07260 TIF45 2,82 1 1 213 24,2 5,49 22,49 
Q04458 HFD1 1,69 1 1 532 59,9 6,76 22,31 
P15496 IDI1 4,51 1 1 288 33,3 4,98 22,29 
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P14284 REV3 1,60 1 1 1504 172,8 8,65 21,87 
P15202 CTA1 4,47 1 1 515 58,5 7,44 21,85 
Q03868 SPO7 0,48 1 1 1245 145,1 9,13 21,66 
Q07451 YET3 5,91 1 1 203 22,9 7,14 21,56 
P38262 SIF2 2,24 1 1 535 59,1 4,96 21,50 
Q02794 STD1 2,70 1 1 444 50,2 8,98 21,26 
P38077 ATP3 3,54 1 1 311 34,3 9,31 21,17 
A6ZPQ6 MPM1 7,14 1 1 252 28,5 5,92 21,14 
P87284 PMP3 34,55 1 1 55 6,1 4,46 21,08 
P00815 HIS4 2,13 1 1 799 87,7 5,29 20,92 
Q02753 RPL21A 5,63 1 1 160 18,2 10,39 20,71 
P26781 RPS11A 6,41 1 1 156 17,7 10,78 20,05 
 
 
 
 
